0000886163-17-000021.txt : 20170228 0000886163-17-000021.hdr.sgml : 20170228 20170228073726 ACCESSION NUMBER: 0000886163-17-000021 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170228 DATE AS OF CHANGE: 20170228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 17644718 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 10-K 1 lgnd-20161231x10k.htm 10-K Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________________________
FORM 10-K
_____________________________________________________________________________________________
Mark One
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2016
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .
Commission File No. 001-33093
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware
 
77-0160744
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
 
 
 
3911 Sorrento Valley Boulevard, Suite 110
San Diego, CA
 
92121
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (858) 550-7500
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Name of Each Exchange on Which Registered
Common Stock, par value $.001 per share
The NASDAQ Global Market of The NASDAQ Stock Market LLC
Preferred Share Purchase Rights
The NASDAQ Global Market of The NASDAQ Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  x    No  o 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.    Yes  o    No  x
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated Filer  x
 
Accelerated Filer  o
 
Non-accelerated Filer  o
 
Smaller reporting company  o
 
 
(Do not check if a smaller reporting company)
 
 
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).    Yes  o    No  x
The aggregate market value of the Registrant’s voting and non-voting stock held by non-affiliates was approximately $2.3 billion based on the last sales price of the Registrant’s Common Stock on the NASDAQ Global Market of the NASDAQ Stock Market LLC on June 30, 2016. For purposes of this calculation, shares of Common Stock held by directors, officers and 10% stockholders known to the Registrant have been deemed to be owned by affiliates which should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant or that such person is controlled by or under common control with the Registrant.



As of February 9, 2017, the Registrant had 20,919,894 shares of Common Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the Registrant’s 2017 Annual Meeting of Stockholders to be filed with the Commission on or before May 1, 2017 are incorporated by reference in Part III of this Annual Report on Form 10-K. With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form 10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.




Table of Contents
 
Part I
 
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
 
 
Part II
 
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
 
 
Part III
 
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
 
 
Part IV
 
Item 15.
Signatures






















GLOSSARY OF TERMS AND ABBREVIATIONS
Abbreviation
Definition
2019 Convertible Senior Notes
$245.0 million aggregate principal amount of convertible senior unsecured notes due 2019
ABSSSI
Acute bacterial skin and skin structure infections
ADHF
Acute decompensated heart failure
Amended ESPP
Employee Stock Purchase Plan, as amended and restated
Amgen
Amgen, Inc.
AML
Acute myeloid leukemia
ANDA
Abbreviated New Drug Application
AOCI
Accumulated Other Comprehensive Income
API
Active pharmaceutical ingredient
ASCT
Autologous Stem Cell Transplantation
ASU
Accounting Standards Update
Azure
Azure Biotech, Inc.
BACE
Beta-secretase
Baxter
Baxter International, Inc.
BMS
Bristol Myers Squibb
CStone
CStone Pharmaceuticals Co., Ltd
Cardioxyl
Cardioxyl Pharmaceuticals, Inc.
CFDA
China Food and Drug Administration
CIT
Chemotherapy-induced thrombocytopenia
CMC
Chemistry, Manufacturing and Controls
Coherus Biosciences
Coherus Biosciences, Inc.
CoM
Composition of Matter
Company
Ligand Pharmaceuticals Incorporated, including subsidiaries
COSO
Committee of Sponsoring Organizations of the Treadway Commission
CRO
Contract Research Organization
CURx
CURx Pharmaceuticals, Inc.
CVR
Contingent value right
CyDex
CyDex Pharmaceuticals, Inc.
Deciphera
Deciphera Pharmaceuticals, LLC
DMF
Drug Master File
EC
European Commission
Eli Lilly
Eli Lilly and Company
EPOR
Erythropoietin receptor
Ethicor
Ethicor Pharmaceuticals, Ltd
EU
European Union
FASB
Financial Accounting Standards Board
FDA
Food and Drug Administration
FSGS
Focal segmental glomerulosclerosis
GCSF
Granulocyte-colony stimulating factor
Hovione
Hovione FarmCiencia
IPR&D
In-Process Research and Development
IRAK-4
Interleukin-1 Receptor Associated Kinase-4
ITP
Chronic immune (idiopathic) thrombocytopenic purpura
IV
Intravenous


Ligand
Ligand Pharmaceuticals Incorporated, including subsidiaries
LSA
Loan and Security Agreement
LTP
Liver-targeted prodrug
Lundbeck
Lundbeck A/S
MDS
Myelodysplastic syndromes
Melinta
Melinta Therapeutics, Inc.
Merck
Merck & Co., Inc.
Merrimack
Merrimack Pharmaceuticals, Inc.
Millenium
Millenium Pharmaceuticals, Inc. (aka Takeda Oncology)
MLA
Master License Agreement
MRSA
Methicillin-resistant Staphylococcus aureu
NASH
Non-alcoholic steatohepatitis
NDA
New Drug Application
NOLs
Net Operating Losses
Novartis
Novartis AG
OMT
OMT, Inc. or Open Monoclonal Technology, Inc.
Omthera
Omthera Pharmaceuticals, Inc.
Orange Book
Publication identifying drug products approved by the FDA based on safety and effectiveness
Par
Par Pharmaceutical, Inc.
Pfizer
Pfizer Inc.
PPD
Post-Partum Depression
Retrophin
Retrophin Inc.
SAA
Severe Aplastic Anemia
SAGE
Sage Therapeutics, Inc.
SARM
Selective Androgen Receptor Modulator
Sedor
Sedor Pharmaceuticals, Inc., or RODES, Inc.
Selexis
Selexis, SA
Sermonix
Sermonix Pharmaceuticals, LLC
Spectrum
Spectrum Pharmaceuticals, Inc.
SRSE
Super-refractory status epilepticus
Takeda
Takeda Pharmaceuticals Company Limited
T2DM
Type 2 Diabetes Mellitis
TG Therapeutics
TG Therapeutics, Inc.
TPE
Third-party evidence
TR-β
Thyroid hormone receptor beta
VentiRx
VentiRx Pharmaceuticals Inc.
VIE
Variable interest entity
Viking
Viking Therapeutics
X-ALD
X-linked adrenoleukodystrophy
Zydus Cadila
Zydus Cadila Healthcare Ltd



PART I
 
 
 
Cautionary Note Regarding Forward-Looking Statements:
You should read the following together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document or incorporated by reference.
This report contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.
Forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “plan,” “intends,” “estimates,” “would,” “continue,” “seeks,” “pro forma,” or “anticipates,” or other similar words (including their use in the negative), or by discussions of future matters such as those related to our royalties and milestones under license agreements, Capitsol materials sales, and product development, as well as other statements that are not historical. You should be aware that the occurrence of any of the events discussed under the caption “Risk Factors” could negatively affect our results of operations and financial condition and the trading price of our stock.
The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended.

References to “Ligand Pharmaceuticals Incorporated,” “Ligand,” the “Company,” “we,” “our” and “us” include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.

Trademarks

Our trademarks, trade names and service marks referenced herein include Ligand®, Captisol®, Captisol-enabled™, LTP technology™, OmniAb®, OmniMouse®, OmniRat® and OmniFlic®. All other trademarks, trade names and service marks including BaxdelaTM, CarnexivTM, Conbriza®, Duavee®, Evomela®,Kyprolis®, Promacta®, Revolade®, SUREtechnology Platform™, and Viviant® are the property of their respective owners. Use or display by us of other parties’ trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.


1

Item 1.
Business

Overview
We are a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. Over our more than 30 year history, we have employed research technologies such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward securing prescription drug approvals. We currently have partnerships and license agreements with over 95 pharmaceutical and biotechnology companies, and over 160 different programs under license with us are currently in various stages of commercialization and development. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Our partners have programs currently in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. We have over 500 issued patents worldwide, and over 200 currently pending patent applications.
We have assembled our large portfolio of fully-funded programs either by licensing our own proprietary drug development programs, licensing our platform technologies such as Captisol or OmniAb to partners for use with their proprietary programs, or acquiring existing partnered programs from other companies. Fully-funded programs are those for which our partners pay all of the development and commercialization costs. For our internal programs, we generally plan to advance drug candidates through early-stage drug development or clinical proof-of-concept.
Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. We believe that focusing on discovery and early-stage drug development while benefiting from our partners’ development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.
Our revenue consists of three primary elements: royalties from commercialized products, license and milestone payments and sale of Captisol material. In addition to discovering and developing our own proprietary drugs, we selectively pursue acquisitions to bring in new assets, pipelines, and technologies to aid in generating additional potential new revenue streams.
2016 Major Business Highlights for Ligand
Acquisitions

•
Ligand acquired OMT in January 2016, conferring ownership of a large portfolio of licenses and the OmniAb platform, for $173.4 million in cash and stock.
•
Ligand acquired the economic rights to multiple medical device programs owned by CorMatrix in May 2016. Ligand paid $17.5 million and in return received a portion of revenue (synthetic royalty) from CorMatrix’s existing marketed products and will have the right to receive future synthetic royalties from potential future products.

Late-Stage Clinical Data

•
On September 7, 2016, Retrophin announced results from the Phase 2 DUET study of sparsentan for the treatment of FSGS, a rare kidney disorder without an FDA-approved pharmacological treatment that often leads to end-stage renal disease. The study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.
•
On December 6, 2016, Sage announced its expedited development plan for Sage-547 for treatment of postpartum depression, from a breakthrough therapy meeting with the FDA. The current Sage-547 program in PPD, along with prior Phase 2 data, were confirmed as supporting, if successful, a potential NDA. Sage’s PPD clinical program, now in Phase 3, will require only minor modifications, including an increase in sample size.

2

•
Merck announced that it stopped the Phase 2/3 EPOCH study evaluating verubecestat in people with mild-to-moderate Alzheimer’s disease due to the conclusion that the efficacy endpoint could not be achieved. No safety concerns where noted. Results from EPOCH will be analyzed and presented at an upcoming scientific meeting. The external Data Monitoring Committee recommended that the ongoing Phase 3 APECS study, which is evaluating verubecestat in people with prodromal Alzheimer’s disease, continue unchanged. Results from the APECS study are expected in February 2019.

NDA Submissions, Approvals or Label Expansion for Products Ligand is Entitled to Royalties

•
On March 15, 2016, Spectrum announced that the FDA approved Evomela for use in two indications: as a high dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
•
On April 7, 2016, the European Commission approved Promacta for the treatment of children one year and above with chronic immune thrombocytopenia who have not responded to other treatments.
•
On July 3, 2016, Amgen announced that the European Commission approved an expanded indication for Kyprolis®, to be used in combination with dexamethasone alone, for adult patients with multiple myeloma who have received at least one prior therapy.
•
On July 4, 2016, Ono Pharmaceuticals, holder of Kyprolis marketing rights in Japan, announced approval in Japan for treatment of patients with relapsed or refractory multiple myeloma.
•
On October 7, 2016, Lundbeck announced approval of Carnexiv IV as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv is the first FDA approved intravenous carbamazepine option.
•
On October 24, 2016, Melinta Therapeutics announced it submitted a NDA for approval of IV Baxdela for the treatment of patients with acute bacterial skin and skin structure infections.
•
On November 10, 2016, Amgen announced a collaboration with Janssen Biotech, Inc. to evaluate the combination of Amgen's Kyprolis (carfilzomib) and Janssen's DARZALEX® (daratumumab) in multiple clinical studies in patients with multiple myeloma. The first study initiated as part of this agreement is a Phase 3 registrational trial evaluating Kyprolis in combination with DARZALEX and dexamethasone compared to Kyprolis and dexamethasone alone in patients with multiple myeloma who have had one, two or three prior lines of therapy. The study is anticipated to start enrolling patients in April 2017.

Licensing Deals Ligand Entered into or Expanded in 2016

•
Worldwide platform license agreement with Emergent Biosolutions for access to the OmniAb technology.
•
Worldwide platform license agreement with Tizona for access to the OmniAb technology.
•
Worldwide platform license agreement with ABBA Therapeutics for access to the OmniAb technology.
•
Worldwide platform license agreement with F-Star for access to the OmniAb technology.
•
Current OmniAb licensee exercised its option to expand access to the OmniAb platform.
•
Wuxi sublicensed the Chinese rights of two antibodies developed with the OmniAb platform, including to CStone, a Chinese start-up developing an immuno-oncology therapy whose investigational new drug application has been accepted by the CFDA.  The additional antibody is in preclinical development with an undisclosed partner.
•
Worldwide platform license agreement with Gilead Sciences for access to the OmniAb technology.
•
Newly formed Nucorion, co-founded by Ligand, licensed three programs utilizing Ligand’s LTP technology and intends to pursue a pipeline of LTP-based programs for China and other markets.
•
Worldwide license agreement with Teneobio for access to the OmniAb technology.
•
License agreement of four programs including aplindore, a CRTH2 antagonist program, CE-acetaminophen, and an H3 receptor antagonist program with Seelos Therapeutics.
•
Worldwide platform license agreement with Ono Pharmaceuticals for access to the OmniAb technology.
•
Global license and supply agreement with Novartis for the development and commercialization of a CE-oral liquid formulation of trametinib.
•
License agreement with Beloteca for the development and commercialization of CE-ziprasidone

Internal Pipeline Highlights

•
Ligand announced that results from two Phase I clinical trials with LGD-6972, the Company’s investigational glucagon receptor antagonist, were published online in the August issue of the journal Diabetes, Obesity and

3

Metabolism. The single- and multiple-dose Phase 1a and Phase 1b studies demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus. The trial results also demonstrate a robust, dose-dependent reduction of fasting plasma glucose.
•
Ligand announced initiation of a Phase 2 clinical trial with LGD-6972 for the treatment of T2DM. The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin. Ligand expects to report the results from the Phase 2 clinical trial in the third quarter of 2017.

Technologies

A variety of technology platforms that enable elements of drug discovery or development form the basis of our portfolio of fully-funded shots on goal. Platform technologies or individual drugs discovered by Ligand are related to a broad estate of intellectual property that includes over 500 issued patents and over 200 pending patent applications.

Captisol Technology

Captisol is Ligand’s patented, uniquely-modified cyclodextrin that is specifically designed to maximize safety, while improving the solubility, stability and bioavailability of APIs. Captisol can enable faster and more efficient development paths for our partners, given its known regulatory acceptance. Ligand maintains both Type IV and Type V DMFs with the FDA. These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs. Ligand also filed a DMF in Japan in 2015. Captisol-enabled drugs are marketed in more than 60 countries, and over 45 partners have Captisol-enabled drugs in development.

OmniAb Technologies

In January of 2016, Ligand acquired OMT and the OmniAb Technologies. OmniAb includes three complementary and globally-branded platforms named OmniRat, OmniMouse and OmniFlic. The OmniAb platforms consist of genetically-engineered transgenic rodents that produce a broadly diversified repertoire of antibodies and enable novel fully-human antibody drug discovery and development by our OmniAb partners. Fully-human OmniAb antibodies provide advantages to our partners in that fully-human antibodies have reduced immunogenicity, streamline development timelines and costs, and accelerate novel antibody discovery. Currently, more than 25 partners are utilizing OmniAb animals in their drug discovery and development efforts

LTP Technology Platform

The LTP Technology platform is a novel prodrug technology designed to selectively deliver a broad range of pharmaceutical agents to the liver. A prodrug is a biologically inactive compound that can be metabolized in the body to produce an active drug. The LTP Technology works by chemically modifying biologically active molecules into an inactive prodrug, which will be administered to a patient and later activated by specific enzymes in the liver. The technology can be used to improve the safety and/or activity of existing drugs, develop new agents to treat certain liver-related diseases, and treat diseases caused by imbalances of circulating molecules that are controlled by the liver. The technology is especially applicable to metabolic and cardiovascular indications, among others. Currently 3 partners are utilizing the LTP Technology or related platform(s).

SUREtechnology Platform (owned by Selexis)

Ligand acquired economic rights to over 30 SUREtechnology Platform programs from Selexis in two separate transactions in 2013 and 2015, granting Ligand rights to downstream economics on novel biologics and biosimilars programs. The SUREtechnology Platform, developed and owned by Selexis, is a novel technology that improves the way that cells are utilized in the development and manufacturing of recombinant proteins and drugs. The technology is based on novel DNA-based elements that control the dynamic organization of chromatin within mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology creates advantages over traditional approaches including accelerated development and manufacturing times, high yields and increased compound stability.

CorMatrix products and technologies/programs (owned by CorMatrix)


4

Ligand acquired economic rights to multiple programs owned by CorMatrix in May 2016, granting Ligand rights to receive a portion of revenue (synthetic royalty) from CorMatrix’s existing marketed products and rights to future synthetic royalties from potential future products. Ligand receives a share of revenue from the currently marketed vascular, cardiac, and pericardial tissue repair products and the CanGaroo Envelope for cardiac implantable electronic devices. Additionally, Ligand has the rights to receive a share of potential future revenues from CorMatrix’s developmental pipeline products.


5

Partners and Licensees
The following table lists our disclosed partners and licensees. In addition to these 83 Companies, we have over 12 additional undisclosed partners and licensees, mostly biotech companies.
Big Pharma
Ticker
 
Generics
Ticker
 
Biotech, continued
Ticker
AstraZeneca
AZN
 
Alvogen
Private
 
Genmab
GEN
Baxter
BAX
 
Avion
Private
 
Genekey Biotech
Private
BMS
BMY
 
BioCad
Private
 
Gilead Sciences
GILD
Daiichi Sankyo
DSKY
 
Coherus
CHRS
 
Hanall
9420
Eli Lilly
LLY
 
Gedeon Richter
GEDSF
 
Harpoon
Private
GSK
GSK
 
IBC Generium
Private
 
Lubris
Private
Janssen
JNJ
 
Oncobiologics
ONS
 
Marinus
MRNS
Merck
MRK
 
Zydus Cadila
CADILAHC
 
MEI
MEIP
Merck KGaA
MRK
 
 
 
 
Melinta
Private
Novartis
NVS
 
Biotech
Ticker
 
Meridian Labs
Private
Otsuka
4768
 
ABBA
Private
 
Millennium
4502
Pfizer
PFE
 
AiCuris
Private
 
Merrimack
MACK
Sanofi
SNY
 
Aldeyra
ALDX
 
Novogen
NVGN
Takeda
4502
 
Amgen
AMGN
 
Nucorion
Private
 
 
 
ARMO
Private
 
Opthea
OPT
Specialty Pharma
Ticker
 
Azure
Private
 
Precision Biologics
Private
CorMatrix
Private
 
bluebird bio
BLUE
 
Retrophin
RTRX
Cuda
Private
 
Cantex
Private
 
ROAR
Private
Gloria
Private
 
Celgene
CELG
 
SAGE
SAGE
Lundbeck
LUN
 
Chiva
Private
 
Seattle Genetics
SGEN
Ono
4528
 
C-Stone
Private
 
Seelos
Private
Sedor
Private
 
CURx
Private
 
Stemcentrx
ABBV
Sermonix
Private
 
Deciphera
Private
 
Symphogen
Private
Shire
SHPG
 
Aptevo
APVO
 
Teneobio
Private
Spectrum
SPPI
 
Exelixis
EXEL
 
Tizona
Private
Teva
TEVA
 
Five Prime
FRPX
 
VentiRx
Private
Vireo Health
Private
 
ForSight Vision
Private
 
Vertex
VRTX
Upsher-Smith
Private
 
F-Star
Private
 
Viking
VKTX
 
 
 
 
 
 
XTL Bio
XTLB
 
 
 
 
 
 
WuXi
Private
 
 
 
 
 
 
 
 








6

Portfolio
We have a large portfolio of current and future potential revenue-generating programs, over 155 of which are fully-funded by our partners. In addition to the table below, we also have more than 40 undisclosed programs.
Commercialized
 
 
Phase 2
 
 
Pre-Clinical
 
Alvogen
Voriconazole
 
Aldeyra
ADX-102
 
ABBA
OmniAb
Amgen
Kyprolis
 
Cardioxyl / BMS
BMS986231-CXL-1427
 
Stemcentryx/AbbVie
OmniAb
Baxter
Nexterone
 
Eli Lilly
LY2606368
 
AiCuris GmBH
Undisclosed
CorMatrix Base
CorMatrix
 
Lubris Biopharma
Lubricin
 
Amgen
OmniAb
Cangaroo Envelope
CorMatrix
 
Merrimack Pharma
MM-121
 
Aptevo
OmniAb
Lundbeck
Carnexiv
 
Merrimack Pharma
MM-141
 
ARMO
OmniAb
Merck
Noxafil-IV
 
Millennium/Takeda
MLN-4924
 
Avion
CE programs
Novartis
Promacta
 
Novartis
KLM465
 
Azure
Lasofoxifene
Pfizer
Viviant/Conbriza
 
Opthea Ltd
OPT-302
 
C-Stone
PDL-1
Pfizer
Duavee
 
Precision Biologics
NPC-1C
 
Celgene
OmniAb
Pfizer
Vfend
 
Retrophin
Sparsentan
 
CorMatrix
CorMatrix Pipeline
Spectrum
Evomela
 
Sanofi
SAR125844
 
Cuda Pharma
CE-Propofol
Zydus Cadila
Exemptia
 
Seelos
Aplindore
 
CURx Pharma
IV Lamotrigine
Zydus Cadila
Vivitra
 
Sermonix Pharma
Lasofoxifene
 
Exelixis (BMS)
XL652
 
 
 
Shire
BAX-69
 
Five Prime
OmniAb
Regulatory Submission Stage
 
VentiRx Pharma
VTX-2337
 
F-Star
OmniAb
Biocad
Interferon beta-1a
 
Vertex
VK-970
 
Genmab
OmniAb
Melinta
Baxdela
 
Viking
VK5211
 
Gilead
OmniAb
Sedor
CE-Fosphenytoin
 
Viking
TR Beta
 
Gloria
PD-1 antibody
 
 
 
Viking
VK0612
 
Hanall Biopharma
OmniAb
Phase 3
 
 
XTL Bio
hCDR1
 
Janssen
OmniAb
Biocad
BCD-066
 
 
 
 
Marinus Pharma
Ganaxalone IV
Coherus
CHS-0214
 
Phase 1
 
 
Merck KGaA
OmniAb
Exelixis/Daiichi-Sankyo
CS-3150
 
 
 
 
 
 
Merck
Verubecestat
 
Amgen
AMG-330
 
Merck KGaA
FGFR1
Oncobiologics
ONS-3010
 
Biocad
EPOR Agonist
 
Merck KGaA
LRP-6
Oncobiologics
ONS-1045
 
Chiva Pharma
Pradefovir
 
Nucorion
NUC-101
SAGE
Brexanolone -SAGE-547
 
Chiva Pharma
MB07133
 
Nucorion
NUC-202
 
 
 
CURx Pharma
IV Topiramate
 
Nucorion
NUC-404
Color Legend
 
 
Deciphera Pharma
Altiratinib
 
Omthera/AstraZeneca
LTP-O3FA
Blood Disorders
 
Eli Lilly
LY3023703
 
Oncobiologics
Rituximab
Cardiovascular
 
Eli Lilly
Merestinib
 
Oncobiologics
ONS4010
CNS
 
Eli Lilly
Prexasertib
 
Ono Pharmaceuticals
OmniAb
Infectious Disease
 
Exelixis/Daiichi-Sankyo
XL652
 
Pfizer
OmniAb
Inflamm/Metabolic
 
F-Star
F-102
 
 
 
Severe and Rare
 
Gedeon Richter
RGB-03
 
SAGE
SAGE-689
Cancer
 
Gedeon Richter
Bevacizumab
 
Seattle Genetics
OmniAb
Other / Undisclosed
 
Gedeon Richter
Trastuzumab
 
Sedor
CE-Meloxicam
Medical Device/Cardiology
 
Gilead
GS-5734
 
Seelos
CE-Acetaminophen
 
 
IBC Generium
GNR-008
 
Seelos
CRTH2 Antagonist

7

 
 
 
IBC Generium
Deplera
 
Seelos
H3 Receptor Antagonist
 
 
 
MEI Pharma
ME-344
 
Symphogen
OmniAb
 
 
 
MEI Pharma
ME-143
 
Teneobio
OmniAb
 
 
 
Merrimack Pharma
MM-151
 
Teva
OmniAb
 
 
 
Novartis
CE-Trametinib
 
TG Therapeutics
IRAK4
 
 
 
Otsuka
OPC-269
 
Tizona
OmniAb
 
 
 
ROAR Therapeutics
UC-961
 
Upsher Smith
CXCR4
 
 
 
Sedor
CE-Budesonide
 
Viking
EPOR Agonist
 
 
 
Takeda
TAK-020
 
Viking
DGAT-1 Inhibitor
 
 
 
Upsher-Smith
CXCR4
 
Vireo Health
CE-Cannabinoids
 
 
 
VentiRx Pharma
VTX-1463
 
WuXi
OmniAb
Selected Commercial Programs
We have multiple programs under license with other companies that have products that are already being commercialized. The following programs represent components of our current portfolio of revenue-generating assets and potential for near-term growth in royalty and other revenue. For information about the royalties owed to Ligand for these programs, see “Royalties” later in this business section.
Promacta (Novartis)
We are party to a license agreement with Novartis related to Promacta, which is an oral medicine that increases the number of platelets in the blood. Platelets are one of the three components of blood and facilitate clotting in the blood. Individuals with low platelets can be at significant risk of bleeding or death. Because of the importance of having a sufficient number of platelets, Promacta has broad potential applicability to a number of medical situations where low platelets exist.
Promacta is currently approved for three indications: (1) the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy, (2) Hepatitis-C associated thrombocytopenia and (3) SAA. Promacta was initially approved in 2008, and the product has been generating royalty revenue for Ligand since 2009. Promacta is known as Revolade in the EU and other non-US markets.

Novartis has been and continues to pursue globalization of the brand and currently markets Promacta in multiple countries for the three approved indications. Specifically, ITP is currently approved in more than 100 countries, the Hepatitis C-related indication is currently approved in more than 50 countries, and the SAA indication is approved in more than 45 counties.

Beyond the currently-approved indications, Novartis is also performing development activities to expand the brand into new indications, including a number of oncology-related indications including MDS, AML and CIT. As of January 2017, there are 23 open clinical trials related to Promacta (listed as recruiting or open, and not yet recruiting) on the clinicaltrials.gov website.
We are entitled to receive royalties related to Promacta during the life of the relevant patents or following patent expiry, at a reduced rate for ten years from the first commercial sale, whichever is longer, on a country-by-country basis. Novartis has listed a patent in the FDA’s, Orange Book for Promacta with an expiration date in 2029, and absent early termination for bankruptcy or material breach, the term of the agreement expires upon expiration of the obligation to pay royalties. There are no remaining milestones to be paid under the agreement.
Kyprolis (Amgen)
Ligand supplies Captisol to Amgen for use with carfilzomib, and granted an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand’s Captisol technology and is approved in the U.S. for the following:

8

•
In combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
•
As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Kyprolis is also approved in multiple countries and Amgen continues to invest significantly in Kyprolis to further expand its label and geography. Amgen’s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol. Our patents and applications relating to the Captisol component of Kyprolis are not expected to expire until 2033. Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. Under this agreement, we are entitled to receive remaining milestones of up to $2 million, revenue from clinical and commercial Captisol material sales and royalties on annual net sales of Kyprolis.

Evomela (Spectrum)

Ligand supplies Captisol to Spectrum for use with Evomela, which is a Captisol-enabled melphalan IV formulation. The FDA approved Evomela for use in two indications:
•
A high-dose conditioning treatment prior to ASCT in patients with multiple myeloma
•
For the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate

Evomela has been granted Orphan Designation by the FDA for use as a high-dose conditioning regimen for patients with multiple myeloma undergoing ASCT. The Evomela formulation avoids the use of propylene glycol, which has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of therapeutic compounds. The use of the Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to safely achieve a higher dose intensity of pre-transplant chemotherapy.
Under the terms of the license agreement, we granted an exclusive license to Spectrum under our patent rights to Captisol relating to the product. We are eligible to receive over $50 million in potential milestone payments under this agreement and royalties on future net sales of the Captisol-enabled melphalan product. Spectrum’s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event within ten years of the commercial launch. Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. The agreement may be terminated by either party for an uncured material breach or unilaterally by Spectrum by prior written notice.

CorMatrix Portfolio (CorMatrix)
Ligand receives a share of revenue from the currently marketed CorMatrix portfolio of vascular, cardiac and pericardial tissue repair products. In addition, Ligand has the potential to receive a share of revenue and potential milestones from the currently marketed CorMatrix CanGaroo® ECM Envelope for cardiac implantable electronic devices. CorMatrix’s products are medical devices that are designed to permit the development and regrowth of human tissue.
Duavee or Duavive (bazedoxifene/conjugated estrogens) and Viviant/Conbriza (Pfizer)
Pfizer is marketing bazedoxifene under the brand names Viviant and Conbriza in various territories for the treatment of postmenopausal osteoporosis. Pfizer is responsible for the registration and worldwide marketing of bazedoxifene, a synthetic drug specifically designed to reduce the risk of osteoporotic fractures while also protecting uterine tissue. Pfizer has combined bazedoxifene with the active ingredient in Premarin to create a combination therapy for the treatment of post-menopausal symptoms in women. Pfizer is marketing the combination treatment under the brand names Duavee and Duavive in various territories. Net royalties on annual net sales of Viviant/Conbriza and Duavee/Duavive are each payable to us through the life of the relevant patents or ten years from the first commercial sale, whichever is longer, on a country by country basis.

9

Carnexiv (Lundbeck)
Lundbeck's Carnexiv is a Captisol-enabled carbamazepine-IV that was approved by the FDA in October 2016. Carnexiv is indicated as replacement therapy for oral carbamazepine formulations, when oral administration is temporarily no feasible, in adults with certain seizure types. Under the terms of our agreement with Lundbeck, we may be entitled to development and regulatory milestones, royalties on potential future sales by Lundbeck and revenue from Captisol material sales. Lundbeck is responsible for all development costs related to the program.
Nexterone (Baxter)
    We have a license agreement with Baxter, related to Baxter's Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada. We supply Captisol to Baxter for use in accordance with the terms of the license agreement under a separate supply agreement. Under the terms of the license agreement we will continue to earn milestone payments, royalties, and revenue from Captisol material sales. We are entitled to earn royalties on sales of Nexterone through early 2033.
Noxafil-IV (Merck)
We have a supply agreement with Merck related to Merck’s NOXAFIL-IV, a Captisol-enabled formulation of posaconazole for IV use. NOXAFIL-IV is marketed in the United States, EU and Canada. We receive our commercial compensation for this program through the sale of Captisol, and we do not receive a royalty on this program.
Exemptia (Zydus Cadila)
Zydus Cadila’s Exemptia (adalimumab biosimilar) is marketed in India for autoimmune diseases. Zydus Cadila uses the Selexis technology platform for Exemptia. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.
Vivitra (Zydus Cadila)
Zydus Cadila’s Vivitra (trastuzumab biosimilar) is marketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following the first commercial sale.
Summary of Selected Development-stage Programs
We have multiple fully-funded partnered programs that are either in or nearing the regulatory approval process, or given the area of research or value of the license terms are considered particularly noteworthy. We are eligible to receive milestone payments and royalties off of these programs. This list does not include all of our partnered programs. For information about the royalties owed to Ligand for these programs, see “Royalties” later in this Business Overview section. In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply.
Baxdela (Melinta)
Our partner, Melinta , submitted an NDA for approval of a Captisol-enabled delafloxacin-IV in October 2016 for the development of Baxdela, a Captisol-enabled delafloxacin-IV. Delafloxacin is a novel hospital-focused fluoroquinolone antibiotic candidate with potency against a variety of disease-causing bacteria-gram-positives, gram-negatives, atypicals and anaerobes, including quinolone-resistant MRSA. Under the terms of the agreement, we may be entitled to up to $2.1 million of development and regulatory milestones, as well as a royalty on potential future sales by Melinta, and revenue from Captisol material sales. Melinta is responsible for all development costs related to the program.

10

Brexanolone-SAGE-547 (SAGE)
    Our partner, SAGE, is conducting a Phase 3 clinical trial for the development of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions. SAGE’s lead clinical program, Captisol-enabled Brexanolone (SAGE-547), is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors that is in clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE. Brexanolone was granted Fast Track designation, which is intended to facilitate the development and expedite the review of drug candidates that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs, and orphan drug designation, which is intended to facilitate drug development for rare diseases, by the FDA for SRSE. Ligand has the potential to receive milestone payments, royalties and revenue from Captisol material sales for Captisol-enabled programs. SAGE is responsible for all development costs related to the program.
SAGE is also conducting a Phase 3 clinical trial for the development of a Captisol-enabled treatment of PPD. In July 2016 SAGE reported top-line results from a Phase 2 placebo-controlled trial in women with severe PPD, in which SAGE-547 achieved a significant, rapid and durable reduction in depression scores. SAGE received Breakthrough Therapy Designation from the FDA for SAGE-547 in PPD in September, 2016. The Breakthrough Therapy Designation is intended to offer a potentially expedited development path and review for promising drug candidates, which includes increased interaction and guidance from the FDA.
Sparsentan (Retrophin)
Our partner, Retrophin, is developing sparsentan for orphan indications of severe kidney diseases, and has completed a Phase 2 clinical trial of sparsentan for the treatment of FSGS. Certain patient groups with severely compromised renal function, including those with FSGS, exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate. Sparsentan, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies. In January 2015, the FDA granted sparsentan orphan drug designation.
Under our license agreement with Retrophin we are entitled to receive potential net milestones of over $75 million in the future and net royalties on future worldwide sales by Retrophin. The royalty term is expected to be 10 years following the first commercial sale. Retrophin is responsible for all development costs related to the program.
Prexasertib- LY2606368 (Eli Lilly)
Our partner, Eli Lilly is conducting Phase 2 clinical trials for Captisol-enabled LY2606368 (Chk 1/2 inhibitor) for solid tumors. Under the terms of the agreement, we may be entitled to regulatory milestones, royalties on potential future sales by Eli Lilly and revenue from Captisol material sales.
CXL-1427 - BMS986231 (Cardioxyl /BMS)
Our partner, Cardioxyl (acquired by BMS in 2015) is conducting Phase 2 clinical trials for Captisol-enabled CXL-1427 (nitroxyl donor prodrug) for ADHF. Under the terms of the agreement, we may be entitled to development and regulatory milestones, and royalties on potential future sales by BMS and revenue from Captisol material sales.
Lasofoxifene (Azure Biotech, and Sermonix)
Our partner Azure is developing a novel formulation of lasofoxifene targeting an underserved market in women’s health. Under the terms of our agreement with Azure, we are entitled to receive up to $2.6 million in potential development and regulatory milestones as well as royalties on future net sales through the later of the life of the relevant patents (currently expected to be at least until 2027) or 10 years after regulatory approval. Azure may terminate the license agreement at any time upon six months’ prior notice.
Lasofoxifene is an estrogen partial agonist for osteoporosis treatment and other diseases, discovered through the research collaboration between us and Pfizer. Under the terms of the license agreement with Azure, we retained the rights to the oral formulation of lasofoxifene originally developed by Pfizer.

11

Our partner, Sermonix has a license for the development of oral lasofoxifene for the United States and additional territories. Under the terms of the agreement, we are entitled to receive up to $45 million in potential regulatory and commercial milestone payments as well as royalties on future net sales.
Verubecestat-MK-8931 (Merck)
Our partner, Merck is developing Verubecestat (MK-8931), a BACE inhibitor for the treatment of Alzheimer’s disease. Alzheimer’s disease is a chronic neurodegenerative disease and responsible for the majority of dementia cases. The leading hypothesis in the field postulates that plaques of amyloid-beta protein within the brain are the main cause of the disease. BACE is a key enzyme in the production of amyloid-beta protein and a BACE inhibitor is expected to reduce amyloid-beta protein generation in Alzheimer’s disease patients to prevent plaques formation. Verubecestat is the leading BACE inhibitor in clinic. In February 2017, Merck halted the first Phase 3 trial in mild-to-moderate Alzheimer’s disease for futility and expects initial data readout from the second Phase 3 trial in prodromal Alzheimer’s disease in 2019.  It is hoped that by attacking amyloid-beta plaque earlier in the disease, Verubecestat can still be effective. We are entitled to a royalty on potential future sales by Merck.  Merck is responsible for all development costs related to the program
TR-Beta - VK2809 (Viking)
Viking is developing VK2809, a novel selective TR-Beta agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Viking initiated a Phase 2 trial for VK2809 in hypercholesterolemia and fatty liver disease in 2016 and expects primary outcome readout this year. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales.
SARM - VK5211 (Viking)
Our partner Viking is developing VK5211, a novel, potentially best-in-class SARM for patients recovering from hip-fracture. SARMs retain the beneficial properties of androgens without undesired side-effects of steroids or other less selective androgens. Viking initiated a Phase 2 trial in hip fracture in 2015. Under the terms of the agreement with Viking, we may be entitled to up to $270 million of development, regulatory and commercial milestones as well as tiered royalties on potential future sales.
Merestinib- LY2801653 (Eli Lilly)
Our partner, Eli Lilly is conducting Phase 2 clinical trials for Captisol-enabled merestinib (LY2801653, formerly known as c-Met inhibitor) for treatment of cancer. Under the terms of the agreement, we may be entitled to regulatory milestones, royalties on potential future sales by Eli Lilly and revenue from Captisol material sales.
Pevonedistat - MLN-4924 (Millennium/Takeda)
Our partner, Millennium/Takeda is currently conducting Phase 2 trials for the development of pevonedistat (MLN-4924) for the treatment of hematological malignancies and solid tumors. Pevonedistat is a Captisol-enabled Nedd8-Activating Enzyme Inhibitor. Under the terms of the clinical-stage agreement, we may be entitled to development milestones from Millennium/Takeda and revenue from Captisol material sales.
Motolimod - VTX-2337 (VentiRx Pharmaceuticals/Celgene)
Our partner, VentiRx is currently conducting Phase 2 trials for the development of motolimod for the treatment of ovarian cancer and head and neck cancer. Motolimod is a Captisol-enabled Toll-like Receptor 8 agonist. Motolimod was granted Fast Track and Orphan Designations by the FDA for the treatment of recurrent or persistent ovarian cancer. VentiRx has an exclusive worldwide collaboration with Celgene to develop motolimod. Under the terms of the clinical-stage agreement, we have earned development milestones from VentiRx and revenue from Captisol material sales.
Seribantumab-MM-121 (Merrimack Pharmaceuticals)
Merrimack Pharmaceuticals is currently conducting a Phase 2 trial of seribantumab (MM-121) in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer whose disease has progressed following immunotherapy. The FDA has granted fast track designation to facilitate and expedite the development. Seribantumab is

12

an antibody-drug that targets ErbB3 that was developed using the Selexis SUREtechnology Platform. Under the terms of the agreement, we may be entitled to development and commercial milestones, royalties on potential future sales.
CHS-0214 (Coherus Biosciences)
Coherus Biosciences has conducted Phase 3 / MAA-enabling clinical trials for CHS-0214 (etanercept biosimilar) for rheumatoid arthritis and psoriasis. Coherus uses the Selexis’ technology platform for CHS-0214. We are entitled to earn regulatory and sales milestones, and royalties on potential future sales through at least 2026.
AM0010+PD-1 (ARMO Biosciences)
Our partner, ARMO Biosciences, is developing an anti-PD-1 antibody discovered with the OmniAb platform technology.  AM0010+PD-1 is a therapeutic target for cancer therapy.  We are entitled to earn regulatory milestones and royalties on future sales.
ADX-102 (Aldeyra)
              Our partner, Aldeyra, is conducting a phase II study for ADX-102 for the treatment of ocular inflammation.  ADX-102 is a Captisol-enabled ophthalmic solution for the treatment of allergic conjunctivitis that could be active in a broad array of inflammatory ocular diseases.  Under the terms of our agreement with Aldeyra, we are entitled to receive regulatory milestones and royalties on future sales.
Esaxerenone (Exelixis)
              Our partner, Exelixis, entered into a collaboration agreement with Daiichi Sankyo and is conducting a phase 3 pivotal trial (ESAX-HTN) to evaluate esaxerenone (CS-3150) versus eplerenone for essential hypertension in Japanese patients.  Under the terms of the agreement with Exelixis, we are entitled to receive a royalty on future sales.
TAK-020 (Takeda)
              Our partner, Takeda, is conducting a phase I study for TAK-020 for the treatment of rheumatoid arthritis.  TAK-020 is a Captisol-enabled formulation.  We have received an up front fee and revenue from Captisol material sales.
The following table represents our various royalty arrangements:
Royalty Table
Ligand Licenses With Tiered Royalties, Tiers Disclosed*
Promacta (Novartis)
 
Kyprolis (Amgen)
 
Duavee (Pfizer)
 
Viviant/Conbriza (Pfizer)
< $100 million
4.7%
 
< $250 million
1.5%
 
<$400 million
0.5%
 
<$400 million
0.5%
$100 to $200 million
6.6%
 
$250 to $500 million
2.0%
 
$400 million to $1.0 billion
1.5%
 
$400 million to $1.0 billion
1.5%
$200 to $400 million
7.5%
 
$500 to $750 million
2.5%
 
>$1.0 billion
2.5%
 
>$1.0 billion
2.5%
$400 million to $1.5 billion
9.4%
 
>$750 million
3.0%
 
 
 
 
 
 
>$1.5 billion
9.3%
 
 
 
 
 
 
 
 
 
CE-Topiramate (CURx)
 
CE-Budesonide (Sedor)
 
CE-Meloxicam (Sedor)
< $50 million
6.0%
 
< $25 million
8.0%
 
< $25 million
8.0%
$50 to $100 million
6.8%
 
> $25 million
10.0%
 
> $25 million
10.0%
>$100 million
7.5%
 
 
 
 
 
 

13

Ligand Licenses With Tiered Royalties, Tiers Undisclosed*
Program
Licensee
Royalty Rate
IRAK4
TG Therapeutics
6.0% - 9.5%
CE-Lamotrigine
CURx
4.0% - 7.0%
Lasofoxifene
Sermonix
6.0% - 10.0%
FBPase Inhibitor
Viking
7.5% - 9.5%
SARM
Viking
7.25% - 9.25%
TR Beta
Viking
3.5% - 7.5%
Oral EPO
Viking
4.5% - 8.5%
DGAT-1
Viking
3.0% - 7.0%
LTP-O3FA
Omthera/AstraZeneca
Tiered mid-to-high single digit royalties
Various
Nucorion
4.0%-9.0%
Various
Seelos
4.0%-10.0%
Ligand Licenses With Fixed Royalties*
Program
Licensee
Royalty Rate
Evomela
Spectrum Pharma
20%
Baxdela
Melinta
2.5%
SAGE-547
SAGE
3%
Sparsentan
Retrophin
9%
CE-Fosphenytoin
Sedor
11%
Pradefovir
Chiva Pharma
9%
MB07133
Chiva Pharma
6%
KLM465
Novartis
14.5% (6.5% in year one)
Topical lasofoxifene
Azure Biotech
5%
MM-121
Merrimack Pharma
<1.0%
MM-151
Merrimack Pharma
<1.0%
MM-141
Merrimack Pharma
<1.0%
ME-143
MEI Pharma
Low single digit royalty
ME-344
MEI Pharma
Low single digit royalty
ADX-102
Aldeyra Therapeutics
Low single digit royalty

*Royalty rates are shown net of sublicense payments. Royalty tier references for specific rates notated in the table are for up to and including the dollar amount referenced. Higher tiers are only applicable for the dollar ranges specified in the table.

Primary Internal Development Program - Glucagon Receptor Antagonist Program

We are currently developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. Compounds that block the action of glucagon may reduce the hyperglycemia that is characteristic of the disease. Glucagon stimulates the production of glucose by the liver and its release into the blood stream. In diabetic patients, glucagon secretion is abnormally elevated and contributes to hyperglycemia in these patients. We announced results in 2016 from two Phase I clinical trials which demonstrated favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus. The trial results also demonstrate a robust, dose-dependent reduction of fasting plasma glucose. We also initiated a Phase 2 clinical trial in September 2016 for the treatment of type 2 diabetes mellitus (T2DM). The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of LGD-6972, as an adjunct to diet and exercise, in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin.

14

The following table represents other internal programs eligible for further development funding, either through Ligand or a partner:
Program
 
Development Stage
 
Indication
CCR1 Antagonist
 
Preclinical
 
Oncology
CE-Busulfan
 
Preclinical
 
Oncology
CE-Cetirizine Injection
 
Preclinical
 
Allergy
CE-Clopidogrel
 
Phase 3
 
Anti-coagulant
CE-Sertraline, Oral Concentrate
 
Phase 1
 
Depression
CE-Silymarin for Topical Formulation
 
Preclinical
 
Sun damage
FLT3 Kinase Inhibitors
 
Preclinical
 
Oncology
GCSF Receptor Agonist
 
Preclinical
 
Blood disorders
Liver Specific Glucokinase Activator
 
Preclinical
 
Diabetes
Manufacturing
We currently have no manufacturing facilities and rely on a third party, Hovione, for Captisol production. Hovione is a global supplier with over 50 years of experience in the development and manufacture of APIs and Drug Product Intermediates. Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal. Manufacturing operations for Captisol are currently performed in both of Hovione's Portugal and Ireland sites with distribution operations also performed from Hovione's Portugal and Ireland sites.
We have ongoing minimum purchase commitments under the agreement and are required to pay Hovione an aggregate minimum amount during the agreement term.
In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione’s assistance, qualify one or more alternate suppliers. If the supply interruption continues beyond a designated period, we may terminate the agreement. In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event or if the unit price of Captisol exceeds a set figure, we may obtain Captisol from a third party.
The current term of the agreement with Hovione is through December 2019. The agreement will automatically renew for successive two year renewal terms unless either party gives written notice of its intention to terminate the agreement no less than two years prior to the expiration of the initial term or renewal term. In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event. We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events. For further discussion of these items, see below under “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Competition
Some of the drugs we and our licensees are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.
Existing or potential competitors to our licensee’s products, particularly large pharmaceutical companies, may have greater financial, technical and human resources than our licensees. Accordingly, these competitors may be better equipped to develop, manufacture and market products. Many of these companies also have extensive experience in preclinical testing and human clinical trials, obtaining FDA and other regulatory approvals and manufacturing and marketing pharmaceutical products.
Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs. Our OmniAb antibody technology faces competition from suppliers of other transgenic animal systems that are also available for antibody drug discovery.

15

Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes. For a discussion of the risks associated with competition, see below under “Item 1A. Risk Factors.”
Government Regulation
The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries.  We and our partners, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products and there are often comparable regulations that apply at the state level.  There are similar regulations in other countries as well. For both currently marketed and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. For a discussion of the risks associated with government regulations, see below under “Item 1A. Risk Factors.”
Patents and Proprietary Rights

We believe that patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.

Patents are issued or pending for the following key products or product families. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. The nominal patent expiration dates have been provided. The actual patent term may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers. For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.

Promacta

Patents covering Promacta are owned by Novartis. The United States patent listed in the FDA’s Orange Book relating to Promacta with the latest expiration date is not expected to expire until 2027. Six months of additional exclusivity has been granted due to pediatric studies conducted by GSK. The type of patent protection (e.g., composition of matter or use) for each patent listed in the Orange Book and the expiration date for each patent listed in the Orange Book are provided in the following table. In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.


16

Promacta
United States
Corresponding Foreign
Type of Protection
U.S. Patent No.
U.S. Expiration Date
Jurisdiction
Patent Number
Expiration Date‡
CoM / Use
6,280,959
10/30/2018
N/A
 
 
CoM / Use
7,160,870
11/20/2022
EU
1,864,981
5/24/2021
EU
1,294,378
5/24/2021
Japan
3,813,875
5/24/2021
Use
7,332,481
5/24/2021
EU
1,889,838
5/24/2021
Japan
4,546,919
5/24/2021
CoM / Use
7,452,874
5/24/2021
EU
1,889,838
5/24/2021
Japan
4,546,919
5/24/2021
CoM / Use
7,473,686
5/24/2021
EU
1,864,981
5/24/2021
EU
1,294,378
5/24/2021
Japan
3,813,875
5/24/2021
CoM / Use
7,547,719
7/13/2025
EU
1,534,390
5/21/2023
Japan
4,612,414
5/21/2023
Use
7,790,704
5/24/2021
N/A
 
 
Use
7,795,293
5/21/2023
N/A
 
 
CoM / Use
8,052,993
8/1/2027
EU
2,152,237
8/1/2027
Japan
5,419,866
8/1/2027
Japan
5,735,078
8/1/2027
CoM / Use
8,052,994
8/1/2027
EU
2,152,237
8/1/2027
Japan
5,419,866
8/1/2027
Japan
5,735,078
8/1/2027
CoM / Use
8,052,995
8/1/2027
EU
2,152,237
8/1/2027
Japan
5,419,866
8/1/2027
Japan
5,735,078
8/1/2027
CoM / Use
8,062,665
8/1/2027
EU
2,152,237
8/1/2027
Japan
5,419,866
8/1/2027
Japan
5,735,078
8/1/2027
CoM / Use
8,071,129
8/1/2027
EU
2,152,237
8/1/2027
Japan
5,419,866
8/1/2027
Japan
5,735,078
8/1/2027
CoM / Use
8,828,430
8/1/2027
EU
2,152,237
8/1/2027
Japan
5,419,866
8/1/2027
Japan
5,735,078
8/1/2027

‡Expiration dates of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.
Kyprolis
Patents protecting Kyprolis include those owned by Amgen and those owned by us. The United States patent listed in the Orange Book relating to Kyprolis with the latest expiration date is not expected to expire until 2029. Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033. The type of patent protection (e.g., composition of matter or use) for each patent listed in the Orange Book and the expiration dates for each patent listed in the Orange Book are provided in the following table. In addition, certain related patents in the commercially important jurisdictions of Europe and Japan are identified in the following table.


17

Kyprolis
United States
Corresponding Foreign
Type of Protection
U.S. Patent No.
U.S. Expiration Date
Jurisdiction
Patent Number
Expiration Date‡
CoM
7,232,818
4/14/2025
EU
1,745,064
4/14/2025
Japan
5,394,423
4/14/2025
CoM
7,417,042
7/20/2026
EU
1,781,688
8/8/2025
Japan
4,743,720
8/8/2025
Use
7,491,704
4/14/2025
EU
1,745,064
4/14/2025
Japan
5,394,423
4/14/2025
CoM
7,737,112
12/7/2027
EU
1,819,353
12/7/2025
EU
2,260,835
12/7/2025
EU
2,261,236
12/7/2025
Japan
4,990,155
12/7/2025
Japan
5,108,509
5/9/2025
Use
8,129,346
4/14/2025
EU
1,745,064
4/14/2025
Japan
5,394,423
4/14/2025
CoM
8,207,125
4/14/2025
EU
1,781,688
8/8/2025
Japan
4,743,720
8/8/2025
CoM / Use
8,207,126
4/14/2025
N/A
 
 
Use
8,207,127
4/14/2025
N/A
 
 
CoM / Use
8,207,297
4/14/2025
N/A
 
 
Use
9,511,109
10/21/2029
Japan
5,675,629
10/21/2029

‡Expiration dates of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.
Captisol
Patents and pending patent applications covering Captisol are owned by us. Other patents and pending patent applications covering methods of making Captisol are owned by Ligand or by Pfizer. The patents covering the Captisol product, if issued, with the latest expiration date would not be set to expire until 2033 (see, e.g., U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)). We also own several patents and pending patent applications covering drug products containing Captisol as a component. The type of patent protection (e.g., composition of matter or use) and the expiration dates for several issued patents covering Captisol are provided in the following table. In addition, certain related patents and applications in the commercially important jurisdictions of Europe and Japan are listed in the following table.


18

Captisol
United States
Corresponding Foreign
Type of Protection
U.S. Patent No.
U.S. Expiration Date
Jurisdiction
Patent Number
Expiration Date‡
CoM
8,114,438
3/19/2028
EU
2,708,225
pending
Japan
2015-163634
pending
CoM
7,629,331
10/26/2025
EU
1,945,228
10/26/2025
EU
2,335,707
10/26/2025
EU
2,581,078
10/26/2025
Use
8,049,003
12/19/2026
EU
2,583,668
10/26/2025
CoM
8,846,901
10/26/2025
EU
1,945,228
10/26/2025
EU
2,335,707
10/26/2025
EU
2,581,078
10/26/2025
CoM
8,829,182
10/26/2025
EU
1,945,228
10/26/2025
EU
2,335,707
10/26/2025
EU
2,581,078
10/26/2025
CoM / Use
7,635,773
3/13/2029
EU
2,268,269
pending
Japan
4,923,144
4/28/2029
Japan
6,039,721
4/28/2029
 
 
 
Japan
2016-216021
pending
CoM
8,410,077
3/13/2029
EU
2,268,269
pending
Japan
4,923,144
4/28/2029
Japan
6,039,721
4/28/2029
 
 
 
Japan
2016-216021
pending
CoM
9,200,088
3/13/2029
EU
2,268,269
pending
Japan
4,923,144
4/28/2029
Japan
6,039,721
4/28/2029
 
 
 
Japan
2016-216021
pending
CoM
9,493,582
2/27/2033
EU
2,748,205
pending
 
 
 
Japan
2016-166368
pending
‡ Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.
Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments. For a discussion of the risks associated with patent and proprietary rights, see below under “Item 1A. Risk Factors.”
OmniAb
Ligand has received patent protection in 27 countries, including the United States, multiple countries throughout Europe, Japan and China (see selected cases listed in the table below) and has 19 patent applications pending worldwide. The patents and applications owned by Ligand are expected to expire between 2028 and 2033 and partners are able to use the OMT patented technology to generate novel antibodies, which may be entitled to additional patent protection.



19

OmniAb
United States
Corresponding Foreign
Type of Protection
U.S. Patent No.
U.S. Expiration Date
Jurisdiction
Patent Number
Expiration Date‡
 
 
 
EU
2,152,880
5/30/2028
 
 
 
EU
2,336,329
5/30/2028
CoM
8,703,485
10/10/2031
Japan
5,823,690
5/30/2028
 
9,388,233
5/30/2028
N/A
 
 
Use
8,907,157
5/30/2028
N/A
 
 
CoM / Use
9,475,859
4/15/2034
N/A
 
 
‡ Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.
LTP Technology
Patent applications related to our LTP Technology include two families owned by Ligand and one owned by Omthera. Each of these patent families include claims directed to composition of matter and use. Patents resulting from these applications, if granted, would have a latest expiration date in 2036.
LGD-6972 (Glucagon Receptor Antagonist)
Patents and pending patent applications covering LGD-6972 are owned by Ligand. Patents covering LGD-6972, if issued, with the latest expiration date would not be set to expire until 2035 (see, e.g., WO 2015/191900 (contains composition of matter and use claims; filed June 11, 2015)). The type of patent protection (e.g., composition of matter or use) and the expiration dates for several issued patents covering LGD-6972 are provided in the following table. In addition, certain related patents and applications in the commercially important jurisdictions of Europe and Japan are listed in the following table.
LGD-6972
United States
Corresponding Foreign
Type of Protection
U.S. Patent No.
U.S. Expiration Date
Jurisdiction
Patent Number
Expiration Date‡
CoM
8,710,236
2/11/2028
EU
2,129,654
2/11/2028
EU
2,786,985
pending
Japan
5,322,951
2/11/2028
Japan
2015-196171
pending
CoM
9,169,201
2/11/2028
EU
2,129,654
2/11/2028
EU
2,786,985
pending
Japan
5,322,951
2/11/2028
Japan
2015-196171
pending
CoM / Use
8,907,103
1/2/2031
EU
2,326,618
8/13/2029
EU
2,799,428
8/13/2029
EU
n/a
pending
Japan
5,684,126
8/13/2029
Japan
2016-251460
pending
‡ Expiration date of European and Japanese patents are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account extensions that are or may be available in these jurisdictions.
Human Resources
As of February 6, 2016, we had 22 full-time employees, of whom eight are involved directly in scientific research and development activities.


20


Investor Information
Financial and other information about us is available on our website at www.ligand.com. We make available on our website copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and Exchange Commission (SEC). In addition, we have previously filed registration statements and other documents with the SEC. Any document we file may be inspected, at the SEC’s public reference room at 100 F Street NE, Washington, DC 20549, or at the SEC’s internet address at www.sec.gov. These website addresses are not intended to function as hyperlinks, and the information contained in our website and in the SEC’s website is not intended to be a part of this filing. Information related to the operation of the SEC’s public reference room may be obtained by calling the SEC at 800-SEC-0330.

ITEM 1A.
RISK FACTORS
The following is a summary description of some of the many risks we face in our business. You should carefully review these risks in evaluating our business, including the businesses of our subsidiaries. You should also consider the other information described in this report.

Future revenue based on Promacta, Kyprolis and Evomela, as well as sales of our other products, may be lower than expected.

Novartis is obligated to pay us royalties on its sales of Promacta, and we receive revenue from Amgen based on both sales of Kyprolis and purchases of Captisol material for clinical and commercial uses. These payments are expected to be a substantial portion of our ongoing revenues for some time. In addition, we receive revenues based on sales of Evomela and other products. Any setback that may occur with respect to any of our partners' products, and in particular Promacta or Kyprolis, could significantly impair our operating results and/or reduce our revenue and the market price of our stock. Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates. These products also are or may become subject to generic competition.

Future revenue from sales of Captisol material to our license partners may be lower than expected.

Revenues from sales of Captisol material to our collaborative partners represent a significant portion of our current revenues. Any setback that may occur with respect to Captisol could significantly impair our operating results and/or reduce the market price of our stock. Setbacks for Captisol could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products using Captisol.

If products or product candidates incorporating Captisol material were to cause any unexpected adverse events, the perception of Captisol safety could be seriously harmed. If this were to occur, we may not be able to sell Captisol unless and until we are able to demonstrate that the adverse event was unrelated to Captisol, which we may not be able to do. Further, the FDA could require us to submit additional information for regulatory review or approval, including data from extensive safety testing or clinical testing of products using Captisol. This would be expensive and it may delay the marketing of Captisol-enabled products and receipt of revenue related to those products, which could significantly impair our operating results and/or reduce the market price of our stock.

We obtain Captisol from a sole source supplier, and if this supplier were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source, which could potentially take a considerable length of time and impact our revenue and customer relationships. We maintain inventory of Captisol, which has a five year shelf life, at three geographically dispersed storage locations in the United States and Europe.  If we were to encounter problems maintaining our inventory, such as natural disasters, at one or more of these locations, it could lead to supply interruptions.

We currently depend on our arrangements with our partners and licensees to sell products using our Captisol technology. These agreements generally provide that our partners may terminate the agreements at will. If our partners discontinue sales of

21

products using Captisol, fail to obtain regulatory approval for products using Captisol, fail to satisfy their obligations under their agreements with us, or choose to utilize a generic form of Captisol should it become available, or if we are unable to establish new licensing and marketing relationships, our financial results and growth prospects would be materially affected. Furthermore, we maintain significant accounts receivable balances with certain customers purchasing Captisol materials, which may result in the concentration of credit risk. We generally do not require any collateral from our customers to secure payment of these accounts receivable. If any of our major customers were to default in the payment of their obligations to us, our business, operating results and cash flows could be adversely affected.

Further, under most of our Captisol outlicenses, the amount of royalties we receive will be reduced or will cease when the relevant patent expires. Our low-chloride patents and foreign equivalents are not expected to expire until 2033, our high purity patents and foreign equivalents, are not expected to expire until 2029 and our morphology patents and foreign equivalents, are not expected to expire until 2025, but the initially filed patents relating to Captisol expired starting in 2010 in the United States and in 2016 in most countries outside the United States. If our other intellectual property rights are not sufficient to prevent a generic form of Captisol from coming to market and if in such case our partners choose to terminate their agreements with us, our Captisol revenue may decrease significantly.

Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners’ intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve.

The manufacture, use or sale of our potential products or our licensees' products or potential products may infringe the patent rights of others. If others obtain patents with conflicting claims, we may be required to obtain licenses to those patents or to develop or obtain alternative technology. We may not be able to obtain any such licenses on acceptable terms, or at all. Any failure to obtain such licenses could delay or prevent us from pursuing the development or commercialization of our potential products.

Generally, our success will depend on our ability and the ability of our partners to obtain and maintain patents and other intellectual property rights for our and their potential products.  Our patent position is uncertain and involves complex legal and technical questions for which legal principles are unresolved.  Even if we or our partners do obtain patents, such patents may not adequately protect the technology we own or have licensed.  For example, in January 2016, we received a paragraph IV certification from a subsidiary of Par advising us that it had filed an ANDA with the FDA seeking approval to market a generic version of Merck’s NOXAFIL-IV product.  The paragraph IV certification alleges that Merck’s U.S. Patent No. 9,023,790 related to NOXAFIL-IV and our U.S. Patent No. 8,410,077 related to Captisol, which we refer to as the ‘077 Patent, are invalid and/or will not be infringed by Par’s manufacture, use or sale of the product for which the ANDA was submitted. Although Merck and Par settled this dispute, we could face similar disputes in the future which, if successful, could result in lost revenues or limit our ability to enter into new licenses using the challenged patent.
 
Any conflicts with the patent rights of others could significantly reduce the coverage of our patents or limit our ability to obtain meaningful patent protection. For example, our European patent related to Agglomerated forms of Captisol was limited during an opposition proceeding, and the rejection of our European patent application related to High Purity Captisol is currently being appealed. In addition, any determination that our patent rights are invalid may result in early termination of our agreements with our license partners and could adversely affect our ability to enter into new license agreements. We also rely on unpatented trade secrets and know-how to protect and maintain our competitive position. We require our employees, consultants, licensees and others to sign confidentiality agreements when they begin their relationship with us. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our competitors may independently discover our trade secrets.

We may also need to initiate litigation, which could be time-consuming and expensive, to enforce our proprietary rights or to determine the scope and validity of others' rights. If this occurs, a court may find our patents or those of our licensors invalid or may find that we have infringed on a competitor's rights. In addition, if any of our competitors have filed patent applications in the United States which claim technology we also have invented, the United States Patent and Trademark Office may require us to participate in expensive interference proceedings to determine who has the right to a patent for the technology.

The occurrence of any of the foregoing problems could be time-consuming and expensive and could adversely affect our financial position, liquidity and results of operations.


22

We rely heavily on licensee relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including milestone payments and future royalty revenues.

Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. Generally, our current collaborative partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all), our product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. For example, we are asserting our rights to receive payment against one of our collaborative partners which could harm our relationship with sch partner. Such disputes or litigation could adversely affect our rights to one or more of our product candidates and could delay, interrupt or terminate the collaborative research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. In addition, a significant downturn or deterioration in the business or financial condition of our collaborators or partners could result in a loss of expected revenue and our expected returns on investment. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.

Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue.

Before we or our partners obtain the approvals necessary to sell any of our unpartnered assets or partnered programs, we must show through preclinical studies and human testing that each potential product is safe and effective. We and/or our partners have a number of partnered programs and unpartnered assets moving toward or currently awaiting regulatory action. Failure to show any product's safety and effectiveness could delay or prevent regulatory approval of a product and could adversely affect our business. The drug development and clinical trials process is complex and uncertain. For example, the results of preclinical studies and initial clinical trials may not necessarily predict the results from later large-scale clinical trials. In addition, clinical trials may not demonstrate a product's safety and effectiveness to the satisfaction of the regulatory authorities. A number of companies have suffered significant setbacks in advanced clinical trials or in seeking regulatory approvals, despite promising results in earlier trials. The FDA may also require additional clinical trials after regulatory approvals are received. Such additional trials may be expensive and time-consuming, and failure to successfully conduct those trials could jeopardize continued commercialization of a product.

The speed at which we and our partners complete our scientific studies and clinical trials depends on many factors, including, but not limited to, our ability to obtain adequate supplies of the products to be tested and patient enrollment. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial and other potential drug candidates being studied. Delays in patient enrollment for our or our partners’ trials may result in increased costs and longer development times. In addition, our partners have rights to control product development and clinical programs for products developed under our collaborations. As a result, these partners may conduct these programs more slowly or in a different manner than expected. Moreover, even if clinical trials are completed, we or our partners still may not apply for FDA approval in a timely manner or the FDA still may not grant approval.

Our drug development programs may require substantial additional capital to complete successfully, arising from costs to: conduct research, preclinical testing and human studies; establish pilot scale and commercial scale manufacturing processes and facilities; and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support these programs. While we expect to fund our research and development activities from cash generated from operations to the extent possible, if we are unable to do so, we may need to complete additional equity or debt financings or seek other external means of financing. These financings could depress our stock price. If additional funds are required to support our operations and we are unable to obtain them on terms favorable to us, we may be required to cease or reduce further development or commercialization of our products, to sell some or all of our technology or assets or to merge with another entity.

Our OmniAb antibody platform faces specific risks, including the fact that no drug using antibodies from the platform has yet advanced to late stage clinical trials.

None of our collaboration partners using our OmniAb antibody platform have tested drugs based on the platform in clinical trials and, therefore, none of our OmniAb collaboration partners’ drugs have received FDA approval. If one of our OmniAb collaboration partners’ drug candidates fails during preclinical studies or clinical trials, our other OmniAb collaboration partners may decide to abandon drugs using antibodies generated from the OmniAb platform, whether or not

23

attributable to the platform. All of our OmniAb collaboration partners may terminate their programs at any time without penalty. In addition, our OmniRat and OmniFlic platforms, which we consider the most promising, are covered by two patents within the U.S. and two patents in the European Union and are subject to the same risks as our patent portfolio discussed above, including the risk that our patents may infringe on third party patent rights or that our patents may be invalidated. Further, we face significant competition from other companies selling human antibody-generating rodents, especially mice which compete with our OmniMouse platform, including the VelocImmune mouse, the AlivaMab mouse, the Trianni mouse and the Kymouse. Many of our competitors have greater financial, technical and human resources than we do and may be better equipped to develop, manufacture and market competing antibody platforms.

If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates.

As is common in our industry, our partners and we face an inherent risk of product liability as a result of the clinical testing of our product candidates in clinical trials and face an even greater risk for commercialized products. Although we are not currently a party to product liability litigation, if we are sued, we may be held liable if any product or product candidate we develop causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates or products that we may develop, injury to our reputation, discontinuation of clinical trials, costs to defend litigation, substantial monetary awards to clinical trial participants or patients, loss of revenue and the inability to commercialize any products that we develop. We have product liability insurance that covers our clinical trials up to a $10.0 million annual limit. If we are sued for any injury caused by our product candidates or any future products, our liability could exceed our total assets.

Any difficulties from strategic acquisitions could adversely affect our stock price, operating results and results of operations.

We may acquire companies, businesses and products that complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources and could prove to be more difficult or expensive than we predict. The diversion of our management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our on-going business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for stockholders or the incurrence of indebtedness.

As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result of unidentified risks, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.

In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired IPR&D charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods.

We have restated prior consolidated financial statements, which may lead to possible additional risks and uncertainties, including possible loss of investor confidence.

We have restated our consolidated financial statements as of and for the year ended December 31, 2015 (including the third quarter within that year) and for the first and second quarters of fiscal year 2016 in order to correct certain accounting errors. For a description of the material weaknesses in our internal control over financial reporting identified by management in

24

connection with the Restatement and management’s plan to remediate those material weaknesses, see “Part II, Item 9A - Controls and Procedures.”

As a result of the Restatement, we have become subject to possible additional costs and risks, including (a) accounting and legal fees incurred in connection with the Restatement and (b) a possible loss of investor confidence. Further, we are subject to a shareholder lawsuit related to the Restatement which may be costly to defend and divert our management's attention from other operating matters. See "Item 3. Legal Proceedings."
We have identified material weaknesses in our internal control over financial reporting that, if not remediated, could result in additional material misstatements in our financial statements.
As described in “Part II, Item 9A - Controls and Procedures,” management identified control deficiencies that represent material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. As a result of the identified material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting as of December 31, 2016. See “Part II, Item 9A - Controls and Procedures.”

We are developing and implementing a remediation plan to address the material weaknesses. If our remediation efforts are insufficient or if additional material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results, which could materially and adversely affect our business, results of operations and financial condition, restrict our ability to access the capital markets, require us to expend significant resources to correct the material weakness, subject us to fines, penalties or judgments, harm our reputation or otherwise cause a decline in investor confidence.

Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.

From time to time, the Financial Accounting Standards Board, or FASB, either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our results of operations. For example, in May 2014, FASB issued a new accounting standard for revenue recognition-Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or ASC 606-that supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. The new guidance becomes effective in fiscal 2018 and early adoption in fiscal 2017 is permitted.

We anticipate this standard will have a material impact on our consolidated financial statements by accelerating the timing of revenue recognition for revenues related to royalties, and potentially certain contingent milestone based payments. Our practice has been to book royalties one quarter after our partners report sales of the underlying product. Now, under ASC 606, Ligand will estimate and book royalties in the same quarter that our partners report the sale of the underlying product. As a result, we will book royalties one quarter earlier compared to our past practice. We will rely on our partners’ earning releases and other information from our partners to determine the sales of our partners’ products and to estimate the related royalty revenues. If our partners report incorrect sales, or if our partners delay reporting of their earnings release, our royalty estimates may need to be revised and/or our financial reporting may be delayed.

Any difficulties in implementing this guidance could cause us to fail to meet our financial reporting obligations, which could result in regulatory discipline and harm investors’ confidence in us. Finally, if we were to change our critical accounting estimates, including those related to the recognition of license revenue and other revenue sources, our operating results could be significantly affected.

Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.
As of December 31, 2016 we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $446.3 million and $140.5 million, respectively, which expire through 2036, if not utilized. As of December 31, 2016, we had federal and California research and development tax credit carryforwards of approximately $21.9 million and $19.4 million, respectively. The federal research and development tax credit carryforwards expire in various years through 2036, if not utilized. The California research and development credit will carry forward indefinitely. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (Code) if a corporation undergoes an “ownership change,” the corporation’s ability to use

25

its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an “ownership change” occurs if there is a cumulative change in our ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results.

We rely on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively.

Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. Despite the implementation of security measures, our internal computer systems and those of our partners are vulnerable to damage from cyber-attacks, computer viruses, security breaches, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, could lead to the loss of trade secrets or other intellectual property, could lead to the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our business and financial condition could be harmed.

The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits or we could lose key data which could cause us to curtail or cease operations.

We are vulnerable to damage and/or loss of vital data from natural disasters, such as earthquakes, tornadoes, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects.

We sold the 2019 Convertible Senior Notes, which may impact our financial results, result in the dilution of existing stockholders, and restrict our ability to take advantage of future opportunities.
    
In August of 2014, we sold $245.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2019, or the 2019 Convertible Senior Notes. We will be required to pay interest on the 2019 Convertible Senior Notes until they come due or are converted, and the payment of that interest will reduce our net income. The sale of the 2019 Convertible Senior Notes may also affect our earnings per share figures, as accounting procedures require that we include in our calculation of earnings per share the number of shares of our common stock into which the 2019 Convertible Senior Notes are convertible. The 2019 Convertible Senior Notes may be converted, under the conditions and at the premium specified in the 2019 Convertible Senior Notes, into cash and shares of our common stock, if any (subject to our right to pay cash in lieu of all or a portion of such shares). If shares of our common stock are issued to the holders of the 2019 Convertible Senior Notes upon conversion, there will be dilution to our shareholders equity. Upon the occurrence of certain circumstances, holders of the 2019 Convertible Senior Notes may require us to purchase all or a portion of their notes for cash, which may require the use of a substantial amount of cash. If such cash is not available, we may be required to sell other assets or enter into alternate financing arrangements at terms that may or may not be desirable. The existence of the 2019 Convertible Senior Notes and the obligations that we incurred by issuing them may restrict our ability to take advantage of certain future opportunities, such as engaging in future debt or equity financing activities.

Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.

The total purchase price pertaining to our acquisitions in recent years of CyDex, Metabasis, Pharmacopeia, Neurogen and OMT have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we

26

will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.

Our charter documents and concentration of ownership may hinder or prevent change of control transactions.

Provisions contained in our certificate of incorporation and bylaws may discourage transactions involving an actual or potential change in our ownership. In addition, our Board of Directors may issue shares of common or preferred stock without any further action by the stockholders. Our directors and certain of our institutional investors collectively beneficially own a significant portion of our outstanding common stock. Such provisions and issuances may have the effect of delaying or preventing a change in our ownership. If changes in our ownership are discouraged, delayed or prevented, it would be more difficult for our current Board of Directors to be removed and replaced, even if you or our other stockholders believe that such actions are in the best interests of us and our stockholders.

We may be subject to prosecution for violation of federal law due to our agreement with Vireo Health, which is developing drugs using cannabis.

In November 2015, we entered into a license agreement and supply agreement with Vireo Health granting Vireo Health an exclusive right in certain states within the United States and certain global territories to use Captisol in Vireo’s development and commercialization of pharmaceutical-grade cannabinoid-based products. However, state laws legalizing medical cannabis use are in conflict with the Federal Controlled Substances Act, which classifies cannabis as a schedule-I controlled substance and makes cannabis use and possession illegal on a national level. The United States Supreme Court has ruled that it is the Federal government that has the right to regulate and criminalize cannabis, even for medical purposes, and thus Federal law criminalizing the use of cannabis preempts state laws that legalize its use. While the Obama administration effectively stated that it is not an efficient use of resources to direct Federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational cannabis, the Trump administration has indicated that it will reconsider such policy and practice, especially with respect to recreational cannabis. Further, even if the Trump administration affirms the same approach with respect to medical or recreational cannabis initially, there is no guarantee that such policy and practice will not change regarding the low-priority enforcement of Federal laws in states where cannabis has been legalized. Any such change in the Federal government’s enforcement of Federal laws could result in Ligand, as the supplier of Captisol, to be charged with violations of Federal laws which may result in significant legal expenses and substantial penalties and fines.

Our stock price has been volatile and could experience a sudden decline in value.

The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has recently experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Continued volatility in the overall capital markets could reduce the market price of our common stock in spite of our operating performance. Further, high stock price volatility could result in higher stock-based compensation expense.

Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future. Many factors may have a significant impact on the market price of our common stock, including, but not limited to, the following factors: results of or delays in our preclinical studies and clinical trials; the success of our collaboration agreements; publicity regarding actual or potential medical results relating to products under development by us or others; announcements of technological innovations or new commercial products by us or others; developments in patent or other proprietary rights by us or others; comments or opinions by securities analysts or major stockholders; future sales of our common stock by existing stockholders; regulatory developments or changes in regulatory guidance; litigation or threats of litigation; economic and other external factors or other disaster or crises; the departure of any of our officers, directors or key employees; period-to-period fluctuations in financial results; and price and volume fluctuations in the overall stock market.

Our results of operations and liquidity needs could be materially negatively affected by market fluctuations and economic downturn.

Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Continuing concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, and the U.S. financial markets have contributed to increased volatility and diminished expectations for the economy and the markets going forward. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if

27

necessary, and our stock price may further decline. We cannot provide assurance that our investments are not subject to adverse changes in market value. If our investments experience adverse changes in market value, we may have less capital to fund our operations.

Item 1B.
Unresolved Staff Comments
None.
 
Item 2.
Properties
We currently lease premises consisting of approximately 5,000 square feet of office space in San Diego which serves as our corporate headquarters. The lease expires in May 2023.
We lease approximately 1,500 square feet of laboratory space located at the Bioscience and Technology Business Center in Lawrence, Kansas, leased through December 2017.

Item 3.
Legal Proceedings

From time to time we are subject to various lawsuits and claims with respect to matters arising out of the normal course of our business.  Due to the uncertainty of the ultimate outcome of these matters, the impact on future financial results is not subject to reasonable estimates.

Paragraph IV Certification by Par Pharmaceuticals

On January 7, 2016, the Company received a paragraph IV certification from Par Sterile Products, LLC, a subsidiary of Par Pharmaceuticals, Inc., or Par, advising us that it had filed an ANDA with the FDA seeking approval to market a generic version of Merck’s NOXAFIL-IV product. On February 19, 2016, Merck filed an action against Par in the United States District Court for the District of New Jersey, asserting that Par's manufacture, use or sale of the product for which the ANDA was submitted would infringe Merck's U.S. Patent No. 9,023,790. On October 31, 2016, the parties to the lawsuit entered into a consent judgment dismissing all claims, counterclaims, affirmative defenses and demands. The parties have reported to the court that they entered into a confidential settlement agreement, and that they submitted the agreement to the Federal Trade Commission and the United States Department of Justice pursuant to Section 112(a) of the Medicare Prescription Drug, Improvement and Modernization Act of 2003. 

Class Action Lawsuit

In November 2016, a putative shareholder class action lawsuit was filed in the United States District Court for the Southern District of California against the Company, its chief executive officer and chief financial officer. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder, and seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company’s securities between November 9, 2015 and November 14, 2016, inclusive. The complaint’s allegations relate generally to the Company’s November 2016 restatement of certain prior period financial statements.  In January 2017, a purported Company shareholder filed a motion for appointment of lead counsel and lead plaintiff. The motion is scheduled to be heard by the court in March 2017. No trial date has been set. The Company believes that the lawsuit is without merit and intends to vigorously defend against the lawsuit.
Securities Litigation

In 2012, a federal securities class action and shareholder derivative lawsuit was filed in Pennsylvania alleging that the Company and its chief executive officer assisted various breaches of fiduciary duties based on our purchase of a licensing interest in a development-stage pharmaceutical program from the Genaera Liquidating Trust in 2010 and our subsequent sale of half of our interest in the transaction to Biotechnology Value Fund, Inc.  The district court granted our motion to dismiss an amended complaint on November 11, 2015 and the plaintiff has appealed that ruling to the U.S. Third Circuit Court of Appeals.  The Company intends to continue to vigorously defend against the claims against the Company and its chief executive officer.  The outcome of the matter is not presently determinable.


28


Item 4.
Mine Safety Disclosures
Not applicable.
PART II
 
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
Market Information
Our common stock is traded on the NASDAQ Global Market under the symbol “LGND.”
The following table sets forth the high and low intraday sales prices for our common stock on the NASDAQ Global Market for the periods indicated:
 
 
Price Range
 
Low
 
High
Year Ended December 31, 2016:
 
 
 
1st Quarter
$
82.06

 
$
108.79

2nd Quarter
95.05

 
131.84

3rd Quarter
97.22

 
139.79

4th Quarter
87.50

 
110.83

Year Ended December 31, 2015:
 
 
 
1st Quarter
$
51.54

 
$
77.11

2nd Quarter
75.67

 
100.90

3rd Quarter
82.10

 
111.25

4th Quarter
84.46

 
111.85

As of February 15, 2017, the closing price of our common stock on the NASDAQ Global Market was $104.28
Holders
As of February 15, 2017, there were approximately 576 holders of record of the common stock.

Purchases of Equity Securities By the Issuer and Affiliated Purchasers

The following table presents information regarding repurchases by us of our common stock during the three months ended December 31, 2016 under the stock repurchase program approved by our board of directors in September 2015, under which we may acquire up to $200 million of our common stock in open market and negotiated purchases for a period of up to three years.

ISSUER PURCHASES OF EQUITY SECURITIES

 
  
Total Number of
Shares Purchased
 
Average Price Paid
Per Share
 
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
 
Maximum Dollar Value of
Shares that May Yet Be
Purchased Under the
Program (in thousands)
October 1 - October 31, 2016
 
15,000

 
$
93.91

 
15,000

 
$
196,548

November 1 - November 30, 2016
 
10,000

 
$
93.83

 
10,000

 
$
195,610

December 1 - December 31, 2016
 
—

 
$
—

 
—

 
$
195,610

Total
  
25,000

 
$
93.88

 
25,000

 
$
195,610

 
Performance Graph

29

The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalizations. The graph compares total stockholder returns of our common stock, of all companies traded on the NASDAQ Stock market, as represented by the NASDAQ Composite® Index, and of the NASDAQ Biotechnology Stock Index, as prepared by The NASDAQ Stock Market Inc. The NASDAQ Biotechnology Stock Index tracks approximately 181 domestic biotechnology stocks.
The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions as to future stockholder returns.
stockperformancegraphv3.jpg
 
 
12/31/2012
 
12/31/2013
 
12/31/2014
 
12/31/2015
 
12/31/2016
Ligand
 
75
%
 
154
%
 
1
%
 
104
%
 
(6
)%
NASDAQ Market (U.S. Companies) Index
 
17
%
 
40
%
 
15
%
 
7
%
 
9
 %
NASDAQ Biotechnology Stocks
 
33
%
 
66
%
 
34
%
 
12
%
 
(21
)%



30

Item 6.
Selected Consolidated Financial Data
The following selected historical consolidated financial and other data are qualified by reference to, and should be read in conjunction with, our consolidated financial statements and the related notes thereto appearing elsewhere herein and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our selected statement of operations data set forth below for each of the years ended December 31, 2016, 2015, 2014, 2013, and 2012 and the balance sheet data as of December 31, 2016, 2015, 2014, 2013 and 2012 are derived from our consolidated financial statements.
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
2013
 
2012
Consolidated Statements of Operations Data:
(in thousands)
Royalties
$
59,423

 
$
38,194

 
$
29,994

 
$
23,584

 
$
14,073

Material sales
22,502

 
27,662

 
28,488

 
19,072

 
9,432

License fees, milestones, and other revenues
27,048

 
6,058

 
6,056

 
6,317

 
7,883

     Total revenues
108,973

 
71,914

 
64,538

 
48,973

 
31,388

Cost of sales
5,571

 
5,807

 
9,136

 
3,357

 
1,226

Intangible Amortization
10,643

 
2,375

 
2,375

 
2,375

 
2,375

Research and development expenses
21,221

 
11,005

 
9,747

 
9,274

 
10,790

General and administrative expenses
26,621

 
24,378

 
22,570

 
17,984

 
15,782

Lease exit and termination costs
1,032

 
1,020

 
1,084

 
560

 
1,022

Write-off of acquired IPR&D
—

 
—

 
—

 
480

 
—

     Total operating costs and expenses
65,088

 
44,585

 
44,912

 
34,030

 
31,195

Income (loss) from operations
43,885

 
27,329

 
19,626

 
14,943

 
193

Income (loss) from continuing operations including noncontrolling interests
(2,367
)
 
227,444

 
10,892

 
8,832

 
(2,674
)
Loss attributable to noncontrolling interests
—

 
(2,380
)
 
(1,132
)
 
—

 
—

Income (loss) from continuing operations
(2,367
)
 
229,824

 
12,024

 
8,832

 
(2,674
)
Discontinued operations (1)
731

 
—

 
—

 
2,588

 
2,147

Net income (loss)
(1,636
)
 
229,824

 
12,024

 
11,420

 
(527
)
Basic per share amounts:
 
 
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.11
)

$
11.61

 
$
0.59

 
$
0.43

 
$
(0.14
)
Discontinued operations (1)
0.04

 
—

 
—

 
0.13

 
0.11

Net income (loss)
$
(0.08
)
 
$
11.61

 
$
0.59

 
$
0.56

 
$
(0.03
)
Weighted average number of common shares-basic
20,831

 
19,790

 
20,419

 
20,312

 
19,853

Diluted per share amounts:
 
 
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.11
)

$
10.83

 
$
0.56

 
$
0.43

 
$
(0.14
)
Discontinued operations (1)
0.04


—

 
—

 
0.12

 
0.11

Net income (loss)
$
(0.08
)
 
$
10.83

 
$
0.56

 
$
0.55

 
$
(0.03
)
Weighted average number of common shares-diluted
20,831

 
21,228

 
21,433

 
20,745

 
19,853

(1) We sold our Oncology product line (“Oncology”) on October 25, 2006.


31

 
 
 
December 31,
 
2016
 
2015
 
2014
 
2013
 
2012
 
(in thousands)
Consolidated Balance Sheet Data:
 
 
 
 
 
 
 
 
 
Cash, cash equivalents, short-term investments, restricted cash and investments
$
149,393

 
$
229,947

 
$
168,597

 
$
17,320

 
$
15,148

Working capital (deficit)
(64,076
)
 
(8,109
)
 
162,379

 
(4,058
)
 
(11,616
)
Total assets
601,585

 
503,061

 
258,029

 
104,713

 
104,260

Long-term obligations (excludes long-term portions of deferred revenue, net and deferred gain)
3,603

 
3,330

 
208,757

 
24,076

 
39,967

Accumulated deficit
(431,127
)
 
(429,491
)
 
(659,315
)
 
(671,339
)
 
(682,759
)
Total stockholders’ equity
341,290

 
237,282

 
26,318

 
49,613

 
26,485


Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations

Revenue
(Dollars in thousands)
2016
 
2015
 
Change
 
% Change
 
2014
 
Change
 
% Change
Royalty Revenue
$
59,423

 
$
38,194

 
$
21,229

 
56
 %
 
$
29,994

 
$
8,200

 
27
 %
Material Sales
22,502

 
27,662

 
(5,160
)
 
(19
)%
 
28,488

 
(826
)
 
(3
)%
License fees, milestones and other revenue
27,048

 
6,058

 
20,990

 
346
 %
 
6,056

 
2

 
—
 %
Total revenue
$
108,973

 
$
71,914

 
$
37,059

 
52
 %
 
$
64,538

 
$
7,376

 
11
 %

Total revenue for 2016 increased $37.1 million or 52% compared with 2015 and for 2015 it increased $7.4 million or 11% compared with 2014. Royalty revenue increased year over year in 2016 and 2015 primarily due to an increase in Promacta and Kyprolis royalties. Material sales decreased year over year in 2016 and 2015 due to timing of customer purchases of Captisol for use in clinical trials and in commercialized products. The increase in license fee, milestones and other revenues in 2016 compared to 2015 is primarily due to OMT license fees and a milestone payment received from Spectrum as a result of the FDA approval of Evomela.

The following table represents royalty revenue by program (in thousands):
 
Year ended December 31,
 
2016
 
2015
 
2014
Promacta / Revolade
$
43,043

 
$
29,295

 
$
23,300

Kyprolis
12,145

 
7,317

 
4,558

Third Largest Royalty
1,357

 
390

 
1,244

Other Royalties
2,878

 
1,192

 
892

     Total
$
59,423

 
$
38,194

 
$
29,994


The following table represents material sales by clinical and commercial use (in thousands):
 
Year ended December 31,
 
2016
 
2015
 
2014
Clinical material sales
$
9,325

 
$
10,049

 
$
13,798

Commercial material sales
13,177

 
17,613

 
14,690

     Total
$
22,502

 
$
27,662

 
$
28,488


32



Operating Costs and Expenses
(Dollars in thousands)
2016
 
2015
 
Change
 
% Change
 
2014
 
Change
 
% Change
Cost of sales
$
5,571

 
$
5,807

 
$
(236
)
 
(4
)%
 
$
9,136

 
$
(3,329
)
 
(36
)%
Amortization of intangibles
10,643

 
2,375

 
8,268

 
348
 %
 
2,375

 
—

 
—
 %
Research and development
21,221

 
11,005

 
10,216

 
93
 %
 
9,747

 
1,258

 
13
 %
General and administrative
26,621

 
24,378

 
2,243

 
9
 %
 
22,570

 
1,808

 
8
 %
Lease exit and termination costs
1,032

 
1,020

 
12

 
1
 %
 
1,084

 
(64
)
 
(6
)%
Total operating costs and expenses
$
65,088

 
$
44,585

 
$
20,503

 
46
 %
 
$
44,912

 
$
(327
)
 
(1
)%

Total operating costs and expenses for 2016 increased $20.5 million or 46% compared with 2015. Cost of sales decreased year over year in 2016 and 2015 primarily due to lower material sales as a result of timing of customer purchases. Amortization of intangibles increased in 2016 compared with 2015 due to the acquisition of OMT and the corresponding amortization of intangible assets. Research and development expenses and general and administrative expenses increased year over year in 2016 and 2015 due primarily to expenses associated with OMT which we acquired in January 2016 and increases in stock-based compensation expense, business development activities, headcount related expenses and timing of internal development costs.

We are developing several proprietary products. Our programs represent a range of future licensing opportunities to expand our partnered asset portfolio. Our development focus for the year ended December 31, 2016, 2015, and 2014 has been LGD-6972, our novel glucagon receptor antagonist program. We completed a Phase 1b trial in 2015 and initiated a Phase 2 trial in 2016.

We do not provide forward-looking estimates of costs and time to complete our ongoing research and development projects as such estimates would involve a high degree of uncertainty. Uncertainties include our inability to predict the outcome of research and clinical studies, regulatory requirements placed upon us by regulatory authorities such as the FDA and EMA, our inability to predict the decisions of our partners, our ability to fund research and development programs, competition from other entities of which we may become aware in future periods, predictions of market potential for products that may be derived from our work, and our ability to recruit and retain personnel or third-party contractors with the necessary knowledge and skills to perform certain research. Refer to “Item 1A. Risk Factors” for additional discussion of the uncertainties surrounding our research and development initiatives.

Other (expense) income
(Dollars in thousands)
2016
 
2015
 
Change
 
% Change
 
2014
 
Change
 
% Change
Interest expense, net
$
(12,178
)
 
$
(11,802
)
 
$
(376
)
 
3
 %
 
$
(4,860
)
 
$
(6,942
)
 
143
 %
Increase in contingent liabilities
(3,334
)
 
(5,013
)
 
1,679

 
(33
)%
 
(5,135
)
 
122

 
(2
)%
Gain on deconsolidation of Viking
—

 
28,190

 
(28,190
)
 
(100
)%
 
—

 
28,190

 
—
 %
Loss from Viking
(23,132
)
 
(5,143
)
 
(17,989
)
 
350
 %
 
—

 
(5,143
)
 
—
 %
Other income, net
2,719

 
1,768

 
951

 
54
 %
 
1,671

 
97

 
6
 %
Total other (expense) income
$
(35,925
)
 
$
8,000

 
$
(43,925
)
 
(549
)%
 
$
(8,324
)
 
$
16,324

 
(196
)%

The year over year increase in interest expense in 2016 and 2015 is due to interest expense related to the 2019 Convertible Senior Notes partially offset by interest income. The year over year increase in contingent liabilities in 2016 and 2015 is due to an increase in the fair value of CyDex and Metabasis related contingent liabilities. We recorded a gain on deconsolidation of Viking in 2015, primarily related to the equity milestone received from Viking upon the close of the Viking

33

IPO. We recorded a loss from Viking in 2016 for our proportionate share of Viking’s losses based on our ownership of Viking common stock and $10.7 million for loss on dilution resulting from Viking's financing. The 2016 year over year increase in loss from Viking is primarily due to an impairment charge of $7.4 million recorded in the fourth quarter of 2016, an increase in Viking's research and development activities as well as a full year of absorbed losses in 2016 versus 2015 which was a partial year as the Company began accounting for Viking under the equity method in May of 2015. The increase in other income in 2016 compared to 2015 is primarily due to the gain on the sale of short-term investments.

Income tax benefit (expense)
(Dollars in thousands)
2016
 
2015
 
Change
 
% Change
 
2014
 
Change
 
% Change
Income before income tax (benefit) expense
$
7,960

 
$
35,329

 
$
(27,369
)
 
(77
)%
 
$
11,302

 
$
24,027

 
213
 %
Income tax benefit (expense)
(10,327
)
 
192,115

 
(202,442
)
 
(105
)%
 
(410
)
 
192,525

 
(46,957
)%
Income from operations
$
(2,367
)
 
$
227,444

 
$
(229,811
)
 
(101
)%
 
$
10,892

 
$
216,552

 
1,988
 %
Effective Tax Rate
130
%
 
(544
)%
 
 
 
 
 
4
%
 
 
 
 


Our effective tax rate for 2016, 2015 and 2014 was 129.7% , (543.8)% , and 3.6% , respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions, which we expect to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. In addition to state income taxes, the following had the most significant impact on the difference between our statutory U.S. income tax rate (35% in 2016 and 2015 and 34% in 2014) and our effective tax rate:

2016

•
$6.3 million (79%) increase in valuation allowance primarily relating to Viking deferred tax asset
•
$1.4 million (18%) increase in uncertain tax positions
•
$1.2 million (15%) increase from non cash contingent liability charges that are nondeductible for tax purposes
•
$1.5 million (19%) reduction from R&D credits

2015

•
$231.4 million (655%) reduction from the valuation allowance release against a significant portion of our deferred tax assets. The tax benefit is primarily comprised of U.S. federal and state net operating loss carryforwards, R&D tax credits, and other temporary differences
•
$5.8 million (16%) reduction from rate changes due to changes in state law
•
$2.1 million (6%) reduction from adjustments relating to the discontinuation of the Avinza product line
•
$27.2 million (77%) increase in uncertain tax positions
•
$3.3 million (9%) increase in deferred tax assets from completion of 382 analysis
•
$1.7 million (5%) increase from non cash CVR and contingent liability charges that are nondeductible for tax purposes

2014

•
$7.2 million (64%) reduction due to release of valuation allowance against a portion of our deferred tax assets.
•
$1.7 million (15%) increase from non cash contingent liability charges that are nondeductible for tax purposes
•
$0.7 million (6%) increase from state taxes net of federal benefit
•
$0.6 million (4%) increase from nondeductible stock based and executive compensation



34


Discontinued operations, net

In 2006, we entered into a purchase agreement with Eisai pursuant to which Eisai agreed to acquire our Oncology product line which included four marketed oncology drugs: ONTAK, Targretin capsules, Targretin gel and Panretin gel. Certain liabilities were recorded associated with the disposal of the product line. During the year ended December 31, 2016 we recognized a $1.1 million gain due to subsequent changes in certain estimates and liabilities previously recorded. We recorded a provision for income taxes related to the gain of $0.4 million.
    
Net loss attributable to noncontrolling interests

We recorded $2.4 million as a net loss attributable to noncontrolling interests for the year ended December 31, 2015 compared with $1.1 million for the year ended December 31, 2014. The net loss attributable to noncontrolling interests was recorded as a result of our determination that prior to Viking's IPO we held a variable interest in Viking. We recorded 100% of the losses incurred from May 21, 2014 through deconsolidation of Viking, as net loss attributable to noncontrolling interest due to the fact that we were considered the primary beneficiary with no equity interest in the variable interest entity.

Liquidity and Capital Resources
We have financed our operations through offerings of our equity securities, borrowings from long-term debt, issuance of convertible notes, product sales and the subsequent sales of our commercial assets, royalties, license fees, milestones and other revenues, capital and operating lease transactions.

We had net loss of $1.6 million for the year ended December 31, 2016. At December 31, 2016, our accumulated deficit was $431.1 million and we had a working capital deficit of $64.1 million. We believe that our currently available funds, cash generated from operations as well as existing sources of and access to financing will be sufficient to fund our anticipated operating, capital requirements and debt service requirement. We expect to build cash in the future as we continue to generate significant cash flow from royalty, license and milestone revenue and Captisol material sales primarily driven by continued increases in Promacta and Kyprolis sales, recent product approvals and regulatory developments, as well as revenue from anticipated new licenses and milestones. In addition, we anticipate that our liquidity needs can be met through other sources, including sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets.

Investments

We invest our excess cash principally in U.S. government debt securities, investment-grade corporate debt securities and certificates of deposit. We have established guidelines relative to diversification and maturities of our investments in order to provide both safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. Additionally, we own certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 6.3 million shares in Viking.     

Borrowings and Other Liabilities

2019 Convertible Senior Notes
    
We have convertible debt outstanding as of December 31, 2016 related to our 2019 Convertible Senior Notes. In August 2014, we issued $245.0 million aggregate principal amount of convertible senior unsecured notes. The Notes are convertible into common stock upon satisfaction of certain conditions. Interest of 0.75% per year is payable semi-annually on August 15th and February 15th through the maturity of the notes in August 2019.

Upon the occurrence of certain circumstances, holders of the 2019 Convertible Senior Notes may redeem all or a portion of their notes, which may require the use of a substantial amount of cash. At December 31, 2016, we had a working capital deficit of $64.1 million, which includes the 2019 Convertible Senior notes that are currently redeemable as of December 31, 2016 but excludes another $30.0 million that is classified as mezzanine equity.  As noted in Note 6, the debt may change from current to non-current period over period, primarily as a result of changes in the Company’s stock price. Management believes that it is remote that holders of the notes would choose to convert their notes early because the fair value of the security that a noteholder can currently realize in an active market is greater than the conversion value the noteholder would realize upon early conversion. In the unlikely event that all the debt was converted, we have 3 business days following a

35

50 trading day observation period from the convert date to pay the principal in cash. We have positive operating income and positive cash flow from operations for the three years ended December 31, 2016 and, accordingly, while there can be no assurance, we believe we have the ability to raise additional capital through our active S-3, by liquidating assets, or via alternative financing arrangements such as convertible or high yield debt.

Repurchases of Common Stock

During the year ended December 31, 2016, we repurchased 40,500 common shares at a weighted average price of $96.90 per share, pursuant to the repurchase plan, or approximately $3.9 million of common shares.

During the year ended December 31, 2015, we repurchased 6,120 common shares at a weighted average price of $79.92 per share, pursuant to the repurchase plan, or approximately 0.5 million of common shares.

Contingent Liabilities

CyDex

In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. We pay CyDex shareholders, through 2016, 20% of all CyDex-related revenue, but only to the extent that, and beginning only when, CyDex-related revenue for the year exceeds $15.0 million; plus an additional 10% of all CyDex-related revenue recognized during such year, but only to the extent, and beginning only when aggregate CyDex-related revenue for such year exceeds $35.0 million. See footnote 7, Balance Sheet Account Details.
 

Metabasis

In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones. See footnote 7, Balance Sheet Account Details.
Leases and Off-Balance Sheet Arrangements

We lease our office facilities under operating lease arrangements with varying terms through April 2023. The agreements provide for increases in annual rents based on changes in the Consumer Price Index or fixed percentage increases of 3.0%. We had no off-balance sheet arrangements at December 31, 2016, 2015 and 2014.
Contractual Obligations
As of December 31, 2016, future minimum payments due under our contractual obligations are as follows (in thousands):
 
 
Payments Due by Period
 
Total
 
Less than 1 year
 
1-2 years
 
3-4 years
 
Thereafter
Purchase obligations (1)
$
61

 
$
36

 
$
25

 
$
—

 
$
—

Contingent liabilities (2)
$
4,977

 
$
4,977

 
$
—

 
$
—

 
$
—

Note and interest payment obligations
$
249,747

 
$
1,838

 
$
247,909

 
$
—

 
$
—

Operating lease obligations (3)
$
2,758

 
$
900

 
$
1,378

 
$
283

 
$
197


(1)
Purchase obligations represent our commitments under our supply agreement with Hovione for Captisol purchases.
(2)
Contingent liabilities to former shareholders and licenseholders are subjective and affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones and affect amounts owed to former license holders and CVR holders. As of December 31, 2016, only those liabilities for revenue sharing payments and milestones achieved as a result of 2016 activities are included in the table above.

36

(3)
We lease an office and research facility, which we have fully vacated under operating lease arrangements expiring on June 2019. We sublet these facilities through the end of our lease. As of December 31, 2016, we expect to receive aggregate future minimum lease payments totaling $1.7 million (non-discounted) over the duration of the sublease agreement as follows and not included in the table above: less than a year $0.7 million and two to three years $1.0 million.
    
Cash Flow Summary
(in thousands)
 
2016
 
2015
 
2014
Net cash provided by operating activities
 
$
63,001

 
$
41,727

 
$
20,566

Net cash used in investing activities
 
(143,192
)
 
(112,862
)
 
(2,027
)
Net cash provided by financing activities
 
1,515

 
8,360

 
130,025

Net increase (decrease) in cash and cash equivalents
 
$
(78,676
)
 
$
(62,775
)
 
$
148,564



Operating Activities
Net cash provided by operating activities in 2016 consisted of net loss of $1.6 million plus net adjustments of $76.0 million partially offset by net changes in net operating assets and liabilities of $10.6 million. The primary non-cash expenses added back to net income included share-based compensation of $18.9 million, loss on equity investment in Viking of $23.1 million, depreciation and amortization of $11.3 million and amortization of debt discount and issuance fees of $10.9 million. Cash flow impact from changes in net operating assets included increases in accounts receivable and inventory, partially offset by increases in accounts payable and accrued liabilities.
Net cash provided by operating activities in 2015 consisted of net income of $227.4 million minus net adjustments of$186.5 million. The primary non-cash items subtracted from net income included $192.1 million income tax benefit from the release of our valuation allowance, a $28.2 million gain on deconsolidation of Viking, and a $2.6 million gain on the sale of investments. The primary non-cash expenses added back to net income included share-based compensation of $12.5 million, amortization of debt discount and issuance fees of $10.3 million, change in estimated value of contingent liabilities of $5.0 million and $5.1 million loss on equity investment of Viking.

Net cash provided by operating activities in 2014 consisted of net income of $10.9 million plus net adjustments of $20.6 million partially offset by net changes in net operating assets and liabilities of $10.9 million. The primary non-cash expenses added back to net income included stock-based compensation of $11.3 million, change in estimated value of contingent liabilities of $5.1 million, amortization of debt discount and issuance fees of $3.7 million, depreciation and amortization of $2.7 million. Cash flow impact from changes in net operating assets included increases in accounts receivable, an increase in other assets and a decrease in accounts payable and accrued liabilities, partially offset by decrease in inventory.

Investing Activities
In 2016 we purchased $164.4 million of short term investments and $143.5 million of our short term investments matured or were sold during the period. We also paid net cash of $92.5 million for acquisitions, $17.7 million for commercial license rights, $8.8 million to CyDex CVR holders and other contingency payments, $1.9 million for capital expenditures, and $0.7 million for Viking common stock.

In 2015 we purchased $166.0 million of short term investments and $73.2 million of our short terms investments matured or were sold during the period. We also paid cash of $9.0 million to purchase Viking common stock, $6.7 million to CyDex CVR holders and other contingency payments and $4.0 million for purchase of commercial license rights.
In 2014 we received $2.3 million in proceeds from the sale of short term investments and we paid cash of $3.5 million to CyDex CVR holders and other contingency payments and $1.0 million for commercial license rights.
Financing Activities

Cash provided by financing activities in 2016 primarily reflects the $6.4 million of proceeds received from stock option exercises and our employee stock purchase plan, partially offset by payment for share repurchases of $3.9 million.


37

Cash provided by financing activities in 2015 primarily reflects the $8.8 million of proceeds received from stock option exercises and our employee stock purchase plan, partially offset by payment for share repurchases of $0.5 million.

Cash provided by financing activities in 2014 primarily reflects the gross proceeds received from the issuance of an aggregate $245.0 million of the 2019 Convertible Senior Notes, proceeds from issuance of warrants of $11.6 million, and $4.6 million of proceeds received from stock option exercises and our employee stock purchase plan, partially offset by repayment of debt of $9.4 million, purchase of convertible bond hedge of $48.1 million, payment for share repurchases of $68.0 million and payment of debt issuance costs of $5.7 million.

Critical Accounting Policies
Certain of our policies require the application of management judgment in making estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes. Those estimates and assumptions are based on historical experience and various other factors deemed to be applicable and reasonable under the circumstances. The use of judgment in determining such estimates and assumptions is by nature, subject to a degree of uncertainty. Accordingly, actual results could differ materially from the estimates made. Our critical accounting policies are as follows:

Revenue Recognition

We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been provided, title has transferred or access has been given, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured.
    
Royalties on sales of products commercialized by our partners are recognized in the quarter reported by the respective partner. Generally, we receive royalty reports from our licensees approximately one quarter in arrears due to the fact that our agreements require partners to report product sales between 30-60 days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received.
Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a 20% restocking fee. To date, product returns by customers have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period.
Many of the Company's revenue arrangements for Captisol involve a license agreement with the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. The Company evaluates the deliverables in these agreements to determine whether they have stand-alone value to our customers and therefore meet the criteria to be accounted for as separate units of accounting or they should be combined with other deliverables and accounted for as a single unit of accounting. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company.
Other nonrefundable, upfront license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria are met. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. The Company evaluates the determination of gross versus net reporting based on each individual agreement.
Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that

38

event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company’s performance obligations under the arrangement.    
Revenue from research funding under our collaboration agreements is earned and recognized on a percentage-of completion basis as research hours are incurred in accordance with the provisions of each agreement.

Intangible Assets and Other Long-Lived Assets — Impairment Assessments

We regularly perform reviews to determine if the carrying values of our long-lived assets are impaired. A review of identifiable intangible assets and other long-lived assets is performed when an event occurs indicating the potential for impairment. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets and compare their fair values to the respective carrying amounts.

In order to estimate the fair value of identifiable intangible assets and other long-lived assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows.

Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.
Contingent Liabilities

In connection with our acquisition of CyDex in January 2011, we recorded contingent liabilities for amounts potentially due to holders of the CyDex CVR's and certain other contingency payments. The fair value of the liability is assessed at each reporting date using the income approach incorporating the estimated future cash flows from potential milestones and revenue sharing. The change in fair value is recorded in our consolidated statements of operations. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different than the carrying amount of the liability.

In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as proceeds are received by us from the sale or partnering of any of the Metabasis drug development programs. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. Changes in the fair values are reported in the statement of operations as income (decreases) or expense (increases). The carrying amount of the liability may fluctuate significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability.
Income Taxes
Our provision for income taxes, deferred tax assets and liabilities, and reserves for unrecognized tax benefits reflect our best assessment of estimated future taxes to be paid. Significant judgments and estimates based on interpretations of existing tax laws or regulations in the United States are required in determining our provision for income taxes. Changes in tax laws, statutory tax rates, and estimates of our future taxable income could impact the deferred tax assets and liabilities provided for in the consolidated financial statements and would require an adjustment to the provision for income taxes.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating our ability to recover deferred tax assets within the jurisdiction which they arise, we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, our history of earnings and reliability of our forecasts, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.


39

We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.

Item 7A.
Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from interest rates and equity prices which could affect our results of operations, financial condition and cash flows. We manage our exposure to these market risks through our regular operating and financing activities.

Investment Portfolio Risk

At December 31, 2016, our investment portfolio included investments in available-for-sale equity securities of $122.3 million. These securities are subject to market risk and may decline in value based on market conditions.

Equity Price Risk

Our 2019 Convertible Senior Notes include conversion and settlement provisions that are based on the price of our common stock at conversion or maturity of the notes, as applicable. The minimum amount of cash we may be required to pay is $245.0 million, but will ultimately be determined by the price of our common stock. The fair values of our 2019 Convertible Senior Notes are dependent on the price and volatility of our common stock and will generally increase or decrease as the market price of our common stock changes. In order to minimize the impact of potential dilution to our common stock upon the conversion of the 2019 Convertible Senior Notes, we entered into convertible bond hedges covering 3,264,643 shares of our common stock. Concurrently with entering into the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants with an exercise price of approximately $125.08 per share, subject to adjustment. Throughout the term of the 2019 Convertible Senior Notes, the notes may have a dilutive effect on our earnings per share to the extent the stock price exceeds the conversion price of the notes. Additionally, the warrants may have a dilutive effect on our earnings per share to the extent the stock price exceeds the strike price of the warrants.

Foreign Currency Risk

Through our licensing and business operations, we are exposed to foreign currency risk. Foreign currency exposures arise from transactions denominated in a currency other than the functional currency and from foreign denominated revenues and profit translated into U.S. dollars. Our license partners sell our products worldwide in currencies other than the U.S. dollar. Because of this, our revenues from royalty payments are subject to risk from changes in exchange rates.

We purchase Captisol from Hovione, located in Lisbon, Portugal. Payments to Hovione are denominated and paid in U.S. dollars; however the unit price of Captisol contains an adjustment factor which is based on the sharing of foreign currency risk between the two parties. The effect of an immediate 10% change in foreign exchange rates would not have a material impact on our financial condition, results of operations or cash flows. We do not currently hedge our exposures to foreign currency fluctuations.

Interest Rate Risk
    
We are exposed to market risk involving rising interest rates. To the extent interest rates rise, our interest costs could increase. An increase in interest costs of 10% would not have a material impact on our financial condition, results of operations or cash flows.

Item 8.
Consolidated Financial Statements and Supplementary Data



40


INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

41


Report of Ernst & Young LLP, Independent Registered Public Accounting Firm

    
The Board of Directors and Stockholders of
Ligand Pharmaceuticals Incorporated

We have audited the accompanying consolidated balance sheet of Ligand Pharmaceuticals Incorporated as of December 31, 2016, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Ligand Pharmaceuticals Incorporated at December 31, 2016, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Ligand Pharmaceuticals Incorporated’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2017 expressed an adverse opinion thereon.

/s/ ERNST & YOUNG LLP

San Diego, California
February 28, 2017


42

Report of Independent Registered Public Accounting Firm


Board of Directors and Shareholders of Ligand Pharmaceuticals Incorporated

We have audited the accompanying consolidated balance sheet of Ligand Pharmaceuticals Incorporated (the “Company”) as of December 31, 2015, and the related consolidated statements of operations, comprehensive income (loss), changes in shareholders’ equity (deficit), and cash flows for each of the years ended December 31, 2015 and 2014. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Ligand Pharmaceuticals Incorporated as of December 31, 2015, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2015 in conformity with accounting principles generally accepted in the United States of America.
/s/ GRANT THORNTON LLP
San Diego, California
February 26, 2016 (except for 2015 Restatement described in Note 1 in the previously filed 2015 financial statements, which is not presented herein and is as of November 14, 2016)






























43

LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
 
 
December 31,
 
2016
 
2015
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
18,752

 
$
97,428

Short-term investments
122,296

 
102,791

Accounts receivable, net
14,700

 
6,170

Note receivable from Viking
3,207

 
4,782

Inventory
1,923

 
1,633

Other current assets
2,175

 
1,908

Total current assets
163,053

 
214,712

Deferred income taxes
123,891

 
189,083

Investment in Viking
8,345

 
29,728

Intangible assets, net
204,705

 
48,347

Goodwill
72,207

 
12,238

Commercial license rights
25,821

 
8,554

Property and equipment, net
1,819

 
372

Other assets
1,744

 
27

Total assets
$
601,585

 
$
503,061

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
2,734

 
$
4,083

Accrued liabilities
6,397

 
5,405

Current contingent liabilities
5,088

 
10,414

Current lease exit obligations
—

 
934

2019 convertible senior notes, net

212,910

 
201,985

Total current liabilities
227,129

 
222,821

Long-term contingent liabilities
2,916

 
3,033

Other long-term liabilities
687

 
297

Total liabilities
230,732

 
226,151

Commitments and contingencies


 


Equity component of currently redeemable convertible notes (Note 6)

29,563

 
39,628

Stockholders’ equity:
 
 
 
Common stock, $0.001 par value; 33,333,333 shares authorized; 20,909,301 and 19,949,012 shares issued and outstanding at December 31, 2016 and 2015, respectively
21

 
20

Additional paid-in capital
769,653

 
661,850

Accumulated other comprehensive income
2,743

 
4,903

Accumulated deficit
(431,127
)
 
(429,491
)
Total stockholders’ equity
341,290

 
237,282

Total liabilities and stockholders’ equity
$
601,585

 
$
503,061

See accompanying notes to these consolidated financial statements.

44

LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Revenues:
 
 
 
 
 
Royalties
$
59,423

 
$
38,194

 
$
29,994

Material sales
22,502

 
27,662

 
28,488

License fees, milestones and other revenues
27,048

 
6,058

 
6,056

Total revenues
108,973

 
71,914

 
64,538

Operating costs and expenses:
 
 
 
 
 
Cost of sales(2)
5,571

 
5,807

 
9,136

Amortization of intangibles
10,643

 
2,375

 
2,375

Research and development
21,221

 
11,005

 
9,747

General and administrative
26,621

 
24,378

 
22,570

Lease exit and termination costs
1,032

 
1,020

 
1,084

Total operating costs and expenses
65,088

 
44,585

 
44,912

Income from operations
43,885

 
27,329

 
19,626

Other (expense) income:
 
 
 
 
 
Interest expense, net
(12,178
)
 
(11,802
)
 
(4,860
)
Increase in contingent liabilities
(3,334
)
 
(5,013
)
 
(5,135
)
Gain on deconsolidation of Viking
—

 
28,190

 
—

Loss from Viking
(23,132
)
 
(5,143
)
 
—

Other income, net
2,719

 
1,768

 
1,671

Total other income (expense), net
(35,925
)
 
8,000

 
(8,324
)
Income before income tax benefit (expense)
7,960

 
35,329

 
11,302

Income tax benefit (expense)
(10,327
)
 
192,115

 
(410
)
Income (loss) from operations
(2,367
)
 
227,444

 
10,892

Discontinued operations:
 
 
 
 
 
Gain on sale of Oncology Product Line before income taxes
1,139

 
—

 
—

Income tax expense on discontinued operations
(408
)
 
—

 
—

      Income from discontinued operations
731

 
—

 
—

Net (loss) income including noncontrolling interests:
(1,636
)
 
227,444

 
10,892

      Less: Net loss attributable to noncontrolling interests
—

 
(2,380
)
 
(1,132
)
Net (loss) income
$
(1,636
)
 
$
229,824

 
$
12,024

 
 
 
 
 
 
      Basic per share amounts(1):
 
 
 
 
 
   Income (loss) from continuing operations
$
(0.11
)
 
$
11.61

 
$
0.59

   Income from discontinued operations
0.04

 
—

 
—

Net (loss) income
$
(0.08
)
 
$
11.61

 
$
0.59

 
 
 
 
 
 
      Diluted per share amounts(1):
 
 
 
 
 
    Income (loss) from continuing operations
$
(0.11
)
 
$
10.83

 
$
0.56

    Income from discontinued operations
0.04

 
—

 
—

Net (loss) income
$
(0.08
)
 
$
10.83

 
$
0.56

 
 
 
 
 
 
Shares used for computation (in thousands)
 
 
 
 
 
   Basic
20,831

 
19,790

 
20,419

   Diluted
20,831

 
21,228

 
21,433

(1) The sum of net income per share amounts may not equal the total due to rounding
(2) Excludes amortization of intangibles
See accompanying notes to these consolidated financial statements.

45

LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands)


 
Year Ended December 31,
 
2016
 
2015
 
2014
Net (loss) income
$
(1,636
)
 
$
229,824

 
$
12,024

Unrealized net gain on available-for-sale securities, net of tax
93

 
1,933

 
3,872

     Less:Reclassification of net realized gains included in net income, net of tax
$
(2,253
)
 
$
(1,965
)
 
$
(1,833
)
Comprehensive (loss) income
$
(3,796
)
 
$
229,792

 
$
14,063


See accompanying notes to these consolidated financial statements.


46

LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(in thousands, except share data)
 
Common Stock
 
Additional
paid-in
capital
 
Accumulated
other
comprehensive
income (loss)
 
Accumulated
deficit
 
Noncontrolling interest
 
Total
stockholders’
equity
 
Shares
 
Amount
 
 
Balance at December 31, 2013
20,468,521

 
$
21

 
$
718,017

 
$
2,914

 
$
(671,339
)
 
$
—

 
$
49,613

Consolidation of Viking
—

 
—

 
—

 
—

 
—

 
(778
)
 
(778
)
Issuance of common stock under employee stock compensation plans, net
360,054

 
—

 
4,561

 
—

 
—

 
—

 
4,561

Stock-based compensation
—

 
—

 
11,270

 
—

 
—

 
—

 
11,270

Repurchase of common stock
(1,253,425
)
 
(1
)
 
(67,954
)
 
—

 
—

 
—

 
(67,955
)
Sale of warrants
—

 
—

 
11,638

 
—

 
—

 
—

 
11,638

Purchase of convertible bond hedge
—

 
—

 
(48,143
)
 
—

 
—

 
—

 
(48,143
)
Equity component of convertible debt issuance, net of issuance costs
—

 
—

 
51,271

 
—

 
—

 
—

 
51,271

Other comprehensive income
—

 
—

 
—

 
2,039

 
—

 
—

 
2,039

Net income
—

 
—

 
—

 
—

 
12,024

 
—

 
12,024

Net loss in noncontrolling interests
—

 
—

 
—

 
—

 
—

 
(1,132
)
 
(1,132
)
Balance at December 31, 2014
19,575,150

 
$
20


$
680,660


$
4,953


$
(659,315
)
 
$
(1,910
)

$
24,408

Issuance of common stock under employee stock compensation plans, net
379,982

 
—

 
8,849

 
—

 
—

 
—

 
8,849

Reclassification of equity component of currently redeemable convertible notes

—

 
—

 
(39,628
)
 
—

 
—

 
—

 
(39,628
)
Stock-based compensation
—

 
—

 
12,458

 
—

 
—

 
—

 
12,458

Repurchase of common stock
(6,120
)
 
—

 
(489
)
 
—

 
—

 
—

 
(489
)
Other comprehensive income
—

 
—

 
—

 
(50
)
 
—

 
—

 
(50
)
Net income
—

 
—

 
—

 
—

 
229,824

 
—

 
229,824

Net loss in noncontrolling interests
—

 
—

 
—

 
—

 
—

 
(2,380
)
 
(2,380
)
Deconsolidation of Viking
—

 
—

 
—

 
—

 
—

 
4,290

 
4,290

Balance at December 31, 2015
19,949,012

 
$
20

 
$
661,850

 
$
4,903

 
$
(429,491
)
 
$
—

 
$
237,282

Issuance of common stock under employee stock compensation plans, net
210,626

 
—

 
5,416

 
—

 
—

 
—

 
5,416

Shares issued in OMT acquisition
790,163

 
1

 
77,330

 
—

 
—

 
—

 
77,331

Reclassification of equity component of currently redeemable convertible notes

—

 
—

 
10,065

 
—

 
—

 
—

 
10,065

Stock-based compensation
—

 
—

 
18,893

 
—

 
—

 
—

 
18,893

Repurchase of common stock
(40,500
)
 
—

 
(3,901
)
 
—

 
—

 
—

 
(3,901
)
Other comprehensive income
—

 
—

 
—

 
(2,160
)
 
—

 
—

 
(2,160
)
Net income
—

 
—

 
—

 
—

 
(1,636
)
 
—

 
(1,636
)
Balance at December 31, 2016
20,909,301

 
$
21

 
$
769,653

 
$
2,743

 
$
(431,127
)
 
$
—

 
$
341,290

See accompanying notes to these consolidated financial statements.

47

LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

 
Year Ended December 31,
 
2016
 
2015
 
2014
Operating activities
 
 
 
 
 
Net (loss) income
$
(1,636
)
 
$
227,444

 
$
10,892

Less: gain from discontinued operations
731

 
—

 
—

Income (loss) from continuing operations
(2,367
)
 
227,444

 
10,892

Adjustments to reconcile net income to net cash used in operating activities:
 
 
 
 
 
Change in estimated fair value of contingent liabilities
3,334

 
5,013

 
5,135

Realized gain on sale of short-term investment
(2,352
)
 
(2,603
)
 
(1,538
)
Gain on disposal of assets

183

 
—

 
—

Depreciation and amortization
11,290

 
2,627

 
2,657

Gain on deconsolidation of Viking
—

 
(28,190
)
 
—

Loss on equity investment in Viking
23,132

 
5,143

 
—

Change in fair value of the convertible debt receivable from Viking and warrants
(462
)
 
765

 
—

Amortization of Premium (discount) on investments, net

348

 
—

 
—

Amortization of debt discount and issuance fees
10,925

 
10,274

 
3,694

Non-cash milestone revenue
—

 
—


(1,211
)
Stock-based compensation
18,893

 
12,458

 
11,270

Deferred income taxes
10,697

 
(192,132
)
 
410

Other
—

 
107

 
206

Changes in operating assets and liabilities, net of acquisition:
 
 
 
 
 
Accounts receivable, net
(8,525
)
 
6,489

 
(10,412
)
Inventory
(244
)
 
(401
)
 
4,369

Restricted cash
—

 
1,261

 
—

Other current assets
558

 
51

 
(426
)
Other long term assets
(32
)
 
(325
)
 
(1,439
)
Accounts payable and accrued liabilities
(2,369
)
 
(4,027
)
 
(3,121
)
Deferred revenue
(8
)
 
(2,227
)
 
80

Net cash provided by operating activities of continuing operations
63,001

 
41,727

 
20,566

Net cash used in operating activities of discontinued operations
—

 
—

 
—

Net cash provided by operating activities
63,001

 
41,727

 
20,566

Investing activities
 
 
 
 
 
Purchase of commercial license rights
(17,695
)
 
(4,030
)
 
(1,000
)
Purchase of Viking common stock and warrant
(700
)
 
(9,000
)
 
—

Reduction of cash due to deconsolidation of Viking
—

 
(247
)
 
—

Purchase of common stock in equity method investment

(1,000
)
 
—

 
—

Cash paid for acquisition, net of cash acquired

(92,502
)
 
—

 
—

Payments to CVR holders and other contingency payments
(8,777
)
 
(6,740
)
 
(3,493
)
Purchases of property and equipment
(1,850
)
 
(93
)
 
(6
)
Purchases of short-term investments
(164,438
)
 
(166,025
)
 
—

Proceeds from sale of short-term investments
24,596

 
16,039

 
2,342

Proceeds from maturity of short-term investments
118,874

 
57,234

 
—

Proceeds received from repayment of Viking note receivable

300

 
—

 
—

Other, net
—

 
—

 
130

Net cash used in investing activities
(143,192
)
 
(112,862
)
 
(2,027
)
Financing activities
 
 
 
 
 
Repayment of debt
—

 
—

 
(9,366
)
Gross proceeds from issuance of 2019 Convertible Senior Notes
—

 
—

 
245,000

Payment of debt issuance costs
—

 
—

 
(5,711
)

48

Proceeds from issuance of warrants
—

 
—

 
11,638

Purchase of convertible bond hedge
—

 
—

 
(48,143
)
Net proceeds from stock option exercises and ESPP
6,415

 
8,849

 
4,561

Taxes paid related to net share settlement of equity awards

(999
)
 
—

 
—

Share repurchases
(3,901
)
 
(489
)
 
(67,954
)
Net cash provided by financing activities
1,515

 
8,360

 
130,025

Net (decrease) increase in cash and cash equivalents
(78,676
)
 
(62,775
)
 
148,564

Cash and cash equivalents at beginning of year
97,428

 
160,203

 
11,639

Cash and cash equivalents at end of year
$
18,752

 
$
97,428

 
$
160,203

Supplemental disclosure of cash flow information
 
 
 
 
 
Cash paid during the year:
 
 
 
 
 
Interest paid
$
1,838

 
$
1,822

 
$
494

Taxes paid
$
38

 
$
28

 
$
18

Supplemental schedule of non-cash investing and financing activities
 
 
 
 
 
Stock issued for acquisition, net of issuance cost

$
(77,331
)
 
$
—

 
$
—

Stock and warrant received for repayment of Viking notes receivable
$
1,200

 
$
—

 
$
—

Accrued inventory purchases
$
646

 
$
1,333

 
$
3,246

Unrealized gain on AFS investments
$
(1,109
)
 
$
3,005

 
$
3,872

See accompanying notes to these consolidated financial statements.

49

LIGAND PHARMACEUTICALS INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation and Summary of Significant Accounting Policies

Business

Ligand is a biopharmaceutical company with a business model based on developing or acquiring assets which generate royalty, milestone or other passive revenue for the Company and using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.

Principles of Consolidation

The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Basis of Presentation
 
The Company’s accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly-owned subsidiaires. All intercompany transactions and balances have been eliminated in consolidation.

Upon the occurrence of certain circumstances, holders of the 2019 Convertible Senior Notes may redeem all or a portion of their notes, which may require the use of a substantial amount of cash. At December 31, 2016, we had a working capital deficit of $64.1 million, which includes the 2019 Convertible Senior notes that are currently redeemable as of December 31, 2016 but excludes another $29.6 million that is classified as mezzanine equity.  As noted in Note 6, the debt may change from current to non-current period over period, primarily as a result of changes in the Company’s stock price. Management believes that it is remote that holders of the notes would choose to convert their notes early because the fair value of the security that a noteholder can currently realize in an active market is greater than the conversion value the noteholder would realize upon early conversion. In the unlikely event that all the debt was converted, we have 3 business days following a 50 trading day observation period from the convert date to pay the principal in cash. We have positive operating income and positive cash flow from operations for the three years ended December 31, 2016 and, accordingly, while there can be no assurance, we believe we have the ability to raise additional capital through our active S-3, by liquidating assets, or via alternative financing arrangements such as convertible or high yield debt.

Reclassifications

Certain reclassifications have been made to the previously issued statement of operations for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity and operating cash flows as previously reported.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates

Recent Accounting Pronouncements
 
 In May 2014, the FASB issued new guidance related to revenue recognition, Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASC 606”), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. ASC 606 defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The new guidance becomes effective in calendar year 2018 and early adoption in calendar year 2017 is permitted. Two methods of adoption are permitted: (a) full retrospective adoption, meaning the standard is applied to all periods presented; or (b) modified retrospective adoption, meaning the

50

cumulative effect of applying the new guidance is recognized at the date of initial application as an adjustment to the opening retained earnings balance.

We are undertaking a substantial effort to be ready for adoption of ASC 606. Some of our contracts have distinct terms which will need to be evaluated separately.  We have started our preliminary assessment of these contracts and although we have not completed our assessment and are in the process of reviewing our contracts, we anticipate this standard will have a material impact on our consolidated financial statements by accelerating the timing of revenue recognition for revenues related to royalties, and potentially certain contingent milestone based payments. We intend to adopt ASC 606 starting as of January 1, 2018 using the modified retrospective method. 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements -Going Concern (Subtopic 205-40). This accounting standard requires management to perform interim and annual assessments of the entity's ability to continue its business operations within one year of the date of issuance of its financial statements. The Company must then provide certain disclosure if there is substantial doubt about its ability to continue as a going concern. As of December 31, 2016, the Company has adopted this standard with no impact to the financial statements.

In March 2016, the FASB issued ASU 2016-09 amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. The guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. In addition, the guidance provides for an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur. The updated guidance is effective in fiscal year 2018 and early adoption in fiscal year 2017 is permitted. We are currently evaluating the adoption timing as well as the impact of the new guidance on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments which requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The new standard will be effective for us in fiscal year 2020 and early adoption in fiscal 2019 is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.

In August 2016 the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. The guidance addresses the classification of cash flows related to (1) debt prepayment or extinguishment costs, (2) settlement of zero-coupon debt instruments or other debt instruments with coupon rates that are insignificant in relation to the effective interest rate of the borrowing, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance, including bank-owned life insurance, (6) distributions received from equity method investees and (7) beneficial interests in securitization transactions. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The new guidance will be effective for fiscal year 2018 and early adoption is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. We expect contingent consideration payment presentation will change to conform to the standard.

We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.

Concentrations of Business Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and investments. The Company invests its excess cash principally in United States government debt securities, investment grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.

51

A relatively small number of partners accounts for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
 
December 31,
 
2016
 
2015
 
2014
Partner A
41
%
 
27
%
 
37
%
Partner B
14
%
 
23
%
 
31
%
Partner C
—

 
18
%
 
10
%

The Company obtains Captisol from a single supplier, Hovione. If this supplier were not able to supply the requested amounts of Captisol, the Company would be unable to continue to derive revenues from the sale of Captisol until it obtained an alternative source, which could take a considerable length of time.

Cash Equivalents & Short Term Investments

Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt securities that have effective maturities greater than three months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss). The Company determines the cost of investments based on the specific identification method.
Accounts Receivable

Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company considers receivables past due based on the contractual payment terms which range from 30 to 90 days. The Company reserves specific receivables if collectibility is no longer reasonably assured. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.
Inventory
Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. The Company analyzes its inventory levels periodically and writes down inventory to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December 31, 2016 and 2015.
Property and Equipment
Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.
Goodwill and Intangible Assets

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The change in the carrying value of goodwill during the year ended December 31, 2016, was due to the acquisition of OMT. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the

52

goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2016 by assessing qualitative factors, noting no impairment.

Intangible assets related to acquired IPR&D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered to be indefinite-lived, they are not amortized but are tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company performed its annual assessment for IPR&D impairment in 2016, noting no impairment.

Commercial license rights

Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015 and Cormatrix in May 2016. Individual commercial license rights acquired are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made. As of December 31, 2016, management does not believe there have been any events or circumstances indicating that the carrying amount of its commercial license rights may not be recoverable.

Royalty income earned from Cormatrix were $1.5 million for the year ended December 31, 2016. Accounts receivable due from Cormatrix were $0.2 million at December 31, 2016.

Relationships between the CorMatrix Parties
    
As previously disclosed in Ligand’s filings, Jason Aryeh is a director of both Ligand and CorMatrix. Mr. Aryeh beneficially owns equity of CorMatrix representing less than 1% of CorMatrix’s outstanding equity. Mr. Aryeh recused himself from all of the board’s consideration of the purchase agreement between the Company and CorMatrix, including any financial analysis, the terms of the purchase agreement and the vote to approve the Purchase Agreement and the related transactions.
Contingent Liabilities

In connection with the Company’s acquisition of CyDex in January 2011, the Company recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. See footnote 7, Other Balance Sheet Details. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the Company’s acquisition of Metabasis in January 2010, the Company issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement.

Any change in fair value is recorded in the Company's consolidated statement of operations.
Revenue Recognition

We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been provided, title has transferred or access has been given, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured.

Royalties on sales of products commercialized by the Company’s partners are recognized in the quarter reported by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between 30 and 60 days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received.

53

Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a 20% restocking fee. To date, product returns have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period.

The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price.
Many of the Company's revenue arrangements for Captisol involve a license agreement and the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company, and in a hypothetical stand-alone transaction, the customer would be able to procure inventory from another manufacturer in the absence of contractual provisions for exclusive supply by the Company.
Other nonrefundable, up-front license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. Management evaluates the determination of gross versus net reporting based on each individual agreement.
Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company’s performance obligations under the arrangement.

Preclinical Study and Clinical Trial Accruals

Substantial portions of the Company’s preclinical studies and all of the Company’s clinical trials have been performed by third-party laboratories, CROs.  The Company accounts for a significant portion of its clinical study costs according to the terms of its contracts with CROs. The terms of its CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. The Company's objective is to reflect the appropriate preclinical and clinical trial expenses in its financial statements in the same period as the services occur. As part of the process of preparing its financial statements, the Company relies on cost information provided by its CROs. The Company is also required to estimate certain of its expenses resulting from its obligations under its CRO contracts. Accordingly, the Company's preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates. No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.


54

Research and Development Expenses

Research and development expense consists of labor, material, equipment, and allocated facilities costs of the Company’s scientific staff who are working pursuant to the Company’s collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for the Company’s research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided

Stock-Based Compensation

The Company incurs share-based compensation expense related to restricted stock, its ESPP, and stock options

Restricted stock units (RSU) and performance stock units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Company’s common stock on the date of grant. The Company recognizes share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration estimated forfeitures. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.

The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The Company looks to historical volatility of the Company's stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that the Company has never declared or paid regular cash dividends on its common stock and does not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards

The Company grants options and restricted stock awards to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and restricted stock awards granted to certain non-employee directors vest in equal monthly installments over one year from the date of grant. Options granted to employees vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. Restricted stock awards granted to employees vest over three years. All option awards generally expire ten years from the date of grant.

Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.
 
Income Taxes

The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when the Company believes it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise the Company considers all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.


55

The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.

Discontinued Operations

In 2006, we entered into a purchase agreement with Eisai pursuant to which Eisai agreed to acquire our Oncology product line which included four marketed oncology drugs: ONTAK, Targretin capsules, Targretin gel and Panretin gel. Certain liabilities were recorded associated with the disposal of the product line. During the year ended December 31, 2016 we recognized a $1.1 million gain due to subsequent changes in certain estimates and liabilities previously recorded. We recorded a provision for income taxes related to the gain of $0.4 million.
Income Per Share
    
Basic income (loss) per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period

Potentially dilutive common shares consist of shares issuable under 2019 convertible senior notes, stock options and restricted stock. 2019 convertible senior notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options; the average amount of unrecognized compensation expense for restricted stock; and estimated tax benefits that will be recorded in additional paid-in capital when expenses related to equity awards become deductible. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded

The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Weighted average shares outstanding:
20,831

 
19,790

 
20,419

Dilutive potential common shares:
 
 
 
 
 
   Restricted stock
—

 
56

 
36

   Stock options
—

 
882

 
978

   2019 Convertible Senior Notes
—

 
499

 
—

Shares used to compute diluted income per share
20,831

 
21,228

 
21,433

Potentially dilutive shares excluded from calculation due to anti-dilutive effect
3,544

 
3,333

 
5,104


Comprehensive Income (Loss)

Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities less reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).





2. Investment in Viking

In 2014, the Company entered into a MLA with Viking to license the rights to five of the Company's programs to Viking. Under the terms of the MLA, no consideration was exchanged upon execution, but rather Viking agreed to issue shares of Viking common stock with an aggregate value of approximately $29.2 million upon consummation of Viking's IPO. As part

56

of this transaction, the Company also extended a $2.5 million convertible loan to Viking under a LSA. As a result of these transactions, the Company determined it held a variable interest in Viking. The Company considered certain criteria in the accounting guidance for VIEs, and determined that Viking was a VIE and Ligand was the primary beneficiary of Viking. As a result, the Company consolidated Viking on its financial statements from May 2014 through May 2015, the effective date of Viking's IPO. The Company recorded 100% of the losses incurred as net loss attributable to noncontrolling interest because it was the primary beneficiary with no equity interest in the VIE.

In May 2015, Viking completed the Viking IPO and issued the Company approximately 3.7 million shares of Viking common stock with an aggregate value of $29.2 million based on the IPO price of $8.00 per share. In connection with the Viking IPO, the Company purchased 1.1 million shares of Viking common stock for an aggregate price of $9.0 million at the initial public offering price. Upon completion of Viking’s IPO, the Company determined that Viking was no longer a VIE and the Company did not have any other element of control that would require consolidation of Viking. In May 2015, the Company deconsolidated Viking and began to account for its equity investment in Viking under the equity method and records its proportional share of Viking gains and losses in Loss from Viking Therapeutics in the Company's consolidated statement of operations. Viking is considered a related party as the Company maintains a seat on Viking's board of directors.

In January 2016, the Company entered into an amendment to the LSA with Viking to extend the maturity of the convertible loan to May 2017, reduce the interest rate from 5.0% to 2.5%, and extend the lock up period by one year such that the Company may not sell, transfer, or dispose of any Viking securities prior to January 23, 2017. Additionally, upon the consummation of a subsequent capital financing transaction, Viking will be required to repay $1.5 million of the Viking Note obligation to the Company, with at least $0.3 million to be paid in cash and the remaining amount to be paid in the form and at the price of the Viking equity securities sold in the financing transaction. Upon maturity or further payments, the Company may elect to receive equity of Viking common stock or cash equal to 200% of the principal amount plus accrued and unpaid interest. The Company has opted to account for the Viking convertible note receivable at fair value.

In April 2016, Viking closed its underwritten public offering of 7.5 million shares of common stock and warrants to purchase up to 7.5 million shares of its common stock at a price of $1.25 per share of its common stock and related warrants. The warrant has an exercise price of $1.50 per share, immediately exercisable and will expire on April 13, 2021. As part of this public offering, the Company purchased 560,000 shares of common stock and warrants to purchase 560,000 shares of Viking's common stock for a total purchase price of $0.7 million. The purchased shares of common stock and warrants are subject to the same terms as the shares issued in this offering. In addition, on April 13, 2016, pursuant to the terms of the amendment to the LSA that was entered in January 2016 between Ligand and Viking, Viking repaid $0.3 million of the convertible notes in cash, and issued the Company 960,000 shares of its common stock and warrants to purchase 960,000 shares of its common stock as repayment of $1.2 million of the convertible notes. The shares received as part of the repayment, like all Viking securities held by the Company, are subject to a lock-up period that ends on January 23, 2017 in accordance with the amended LSA. A gain of $0.3 million representing the fair market value of the warrants is included within other income for the year ended December 31, 2016. As of December 31, 2016, the aggregate fair value of the note receivable was 3.2 million .
 
The Company's ownership in Viking decreased to 32.7% after the public offering and the repayment of the convertible notes and further decreased to 30.3% as of December 31, 2016. Accordingly, the book value of the Company's equity method investment in Viking decreased by $10.7 million. The resulting net loss was recognized in Loss from Viking in the Company's consolidated statement of operations for the year ended December 31, 2016.

The Company reviews its investment in Viking on a regular basis and assesses whether events, changes in circumstances or the passage of time, in management's judgment, indicate that a loss in the market value of the investment may be other than temporary. This might include, but would not necessarily be limited to, the period of time during which the carrying value of our investment is significantly above the observed market value, a deterioration in Viking's financial condition, or an adverse event relating to its lead clinical programs.

Based on the sustained low Viking common stock unit price during the year ended December 31, 2016, the Company determined that an other than temporary decrease in the value of its investment in Viking had occurred. The Company wrote down the value of its investment in Viking to its estimated fair value which resulted in impairment charges of $7.4 million for the year ended December 31, 2016.

3. Business Combinations

On January 8, 2016, the Company acquired substantially all of the assets and liabilities of OMT. OMT is a biotechnology company engaged in the genetic engineering of animals for the generation of human therapeutic antibodies through its OmniAb® technology, which currently offers three transgenic animal platforms for license, including OmniRat®,

57

OmniMouse® and OmniFlic®. The transaction, which was accounted for as a business combination, initially added 16 partnerships to the Company's portfolio and provides the Company with opportunities for further licensing and collaborations in the area. The aggregate acquisition consideration was $173.4 million, consisting of (in thousands, except per share amounts):

Cash consideration
$
96,006

Total share consideration:
 
  Actual number of shares issued
790

  Multiplied by: Ligand closing share price on January 8, 2016
98

Total share consideration
$
77,373

Total consideration
$
173,379

The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):

     Cash and cash equivalents
$
3,504

     Accounts receivable
5

     Income tax receivable
136

     Prepaid expenses and other current assets
1

     Deferred tax liabilities, net
(55,708
)
     Intangible asset with finite life - core technology
167,000

     Liabilities assumed
(1,528
)
     Goodwill
59,969

Total consideration
$
173,379


The fair value of the core technology, or OMT's OmniAb technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniAb technology. These projected cash flows were discounted to present value using a discount rate of 15.5%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 20 years.

The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed was $60.0 million and was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to OMT’s potential revenue growth from combining the OMT and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.

The following table presents supplemental pro forma information for the three and twelve months ended December 31, 2016 and December 31, 2015, as if the acquisition of OMT had occurred on January 1, 2015 (in thousands except for income per share):

 
Three months ended
Twelve months ended
December 31,
December 31,
2016
 
2015
2016
 
2015
Revenue
$
38,185

 
$
24,571

$
111,449

 
$
80,365

Net (loss) income
$
(3,126
)
 
5,888

$
632

 
$
222,788

 
 
 
 
 
 
 
Basic (loss) income per share:
$
(0.15
)
 
$
0.30

$
0.03

 
$
11.26

Diluted (loss) income per share:
$
(0.15
)
 
$
0.27

$
0.03

 
$
10.50


The unaudited pro forma consolidated results include pro forma adjustments that assume the acquisition occurred on January 1, 2015. The primary adjustments include: (i) the $0.3 million and $0.9 million for the three and twelve months ended December 31, 2015, respectively, for share based compensation expenses related to the stock awards issued to the retained OMT employees after the acquisition, (ii) additional intangible amortization expense of  $2.1 million and $6.3 million was

58

included in the three and twelve months ended December 31, 2015, respectively and (iii) a platform license fee of $3.0 million paid by OMT during the twelve months ended December 31, 2015. The license agreement was terminated upon acquisition by Ligand. The adjustments also include $2.5 million license revenue recognized by OMT from January 1, 2016 to the acquisition date. The unaudited pro forma consolidated results are not necessarily indicative of what our consolidated results of operations actually would have been had we completed the acquisition on January 1, 2015. In addition, the unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition.

4. Fair Value Measurement

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The Company establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:
Level 1 - Observable inputs such as quoted prices in active markets
Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly
Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions
The following table provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2016 and 2015 (in thousands):

Fair Value Measurements at Reporting Date Using
December 31, 2016
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Short-term investments (1)
$
122,296

 
$
3,054

 
$
119,242

 
$
—

Note receivable Viking (2)
3,207

 
—

 
—

 
3,207

Investment in warrants (3)
684

 
684

 
—

 
—

     Total assets
$
126,187

 
$
3,054

 
$
119,242

 
$
3,207

Liabilities:
 
 
 
 
 
 
 
Current contingent liabilities - CyDex (4a)
$
101

 
$
—

 
$
—

 
$
101

Long-term contingent liabilities - Metabasis (5)
1,413

 
—

 
1,413

 
—

Long-term contingent liabilities - CyDex (4)
1,503

 
—

 
—

 
1,503

Liability for amounts owed to former licensees (6)
371

 
371

 
—

 
—

     Total liabilities
$
3,388

 
$
371

 
$
1,413

 
$
1,604



59

Fair Value Measurements at Reporting Date Using
December 31, 2015
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents (7)
$
3,015

 
$
—

 
$
3,015

 
$
—

Short-term investments (1)
92,775

 
6,786

 
85,989

 
—

Note receivable Viking (2)
4,782

 
—

 
—

 
4,782

     Total assets
$
100,572

 
$
6,786

 
$
89,004

 
$
4,782

Liabilities:
 
 
 
 
 
 
 
Current contingent liabilities - CyDex(4)
$
7,812

 
$
—

 
$
—

 
$
7,812

Current contingent liabilities-Metabasis (5)
2,602

 
—

 
2,602

 
—

Long-term contingent liabilities - Metabasis (5)
1,355

 
—

 
1,355

 
—

Long-term contingent liabilities - CyDex (4)
1,678

 
—

 
—

 
1,678

Liability for amounts owed to former licensees (6)
794

 
794

 
—

 
—

     Total liabilities
$
14,241

 
$
794


$
3,957


$
9,490

    

(1) Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.

(2) The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 75% at December 31, 2016 and 65% at December 31, 2015. Changes in these assumptions may materially affect the fair value estimate. For the year ended December 31, 2016 and December 31, 2015, the Company reported a decrease in the fair value of the Viking convertible notes of $0.2 million and$0.8 million respectively in "Other, net" of the consolidated statement of operations.

(3) Investment in warrants, which the Company received as a result of Viking’s partial repayment of the Viking note receivable and the Company’s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities.

(4) The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.

(4a) The fair value of the liabilities for short-term CyDex contingent liabilities at December 31, 2016 disclosed herein represents the fair value of the estimated contingent considerations owed to former license holder only, which is determined based on the methodology described in (4) above. The contingent considerations owed to the Cydex CVR holders at December 31, 2016 is determined based on actual amount owed at December 31, 2016 as the Cydex CVR agreement ended at December 31, 2016.

(5) The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR.

(6) The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.

(7) Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.









60





The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:

 
 
December 31,
 
 
2016
 
2015
Range of annual revenue subject to revenue sharing (1)
 
N/A
 
$22.5 million
Revenue volatility
 
25%
 
25%
Average of probability of commercialization
 
12.5%
 
73%
Sales beta
 
N/A
 
0.40
Credit rating
 
BB
 
BB
Equity risk premium
 
6%
 
6%
Market price of risk
 
3.2%
 
N/A

(1)
For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual $5.0 million amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017.


A reconciliation of the level 3 financial instruments as of December 31, 2016 is as follows (in thousands):

Assets:
 
Fair value of level 3 financial instruments as of December 31, 2015
$
4,782

Viking note receivable fair market value adjustment

(215
)
Cash payment received as partial repayment of note receivable

(300
)
Fair market value of stock received as partial repayment of note receivable

(1,060
)
Fair value of level 3 financial instrument assets as of December 31, 2016
$
3,207

 
 
Liabilities
 
Fair value of level 3 financial instruments as of December 31, 2015
$
9,490

Payments to CVR holders and other contingency payments
(6,158
)
Fair value adjustments to contingent liabilities
3,259

Other (1)
(4,987
)
Fair value of level 3 financial instruments as of December 31, 2016
$
1,604

(1)
Balance represents Cydex CVR obligation, which was determined based on actual amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016.

Other Fair Value Measurements-2019 Convertible Senior Notes

In August 2014, the Company issued the 2019 Convertible Senior Notes. The Company uses a quoted market rate in an inactive market, which is classified as a Level 2 input, to estimate the current fair value of its 2019 Convertible Senior Notes. The estimated fair value of the 2019 Senior Convertible Notes was $331.7 million as of December 31, 2016. The carrying value of the notes does not reflect the market rate. See Note 7 Financing Arrangements for additional information.

Viking

The Company records its investment in Viking under the equity method of accounting. The investment is subsequently adjusted for the Company’s share of Viking's operating results, and if applicable, cash contributions and distributions. See Note

61

2 Investment in Viking for additional information. The market value of the Company's investment in Viking was $7.5 million as of December 31, 2016.


5. Lease Obligations
The Company leases office facilities in California and Kansas. These leases expire between 2017 and 2023. Total rent expense, net under all office leases for 2016, 2015 and 2014 was $0.3 million, $0.4 million and $0.7 million, respectively. The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of December 31, 2016 (in thousands):

Operating lease obligations:
 
Lease
Termination
Date
 
Less than 1
year
 
1-2 years
 
3-4 years
 
Thereafter
 
Total
Corporate headquarters-San Diego, CA
 
April 2023
 
$
128

 
$
267

 
$
283

 
$
197

 
$
875

Office and research facility-La Jolla, CA
 
June 2019
 
718

 
1,111

 
—

 
—

 
1,829

Bioscience and Technology Business Center-Lawrence, KS
 
December 2017
 
54

 
—

 
—

 
—

 
54

Total operating lease obligations
 
 
 
$
900

 
$
1,378

 
$
283

 
$
197

 
$
2,758

 
 
 
 
 
 
 
 
 
 
 
 
 
Sublease payments expected to be received:
 
 
 
 
 
 
 
 
 
 
 
 
Office and research facility-La Jolla, CA
 
June 2019
 
656

 
1,002

 
—

 
—

 
1,658

Net operating lease obligations
 
 
 
$
244

 
$
376

 
$
283

 
$
197

 
$
1,100


Lease termination

In November 2015, the Company entered into a lease termination agreement with its current lessor for the corporate headquarters facility located in La Jolla, California. The termination agreement accelerated the expiration date of the lease to April 2016, through which date, the Company is obligated to pay all base rent, operating expenses and other obligations due under the current lease.

In conjunction with the execution of the termination agreement, the Company entered into a new lease agreement with a different lessor for its corporate headquarters located in San Diego, California. The new lease has an initial term of approximately 7 years and commenced in May 2016. The base rent under the new facility lease agreement is approximately $0.1 million per year for the first year, escalating 3.0% annually thereafter over the initial term. The Company has an option to extend the term of the lease for an additional five years. The lease is subject to additional charges for property management, common area maintenance and other costs.

Lease exit obligations

As of December 31, 2016 and 2015, the Company had lease exit obligations of $0 million and $0.9 million, respectively. The Company no longer records a lease obligation with respect to its vacated space expiring in June 2019 as the sublease proceeds offset the estimated lease exit obligations. For the years ended December 31, 2016 and 2015, the Company made cash payments, net of sublease payments received of $1.7 million and $3.3 million, respectively. The Company recognized adjustments for accretion and changes in leasing assumptions of $0.7 million, $0.9 million and $1.1 million for the years ended December 31, 2016, 2015 and 2014, respectively.

62

6. Financing Arrangements

2019 Convertible Senior Notes

In August 2014, the Company issued $245.0 million aggregate principal amount of its 2019 Convertible Senior Notes, resulting in net proceeds of $239.3 million. The 2019 Convertible Senior Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually.

Holders of the 2019 Convertible Senior Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances:

(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December 31, 2014, if,
for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Company's common stock on such trading day is greater than 130% of the conversion price on such trading day;

(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on each such trading day; or

(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.
    
As of December 31 2016, the Company's last reported sale price exceeded the 130% threshold described above and accordingly the Convertible Notes have been classified as a current liability as of December 31, 2016. As a result, the related unamortized discount of $29.6 million was classified as temporary equity component of currently redeemable convertible notes on our consolidated balance sheet. The determination of whether or not the Convertible Notes are convertible as described above is made each quarter until maturity, conversion or repurchase. It is possible that the Convertible Notes may not be convertible in future periods, in which case the Convertible Notes would be classified as long-term debt, and the unamortized discount would be classified as permanent equity unless one of the other conversion events described above were to occur.

On or after May 15, 2019 until the close of business on the second scheduled trading day immediately preceding August 15, 2019, holders of the notes may convert all or a portion of their notes at any time. Upon conversion, Ligand must deliver cash to settle the principal and may deliver cash or shares of common stock, at the option of the Company, to settle any premium due upon conversion.
    
The Company accounted for the debt and equity components of the 2019 Convertible Senior Notes by allocating the $245.0 million total proceeds between the debt component and the embedded conversion option, or equity component, due to Ligand's ability to settle the 2019 Convertible Senior Notes in cash for the principal portion and to settle any premium in cash or common stock, at the Company's election. The debt allocation was performed in a manner that reflected the Company's non-convertible borrowing rate for similar debt of 5.83% derived from independent valuation analysis. The initial debt value of $192.5 million accretes at 5.83% to reach $245.0 million at the maturity date. The equity component of the 2019 Convertible Senior Notes was recognized as a debt discount and represents the difference between the $245.0 million proceeds at issuance of the 2019 Convertible Senior Notes and the fair value of the debt allocation on their respective issuance dates. The debt discount is amortized to interest expense using the effective interest method over the expected life of a similar liability without an equity component. As of December 31, 2016, the “if-converted value” exceeded the principal amount of the 2019 Convertible Senior Notes by $86.7 million.    

In connection with the issuance of the 2019 Convertible Senior Notes, the Company incurred $5.7 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portions of these costs allocated to the equity components totaling $1.2 million were recorded as a reduction to additional paid-in capital. The portions of these costs allocated to the liability components totaling $4.5 million were recorded as assets on the balance sheet at the time the debt was issued.  Beginning in 2016, the unamortized issuance costs allocated to the liability components are recorded as part of debt discount on the consolidated balance sheet upon the Company's respective adoption of ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. Issuance cost included in the unamortized debt discount was $2.5 million and $3.4 million as of December 31, 2016 and 2015, respectively.
 

63

The Company determined the expected life of the debt discount for the 2019 Convertible Senior Notes to be equal to the original five-year term of the notes. The carrying value of the equity component related to the 2019 Convertible Senior Notes as of December 31, 2016, net of issuance costs, was $51.3 million.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Convertible Bond Hedge and Warrant Transactions

In August 2014, to minimize the impact of potential dilution to the Company's common stock upon conversion of the 2019 Convertible Senior Notes, in August 2014, the Company entered into convertible bond hedges and sold warrants covering 3,264,643 shares of its common stock. The convertible bond hedges have an exercise price of $75.05 per share and are exercisable when and if the 2019 Convertible Senior Notes are converted. If upon conversion of the 2019 Convertible Senior Notes, the price of the Company's common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by the Company and are not part of the terms of the 2019 Convertible Senior Notes. Holders of the 2019 Convertible Senior Notes and warrants will not have any rights with respect to the convertible bond hedges. The Company paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.

Concurrently with the convertible bond hedge transactions, the Company entered into warrant transactions whereby it sold warrants to acquire approximately 3,264,643 shares of common stock with an exercise price of approximately $125.08 per share, subject to certain adjustments. None of the warrants have been exercised as of December 31, 2016. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The Company received $11.6 million for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and the Company does not have the obligation and does not intend to file any registration statement with the Securities and Exchange Commission registering the issuance of the shares under the warrants.

The following table summarizes information about the liability components the Company's financing arrangement (dollars in thousands):
 
December 31, 2016
 
December 31, 2015

2019 Convertible Senior Notes
 
 
 
     Principal amount outstanding
$
245,000

 
$
245,000

     Unamortized discount
(32,090
)
 
(43,015
)
Total current portion of notes payable
$
212,910

 
$
201,985

As of December 31, 2016, there were no events of default or violation of any covenants under the Company's financing obligations.
7. Balance Sheet Account Details

Short-term Investments

64

The following table summarizes the various investment categories at December 31, 2016 and 2015 (in thousands):
 
Cost
 
Gross unrealized
gains
 
Gross unrealized
losses
 
Estimated
fair value
December 31, 2016
 
 
 
 
 
 
 
Short-term investments
 
 
 
 
 
 
 
     Bank deposits
$
40,715

 
$
19

 
$
—

 
$
40,734

     Corporate bonds
11,031

 
—

 
(5
)
 
11,026

     Corporate equity securities
1,512

 
1,542

 
—

 
3,054

     Commercial paper
33,074

 
2

 
(9
)
 
33,067

     Agency bonds
7,294

 
1

 
—

 
7,295

     U.S. Government bonds
7,508

 
—

 
(1
)
 
7,507

     Municipal bonds
19,624

 
—

 
(11
)
 
19,613

 
$
120,758

 
$
1,564

 
$
(26
)
 
$
122,296

December 31, 2015
 
 
 
 
 
 
 
Short-term investments
 
 
 
 
 
 
 
     Bank deposits
$
43,043

 
$
—

 
$
(4
)
 
$
43,039

     Corporate bonds
41,238

 
—

 
(35
)
 
41,203

     Commercial paper
1,747

 
—

 
—

 
1,747

     Asset backed securities
10,020

 
—

 
(5
)
 
10,015

     Corporate equity securities
1,843

 
4,944

 
—

 
6,787

 
$
97,891

 
$
4,944

 
$
(44
)
 
$
102,791


Other current assets consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Prepaid expenses
$
1,864

 
$
1,177

Other receivables
311

 
731

 
$
2,175

 
$
1,908


Property and equipment is stated at cost and consists of the following (in thousands):
 
December 31,
 
2016
 
2015
Lab and office equipment
$
1,067

 
$
2,248

Leasehold improvements
1,754

 
273

Computer equipment and software
569

 
632

 
3,390

 
3,153

Less accumulated depreciation and amortization
(1,571
)
 
(2,781
)
 
$
1,819

 
$
372

Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $0.2 million, $0.2 million, and $0.3 million was recognized for the years ended December 31, 2016, 2015, and 2014, respectively and is included in operating expenses.

65


Goodwill and identifiable intangible assets consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Indefinite lived intangible assets
 
 
 
     IPR&D
$
12,246

 
$
12,556

     Goodwill
72,207

 
12,238

Definite lived intangible assets
 
 
 
     Complete technology
182,577

 
15,267

          Less: Accumulated amortization
(12,792
)
 
(3,762
)
     Trade name
2,642

 
2,642

          Less: Accumulated amortization
(784
)
 
(652
)
     Customer relationships
29,600

 
29,600

          Less: Accumulated amortization
(8,784
)
 
(7,304
)
Total goodwill and other identifiable intangible assets, net
$
276,912

 
$
60,585


Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $10.6 million, $2.4 million, and $2.4 million was recognized for the years ended December 31, 2016 and 2015, and 2014. Estimated amortization expense for the years ending December 31, 2017 through 2021 is $10.6 million per year. For each of the years ended December 31, 2016, 2015, and 2014, there was no impairment of intangible assets with finite lives.

Commercial license rights consist of the following (in thousands):
 
December 31,
 
December 31,
 
2016
 
2015
CorMatrix
$
17,696

 
$
—

Selexis
8,602

 
8,602

 
26,298

 
8,602

Less: accumulated amortization
(477
)
 
(48
)
     Total commercial rights, net
$
25,821

 
$
8,554


Accrued liabilities consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Compensation
$
2,603

 
$
1,711

Legal
829

 
726

Amounts owed to former licensees
899

 
915

Royalties owed to third parties
942

 
823

Other
1,124

 
1,230

 
$
6,397

 
$
5,405


In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. We pay CyDex shareholders, through 2016, 20% of all CyDex-related revenue, but only to the extent that, and beginning only when, CyDex-related revenue for the year exceeds $15.0 million; plus an additional 10% of all CyDex-related revenue recognized during such year, but only to the extent, and beginning only when aggregate CyDex-related revenue for such year exceeds $35.0 million.

In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are

66

received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.
  
Contingent liabilities consist of the following (in millions):
 
December 31, 2014
Payments
Fair Value Adjustment
December 31, 2015
Payments
Fair Value Adjustment
December 31, 2016
Cydex
$
11.5

$
(5.8
)
$
3.8

$
9.5

(6.2
)
$
3.3

$
6.6

Metabasis
3.7

(0.9
)
1.2

4.0

(2.6
)
0.1

1.5

Total
15.2

(6.7
)
5.0

13.5

(8.8
)
3.4

8.1


Other long-term liabilities consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Deferred rent
$
357

 
$
—

Deposits
43

 
268

Other
287

 
29

 
$
687

 
$
297


8. Stockholders’ Equity

Share-based Compensation Expense

The following table summarizes stock-based compensation expense (in thousands):
 
December 31,
 
2016
 
2015
 
2014
Stock-based compensation expense as a component of:
 
 
 
 
 
Research and development expenses
$
8,836

 
$
4,080

 
$
3,595

General and administrative expenses
10,057

 
8,378

 
7,675

 
$
18,893

 
$
12,458

 
$
11,270


Stock Plans

In May 2009, the Company’s stockholders approved the amendment and restatement of the Company’s 2002 Stock Incentive Plan (the “Amended 2002 Plan”). The Company’s 2002 Stock Incentive Plan was amended to (i) increase the number of shares available for issuance under the Amended 2002 Plan by 1.3 million shares, (ii) revise the list of performance criteria that may be used by the compensation committee for purposes of granting awards under the Amended 2002 Plan that are intended to qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code, as amended, and (iii) eliminate the automatic option grant program for non-employee directors, the director fee stock issuance program and the director fee option grant program, which programs have been superseded by the Company’s amended and restated Director Compensation Policy. Additionally, in May 2012 and May 2016, the Company’s stockholders approved an amendment and restatement of the Company’s 2002 Stock Incentive Plan to increase the number of shares available for issuance by 1.8 million and 0.9 million shares, respectively. As of December 31, 2016, there were 1.0 million shares available for future option grants or direct issuance under the Amended 2002 Plan.

67

Following is a summary of the Company’s stock option plan activity and related information:
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term in
Years
 
Aggregate
Intrinsic
Value
(In  thousands)
Balance at December 31, 2015
1,683,341

 
$
34.19

 
6.48
 
$
124,800

Granted
263,489

 
92.09

 
 
 
 
Exercised
(164,440
)
 
38.08

 
 
 
 
Forfeited
(28,115
)
 
60.17

 
 
 
 
Balance at December 31, 2016
1,754,275

 
42.12

 
6.19
 
104,247

Exercisable at December 31, 2016
1,298,561

 
30.21

 
5.44
 
92,723

Options vested and expected to vest as of December 31, 2016
1,752,275

 
$
42.12

 
6.19
 
$
104,247


The weighted-average grant-date fair value of all stock options granted during 2016, 2015 and 2014 was $46.53, $35.39 and $46.20 per share, respectively. The total intrinsic value of all options exercised during 2016, 2015 and 2014 was approximately $12.0 million, $20.7 million and $15.3 million, respectively.
Cash received from options exercised, net of fees paid, in 2016, 2015 and 2014 was $6.2 million, $8.7 million and $4.4 million, respectively.
Following is a further breakdown of the options outstanding as of December 31, 2016:
 
Range of exercise prices
Options
outstanding
 
Weighted
average
remaining  life
in years
 
Weighted average
exercise price
 
Options
exercisable
 
Weighted average
exercise price
$8.58 - $12.53
247,574

 
3.94
 
$
9.98

 
247,574

 
$
9.98

$10.12 - $12.81
76,100

 
4.92
 
11.38

 
76,100

 
11.38

$14.47 - $14.47
288,887

 
5.11
 
14.47

 
274,887

 
14.47

$16.14 - $21.00
106,242

 
1.85
 
17.76

 
106,242

 
17.76

$21.92 - $21.92
225,105

 
6.13
 
21.92

 
213,199

 
21.92

$32.00 - $53.34
72,330

 
6.02
 
36.18

 
62,747

 
34.73

$56.26 - $59.26
183,595

 
8.11
 
56.26

 
70,877

 
56.26

$63.58 - $68.62
26,382

 
7.50
 
67.20

 
21,976

 
67.50

$74.42 - $74.42
227,856

 
7.12
 
74.42

 
162,233

 
74.42

$85.79 - $138.53
298,204

 
9.03
 
93.19

 
62,726

 
89.71

$8.58 – $138.53
1,752,275

 
6.19
 
$
42.12

 
1,298,561

 
$
30.21


The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:

 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Risk-free interest rate
1.3%-1.9%
 
1.7%-2.0%
 
1.9%
 
Expected volatility
48%-50%
 
50%-58%
 
62%-69%
 
Expected term
6.6 to 6.7 years
 
6.5 years
 
6.0 years
 
Forfeiture rate
5.00%
 
8.52%
 
8.6%-9.7%
 

As of December 31, 2016, there was $17.5 million of total unrecognized compensation cost related to non-vested stock options. That cost is expected to be recognized over a weighted average period of 2.22 years.

68

Restricted Stock Activity
The following is a summary of the Company’s restricted stock activity and related information:
 
 
Shares
 
Weighted-Average
Grant Date Fair
Value
Outstanding at December 31, 2015
130,749

 
$
60.36

Granted
234,855

 
95.31

Vested
(54,421
)
 
66.79

Forfeited
(2,483
)
 
67.95

Outstanding at December 31, 2016
308,700

 
$
86.61

As of December 31, 2016, unrecognized compensation cost related to non-vested stock awards amounted to $13.8 million. That cost is expected to be recognized over a weighted average period of 1.14 years.

Employee Stock Purchase Plan

As of December 31, 2016, 70,406 shares of the Company's common stock are available for future issuance under it's Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 1,961, 3,374 and 3,774 shares issued under the ESPP in 2016, 2015 and 2014, respectively.

Share Repurchases
    
During the years ended December 31, 2016, 2015 and 2014 the Company repurchased 40,500 shares for $3.9 million, 6,120 shares for $0.5 million, and 1,253,425 shares for $68.0 million, respectively.
    
In September 2015, the Company's Board of Directors authorized the Company to repurchase up to $200.0 million of its own stock in privately negotiated and open market transactions for a period of up to three years, subject to the Company's evaluation of market conditions. Authorization to repurchase up to an additional $195.6 million of its common stock remained as of December 31, 2016.






9. Litigation

The Company records an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, The Company records the minimum estimated liability related to the claim in accordance with FASB ASC Topic 450 Contingencies. As additional information becomes available, the Company assesses the potential liability related to its pending litigation and revises its estimates. Revisions in the Company's estimates of potential liability could materially impact its results of operations.

Securities Litigation

In 2012, a federal securities class action and shareholder derivative lawsuit was filed in Pennsylvania alleging that the Company and its chief executive officer assisted various breaches of fiduciary duties based on the Company’s purchase of a licensing interest in a development-stage pharmaceutical program from the Genaera Liquidating Trust in 2010 and the Company’s subsequent sale of half of its interest in the transaction to Biotechnology Value Fund, Inc.  Plaintiff filed a second

69

amended complaint in February 2015, which the Company moved to dismiss in March 2015.  The district court granted the motion to dismiss on November 11, 2015.  The plaintiff has appealed that ruling to the U.S. Third Circuit Court of Appeals.  The Company intends to continue to vigorously defend against the claims against the Company and its chief executive officer.  The outcome of the matter is not presently determinable.

Paragraph IV Certification by Par Pharmaceuticals

On January 7, 2016, the Company received a paragraph IV certification from Par Sterile Products, LLC, a subsidiary of Par Pharmaceuticals, Inc., or Par, advising us that it had filed an ANDA with the FDA seeking approval to market a generic version of Merck’s NOXAFIL-IV product. On February 19, 2016, Merck filed an action against Par in the United States District Court for the District of New Jersey, asserting that Par's manufacture, use or sale of the product for which the ANDA was submitted would infringe Merck's U.S. Patent No. 9,023,790. On October 31, 2016, the parties entered into a consent judgment dismissing all claims, counterclaims, affirmative defenses and demands. The parties have reported to the court that they entered into a confidential settlement agreement, and that they submitted the agreement to the Federal Trade Commission and the United States Department of Justice pursuant to Section 112(a) of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.

Class Action Lawsuit

In November 2016, a putative shareholder class action lawsuit was filed in the United States District Court for the Southern District of California against the Company, its chief executive officer and chief financial officer. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder, and seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company’s securities between November 9, 2015 and November 14, 2016, inclusive. The complaint’s allegations relate generally to the Company’s November 2016 restatement of certain prior period financial statements.  In January 2017, a purported Company shareholder filed a motion for appointment of lead counsel and lead plaintiff. The motion is scheduled to be heard by the Court in March 2017. No trial date has been set. The Company believes that the lawsuit is without merit and intends to vigorously defend against the lawsuit.


10. Income Taxes
The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):

70

 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Current expense (benefit):
 
 
 
 
 
 
Federal
$
21

 
$
11

 
$
15

 
State
12

 
7

 
19

 
 
33

 
18

 
34

 
Deferred expense (benefit):
 
 
 
 
 
 
Federal
10,534

 
(167,413
)
 
406

 
State
(240
)
 
(24,720
)
 
(30
)
 
 
$
10,327

 
$
(192,115
)
 
$
410

 

A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows:
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Amounts computed at statutory federal rate
$
2,786

 
$
13,198

 
$
3,843

State taxes net of federal benefit
175

 
386

 
697

Meals & entertainment
16

 
16

 
9

Imputed interest
(1
)
 
(161
)
 
53

Section 162(m) limitation
94

 
197

 
490

Contingent liabilities
1,225

 
1,684

 
1,748

Stock-based compensation
263

 
140

 
89

Expired NOLs
—

 
232

 
88

Research and development credits
(1,525
)
 
304

 
(113
)
Change in uncertain tax positions
1,423

 
27,188

 
7

Rate change for changes in state law
25

 
(5,756
)
 
119

APIC Excess Tax Benefit True Up

(622
)
 
—

 
—

Increase in deferred tax assets from completion of 382 analysis
(120
)
 
3,329

 
43

Avinza true up
—


(2,107
)

—

Change in valuation allowance
6,283

 
(231,370
)
 
(7,243
)
Other
305

 
605

 
580

 
$
10,327

 
$
(192,115
)
 
$
410

 
    
Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2016 and 2015 are shown below. The Company assesses the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company's evaluation of evidence resulted in management concluding that the majority of the Company's deferred tax assets will be realized. However, the Company maintains a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December 31, 2016, 2015 and 2014. The valuation allowance increased $6.3 million in 2016, decreased $231.7 million in 2015

71

and decreased $7.2 million in 2014.
 
December 31,
 
2016
 
2015
 
(in thousands)
Deferred assets:
 
 
 
Net operating loss carryforwards
$
150,226

 
$
160,595

Research credit carryforwards
26,878

 
25,613

Fixed assets and intangibles
4,385

 
8,839

Accrued expenses
943

 
1,523

Contingent liabilities
578

 
707

Deferred revenue
—

 
3

Present value of royalties
591

 
3,007

Deferred rent
45

 
68

Capital Loss Carryforward
4,432

 
—

Viking Equity Method Investment
5,692

 
1,840

Other
19,312

 
15,441

 
213,082

 
217,636

Valuation allowance for deferred tax assets
(15,349
)
 
(9,066
)
Net deferred tax assets
$
197,733

 
$
208,570

Deferred tax liabilities:
 
 
 
Retrophin fair value adjustment
$
(52
)
 
$
(1,256
)
Convertible debt
(1,196
)
 
(1,844
)
Identified intangibles
(68,631
)
 
(12,770
)
Identified indefinite lived intangibles
(3,963
)
 
(3,617
)
Total
$
123,891

 
$
189,083


    
Sections 382 and 383 of the U.S. tax code impose limitations (“382 and 383 limitations”) on the annual utilization of operating loss and credit carryforwards whenever a greater than fifty percent change in the ownership of a company occurs within a three year period. In addition to the annual limitations on operating loss and credit carryforwards, Section 382 can also restrict the utilization of certain post change losses if the tax basis in assets exceeds the fair value of assets (“net unrealized built in loss”) at the date of an ownership change. Companies with operating loss and credit carryforwards are required to test the cumulative three year change whenever there is an equity transaction that impacts the ownership of holders of more than five percent of the Company’s stock. During 2016, the Company completed a rollforward analysis through December 31, 2016. As a result of the rollforward analysis, it was determined that no additional ownership changes occurred at the Company within the meaning of section 382 since June 20, 2007. Future changes in the ownership of the Company could place additional restrictions on the Company’s ability to utilize operating loss and credit carryforwards arising through December 31, 2016.

As of December 31, 2016, the Company had federal and state net operating loss carryforwards set to expire through 2036 of $446.3 million and $140.5 million of state net operating loss carryforwards. The Company also has $21.9 million of federal research and development credit carryforwards, which expire through 2036. The Company has $19.4 million of California research and development credit carryforwards that have no expiration date.  
The Company accounts for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company’s remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.
A reconciliation of the amount of unrecognized tax benefits at December 31, 2016, 2015 and 2014 is as follows (in thousands):

72

 
December 31,
 
2016
 
2015
 
2014
Balance at beginning of year
$
36,452

 
$
8,524

 
$
8,504

     Additions based on tax positions related to the current year
70

 
154

 
40

     Additions for tax positions of prior years
2,408

 
28,224

 
—

     Reductions for tax positions of prior years
(160
)
 
(450
)
 
(20
)
Balance at end of year
$
38,770

 
$
36,452

 
$
8,524


Included in the balance of unrecognized tax benefits at December 31, 2016 is $35.5 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2016 and December 31, 2015, the Company recognized an immaterial amount of interest and penalties. The Company files income tax returns in the United States and in various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2013 tax year to present.  The state income tax returns generally remain open for the 2012 tax years through present.  Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.

In March 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting (''ASU 2016-09''). ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements.  ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. The Company will adopt this ASU in the first quarter of 2017. The Company has excess tax federal and state benefits for which a benefit could not be previously recognized of approximately $13.7 million and $11.5 million, respectively. Upon adoption the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption.  

11. Summary of Unaudited Quarterly Financial Information

The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for fiscal years 2016 and 2015 are as follows (in thousands, except per share amounts):

73

 
First Quarter
 
Second Quarter
 
 Third Quarter
 
Fourth Quarter
2016
 
 
 
 
 
 
 
Total revenues
$
29,648

 
$
19,521

 
$
21,619

 
$
38,185

Total operating costs and expenses
14,552

 
15,552

 
16,153

 
18,831

Income tax (expense) benefit
(3,694
)
 
3,881

 
(160
)
 
(10,354
)
Income (loss) from continuing operations
5,877

 
(6,170
)
 
1,051

 
(3,125
)
Income from discontinued operations
731

 
—

 
—

 
—

Net income (loss)
6,608

 
(6,170
)
 
1,051

 
(3,125
)
Basic per share amounts:
 
 
 
 
 
 
 
     Net income (loss)
$
0.32

 
$
(0.30
)
 
$
0.05

 
$
0.15

Diluted per share amounts:
 
 
 
 
 
 
 
     Net income (loss)
0.30

 
(0.30
)
 
0.05

 
0.15

 
 
 
 
 
 
 
 
Weighted average shares—basic
20,708

 
20,832

 
20,887

 
20,898

Weighted average shares—diluted
22,284

 
20,832

 
22,997

 
20,898

 
 
 
 
 
 
 
 
2015
 
 
 
 
 
 
 
Total revenues
$
14,602

 
$
18,418

 
$
17,701

 
$
21,193

Total operating costs and expenses
11,253

 
14,053

 
9,104

 
10,175

Income tax (expense) benefit
(15
)
 
(265
)
 
191,881

 
514

(Loss) income from continuing operations
(89
)
 
22,027

 
199,165

 
6,341

Net loss attributable to noncontrolling interests
(843
)
 
(1,537
)
 
—

 
—

Net income
754

 
23,564

 
199,165

 
6,341

Basic per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.19

 
$
10.01

 
$
0.32

Diluted per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.11

 
$
9.28

 
$
0.29

 
 
 
 
 
 
 
 
Weighted average shares—basic
19,612

 
19,725

 
19,887

 
19,933

Weighted average shares—diluted
20,631

 
21,276

 
21,460

 
21,542




Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
 

Item 9A.
Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures

We are responsible for maintaining disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer,

74

of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, and have concluded our disclosure controls and procedures were not effective at a reasonable assurance level as of December 31, 2016. This conclusion was based on the material weakness identified in our internal control over financial reporting, as described in (b) below.

A material weakness is defined as “a deficiency, or a combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.”

In light of the material weakness described below, we performed additional analysis and other procedures to ensure that our consolidated financial statements included in this Annual Report on Form 10-K were prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Notwithstanding the existence of the material weakness in internal control over financial reporting, we believe that our consolidated balance sheets as of December 31, 2016 and 2015 and the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for the years ended December 31, 2016, 2015 and 2014 included in this Annual Report on Form 10-K fairly present, in all material respects, the Company’s financial condition, results of operations and cash flows for the periods presented therein in conformity with GAAP.

Changes in Internal Control over Financial Reporting

As disclosed in Form 10-K/A for the year ended December 31, 2015, we have identified material weaknesses in internal control over financial reporting:

(1) A material weakness in the design of our internal control over the tax accounting for complex transactions that have a significant tax impact, specifically, management did not have adequate supervision and review of certain technical tax accounting performed by third party tax specialists.    

(2) A material weakness in the design of our internal control over the presentation and disclosure of our 2019 convertible senior notes, specifically, management review control is not precise and adequate to capture the appropriate presentation and disclosure of our 2019 convertible senior notes that is triggered by certain specific contractual conditions.

To remediate the material weakness described in (1) above and to prevent similar deficiencies in the future, we are implementing additional controls and procedures, which includes but are not limited to:

•
engagement of additional independent third party tax experts to assist or review in the tax accounting for non-routine, complex transactions or give a “second opinion” on the same transaction; and

•
additional training for staff involved in the tax accounting for non-routine, complex transactions

While we continue to strive to improve the respective process and controls over management supervision and review of certain technical tax accounting prepared by third parties, we do not believe the new controls have been functioning for sufficient time for management to conclude the material weakness has been remediated at December 31, 2016

With regards to the material weakness described in (2) above, subsequent to the third and fourth quarter of 2016, we undertook the following steps to remediate the identified material weakness:

•
Developed and refined certain spreadsheet tools to enhance the precision of the review for various inputs including our stock price, which would trigger the early conversion conditions under the debt indenture agreement;
•
Implemented additional management reviews of the presentation including the classification and presentation of our convertible debt; and
•
Hired additional accounting personnel to assist with the review of the presentation and classification of our convertible debt as well as overall external financial reporting

Except for the changes mentioned above, there have been no changes in our internal control over financial reporting that occurred in our fourth fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(b) Management’s Report on Internal Control over Financial Reporting

75


Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles; providing reasonable assurance that receipts and expenditures are made in accordance with our management and directors; and providing reasonable assurance that
unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework established by the COSO as set forth in the 2013 Internal Control-Integrated Framework. Based on our evaluation under the 2013 framework in Internal Control - Integrated Framework, management concluded that our internal controls over financial reporting were not effective as of December 31, 2016 because the following material weakness identified in the year ended December 31, 2015 has not been remediated:

A material weakness in the design of our internal control over the tax accounting for complex transactions that have a significant tax impact, specifically, management did not have adequate supervision and review of certain technical tax accounting performed by third party tax specialists.

Ernst & Young LLP, an independent registered public accounting firm, has audited the Company’s consolidated financial statements included in this Annual Report on Form 10-K and has issued an attestation report, included herein, on the effectiveness of our internal control over financial reporting as of December 31, 2016.

    
































76


Report of Ernst & Young LLP, Independent Registered Public Accounting Firm

The Board of Directors and Stockholders of
Ligand Pharmaceuticals Incorporated
We have audited Ligand Pharmaceuticals Incorporated’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). Ligand Pharmaceutical Incorporated’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment. Management has identified a material weakness in controls related to the Company’s design of internal control over the tax accounting for complex transactions that have a significant tax impact, specifically, management did not have adequate supervision and review of certain technical tax accounting performed by third party tax specialists. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Ligand Pharmaceuticals Incorporated as of December 31, 2016 and the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for the year then ended. This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the 2016 financial statements, and this report does not affect our report dated February 28, 2017, which expressed an unqualified opinion on those financial statements.
In our opinion, because of the effect of the material weakness described above on the achievement of the objectives of the control criteria, Ligand Pharmaceuticals Incorporated has not maintained effective internal control over financial reporting as of December 31, 2016, based on the COSO criteria.
/s/ Ernst & Young LLP
San Diego, California
February 28, 2017






77




78

Part III
 
Item 10.
Directors, Executive Officers and Corporate Governance
Code of Conduct
The Board of Directors has adopted a Code of Conduct and Ethics Policy (“Code of Conduct”) that applies to all officers, directors and employees. The Company will promptly disclose any material amendment or waiver to the Code of Conduct which affects any corporate officer. The Code of Conduct can be accessed via our website (http://www.ligand.com), Corporate Overview page. You may also request a free copy by writing to: Investor Relations, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA 92121.
The other information under Item 10 is hereby incorporated by reference to Ligand’s Definitive Proxy Statement to be filed with the SEC on or prior to April 29, 2017. 
 
Item 11.
Executive Compensation
Item 11 is hereby incorporated by reference to Ligand’s Definitive Proxy Statement to be filed with the SEC on or prior to April 29, 2017.
 
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 12 is hereby incorporated by reference to Ligand’s Definitive Proxy Statement to be filed with the SEC on or prior to April 29, 2017.
 
Item 13.
Certain Relationships and Related Transactions, and Director Independence
Item 13 is hereby incorporated by reference to Ligand’s Definitive Proxy Statement to be filed with the SEC on or prior to April 29, 2017.
 
Item 14.
Principal Accountant Fees and Services
Item 14 is hereby incorporated by reference to Ligand’s Definitive Proxy Statement to be filed with the SEC on or prior to April 29, 2017.

79

PART IV
 
Item 15.
Exhibits and Financial Statement Schedule
(a) The following documents are included as part of this Annual Report on Form 10-K.
(1) Financial statements
 
(2) Schedules not included herein have been omitted because they are not applicable or the required information is in the consolidated financial statements or notes thereto.
(3) The following exhibits are filed as part of this Form 10-K and this list includes the Exhibit Index.
 
 
 
Incorporated by Reference
 
Exhibit
Number
Description of Exhibit
Form
File Number
Date of Filing
Exhibit
Number
Filed
Herewith
2.1
Agreement and Plan of Merger, dated January 14, 2011 by and among the Company, CyDex Pharmaceuticals, Inc., and Caymus Acquisition, Inc.,
8-K
001-33093
January 26, 2011
10.1
 
2.2
Agreement and Plan of Merger, dated as of December 17, 2015, by and among Ligand Pharmaceuticals Incorporated, Open Monoclonal Technology, Inc., OMT, LLC, Schrader 1 Acquisition, Inc., Schrader 2 Acquisition, Inc. and Fortis Advisors LLC
8-K
001-33093
December 18, 2015
2.1
 
3.1
Amended and Restated Certificate of Incorporation of the Company.
S-4
333-58823
July 9, 1998
3.1
 
3.2
Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2000
10-K
0-20720
March 29, 2001
3.5
 
3.3
Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 30, 2004
10-Q
0-20720
August 5, 2004
3.6
 
3.4
Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010
8-K
001-33093
November 19, 2010
3.1
 
3.5
Amended Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock of the Company
10-Q
0-20720
May 14, 1999
3.3
 
3.6
Third Amended and Restated Bylaws of the Company
8-K
001-33093
September 10, 2015
3.1
 
4.1
Specimen stock certificate for shares of the common stock of the Company
S-1
33-47257
April 16, 1992
 
 
4.2
2006 Preferred Shares Rights Agreement, by and between the Company and Mellon Investor Services LLC, dated October 13, 2006
8-K
000-20720
October 17, 2006
4.1
 
4.3
First Amendment to 2006 Preferred Shares Rights Agreement, by and between the Company and Computershare Shareowner Services LLC (f/k/a Mellon Investor Services LLC), dated June 19, 2013
8-K
001-33093
June 20, 2013
4.1
 

80

4.4
Indenture dated August 18, 2014 between the Company and Wilmington Trust, National Association
8-K
001-33093
August 18, 2014
4.1
 
10.1#
Form of Indemnification Agreement between the Company and each of its directors
S-1
33-47257
April 16, 1992
 
 
10.2#
Form of Indemnification Agreement between the Company and each of its officers
S-1
33-47257
April 16, 1992
 
 
10.3#
2002 Stock Incentive Plan (as amended and restated through May 23, 2016)
S-8
333-212775
July 29, 2016
10.1
 
10.4#
2002 Employee Stock Purchase Plan (as amended effective July 1, 2009)
S-8
333-160132
June 22, 2009
10.2
 
10.5#
Form of Stock Option Grant Notice and Stock Option Agreement under the Company’s 2002 Stock Incentive Plan
10-K
001-33093
February 24, 2014
10.5
 
10.6#
Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company’s 2002 Stock Incentive Plan
10-K
001-33093
March 12, 2004
 
 
10.7#
Form of Stock Issuance Agreement for non-employee directors under the Company’s 2002 Stock Incentive Plan
S-1
333-131029
January 13, 2006
10.289
 
10.8#
Form of Letter Agreement regarding Change of Control Severance Benefits between the Company and its officers
10-K
001-33093
March 16, 2007
10.309
 
10.9#
Form of Executive Officer Change in Control Severance Agreement
8-K
001-33093
August 22, 2007
10.1
 
10.10#
Amended and Restated Severance Plan, dated December 20, 2008
8-K
001-33093
December 24, 20008
10.2
 
10.11#
Amended and Restated Director Compensation and Stock Ownership Policy, effective as of June 1, 2011
10-Q
001-33093
August 8, 2011
10.24
 
10.12#
Letter Agreement by and between the Company and John L. Higgins, dated January 10, 2007
8-K
001-33093
January 16, 2007
10.1
 
10.13†
Research, Development and License Agreement, dated December 29, 1994, between SmithKline Beecham Corporation and the Company .
S-1
S-3
33-87598
33-87600
December 20, 1994
 
 
10.14†
Amended and Restated Research, Development and License Agreement, dated December 1, 2005, between the Company and Wyeth (formerly American Home Products Corporation)
S-1
333-131029
January 13, 2006
10.287
 
10.15
Purchase Agreement, by and between the Company, King Pharmaceuticals, Inc. and King Pharmaceuticals Research and Development, Inc., dated September 6, 2006
8-K
000-20720
September 11, 2006
2.1
 
10.16
Loan Agreement by and between the Company and King Pharmaceuticals, 303 Inc., dated October 12, 2006
10-K
001-33093
March 16, 2006
10.303
 
10.17
Letter Agreement by and between the Company and King Pharmaceuticals, Inc. effective as of December 29, 2006
8-K
001-33093
January 5, 2007
10.1
 
10.18
Amendment Number 2 to Purchase Agreement, by and between the Company and King Pharmaceuticals, Inc., effective February 26, 2007.
8-K
001-33093
February 28, 2007
2.1
 
10.19
Amendment to Lease, dated September 10, 2007, between Pharmacopeia, Inc. and Eastpark at 8A (Building 1000)
10-Q
000-50523
November 5, 2007
10.1
 
10.42
Lease, dated August 20, 2003, between Pharmacopeia, Inc. and Eastpark at 8A (Building 3000)
10-K
001-33093
March 16, 2009
10.327
 
10.21
Amendment to Lease, dated April 18, 2007, between Pharmacopeia, Inc. and Eastpark at 8A (Building 3000)
10-Q
000-50523
November 5, 2007
10.2
 
10.22†
Collaboration and License Agreement, dated July 9, 2003 and effective August 8, 2003, between Pharmacopeia, Inc. and Schering-Plough Ltd
10-K
001-33093
March 16, 2009
10.324
 
10.23†
Collaboration and License Agreement, dated July 9, 2003 and effective August 8, 2003, between Pharmacopeia, Inc. and Schering Corporation
10-K
001-33093
March 16, 2009
10.325
 

81

10.24
Amendment No. 1, dated July 27, 2006, to the Collaboration and License Agreements, effective as of July 9, 2003, between (i) Pharmacopeia, Inc. and Schering Corporation and (ii) Pharmacopeia, Inc. and Schering-Plough Ltd.
8-K
000-50523
August 2, 2006
10.1
 
10.25
Settlement Agreement and Mutual Release, by and between the Company and The Rockefeller University, dated February 11, 2009
10-Q
001-33093
May 11, 2009
10.318
 
10.26
TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC
8-K
001-33093
January 28, 2010
10.2
 
10.27
Glucagon Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC
8-K
001-33093
January 28, 2010
10.3
 
10.28
General Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC
8-K
001-33093
January 28, 2010
10.4
 
10.29
Amendment of General Contingent Value Rights Agreement, dated January 26, 2011, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC
8-K
001-33093
January 31, 2011
10.1
 
10.30
Purchase and Sale Agreement, dated May 18, 2010, between the Company and The Genaera Liquidating Trust
8-K
001-33093
May 24, 2010
10.1
 
10.31
Purchase Agreement, dated May 20, 2010, between the Company and Biotechnology Value Fund, L.P., on its own behalf and on behalf of Biotechnology Value Fund II, L.P. and Investment 10, L.L.C.
10-Q
001-33093
August 5, 2010
10.1
 
10.32
Contingent Value Rights Agreement, by and among the Company, CyDex Pharmaceuticals, Inc., and Allen K. Roberson and David Poltack, acting jointly as Shareholders’ Representative, dated January 14, 2011
8-K
001-33093
January 26, 2011
10.2
 
10.33†
Captisol® Supply Agreement, dated December 20, 2002, among CyDex, Inc., Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited and Hovione International Limited
10-K
001-33093
March 3, 2011
10.100
 
10.34†
1st Amendment to Captisol® Supply Agreement, dated July 29, 2005, among CyDex, Inc., Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited and Hovione International Limited
10-K
001-33093
March 3, 2011
10.101
 
10.35
2nd Amendment to Captisol® Supply Agreement, dated March 1, 2007, among CyDex, Inc., Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited, and Hovione International Limited
10-K
001-33093
March 3, 2011
10.102
 
10.36†
3rd Amendment to Captisol® Supply Agreement, dated January 25, 2008, among CyDex, Inc., Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited, and Hovione International Limited
10-K
001-33093
March 3, 2011
10.103
 
10.37†
4th Amendment to Captisol® Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione LLC, Hovione FarmaCiencia S.A., Hovione Pharmascience Limited and Hovione International Limited
10-K
001-33093
March 3, 2011
10.104
 
10.38†
License Agreement, dated September 3, 1993, between CyDex L.C. and The University of Kansas
10-K
001-33093
March 3, 2011
10.105
 
10.39†
Second Amendment to License Agreement, dated August 4, 2004, between CyDex, Inc. and The University of Kansas
10-K
001-33093
March 3, 2011
10.107
 
10.40†
Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas
10-K
001-33093
March 3, 2011
10.111
 
10.41†
Exclusive License Agreement, dated June 4, 1996, between Pfizer, Inc. and The University of Kansas
10-K
001-33093
March 3, 2011
10.108
 

82

10.42†
Nonexclusive License Agreement, dated June 4, 1996, between Pfizer, Inc. and The University of Kansas
10-K
001-33093
March 3, 2011
10.109
 
10.43†
Addendum to Nonexclusive License Agreement, dated December 11, 2001, between CyDex, Inc. and Pfizer, Inc.
10-K
001-33093
March 3, 2011
10.110
 
10.44†
License Agreement, dated January 4, 2006, between CyDex, Inc. and Prism Pharmaceuticals, Inc.
10-K
001-33093
March 3, 2011
10.112
 
10.45†
Amendment to License Agreement, dated May 12, 2006, between CyDex, Inc. and Prism Pharmaceuticals, Inc.
10-K
001-33093
March 3, 2011
10.113
 
10.46†
Supply Agreement, dated March 5, 2007, between CyDex, Inc. and Prism Pharmaceuticals, Inc.
10-K
001-33093
March 3, 2011
10.114
 
10.47†
License and Supply Agreement, dated October 12, 2005, between CyDex Pharmaceuticals, Inc. and Proteolix, Inc.
10-K
000-28298
February 23, 2010
10.22
 
10.48†
Supply Agreement, dated June 13, 2011 by and between CyDex Pharmaceuticals, Inc. and Merck Sharp & Dohme Corporation
10-Q
001-33093
June 30, 2011
10.27
 
10.49†
License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013
10-Q
001-33093
May 8, 2013
10.2
 
10.50†
Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013
10-Q
001-33093
May 8, 2013
10.3
 
10.51†
Royalty Stream and Milestone Payments Purchase Agreement, dated April 29, 2013, between the Company and Selexis S.A.
10-Q
001-33093
August 1, 2013
10.2
 
10.52
Amendment of “General” Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare Inc.
8-K
001-33093
May 22, 2014
10.1
 
10.53
Amendment of “TR Beta” Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare, Inc.
8-K
001-33093
May 22, 2014
10.2
 
10.54†
Loan and Security Agreement dated May 21, 2014 between the Company and Viking Therapeutics, Inc.
10-Q
001-33093
August 5, 2014
10.1
 
10.55†
Master License Agreement dated May 21, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.
10-Q
001-33093
August 5, 2014
10.2
 
10.56
Letter Agreement, dated as of August 12, 2014, between Bank of America, N.A. and the Company regarding the Base Convertible Note Hedge Transaction
8-K
001-33093
August 18, 2014
10.1
 
10.57
Letter Agreement, dated as of August 12, 2014, between Bank of America, N.A. and the Company regarding the Base Issuer Warrant Transaction
8-K
001-33093
August 18, 2014
10.2
 
10.58
Letter Agreement, dated as of August 12, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Base Convertible Bond Hedge Transaction
8-K
001-33093
August 18, 2014
10.3
 
10.59
Letter Agreement, dated as of August 12, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Base Issuer Warrant Transaction
8-K
001-33093
August 18, 2014
10.4
 
10.60
Letter Agreement, dated as of August 14, 2014, between Bank of America, N.A. and the Company regarding the Additional Convertible Bond Hedge Transaction
8-K
001-33093
August 18, 2014
10.5
 
10.61
Letter Agreement, dated as of August 14, 2014, between Bank of America, N.A. and the Company regarding the Additional Issuer Warrant Transaction
8-K
001-33093
August 18, 2014
10.6
 
10.62
Letter Agreement, dated as of August 14, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Additional Convertible Bond Hedge Transaction
8-K
001-33093
August 18, 2014
10.7
 

83

10.63
Letter Agreement, dated as of August 14, 2014, between Deutsche Bank AG, London Branch and the Company regarding the Additional Issuer Warrant Transaction
8-K
001-33093
August 18, 2014
10.8
 
10.64†
First Amendment to Master License Agreement dated September 6, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.
10-Q
001-33093
October 31, 2014
10.9
 
10.65†
Second Amendment to Master License Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.
10-Q
001-33093
August 5, 2015
10.1
 
10.66†
First Amendment to Loan and Security Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.
10-Q
001-33093
August 5, 2015
10.2
 
10.67†
Amendment No. 4 to Sublicense Agreement, dated September 17, 2015, among the Company, Pharmacopeia, LLC and Retrophin, Inc.
10-Q/A
001-33093
December 23, 2015
10.1
 
10.68†
Lease, dated November 3, 2015, between the Company and 3911/3931 SVB, LLC
8-K
001-33093
November 10, 2015
10.1
 
10.69#
Amended and Restated Director Compensation and Stock Ownership Policy, effective as of March 2014
10-Q
001-33093
November 14, 2016
10.1
 
10.70†
Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.
8-K/A
001-33093
May 9, 2016
10.1
 
10.71
Second Amendment to Loan and Security Agreement, dated January 22, 2016, between the Company and Viking Therapeutics, Inc.
10-Q/A
001-33093
November 14, 2016
10.1
 
21.1
Subsidiaries of the Company
10-K
001-33093
February 23, 2012
21.1
 
23.1
Consent of independent registered public accounting firm-Ernst & Young LLP
 
 
 
 
X
23.2
Consent of independent registered public accounting firm-Grant Thornton LLP
 
 
 
 
X
31.1
Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
X
31.2
Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
X
32.1
Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
X
101.INS
XBRL Instance Document.
 
 
 
 
 
101.SCH
XBRL Taxonomy Extension Schema Document.
 
 
 
 
 
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document.
 
 
 
 
 
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document.
 
 
 
 
 
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document.
 
 
 
 
 

†
Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and submitted separately to the Securities and Exchange Commission.
#
Indicates management contract or compensatory plan.



84

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LIGAND PHARMACEUTICALS INCORPORATED
 
 
By:
/S/    JOHN L. HIGGINS        
 
John L. Higgins,
 
Chief Executive Officer
Date: February 28, 2017
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Signature
 
Title
 
Date
 
 
 
 
 
/s/    JOHN L. HIGGINS
 
Chief Executive Officer and Director (Principal Executive Officer)
 
February 28, 2017
John L. Higgins
 
 
 
 
 
 
 
/s/    MATTHEW KORENBERG
 
Vice President, Finance and Chief Financial Officer (Principal Financial and Accounting Officer)
 
February 28, 2017
Matthew Korenberg
 
 
 
 
 
 
 
/s/    TODD C. DAVIS
 
Director
 
February 28, 2017
Todd C. Davis
 
 
 
 
 
 
 
/s/    SUNIL PATEL
 
Director
 
February 28, 2017
Sunil Patel
 
 
 
 
 
 
 
/s/    STEPHEN L. SABBA
 
Director
 
February 28, 2017
Stephen L. Sabba
 
 
 
 
 
 
 
 
 
 
 
 
/s/    John W. Kozarich
 
Director
 
February 28, 2017
John W. Kozarich
 
 
 
 
 
 
 
/s/    John L. Lamattina
 
Director
 
February 28, 2017
John L. Lamattina
 
 
 
 
 
 
 
/s/    Jason M. Aryeh
 
Director
 
February 28, 2017
Jason M. Aryeh
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


85
 EX-23.1 2 lgnd_123116xexhibit231.htm EXHIBIT 23.1 Exhibit
Exhibit 23.1

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:
 
(1) Registration Statement (Form S-3 No. 333-208919) of Ligand Pharmaceuticals Incorporated,
 
(2) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,

(3) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,

(4) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and

(5) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated;
  
of our reports dated February 28, 2017, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December 31, 2016.
 

/s/ Ernst & Young LLP
 
San Diego, California
February 28, 2017


 EX-23.2 3 lgnd_123116xexhibit232.htm EXHIBIT 23.2 Exhibit
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated February 26, 2016 (except for 2015 Restatement described in Note 1 in the previously filed 2015 financial statements, which is not presented herein and is as of November 14, 2016) with respect to the consolidated financial statements included in the Annual Report of Ligand Pharmaceuticals Incorporated on Form 10-K for the year ended December 31, 2015. We consent to the incorporation by reference of said report in the Registration Statements of Ligand Pharmaceuticals Incorporated on Forms S-3 (File No. 333-208919 and 333-191523) and on Forms S-8 (File No. 333-182547, File No. 333-160132 and File No. 333-131029).
/s/ GRANT THORNTON LLP
San Diego, California
February 28, 2017


EX-31.1 4 lgnd_123116xexhibit311.htm EXHIBIT 31.1 Exhibit
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002



I, John L. Higgins, certify that:

1.
I have reviewed this Annual Report on Form 10K of Ligand Pharmaceuticals Incorporated;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and



Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:   February 28, 2017
/s/ John L. Higgins
John L. Higgins
Chief Executive Officer
(Principal Executive Officer)



 EX-31.2 5 lgnd_123116xexhibit312.htm EXHIBIT 31.2 Exhibit
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002






I, Matthew Korenberg, certify that:

1.
I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and



Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002





b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:    February 28, 2017

/s/ Matthew Korenberg
Matthew Korenberg
Vice President, Finance and Chief Financial Officer
(Principal Financial Officer)



 EX-32.1 6 lgnd_123116xexhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John L. Higgins, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
February 28, 2017
 
/s/ John L. Higgins
 
 
 
John L. Higgins
Chief Executive Officer
(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthew Korenberg, Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and





(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
February 28, 2017
 
 
/s/ Matthew Korenberg
 
 
 
Matthew Korenberg
Vice President, Finance and Chief Financial Officer
(Principal Financial Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.





 EX-101.INS 7 lgnd-20151231.xml XBRL INSTANCE DOCUMENT 0000886163 2016-01-01 2016-12-31 0000886163 2016-06-30 0000886163 2017-02-09 0000886163 2016-12-31 0000886163 2015-12-31 0000886163 2014-01-01 2014-12-31 0000886163 2015-01-01 2015-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0000886163 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000886163 us-gaap:RetainedEarningsMember 2015-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000886163 us-gaap:RetainedEarningsMember 2013-12-31 0000886163 us-gaap:CommonStockMember 2013-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000886163 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0000886163 us-gaap:NoncontrollingInterestMember 2014-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000886163 2013-12-31 0000886163 us-gaap:CommonStockMember 2014-12-31 0000886163 us-gaap:CommonStockMember 2015-12-31 0000886163 us-gaap:CommonStockMember 2016-12-31 0000886163 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-12-31 0000886163 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000886163 us-gaap:RetainedEarningsMember 2014-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000886163 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0000886163 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0000886163 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0000886163 us-gaap:NoncontrollingInterestMember 2014-01-01 2014-12-31 0000886163 2014-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000886163 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000886163 us-gaap:RetainedEarningsMember 2016-12-31 0000886163 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0000886163 lgnd:PurchaseofCommonStockMember 2014-01-01 2014-12-31 0000886163 lgnd:PurchaseofCommonStockMember 2016-01-01 2016-12-31 0000886163 lgnd:VikingTherapeuticsInc.Member 2016-01-01 2016-12-31 0000886163 lgnd:VikingTherapeuticsInc.Member 2014-01-01 2014-12-31 0000886163 lgnd:VikingTherapeuticsInc.Member 2015-01-01 2015-12-31 0000886163 lgnd:PurchaseofCommonStockMember 2015-01-01 2015-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerAMember 2015-01-01 2015-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerAMember 2016-01-01 2016-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerCMember 2016-01-01 2016-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerBMember 2014-01-01 2014-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerBMember 2016-01-01 2016-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerCMember 2014-01-01 2014-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerBMember 2015-01-01 2015-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerCMember 2015-01-01 2015-12-31 0000886163 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember lgnd:PartnerAMember 2014-01-01 2014-12-31 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember 2016-01-01 2016-12-31 0000886163 lgnd:TwoThousandTwoStockIncentivePlanMember us-gaap:DirectorMember 2016-01-01 2016-12-31 0000886163 lgnd:MetabasisTherapeuticsMember 2010-01-31 0000886163 us-gaap:MaximumMember 2016-01-01 2016-12-31 0000886163 us-gaap:MinimumMember 2016-01-01 2016-12-31 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember lgnd:VestingPeriodOneMember 2016-01-01 2016-12-31 0000886163 lgnd:CorMatrixMember 2016-12-31 0000886163 us-gaap:DirectorMember 2016-12-31 0000886163 us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-12-31 0000886163 lgnd:CorMatrixMember 2016-01-01 2016-12-31 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember lgnd:VestingPeriodTwoMember 2016-01-01 2016-12-31 0000886163 us-gaap:EquityMethodInvesteeMember us-gaap:CommonStockMember us-gaap:IPOMember 2015-05-01 2015-05-31 0000886163 us-gaap:EquityMethodInvesteeMember 2016-04-01 2016-04-30 0000886163 us-gaap:CommonStockMember 2015-05-01 2015-05-31 0000886163 us-gaap:EquityMethodInvesteeMember us-gaap:CommonStockMember us-gaap:IPOMember 2015-05-31 0000886163 us-gaap:EquityMethodInvesteeMember 2016-04-13 2016-04-13 0000886163 us-gaap:EquityMethodInvesteeMember 2016-01-31 0000886163 us-gaap:EquityMethodInvesteeMember 2016-04-30 0000886163 us-gaap:EquityMethodInvesteeMember 2015-12-31 0000886163 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-05-01 2014-05-31 0000886163 us-gaap:DebtMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-05-01 2014-05-31 0000886163 us-gaap:EquityMethodInvesteeMember 2016-01-01 2016-01-31 0000886163 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-05-01 2015-05-31 0000886163 us-gaap:DebtMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-04-01 2015-04-30 0000886163 us-gaap:EquityMethodInvesteeMember 2016-12-31 0000886163 us-gaap:EquityMethodInvesteeMember 2016-01-01 2016-12-31 0000886163 lgnd:OMTInc.Member 2016-01-08 0000886163 lgnd:OMTInc.Member 2016-01-08 2016-01-08 0000886163 lgnd:OMTInc.Member 2015-01-01 2015-12-31 0000886163 lgnd:OMTInc.Member 2016-10-01 2016-12-31 0000886163 lgnd:OMTInc.Member 2016-01-01 2016-12-31 0000886163 lgnd:OMTInc.Member 2015-10-01 2015-12-31 0000886163 lgnd:OMTInc.Member us-gaap:DevelopedTechnologyRightsMember 2016-01-08 2016-01-08 0000886163 lgnd:OMTInc.Member us-gaap:DevelopedTechnologyRightsMember 2016-01-08 0000886163 lgnd:OMTInc.Member 2016-01-01 2016-01-07 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:SeniorNotesMember 2016-12-31 0000886163 lgnd:CydexPharmaceuticalsIncMember 2015-01-01 2015-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2015-01-01 2015-12-31 0000886163 lgnd:VikingTherapeuticsInc.Member 2016-12-31 0000886163 lgnd:CydexPharmaceuticalsIncMember 2016-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2016-01-01 2016-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:CurrentPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:CurrentPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:NotesReceivableMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:CurrentPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 lgnd:CurrentPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel2Member lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 lgnd:LiabilityForRestrictedInvestmentsOwedToFormerLicenseesMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel3Member lgnd:LiabilityForContingentValueRightCompanyOneMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 us-gaap:FairValueInputsLevel1Member lgnd:CurrentPortionOfLiabilityForContingentValueRightsCompanyMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000886163 lgnd:CydexPharmaceuticalsIncMember 2016-01-01 2016-12-31 0000886163 us-gaap:ContractTerminationMember 2016-01-01 2016-12-31 0000886163 lgnd:CorporateHeadquartersSanDiegoCAMember stpr:CA 2016-05-01 2016-05-31 0000886163 us-gaap:ContractTerminationMember 2015-01-01 2015-12-31 0000886163 lgnd:BioscienceandTechnologyBusinessCenterLawrenceKSMember stpr:KS 2016-01-01 2016-12-31 0000886163 lgnd:OfficeandResearchFacilityLaJollaCAMember stpr:CA 2016-01-01 2016-12-31 0000886163 lgnd:OfficeandResearchFacilityLaJollaCAMember stpr:CA 2016-12-31 0000886163 lgnd:CorporateHeadquartersSanDiegoCAMember stpr:CA 2016-01-01 2016-12-31 0000886163 lgnd:CorporateHeadquartersSanDiegoCAMember stpr:CA 2016-12-31 0000886163 lgnd:BioscienceandTechnologyBusinessCenterLawrenceKSMember stpr:KS 2016-12-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember 2015-12-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember 2016-12-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:SeniorNotesMember 2014-08-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:SeniorNotesMember 2016-01-01 2016-12-31 0000886163 2014-08-01 2014-08-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2014-08-01 2014-08-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2014-08-01 2014-08-31 0000886163 2014-08-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:SeniorNotesMember 2014-08-01 2014-08-31 0000886163 lgnd:A2019ConvertibleSeniorNotesMember us-gaap:SeniorNotesMember 2015-12-31 0000886163 us-gaap:SeniorNotesMember 2014-08-01 2014-08-31 0000886163 us-gaap:EquitySecuritiesMember 2016-12-31 0000886163 us-gaap:CorporateDebtSecuritiesMember 2016-12-31 0000886163 us-gaap:DemandDepositsMember 2016-12-31 0000886163 us-gaap:DemandDepositsMember 2015-12-31 0000886163 us-gaap:USTreasurySecuritiesMember 2016-12-31 0000886163 us-gaap:ShortTermInvestmentsMember 2016-12-31 0000886163 us-gaap:AssetBackedSecuritiesMember 2015-12-31 0000886163 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000886163 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2016-12-31 0000886163 us-gaap:ShortTermInvestmentsMember 2015-12-31 0000886163 us-gaap:MunicipalBondsMember 2016-12-31 0000886163 us-gaap:CommercialPaperMember 2016-12-31 0000886163 us-gaap:CommercialPaperMember 2015-12-31 0000886163 us-gaap:EquitySecuritiesMember 2015-12-31 0000886163 us-gaap:OfficeEquipmentMember 2016-12-31 0000886163 us-gaap:OfficeEquipmentMember 2015-12-31 0000886163 us-gaap:LeaseholdImprovementsMember 2016-12-31 0000886163 lgnd:ComputerEquipmentAndSoftwareMember 2015-12-31 0000886163 lgnd:ComputerEquipmentAndSoftwareMember 2016-12-31 0000886163 us-gaap:LeaseholdImprovementsMember 2015-12-31 0000886163 us-gaap:PatentedTechnologyMember 2016-12-31 0000886163 us-gaap:CustomerRelationshipsMember 2016-12-31 0000886163 lgnd:AcquiredInProcessResearchAndDevelopmentMember 2015-12-31 0000886163 us-gaap:PatentedTechnologyMember 2015-12-31 0000886163 us-gaap:TradeNamesMember 2016-12-31 0000886163 us-gaap:TradeNamesMember 2015-12-31 0000886163 lgnd:AcquiredInProcessResearchAndDevelopmentMember 2016-12-31 0000886163 us-gaap:CustomerRelationshipsMember 2015-12-31 0000886163 lgnd:CorMatrixMember us-gaap:LicensingAgreementsMember 2015-12-31 0000886163 us-gaap:LicensingAgreementsMember 2015-12-31 0000886163 us-gaap:LicensingAgreementsMember 2016-12-31 0000886163 lgnd:CorMatrixMember us-gaap:LicensingAgreementsMember 2016-12-31 0000886163 lgnd:SelexisMember us-gaap:LicensingAgreementsMember 2015-12-31 0000886163 lgnd:SelexisMember us-gaap:LicensingAgreementsMember 2016-12-31 0000886163 lgnd:MetabasisTherapeuticsMember 2016-01-01 2016-12-31 0000886163 lgnd:MetabasisTherapeuticsMember 2014-12-31 0000886163 lgnd:CydexPharmaceuticalsIncMember 2015-12-31 0000886163 lgnd:MetabasisTherapeuticsMember 2015-01-01 2015-12-31 0000886163 lgnd:CydexPharmaceuticalsIncMember 2014-12-31 0000886163 lgnd:MetabasisTherapeuticsMember 2016-12-31 0000886163 lgnd:MetabasisTherapeuticsMember 2015-12-31 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember 2016-12-31 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember 2009-05-28 2009-05-29 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember 2012-05-30 2012-05-31 0000886163 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0000886163 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0000886163 us-gaap:EmployeeStockOptionMember 2016-12-31 0000886163 lgnd:AmendedESPPMember 2014-01-01 2014-12-31 0000886163 lgnd:AmendedESPPMember 2016-01-01 2016-12-31 0000886163 2015-09-01 2015-09-30 0000886163 lgnd:AmendedESPPMember 2015-01-01 2015-12-31 0000886163 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0000886163 2015-09-30 0000886163 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0000886163 us-gaap:RestrictedStockMember 2016-12-31 0000886163 us-gaap:EmployeeStockOptionMember lgnd:TwoThousandTwoStockIncentivePlanMember 2016-05-01 2016-05-31 0000886163 us-gaap:RestrictedStockMember 2015-12-31 0000886163 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-12-31 0000886163 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-12-31 0000886163 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0000886163 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-12-31 0000886163 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-12-31 0000886163 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-12-31 0000886163 lgnd:ExercisePriceRangeSixMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeEightMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeOneMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeOneMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeTwoMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeNineMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeSevenMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeTenMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeFiveMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeElevenMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeElevenMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeThreeMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeTwoMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeFourMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeSixMember 2016-12-31 0000886163 lgnd:ExercisePriceRangeFiveMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeEightMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeFourMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeSevenMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeNineMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeThreeMember 2016-01-01 2016-12-31 0000886163 lgnd:ExercisePriceRangeTenMember 2016-01-01 2016-12-31 0000886163 us-gaap:MinimumMember 2014-01-01 2014-12-31 0000886163 us-gaap:MinimumMember 2015-01-01 2015-12-31 0000886163 us-gaap:MaximumMember 2015-01-01 2015-12-31 0000886163 us-gaap:MaximumMember 2014-01-01 2014-12-31 0000886163 us-gaap:InternalRevenueServiceIRSMember 2016-12-31 0000886163 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0000886163 lgnd:RealizationOfExcessTaxBenefitsFromShareBasedCompensationMember 2016-12-31 0000886163 us-gaap:ResearchMember 2016-12-31 0000886163 lgnd:RealizationOfExcessTaxBenefitsFromShareBasedCompensationMember 2015-12-31 0000886163 lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember 2016-12-31 0000886163 2015-04-01 2015-06-30 0000886163 2016-07-01 2016-09-30 0000886163 2015-10-01 2015-12-31 0000886163 2015-07-01 2015-09-30 0000886163 2016-01-01 2016-03-31 0000886163 2016-10-01 2016-12-31 0000886163 2015-01-01 2015-03-31 0000886163 2016-04-01 2016-06-30 lgnd:program lgnd:platform xbrli:shares utreg:D iso4217:USD lgnd:right xbrli:pure iso4217:USD xbrli:shares false --12-31 FY 2016 2016-12-31 10-K 0000886163 20919894 Yes Large Accelerated Filer 2300000000 LIGAND PHARMACEUTICALS INC No No 3246000 1333000 646000 0.1 48143000 48143000 15200000 11497000 3652000 13500000 9500000 4000000 8100000 6600000 1500000 2100000 6300000 300000 900000 3000000 0.155 16 2500000 136000 6056000 6058000 27048000 8554000 25821000 -800000 -200000 10414000 5088000 P3D 0.98 11500000 13700000 3007000 591000 8839000 4385000 12770000 68631000 3617000 3963000 1256000 52000 268000 43000 0 0 -622000 490000 197000 94000 0 -2107000 0 960000 29200000 960000 1100000 560000 560000 0 0 1200000 75.05 4987000 22500000 0.73 0.125 BB BB 0.40 -1060000 5000000 3800000 1172000 3400000 3259000 74000 43000 3329000 -120000 -7000 -27188000 -1423000 1748000 1684000 1225000 88000 232000 0 -113000 304000 -1525000 53000 -161000 -1000 -10700000 0 -765000 462000 2023 3033000 2916000 5000000 P1Y P3M 30000000 -5135000 -5013000 -3334000 1211000 0 0 1500000 300000 0.05 0.025 4 3 1100000 900000 700000 0.03 197000 197000 0 197000 0 656000 1002000 0 1100000 244000 1378000 267000 1111000 376000 283000 283000 0 283000 3493000 6740000 5848000 865000 8777000 6158000 2618000 48100000 48143000 0 0 0.85 1000000 4030000 17695000 0.01 P60D P30D 0.2 15000000 0.2 0.097 0.086 0.0852 0.05 934000 35000000.0 15000000.0 2 5 1 64100000 731000 311000 4083000 2734000 0 0 -348000 5405000 6397000 726000 829000 823000 942000 915000 899000 2781000 1571000 4903000 2743000 661850000 769653000 1200000 51271000 51271000 -39628000 -39628000 10065000 10065000 11270000 11270000 12458000 12458000 18893000 18893000 11600000 11638000 11638000 11270000 7675000 3595000 12458000 8378000 4080000 18893000 10057000 8836000 3694000 10274000 10925000 2400000 2400000 10600000 5104000 3333000 3544000 0 503061000 601585000 214712000 163053000 0 3015000 3015000 0 0 4782000 4782000 6786000 85989000 0 92775000 6786000 89004000 4782000 100572000 0 0 3207000 3207000 3054000 119242000 0 122296000 684000 0 0 684000 3054000 119242000 3207000 126187000 10015000 1747000 41203000 43039000 6787000 102791000 33067000 11026000 40734000 3054000 19613000 122296000 7295000 7507000 0 0 0 0 4944000 4944000 2000 0 19000 1542000 0 1564000 1000 0 5000 0 35000 4000 0 44000 9000 5000 0 0 11000 26000 0 1000 10020000 1747000 41238000 43043000 1843000 97891000 33074000 11031000 40715000 1512000 19624000 120758000 7294000 7508000 77373000 790000 0.30 11.26 -0.15 0.03 0.27 10.50 -0.15 0.03 5888000 222788000 -3126000 632000 24571000 80365000 38185000 111449000 173400000 -5135000 -5013000 -3334000 3504000 1000 5000 55708000 167000000 1528000 173379000 1084000 1020000 900000 1032000 0 11639000 160203000 97428000 18752000 148564000 -62775000 -78676000 0 247000 0 0 0 0 125.08 1.50 3264643 7500000 0.001 0.001 33333333 33333333 19949012 20909301 19949012 20909301 20000 21000 14063000 229792000 -3796000 0.37 0.31 0.10 0.27 0.23 0.18 0.41 0.14 0.00 201985000 212910000 331700000 192500000 9136000 5807000 5571000 2375000 2375000 10643000 15000 11000 21000 34000 18000 33000 19000 7000 12000 39628000 29563000 51300000 75.05 0.0133251 86700000 P30D P10D P50D 1.3 20 5 245000000 245000000 245000000.0 0.0075 P5Y 43015000 32090000 0 28190000 0 406000 -167413000 10534000 5700000 3400000 2500000 0 357000 -30000 -24720000 -240000 0 4432000 3000 0 1840000 5692000 217636000 213082000 189083000 123891000 189083000 123891000 208570000 197733000 160595000 150226000 15441000 19312000 25613000 26878000 1523000 943000 707000 578000 68000 45000 9066000 15349000 1844000 1196000 300000 200000 200000 2657000 2627000 11290000 0 0 1139000 0 0 731000 731000 0 0 731000 0 0 400000 408000 0.59 0.04 1.19 10.01 0.32 11.61 0.32 -0.30 0.05 0.15 -0.08 0.56 0.04 1.11 9.28 0.29 10.83 0.30 -0.30 0.05 0.15 -0.08 1711000 2603000 P2Y2M20D P1Y1M20D 13800000 17500000 0.303 0.327 7500000 29728000 8345000 0 0.25 0.65 0.25 0.75 0.06 0.06 0.032 0.0583 215000 300000 4782000 3207000 9490000 1604000 P20Y P20Y 7304000 48000 3762000 652000 8784000 477000 12792000 784000 10600000 10600000 10600000 10600000 10600000 0 8602000 29600000 8602000 15267000 2642000 17696000 8602000 29600000 26298000 182577000 2642000 0 0 -183000 1100000 22570000 24378000 26621000 12238000 72207000 59969000 0 0 7400000 -89000 22027000 199165000 6341000 5877000 -6170000 1051000 -3125000 11302000 35329000 7960000 10892000 227444000 -2367000 0.59 11.61 -0.11 0.56 10.83 -0.11 0.00 0.00 0.04 0.00 0.00 0.04 0 -5143000 -23132000 410000 15000 265000 -191881000 -514000 -192115000 3694000 -3881000 160000 10354000 10327000 -7243000 -231370000 6283000 119000 -5756000 25000 3843000 13198000 2786000 9000 16000 16000 89000 140000 263000 580000 605000 305000 697000 386000 175000 18000 28000 38000 -3121000 -4027000 -2369000 10412000 -6489000 8525000 -410000 192132000 -10697000 80000 -2227000 -8000 -4369000 401000 244000 1439000 325000 32000 426000 -51000 -558000 0 -1261000 0 0 499000 0 978000 882000 0 12556000 12246000 48347000 204705000 60585000 8554000 276912000 25821000 -4860000 -11802000 -12178000 494000 1822000 1838000 1633000 1923000 0 0 100000 700000 400000 300000 2017-12-01 2023-04-30 2019-06-30 P5Y P7Y 226151000 230732000 503061000 601585000 222821000 227129000 0 0 0 794000 0 794000 0 2602000 0 0 1355000 3957000 7812000 0 1678000 0 0 9490000 7812000 2602000 1678000 794000 1355000 14241000 0 0 371000 0 371000 0 0 0 1413000 1413000 101000 1503000 0 0 1604000 101000 1503000 371000 1413000 3388000 130025000 8360000 1515000 -2027000 -112862000 -143192000 20566000 41727000 63001000 20566000 41727000 63001000 12024000 12024000 754000 23564000 199165000 6341000 229824000 229824000 6608000 -6170000 1051000 -3125000 -1636000 -1636000 -1132000 -1132000 -843000 -1537000 0 0 -2380000 -2380000 0 4290000 4290000 -8324000 8000000 -35925000 4782000 3207000 201985000 212910000 44912000 11253000 14053000 9104000 10175000 44585000 14552000 15552000 16153000 18831000 65088000 19626000 27329000 43885000 2758000 54000 875000 1829000 900000 54000 128000 718000 1658000 3300000 1700000 446300000 140500000 1230000 1124000 1908000 2175000 27000 1744000 3872000 1933000 93000 2039000 2039000 -50000 -50000 -2160000 -2160000 1833000 1965000 2253000 297000 687000 1671000 1768000 2719000 206000 107000 0 1200000 29000 287000 -130000 0 0 67954000 489000 3901000 5711000 0 0 0 0 999000 96006000 0 0 92502000 9000000 700000 0 0 0 9000000 1000000 700000 6000 93000 1850000 0 166025000 164438000 1177000 1864000 300000 0 0 300000 245000000 0 0 239300000 245000000 4400000 8700000 6200000 11638000 0 0 0 57234000 118874000 2342000 16039000 24596000 4561000 8849000 6415000 10892000 227444000 -1636000 3153000 632000 273000 2248000 3390000 569000 1754000 1067000 372000 1819000 P10Y P3Y 1538000 2603000 2352000 6170000 14700000 200000 9366000 0 0 9747000 11005000 21221000 -429491000 -431127000 64538000 14602000 18418000 17701000 21193000 71914000 29648000 19521000 21619000 38185000 108973000 29994000 38194000 59423000 1500000 8.00 1.25 28488000 27662000 22502000 11270000 12458000 18893000 P6M P42M P1Y 2483 67.95 234855 95.31 130749 308700 60.36 86.61 54421 66.79 0.69 0.62 0.58 0.50 0.50 0.48 0.019 0.020 0.017 0.019 0.013 1250 1300000 1800000 900000 1000000 1298561 30.21 15300000 20700000 12000000 28115 263489 46.20 35.39 46.53 124800000 104247000 1683341 1754275 34.19 42.12 104247000 1752275 42.12 3774 3374 1961 38.08 60.17 92.09 63.58 8.58 21.92 16.14 74.42 8.58 56.26 32.00 85.79 14.47 10.12 21976 1298561 213199 106242 162233 247574 70877 62747 62726 274887 76100 26382 1752275 225105 106242 227856 247574 183595 72330 298204 288887 76100 68.62 138.53 21.92 21 74.42 12.53 59.26 53.34 138.59 14.47 12.81 98 0.1250 0.0208 P10Y P6Y P6Y6M P6Y8M12D P6Y7M6D 92723000 P5Y5M9D P6Y5M23D P6Y2M9D P6Y2M9D 67.50 30.21 21.92 17.76 74.42 9.98 56.26 34.73 89.71 14.47 11.38 67.20 42.12 21.92 17.76 74.42 9.98 56.26 36.18 93.19 14.47 11.38 P7Y6M P6Y2M9D P6Y1M17D P1Y10M6D P7Y1M13D P3Y11M9D P8Y1M10D P6Y0M7D P9Y0M11D P5Y1M10D P4Y11M1D 20468521 19575150 19949012 20909301 102791000 122296000 790163 360054 379982 210626 3700000 7500000 164440 0 0 77331000 77330000 1000 4561000 4561000 8849000 8849000 5416000 5416000 29200000 200000000.0 P3Y 195600000 1253425 1253425 6120 6120 40500 40500 67955000 67954000 1000 489000 489000 3901000 3901000 237282000 341290000 49613000 2914000 718017000 21000 -671339000 24408000 4953000 680660000 20000 -1910000 -659315000 237282000 4903000 661850000 20000 -429491000 341290000 2743000 769653000 21000 -431127000 19400000 21900000 4500000 3872000 3005000 -1109000 8504000 8524000 36452000 38770000 20000 450000 160000 40000 154000 70000 0 28224000 2408000 35500000 -7200000 -231700000 6300000 2500000 -778000 -778000 21433000 20631000 21276000 21460000 21542000 21228000 22284000 20832000 22997000 20898000 20831000 20419000 19612000 19725000 19887000 19933000 19790000 20708000 20832000 20887000 20898000 20831000 36000 56000 0 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:10pt;">Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company considers receivables past due based on the contractual payment terms which range from 30 to 90 days. The Company reserves specific receivables if collectibility is no longer reasonably assured. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Equivalents &amp; Short Term Investments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of all investments with maturities of&#160;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months or less from the date of acquisition. Short-term investments primarily consist of investments in debt securities that have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss).&#160;The Company determines the cost of investments based on the specific identification method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial license rights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">April 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">April 2015</font><font style="font-family:inherit;font-size:10pt;"> and Cormatrix in May 2016. Individual commercial license rights acquired are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the level 3 financial instruments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instruments as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking note receivable fair market value adjustment</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payment received as partial repayment of note receivable</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair market value of stock received as partial repayment of note receivable</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instrument assets as of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instruments as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments to CVR holders and other contingency payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,158</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value adjustments to contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instruments as of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Study and Clinical Trial Accruals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantial portions of the Company&#8217;s preclinical studies and all of the Company&#8217;s clinical trials have been performed by third-party laboratories, CROs.&#160; The Company accounts for a significant portion of its clinical study costs according to the terms of its contracts with CROs. The terms of its CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. The Company's objective is to reflect the appropriate preclinical and clinical trial expenses in its financial statements in the same period as the services occur. As part of the process of preparing its financial statements, the Company relies on cost information provided by its CROs. The Company is also required to estimate certain of its expenses resulting from its obligations under its CRO contracts. Accordingly, the Company's preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense as a component of:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deposits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate acquisition consideration was </font><font style="font-family:inherit;font-size:10pt;">$173.4 million</font><font style="font-family:inherit;font-size:10pt;">, consisting of (in thousands, except per share amounts):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share consideration:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Actual number of shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Multiplied by: Ligand closing share price on January 8, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share consideration</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,373</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial license rights consist of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CorMatrix</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selexis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total commercial rights, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent liabilities consist of the following (in millions):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustment</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustment</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cydex</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Metabasis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:8pt;"> </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the various investment categories at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Bank deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,026</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;U.S. Government bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Bank deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,791</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents supplemental pro forma information for the </font><font style="font-family:inherit;font-size:10pt;">three and twelve months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, as if the acquisition of OMT had occurred on January&#160;1, 2015 (in thousands except for income per share):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Twelve months ended</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic (loss) income per share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted (loss) income per share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Combinations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the Company acquired substantially all of the assets and liabilities of OMT. OMT is a biotechnology company engaged in the genetic engineering of animals for the generation of human therapeutic antibodies through its OmniAb&#174; technology, which currently offers </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> transgenic animal platforms for license, including OmniRat&#174;, OmniMouse&#174; and OmniFlic&#174;. The transaction, which was accounted for as a business combination, initially added </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> partnerships to the Company's portfolio and provides the Company with opportunities for further licensing and collaborations in the area. The aggregate acquisition consideration was </font><font style="font-family:inherit;font-size:10pt;">$173.4 million</font><font style="font-family:inherit;font-size:10pt;">, consisting of (in thousands, except per share amounts):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share consideration:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Actual number of shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Multiplied by: Ligand closing share price on January 8, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share consideration</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,373</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Income tax receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The fair value of the core technology, or OMT's OmniAb technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniAb technology. These projected cash flows were discounted to present value using a discount rate of </font><font style="font-family:inherit;font-size:10pt;">15.5%</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed was </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> and was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to OMT&#8217;s potential revenue growth from combining the OMT and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents supplemental pro forma information for the </font><font style="font-family:inherit;font-size:10pt;">three and twelve months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, as if the acquisition of OMT had occurred on January&#160;1, 2015 (in thousands except for income per share):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Twelve months ended</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic (loss) income per share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted (loss) income per share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited pro forma consolidated results include pro forma adjustments that assume the acquisition occurred on January 1, 2015. The primary adjustments include: (i) the&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and twelve months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, for share based compensation expenses&#160;related to the stock awards issued to the retained OMT employees after the acquisition, (ii) additional intangible amortization expense of&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">&#160;was included in the </font><font style="font-family:inherit;font-size:10pt;">three and twelve months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively and (iii) a platform license fee of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> paid by OMT during the twelve months ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The license agreement was terminated upon acquisition by Ligand. The adjustments also include </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> license revenue recognized by OMT from January 1, 2016 to the acquisition date. The unaudited pro forma consolidated results are not necessarily indicative of what our consolidated results of operations actually would have been had we completed the acquisition on January 1, 2015. In addition, the unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities less reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Business Risk</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and investments. The Company invests its excess cash principally in United States government debt securities, investment grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principles of Consolidation</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Liabilities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Company&#8217;s acquisition of CyDex in </font><font style="font-family:inherit;font-size:10pt;">January 2011</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See footnote 7, </font><font style="font-family:inherit;font-size:10pt;">Other Balance Sheet Details. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the Company&#8217;s acquisition of Metabasis in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 2010</font><font style="font-family:inherit;font-size:10pt;">, the Company issued Metabasis stockholders </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any change in fair value is recorded in the Company's consolidated statement of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financing Arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Convertible Senior Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$245.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its 2019 Convertible Senior Notes, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$239.3 million</font><font style="font-family:inherit;font-size:10pt;">. The 2019 Convertible Senior Notes are convertible into common stock at an initial conversion rate of </font><font style="font-family:inherit;font-size:10pt;">13.3251</font><font style="font-family:inherit;font-size:10pt;"> shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$75.05</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock. The notes bear cash interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">0.75%</font><font style="font-family:inherit;font-size:10pt;"> per year, payable semi-annually. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the 2019 Convertible Senior Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) during any fiscal quarter (and only during such fiscal quarter) commencing after </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, if,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Company's common stock on such trading day is greater than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price on such trading day; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) during the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> business day period immediately following any </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on each such trading day; or </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31 2016, the Company's last reported sale price exceeded the 130% threshold described above and accordingly the Convertible Notes have been classified as a current liability as of December 31, 2016. As a result, the related unamortized discount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$29.6 million</font><font style="font-family:inherit;font-size:10pt;"> was classified as temporary equity component of currently redeemable convertible notes on our consolidated balance sheet. The determination of whether or not the Convertible Notes are convertible as described above is made each quarter until maturity, conversion or repurchase. It is possible that the Convertible Notes may not be convertible in future periods, in which case the Convertible Notes would be classified as long-term debt, and the unamortized discount would be classified as permanent equity unless one of the other conversion events described above were to occur. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On or after </font><font style="font-family:inherit;font-size:10pt;">May&#160;15, 2019</font><font style="font-family:inherit;font-size:10pt;"> until the close of business on the second scheduled trading day immediately preceding </font><font style="font-family:inherit;font-size:10pt;">August&#160;15, 2019</font><font style="font-family:inherit;font-size:10pt;">, holders of the notes may convert all or a portion of their notes at any time. Upon conversion, Ligand must deliver cash to settle the principal and may deliver cash or shares of common stock, at the option of the Company, to settle any premium due upon conversion.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounted for the debt and equity components of the 2019 Convertible Senior Notes by allocating the </font><font style="font-family:inherit;font-size:10pt;">$245.0 million</font><font style="font-family:inherit;font-size:10pt;"> total proceeds between the debt component and the embedded conversion option, or equity component, due to Ligand's ability to settle the 2019 Convertible Senior Notes in cash for the principal portion and to settle any premium in cash or common stock, at the Company's election. The debt allocation was performed in a manner that reflected the Company's non-convertible borrowing rate for similar debt of </font><font style="font-family:inherit;font-size:10pt;">5.83%</font><font style="font-family:inherit;font-size:10pt;"> derived from independent valuation analysis. The initial debt value of </font><font style="font-family:inherit;font-size:10pt;">$192.5 million</font><font style="font-family:inherit;font-size:10pt;"> accretes at </font><font style="font-family:inherit;font-size:10pt;">5.83%</font><font style="font-family:inherit;font-size:10pt;"> to reach </font><font style="font-family:inherit;font-size:10pt;">$245.0 million</font><font style="font-family:inherit;font-size:10pt;"> at the maturity date. The equity component of the 2019 Convertible Senior Notes was recognized as a debt discount and represents the difference between the </font><font style="font-family:inherit;font-size:10pt;">$245.0 million</font><font style="font-family:inherit;font-size:10pt;"> proceeds at issuance of the 2019 Convertible Senior Notes and the fair value of the debt allocation on their respective issuance dates. The debt discount is amortized to interest expense using the effective interest method over the expected life of a similar liability without an equity component. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the &#8220;if-converted value&#8221; exceeded the principal amount of the 2019 Convertible Senior Notes by </font><font style="font-family:inherit;font-size:10pt;">$86.7 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of the 2019 Convertible Senior Notes, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portions of these costs allocated to the equity components totaling </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded as a reduction to additional paid-in capital. The portions of these costs allocated to the liability components totaling </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded as assets on the balance sheet at the time the debt was issued.&#160; Beginning in 2016, the unamortized issuance costs allocated to the liability components are recorded as part of debt discount on the consolidated balance sheet upon the Company's respective adoption of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ASU 2015-03,&#160;Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;">. Issuance cost included in the unamortized debt discount was </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2016 and 2015, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined the expected life of the debt discount for the 2019 Convertible Senior Notes to be equal to the original </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the notes. The carrying value of the equity component related to the 2019 Convertible Senior Notes as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, net of issuance costs, was </font><font style="font-family:inherit;font-size:10pt;">$51.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Bond Hedge and Warrant Transactions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, to minimize the impact of potential dilution to the Company's common stock upon conversion of the 2019 Convertible Senior Notes, in August 2014, the Company entered into convertible bond hedges and sold warrants covering </font><font style="font-family:inherit;font-size:10pt;">3,264,643</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock. The convertible bond hedges have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$75.05</font><font style="font-family:inherit;font-size:10pt;"> per share and are exercisable when and if the 2019 Convertible Senior Notes are converted. If upon conversion of the 2019 Convertible Senior Notes, the price of the Company's common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by the Company and are not part of the terms of the 2019 Convertible Senior Notes. Holders of the 2019 Convertible Senior Notes and warrants will not have any rights with respect to the convertible bond hedges. The Company paid </font><font style="font-family:inherit;font-size:10pt;">$48.1 million</font><font style="font-family:inherit;font-size:10pt;"> for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concurrently with the convertible bond hedge transactions, the Company entered into warrant transactions whereby it sold warrants to acquire approximately </font><font style="font-family:inherit;font-size:10pt;">3,264,643</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock with an exercise price of approximately </font><font style="font-family:inherit;font-size:10pt;">$125.08</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to certain adjustments. None of the warrants have been exercised as of December 31, 2016. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The Company received </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;"> for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and the Company does not have the obligation and does not intend to file any registration statement with the Securities and Exchange Commission registering the issuance of the shares under the warrants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the liability components the Company's financing arrangement (dollars in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Convertible Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Principal amount outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were no events of default or violation of any covenants under the Company's financing obligations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Per Share</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic income (loss) per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive common shares consist of shares issuable under 2019 convertible senior notes, stock options and restricted stock. 2019 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options; the average amount of unrecognized compensation expense for restricted stock; and estimated tax benefits that will be recorded in additional paid-in capital when expenses related to equity awards become deductible. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investment in Viking</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, the Company entered into a MLA with Viking to license the rights to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> of the Company's programs to Viking. Under the terms of the MLA, no consideration was exchanged upon execution, but rather Viking agreed to issue shares of Viking common stock with an aggregate value of approximately </font><font style="font-family:inherit;font-size:10pt;">$29.2 million</font><font style="font-family:inherit;font-size:10pt;"> upon consummation of Viking's IPO. As part of this transaction, the Company also extended a </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> convertible loan to Viking under a LSA. As a result of these transactions, the Company determined it held a variable interest in Viking. The Company considered certain criteria in the accounting guidance for VIEs, and determined that Viking was a VIE and Ligand was the primary beneficiary of Viking. As a result, the Company consolidated Viking on its financial statements from May 2014 through May 2015, the effective date of Viking's IPO. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the losses incurred as net loss attributable to noncontrolling interest because it was the primary beneficiary with no equity interest in the VIE.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, Viking completed the Viking IPO and issued the Company approximately </font><font style="font-family:inherit;font-size:10pt;">3.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Viking common stock with an aggregate value of </font><font style="font-family:inherit;font-size:10pt;">$29.2 million</font><font style="font-family:inherit;font-size:10pt;"> based on the IPO price of </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;"> per share. In connection with the Viking IPO, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares of Viking common stock for an aggregate price of </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> at the initial public offering price. Upon completion of Viking&#8217;s IPO, the Company determined that Viking was no longer a VIE and the Company did not have any other element of control that would require consolidation of Viking. In May 2015, the Company deconsolidated Viking and began to account for its equity investment in Viking under the equity method and records its proportional share of Viking gains and losses in Loss from Viking Therapeutics in the Company's consolidated statement of operations. Viking is considered a related party as the Company maintains a seat on Viking's board of directors.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the Company entered into an amendment to the LSA with Viking to extend the maturity of the convertible loan to May 2017, reduce the interest rate from </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">, and extend the lock up period by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year such that the Company may not sell, transfer, or dispose of any Viking securities prior to January 23, 2017. Additionally, upon the consummation of a subsequent capital financing transaction, Viking will be required to repay </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> of the Viking Note obligation to the Company, with at least </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid in cash and the remaining amount to be paid in the form and at the price of the Viking equity securities sold in the financing transaction. Upon maturity or further payments, the Company may elect to receive equity of Viking common stock or cash equal to </font><font style="font-family:inherit;font-size:10pt;">200%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount plus accrued and unpaid interest. The Company has opted to account for the Viking convertible note receivable at fair value. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, Viking closed its underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">7.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">7.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$1.25</font><font style="font-family:inherit;font-size:10pt;"> per share of its common stock and related warrants. The warrant has an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;"> per share, immediately exercisable and will expire on April 13, 2021. As part of this public offering, the Company purchased </font><font style="font-family:inherit;font-size:10pt;">560,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">560,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Viking's common stock for a total purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">. The purchased shares of common stock and warrants are subject to the same terms as the shares issued in this offering. In addition, on April 13, 2016, pursuant to the terms of the amendment to the LSA that was entered in January 2016 between Ligand and Viking, Viking repaid </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of the convertible notes in cash, and issued the Company </font><font style="font-family:inherit;font-size:10pt;">960,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock and warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">960,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock as repayment of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> of the convertible notes. The shares received as part of the repayment, like all Viking securities held by the Company, are subject to a lock-up period that ends on January 23, 2017 in accordance with the amended LSA. A gain of $0.3 million representing the fair market value of the warrants is included within other income for the year ended December 31, 2016. As of December 31, 2016, the aggregate fair value of the note receivable was </font><font style="font-family:inherit;font-size:10pt;">3.2 million</font><font style="font-family:inherit;font-size:10pt;"> . </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's ownership in Viking decreased to </font><font style="font-family:inherit;font-size:10pt;">32.7%</font><font style="font-family:inherit;font-size:10pt;"> after the public offering and the repayment of the convertible notes and further decreased to </font><font style="font-family:inherit;font-size:10pt;">30.3%</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, 2016. Accordingly, the book value of the Company's equity method investment in Viking decreased by </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;">. The resulting net loss was recognized in Loss from Viking in the Company's consolidated statement of operations for the year ended December 31, 2016. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews its investment in Viking on a regular basis and assesses whether events, changes in circumstances or the passage of time, in management's judgment, indicate that a loss in the market value of the investment may be other than temporary. This might include, but would not necessarily be limited to, the period of time during which the carrying value of our investment is significantly above the observed market value, a deterioration in Viking's financial condition, or an adverse event relating to its lead clinical programs. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the sustained low Viking common stock unit price during the year ended December 31, 2016, the Company determined that an other than temporary decrease in the value of its investment in Viking had occurred. The Company wrote down the value of its investment in Viking to its estimated fair value which resulted in impairment charges of&#160;</font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;">&#160;for the year ended December 31, 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="16" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable Viking </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in warrants </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current contingent liabilities - CyDex </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - Metabasis </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - CyDex </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for amounts owed to former licensees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="16" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable Viking </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current contingent liabilities - CyDex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current contingent liabilities-Metabasis </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - Metabasis</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - CyDex </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,678</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,678</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for amounts owed to former licensees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">(2) The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be </font><font style="font-family:inherit;font-size:8pt;">75%</font><font style="font-family:inherit;font-size:8pt;"> at </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">65%</font><font style="font-family:inherit;font-size:8pt;"> at </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:8pt;">. Changes in these assumptions may materially affect the fair value estimate. For the year ended </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:8pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:8pt;">, the Company reported a decrease in the fair value of the Viking convertible notes of </font><font style="font-family:inherit;font-size:8pt;">$0.2 million</font><font style="font-family:inherit;font-size:8pt;"> and</font><font style="font-family:inherit;font-size:8pt;">$0.8 million</font><font style="font-family:inherit;font-size:8pt;"> respectively in "Other, net" of the consolidated statement of operations.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) Investment in warrants, which the Company received as a result of Viking&#8217;s partial repayment of the Viking note receivable and the Company&#8217;s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4) The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4a) The fair value of the liabilities for short-term CyDex contingent liabilities at December 31, 2016 disclosed herein represents the fair value of the estimated contingent considerations owed to former license holder only, which is determined based on the methodology described in (4) above. The contingent considerations owed to the Cydex CVR holders at December 31, 2016 is determined based on actual amount owed at December 31, 2016 as the Cydex CVR agreement ended at December 31, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5) The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6) The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7) Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.2421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of annual revenue subject to revenue sharing </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$22.5 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average of probability of commercialization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales beta</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit rating</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BB</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BB</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity risk premium</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market price of risk</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management&#8217;s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of </font><font style="font-family:inherit;font-size:10pt;">$15 million</font><font style="font-family:inherit;font-size:10pt;">) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The Company establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Observable inputs such as quoted prices in active markets </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="16" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable Viking </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in warrants </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current contingent liabilities - CyDex </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4a)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - Metabasis </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - CyDex </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for amounts owed to former licensees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,388</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="16" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">for Identical</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note receivable Viking </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current contingent liabilities - CyDex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current contingent liabilities-Metabasis </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - Metabasis</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(5)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term contingent liabilities - CyDex </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,678</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,678</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability for amounts owed to former licensees </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,957</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1) Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">(2) The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be </font><font style="font-family:inherit;font-size:8pt;">75%</font><font style="font-family:inherit;font-size:8pt;"> at </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:8pt;"> and </font><font style="font-family:inherit;font-size:8pt;">65%</font><font style="font-family:inherit;font-size:8pt;"> at </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:8pt;">. Changes in these assumptions may materially affect the fair value estimate. For the year ended </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:8pt;">and</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:8pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:8pt;">, the Company reported a decrease in the fair value of the Viking convertible notes of </font><font style="font-family:inherit;font-size:8pt;">$0.2 million</font><font style="font-family:inherit;font-size:8pt;"> and</font><font style="font-family:inherit;font-size:8pt;">$0.8 million</font><font style="font-family:inherit;font-size:8pt;"> respectively in "Other, net" of the consolidated statement of operations.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3) Investment in warrants, which the Company received as a result of Viking&#8217;s partial repayment of the Viking note receivable and the Company&#8217;s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4) The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management&#8217;s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4a) The fair value of the liabilities for short-term CyDex contingent liabilities at December 31, 2016 disclosed herein represents the fair value of the estimated contingent considerations owed to former license holder only, which is determined based on the methodology described in (4) above. The contingent considerations owed to the Cydex CVR holders at December 31, 2016 is determined based on actual amount owed at December 31, 2016 as the Cydex CVR agreement ended at December 31, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5) The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6) The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7) Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.2421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Range of annual revenue subject to revenue sharing </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$22.5 million</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average of probability of commercialization</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales beta</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.40</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit rating</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BB</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BB</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity risk premium</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market price of risk</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management&#8217;s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of </font><font style="font-family:inherit;font-size:10pt;">$15 million</font><font style="font-family:inherit;font-size:10pt;">) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the level 3 financial instruments as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instruments as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking note receivable fair market value adjustment</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(215</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payment received as partial repayment of note receivable</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair market value of stock received as partial repayment of note receivable</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instrument assets as of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instruments as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments to CVR holders and other contingency payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,158</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value adjustments to contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of level 3 financial instruments as of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance represents Cydex CVR obligation, which was determined based on actual amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Fair Value Measurements-2019 Convertible Senior Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the Company issued the 2019 Convertible Senior Notes. The Company uses a quoted market rate in an inactive market, which is classified as a Level 2 input, to estimate the current fair value of its 2019 Convertible Senior Notes. The estimated fair value of the 2019 Senior Convertible Notes was </font><font style="font-family:inherit;font-size:10pt;">$331.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The carrying value of the notes does not reflect the market rate. See Note 7 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Arrangements </font><font style="font-family:inherit;font-size:10pt;">for additional information.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Viking </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records its investment in Viking under the equity method of accounting. The investment is subsequently adjusted for the Company&#8217;s share of Viking's operating results, and if applicable, cash contributions and distributions. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 2 Investment in Viking </font><font style="font-family:inherit;font-size:10pt;">for additional information. The market value of the Company's investment in Viking was </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The change in the carrying value of goodwill during the year ended December 31, 2016, was due to the acquisition of OMT. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2016 by assessing qualitative factors, noting </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets related to acquired IPR&amp;D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered to be indefinite-lived, they are not amortized but are tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company performed its annual assessment for IPR&amp;D impairment in 2016, noting </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(167,413</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(192,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts computed at statutory federal rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes net of federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">386</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Meals&#160;&amp; entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 162(m) limitation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired NOLs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in uncertain tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate change for changes in state law</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APIC Excess Tax Benefit True Up</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(622</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in deferred tax assets from completion of 382 analysis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avinza true up</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(231,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(192,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> are shown below. The Company assesses the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company's evaluation of evidence resulted in management concluding that the majority of the Company's deferred tax assets will be realized. However, the Company maintains a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. The valuation allowance increased </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;"> in 2016, decreased </font><font style="font-family:inherit;font-size:10pt;">$231.7 million</font><font style="font-family:inherit;font-size:10pt;"> in 2015 and decreased </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets and intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of royalties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital Loss Carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,432</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking Equity Method Investment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,312</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,066</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retrophin fair value adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,196</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identified intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identified indefinite lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,963</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sections 382 and 383 of the U.S. tax code impose limitations (&#8220;382 and 383 limitations&#8221;) on the annual utilization of operating loss and credit carryforwards whenever a greater than fifty percent change in the ownership of a company occurs within a three year period. In addition to the annual limitations on operating loss and credit carryforwards, Section 382 can also restrict the utilization of certain post change losses if the tax basis in assets exceeds the fair value of assets (&#8220;net unrealized built in loss&#8221;) at the date of an ownership change. Companies with operating loss and credit carryforwards are required to test the cumulative three year change whenever there is an equity transaction that impacts the ownership of holders of more than five percent of the Company&#8217;s stock. During 2016, the Company completed a rollforward analysis through December&#160;31, 2016. As a result of the rollforward analysis, it was determined that no additional ownership changes occurred at the Company within the meaning of section 382 since </font><font style="font-family:inherit;font-size:10pt;">June&#160;20, 2007</font><font style="font-family:inherit;font-size:10pt;">. Future changes in the ownership of the Company could place additional restrictions on the Company&#8217;s ability to utilize operating loss and credit carryforwards arising through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had federal and state net operating loss carryforwards set to expire through </font><font style="font-family:inherit;font-size:10pt;">2036</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$446.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$140.5 million</font><font style="font-family:inherit;font-size:10pt;"> of state net operating loss carryforwards. The Company also has </font><font style="font-family:inherit;font-size:10pt;">$21.9 million</font><font style="font-family:inherit;font-size:10pt;"> of federal research and development credit carryforwards, which expire through </font><font style="font-family:inherit;font-size:10pt;">2036</font><font style="font-family:inherit;font-size:10pt;">. The Company has </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;"> of California research and development credit carryforwards that have no expiration date.&#160;&#160; </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company&#8217;s remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the amount of unrecognized tax benefits at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in the balance of unrecognized tax benefits at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$35.5 million</font><font style="font-family:inherit;font-size:10pt;"> of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized an immaterial amount of interest and penalties. The Company files income tax returns in the United States and in various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2013 tax year to present.&#160; The state income tax returns generally remain open for the 2012 tax years through present.&#160; Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting (''ASU 2016-09''). ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements.&#160; ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. The Company will adopt this ASU in the first quarter of 2017. The Company has excess tax federal and state benefits for which a benefit could not be previously recognized of approximately </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Upon adoption the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when the Company believes it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise the Company considers all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. The Company analyzes its inventory levels periodically and writes down inventory to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases office facilities in California and Kansas. These leases expire between 2017 and </font><font style="font-family:inherit;font-size:10pt;">2023</font><font style="font-family:inherit;font-size:10pt;">. Total rent expense, net under all office leases for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.2421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="23" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating lease obligations:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Lease</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 1</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1-2 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3-4 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate headquarters-San Diego, CA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office and research facility-La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioscience and Technology Business Center-Lawrence, KS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,758</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sublease payments expected to be received:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office and research facility-La Jolla, CA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease termination</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the Company entered into a lease termination agreement with its current lessor for the corporate headquarters facility located in La Jolla, California. The termination agreement accelerated the expiration date of the lease to April 2016, through which date, the Company is obligated to pay all base rent, operating expenses and other obligations due under the current lease. </font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the execution of the termination agreement, the Company entered into a new lease agreement with a different lessor for its corporate headquarters located in San Diego, California. The new lease has an initial term of approximately </font><font style="font-family:inherit;font-size:10pt;">7 years</font><font style="font-family:inherit;font-size:10pt;"> and commenced in May 2016. The base rent under the new facility lease agreement is approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;per year for the first year, escalating </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> annually thereafter over the initial term. The Company has an option to extend the term of the lease for an additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. The lease is subject to additional charges for property management, common area maintenance and other costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease exit obligations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, 2016 and 2015, the Company had lease exit obligations of </font><font style="font-family:inherit;font-size:10pt;">$0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company no longer records a lease obligation with respect to its vacated space expiring in June 2019 as the sublease proceeds offset the estimated lease exit obligations. For the years ended December&#160;31, 2016 and 2015, the Company made cash payments, net of sublease payments received of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company recognized adjustments for accretion and changes in leasing assumptions of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, 2016, 2015 and 2014, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Litigation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, The Company records the minimum estimated liability related to the claim in accordance with </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">FASB ASC Topic&#160;450 Contingencies.</font><font style="font-family:inherit;font-size:10pt;"> As additional information becomes available, the Company assesses the potential liability related to its pending litigation and revises its estimates. Revisions in the Company's estimates of potential liability could materially impact its results of operations. </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2012, a federal securities class action and shareholder derivative lawsuit was filed in Pennsylvania alleging that the Company and its chief executive officer assisted various breaches of fiduciary duties based on the Company&#8217;s purchase of a licensing interest in a development-stage pharmaceutical program from the Genaera Liquidating Trust in 2010 and the Company&#8217;s subsequent sale of half of its interest in the transaction to Biotechnology Value Fund, Inc.&#160; Plaintiff filed a second amended complaint in February 2015, which the Company moved to dismiss in March 2015.&#160; The district court granted the motion to dismiss on November 11, 2015.&#160; The plaintiff has appealed that ruling to the U.S. Third Circuit Court of Appeals.&#160; The Company intends to continue to vigorously defend against the claims against the Company and its chief executive officer.&#160; The outcome of the matter is not presently determinable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paragraph IV Certification by Par Pharmaceuticals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 7, 2016, the Company received a paragraph IV certification from Par Sterile Products, LLC, a subsidiary of Par Pharmaceuticals, Inc., or Par, advising us that it had filed an ANDA with the FDA seeking approval to market a generic version of Merck&#8217;s NOXAFIL-IV product. On February 19, 2016, Merck filed an action against Par in the United States District Court for the District of New Jersey, asserting that Par's manufacture, use or sale of the product for which the ANDA was submitted would infringe Merck's U.S. Patent No. 9,023,790. On October 31, 2016, the parties entered into a consent judgment dismissing all claims, counterclaims, affirmative defenses and demands. The parties have reported to the court that they entered into a confidential settlement agreement, and that they submitted the agreement to the Federal Trade Commission and the United States Department of Justice pursuant to Section 112(a) of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Class Action Lawsuit </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, a putative shareholder class action lawsuit was filed in the United States District Court for the Southern District of California against the Company, its chief executive officer and chief financial officer. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder, and seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between November 9, 2015 and November 14, 2016, inclusive. The complaint&#8217;s allegations relate generally to the Company&#8217;s November 2016 restatement of certain prior period financial statements.&#160; In January 2017, a purported Company shareholder filed a motion for appointment of lead counsel and lead plaintiff. The motion is scheduled to be heard by the Court in March 2017. No trial date has been set. The Company believes that the lawsuit is without merit and intends to vigorously defend against the lawsuit.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:11pt;">I</font><font style="font-family:inherit;font-size:10pt;">n May 2014, the FASB issued new guidance related to revenue recognition, Accounting Standards Update 2014-09, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. ASC 606 defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The new guidance becomes effective in calendar year 2018 and early adoption in calendar year 2017 is permitted. Two methods of adoption are permitted: (a) full retrospective adoption, meaning the standard is applied to all periods presented; or (b) modified retrospective adoption, meaning the cumulative effect of applying the new guidance is recognized at the date of initial application as an adjustment to the opening retained earnings balance. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are undertaking a substantial effort to be ready for adoption of ASC 606. Some of our contracts have distinct terms which will need to be evaluated separately. &#160;We have started our preliminary assessment of these contracts and although we have not completed our assessment and are in the process of reviewing our contracts, we anticipate this standard will have a material impact on our consolidated financial statements by accelerating the timing of revenue recognition for revenues related to royalties, and potentially certain contingent milestone based payments. We intend to adopt ASC 606 starting as of January 1, 2018 using the modified retrospective method.&#160; </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&#160;Presentation of Financial Statements -Going Concern (Subtopic 205-40). This accounting standard requires management to perform interim and annual assessments of the entity's ability to continue its business operations within one year of the date of issuance of its financial statements. The Company must then provide certain disclosure if there&#160;is substantial doubt&#160;about its ability to continue as a going concern. As of December 31, 2016, the Company has adopted this standard with no impact to the financial statements.</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued&#160;ASU&#160;2016-09&#160;amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards&#160;vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. The guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. In addition, the guidance provides for an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur. The updated guidance is effective in fiscal year 2018 and early adoption in fiscal year 2017 is permitted. We are currently evaluating the adoption timing as well as the impact of the new guidance on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> which requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The new standard will be effective for us in fiscal year 2020 and early adoption in fiscal 2019 is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230)</font><font style="font-family:inherit;font-size:10pt;">, Classification of Certain Cash Receipts and Cash Payments. The guidance addresses the classification of cash flows related to (1) debt prepayment or extinguishment costs, (2) settlement of zero-coupon debt instruments or other debt instruments with coupon rates that are insignificant in relation to the effective interest rate of the borrowing, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance, including bank-owned life insurance, (6) distributions received from equity method investees and (7) beneficial interests in securitization transactions. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The new guidance will be effective for fiscal year 2018 and early adoption is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. We expect contingent consideration payment presentation will change to conform to the standard.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basis of Presentation and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Business</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand is a biopharmaceutical company with a business model based on developing or acquiring assets which generate royalty, milestone or other passive revenue for the Company and using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principles of Consolidation</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly-owned subsidiaires. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the occurrence of certain circumstances, holders of the 2019 Convertible Senior Notes may redeem all or a portion of their notes, which may require the use of a substantial amount of cash. At December 31, 2016, we had a working capital deficit of </font><font style="font-family:inherit;font-size:10pt;">$64.1 million</font><font style="font-family:inherit;font-size:10pt;">, which includes the 2019 Convertible Senior notes that are currently redeemable as of December 31, 2016 but excludes another </font><font style="font-family:inherit;font-size:10pt;">$29.6 million</font><font style="font-family:inherit;font-size:10pt;"> that is classified as mezzanine equity.&#160; As noted in Note 6, the debt may change from current to non-current period over period, primarily as a result of changes in the Company&#8217;s stock price. Management believes that it is remote that holders of the notes would choose to convert their notes early because the fair value of the security that a noteholder can currently realize in an active market is greater than the conversion value the noteholder would realize upon early conversion. In the unlikely event that all the debt was converted, we have </font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;"> business days following a </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> trading day observation period from the convert date to pay the principal in cash. We have positive operating income and positive cash flow from operations for the three years ended December 31, 2016 and, accordingly, while there can be no assurance, we believe we have the ability to raise additional capital through our active S-3, by liquidating assets, or via alternative financing arrangements such as convertible or high yield debt.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to the previously issued statement of operations for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity and operating cash flows as previously reported.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:11pt;">I</font><font style="font-family:inherit;font-size:10pt;">n May 2014, the FASB issued new guidance related to revenue recognition, Accounting Standards Update 2014-09, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. ASC 606 defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The new guidance becomes effective in calendar year 2018 and early adoption in calendar year 2017 is permitted. Two methods of adoption are permitted: (a) full retrospective adoption, meaning the standard is applied to all periods presented; or (b) modified retrospective adoption, meaning the cumulative effect of applying the new guidance is recognized at the date of initial application as an adjustment to the opening retained earnings balance. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are undertaking a substantial effort to be ready for adoption of ASC 606. Some of our contracts have distinct terms which will need to be evaluated separately. &#160;We have started our preliminary assessment of these contracts and although we have not completed our assessment and are in the process of reviewing our contracts, we anticipate this standard will have a material impact on our consolidated financial statements by accelerating the timing of revenue recognition for revenues related to royalties, and potentially certain contingent milestone based payments. We intend to adopt ASC 606 starting as of January 1, 2018 using the modified retrospective method.&#160; </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued Accounting Standards Update No. 2014-15,&#160;Presentation of Financial Statements -Going Concern (Subtopic 205-40). This accounting standard requires management to perform interim and annual assessments of the entity's ability to continue its business operations within one year of the date of issuance of its financial statements. The Company must then provide certain disclosure if there&#160;is substantial doubt&#160;about its ability to continue as a going concern. As of December 31, 2016, the Company has adopted this standard with no impact to the financial statements.</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued&#160;ASU&#160;2016-09&#160;amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards&#160;vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. The guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. In addition, the guidance provides for an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur. The updated guidance is effective in fiscal year 2018 and early adoption in fiscal year 2017 is permitted. We are currently evaluating the adoption timing as well as the impact of the new guidance on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments</font><font style="font-family:inherit;font-size:10pt;"> which requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The new standard will be effective for us in fiscal year 2020 and early adoption in fiscal 2019 is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230)</font><font style="font-family:inherit;font-size:10pt;">, Classification of Certain Cash Receipts and Cash Payments. The guidance addresses the classification of cash flows related to (1) debt prepayment or extinguishment costs, (2) settlement of zero-coupon debt instruments or other debt instruments with coupon rates that are insignificant in relation to the effective interest rate of the borrowing, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance, including bank-owned life insurance, (6) distributions received from equity method investees and (7) beneficial interests in securitization transactions. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The new guidance will be effective for fiscal year 2018 and early adoption is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. We expect contingent consideration payment presentation will change to conform to the standard.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Business Risk</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and investments. The Company invests its excess cash principally in United States government debt securities, investment grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A relatively small number of partners accounts for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company obtains Captisol from a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol, the Company would be unable to continue to derive revenues from the sale of Captisol until it obtained an alternative source, which could take a considerable length of time.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Equivalents &amp; Short Term Investments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents consist of all investments with maturities of&#160;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months or less from the date of acquisition. Short-term investments primarily consist of investments in debt securities that have effective maturities greater than&#160;three&#160;months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss).&#160;The Company determines the cost of investments based on the specific identification method. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:10pt;">Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company considers receivables past due based on the contractual payment terms which range from 30 to 90 days. The Company reserves specific receivables if collectibility is no longer reasonably assured. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. The Company analyzes its inventory levels periodically and writes down inventory to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> write downs related to obsolete inventory recorded for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The change in the carrying value of goodwill during the year ended December 31, 2016, was due to the acquisition of OMT. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2016 by assessing qualitative factors, noting </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets related to acquired IPR&amp;D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered to be indefinite-lived, they are not amortized but are tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company performed its annual assessment for IPR&amp;D impairment in 2016, noting </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial license rights</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">April 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">April 2015</font><font style="font-family:inherit;font-size:10pt;"> and Cormatrix in May 2016. Individual commercial license rights acquired are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, management does not believe there have been any events or circumstances indicating that the carrying amount of its commercial license rights may not be recoverable. </font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty income earned from Cormatrix were </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2016. Accounts receivable due from Cormatrix were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> at December 31, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Relationships between the CorMatrix Parties </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As previously disclosed in Ligand&#8217;s filings, Jason Aryeh is a director of both Ligand and CorMatrix. Mr. Aryeh beneficially owns equity of CorMatrix representing less than </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> of CorMatrix&#8217;s outstanding equity. Mr. Aryeh recused himself from all of the board&#8217;s consideration of the purchase agreement between the Company and CorMatrix, including any financial analysis, the terms of the purchase agreement and the vote to approve the Purchase Agreement and the related transactions. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Liabilities</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Company&#8217;s acquisition of CyDex in </font><font style="font-family:inherit;font-size:10pt;">January 2011</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">See footnote 7, </font><font style="font-family:inherit;font-size:10pt;">Other Balance Sheet Details. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the Company&#8217;s acquisition of Metabasis in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 2010</font><font style="font-family:inherit;font-size:10pt;">, the Company issued Metabasis stockholders </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any change in fair value is recorded in the Company's consolidated statement of operations.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been provided, title has transferred or access has been given, the price is fixed or determinable, there are no remaining customer&#160;acceptance requirements, and collectability of the resulting receivable is reasonably assured.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties on sales of products commercialized by the Company&#8217;s partners are recognized in the quarter reported by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;"> days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> restocking fee. To date, product returns have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price.</font></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the Company's revenue arrangements for Captisol involve a license agreement and the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company, and in a hypothetical stand-alone transaction, the customer would be able to procure inventory from another manufacturer in the absence of contractual provisions for exclusive supply by the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other nonrefundable, up-front license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. Management evaluates the determination of gross versus net reporting based on each individual agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company&#8217;s performance obligations under the arrangement.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Study and Clinical Trial Accruals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantial portions of the Company&#8217;s preclinical studies and all of the Company&#8217;s clinical trials have been performed by third-party laboratories, CROs.&#160; The Company accounts for a significant portion of its clinical study costs according to the terms of its contracts with CROs. The terms of its CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. The Company's objective is to reflect the appropriate preclinical and clinical trial expenses in its financial statements in the same period as the services occur. As part of the process of preparing its financial statements, the Company relies on cost information provided by its CROs. The Company is also required to estimate certain of its expenses resulting from its obligations under its CRO contracts. Accordingly, the Company's preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates.&#160;No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of the Company&#8217;s scientific staff who are working pursuant to the Company&#8217;s collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for the Company&#8217;s research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs share-based compensation expense related to restricted stock, its ESPP, and stock options</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units (RSU) and performance stock units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Company&#8217;s common stock on the date of grant. The Company recognizes share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration estimated forfeitures. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The Company looks to historical volatility of the Company's stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be </font><font style="font-family:inherit;font-size:10pt;">0%</font><font style="font-family:inherit;font-size:10pt;"> given that the Company has never declared or paid regular cash dividends on its common stock and does not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company grants options and restricted stock awards to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and restricted stock awards granted to certain non-employee directors vest in equal monthly installments over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> year from the date of grant. Options granted to employees vest 1/8 on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> month anniversary of the date of grant, and 1/48 each month thereafter for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">forty-two</font><font style="font-family:inherit;font-size:10pt;"> months. Restricted stock awards granted to employees vest over three years. All option awards generally expire </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when the Company believes it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise the Company considers all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Discontinued Operations</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">In 2006, we entered into a purchase agreement with Eisai pursuant to which Eisai agreed to acquire our Oncology product line which included four marketed oncology drugs: ONTAK, Targretin capsules, Targretin gel and Panretin gel. Certain liabilities were recorded associated with the disposal of the product line. During the year ended December 31, 2016 we recognized a </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> gain due to subsequent changes in certain estimates and liabilities previously recorded. We recorded a provision for income taxes related to the gain of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Per Share</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic income (loss) per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive common shares consist of shares issuable under 2019 convertible senior notes, stock options and restricted stock. 2019 convertible senior notes have a dilutive impact when the average market price of the Company&#8217;s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options; the average amount of unrecognized compensation expense for restricted stock; and estimated tax benefits that will be recorded in additional paid-in capital when expenses related to equity awards become deductible. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive potential common shares:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Restricted stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;2019 Convertible Senior Notes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used to compute diluted income per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,433</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities less reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to the previously issued statement of operations for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity and operating cash flows as previously reported.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment is stated at cost and consists of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Summary of Unaudited Quarterly Financial Information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for fiscal years 2016 and 2015 are as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth Quarter</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,832</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,418</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(265</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(843</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,537</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,933</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense consists of labor, material, equipment, and allocated facilities costs of the Company&#8217;s scientific staff who are working pursuant to the Company&#8217;s collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for the Company&#8217;s research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been provided, title has transferred or access has been given, the price is fixed or determinable, there are no remaining customer&#160;acceptance requirements, and collectability of the resulting receivable is reasonably assured.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties on sales of products commercialized by the Company&#8217;s partners are recognized in the quarter reported by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;"> days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> restocking fee. To date, product returns have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price.</font></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the Company's revenue arrangements for Captisol involve a license agreement and the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company, and in a hypothetical stand-alone transaction, the customer would be able to procure inventory from another manufacturer in the absence of contractual provisions for exclusive supply by the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other nonrefundable, up-front license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. Management evaluates the determination of gross versus net reporting based on each individual agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company&#8217;s performance obligations under the arrangement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">726</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts owed to former licensees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties owed to third parties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">823</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(167,413</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(192,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about the liability components the Company's financing arrangement (dollars in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Convertible Senior Notes</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Principal amount outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">212,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> are shown below. The Company assesses the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company's evaluation of evidence resulted in management concluding that the majority of the Company's deferred tax assets will be realized. However, the Company maintains a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. The valuation allowance increased </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;"> in 2016, decreased </font><font style="font-family:inherit;font-size:10pt;">$231.7 million</font><font style="font-family:inherit;font-size:10pt;"> in 2015 and decreased </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150,226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,595</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets and intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">707</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of royalties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">591</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital Loss Carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,432</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking Equity Method Investment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,312</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,066</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retrophin fair value adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,196</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identified intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identified indefinite lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,963</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,790</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive potential common shares:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Restricted stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;2019 Convertible Senior Notes</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used to compute diluted income per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,433</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts computed at statutory federal rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes net of federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">386</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Meals&#160;&amp; entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 162(m) limitation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,748</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired NOLs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in uncertain tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,423</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rate change for changes in state law</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APIC Excess Tax Benefit True Up</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(622</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in deferred tax assets from completion of 382 analysis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avinza true up</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,107</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(231,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(192,115</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill and identifiable intangible assets consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite lived intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Complete technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,267</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Trade name</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,784</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total goodwill and other identifiable intangible assets, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s restricted stock activity and related information:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,483</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.2421875%;border-collapse:collapse;text-align:left;"><tr><td colspan="23" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating lease obligations:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Lease</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Termination</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than 1</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1-2 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3-4 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate headquarters-San Diego, CA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office and research facility-La Jolla, CA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioscience and Technology Business Center-Lawrence, KS</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">900</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,758</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Sublease payments expected to be received:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office and research facility-La Jolla, CA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating lease obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for fiscal years 2016 and 2015 are as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth Quarter</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,648</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,552</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,831</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,354</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,051</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,708</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,832</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,602</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,418</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (expense) benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(265</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,881</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(843</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,537</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.01</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted per share amounts:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,725</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,933</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares&#8212;diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,460</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,542</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Income tax receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Deferred tax liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Intangible asset with finite life - core technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Liabilities assumed</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,969</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a further breakdown of the options outstanding as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of exercise prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">remaining&#160; life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise&#160;price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.58 - $12.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.12 - $12.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$14.47 - $14.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$16.14 - $21.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21.92 - $21.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$32.00 - $53.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.02</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,747</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$56.26 - $59.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$63.58 - $68.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,976</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$74.42 - $74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$85.79 - $138.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,726</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.58 &#8211; $138.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,752,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of the Company&#8217;s stock option plan activity and related information:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160; thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,754,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and expected to vest as of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,752,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,247</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3%-1.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%-2.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48%-50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%-58%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62%-69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6 to 6.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.52%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6%-9.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the amount of unrecognized tax benefits at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,524</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A relatively small number of partners accounts for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Partner C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs share-based compensation expense related to restricted stock, its ESPP, and stock options</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units (RSU) and performance stock units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Company&#8217;s common stock on the date of grant. The Company recognizes share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration estimated forfeitures. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The Company looks to historical volatility of the Company's stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be </font><font style="font-family:inherit;font-size:10pt;">0%</font><font style="font-family:inherit;font-size:10pt;"> given that the Company has never declared or paid regular cash dividends on its common stock and does not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company grants options and restricted stock awards to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and restricted stock awards granted to certain non-employee directors vest in equal monthly installments over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> year from the date of grant. Options granted to employees vest 1/8 on the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> month anniversary of the date of grant, and 1/48 each month thereafter for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">forty-two</font><font style="font-family:inherit;font-size:10pt;"> months. Restricted stock awards granted to employees vest over three years. All option awards generally expire </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">ten</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation Expense</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense as a component of:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Plans</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2009, the Company&#8217;s stockholders approved the amendment and restatement of the Company&#8217;s 2002 Stock Incentive Plan (the &#8220;Amended 2002 Plan&#8221;). The Company&#8217;s 2002 Stock Incentive Plan was amended to (i)&#160;increase the number of shares available for issuance under the Amended 2002 Plan by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares, (ii)&#160;revise the list of performance criteria that may be used by the compensation committee for purposes of granting awards under the Amended 2002 Plan that are intended to qualify as performance-based compensation under Section&#160;162(m) of the Internal Revenue Code, as amended, and (iii)&#160;eliminate the automatic option grant program for non-employee directors, the director fee stock issuance program and the director fee option grant program, which programs have been superseded by the Company&#8217;s amended and restated Director Compensation Policy. Additionally, in May 2012 and May 2016, the Company&#8217;s stockholders approved an amendment and restatement of the Company&#8217;s 2002 Stock Incentive Plan to increase the number of shares available for issuance by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">0.9 million</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares available for future option grants or direct issuance under the Amended 2002 Plan.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of the Company&#8217;s stock option plan activity and related information:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160; thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,683,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,489</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(164,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,754,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,561</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,723</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested and expected to vest as of December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,752,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,247</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of all stock options granted during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$46.53</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$35.39</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$46.20</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively. The total intrinsic value of all options exercised during </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was approximately </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$15.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash received from options exercised, net of fees paid, in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a further breakdown of the options outstanding as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range of exercise prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">remaining&#160; life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">exercise&#160;price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.58 - $12.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">247,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.12 - $12.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.92</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.38</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$14.47 - $14.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$16.14 - $21.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$21.92 - $21.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$32.00 - $53.34</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.02</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,747</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$56.26 - $59.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$63.58 - $68.62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,976</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$74.42 - $74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,233</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$85.79 - $138.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298,204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,726</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.58 &#8211; $138.53</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,752,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,298,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3%-1.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7%-2.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48%-50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50%-58%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62%-69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6 to 6.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.52%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.6%-9.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$17.5 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested stock options. That cost is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.22 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Activity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s restricted stock activity and related information:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">234,855</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,483</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, unrecognized compensation cost related to non-vested stock awards amounted to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$13.8 million</font><font style="font-family:inherit;font-size:10pt;">. That cost is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">1.14</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, 70,406 shares of the Company's common stock are available for future issuance under it's Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to </font><font style="font-family:inherit;font-size:10pt;">1,250</font><font style="font-family:inherit;font-size:10pt;"> shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were </font><font style="font-family:inherit;font-size:10pt;">1,961</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">3,374</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3,774</font><font style="font-family:inherit;font-size:10pt;"> shares issued under the ESPP in 2016, 2015 and 2014, respectively. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share Repurchases </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, 2015 and 2014 the Company repurchased </font><font style="font-family:inherit;font-size:10pt;">40,500</font><font style="font-family:inherit;font-size:10pt;"> shares for </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">6,120</font><font style="font-family:inherit;font-size:10pt;"> shares for </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">1,253,425</font><font style="font-family:inherit;font-size:10pt;"> shares for </font><font style="font-family:inherit;font-size:10pt;">$68.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the Company's Board of Directors authorized the Company to repurchase up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> of its own stock in privately negotiated and open market transactions for a period of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years, subject to the Company's evaluation of market conditions. Authorization to repurchase up to an additional </font><font style="font-family:inherit;font-size:10pt;">$195.6 million</font><font style="font-family:inherit;font-size:10pt;"> of its common stock remained as of December 31, 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Account Details</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Short-term Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the various investment categories at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">fair value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Bank deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,026</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Agency bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;U.S. Government bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,758</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Bank deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Corporate equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,843</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,944</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,791</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment is stated at cost and consists of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,754</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">632</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,153</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">372</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $</font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively and is included in operating expenses.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill and identifiable intangible assets consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;IPR&amp;D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,238</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite lived intangible assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Complete technology</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,267</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,762</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Trade name</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,784</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total goodwill and other identifiable intangible assets, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> years. Amortization expense of </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> was recognized for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. Estimated amortization expense for the years ending December&#160;31, 2017 through </font><font style="font-family:inherit;font-size:10pt;">2021</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;"> per year. For each of the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment of intangible assets with finite lives.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial license rights consist of the following (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CorMatrix</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,696</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selexis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Total commercial rights, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,554</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">726</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts owed to former licensees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties owed to third parties</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">823</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. We pay CyDex&#160;shareholders, through 2016, </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of all&#160;CyDex-related revenue, but only to the extent that, and beginning only when,&#160;CyDex-related revenue for the year exceeds </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">; plus an additional </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of all CyDex-related revenue recognized during such year, but only to the extent, and beginning only when aggregate CyDex-related revenue for such year exceeds </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent liabilities consist of the following (in millions):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustment</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustment</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cydex</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Metabasis</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:8pt;"> </font></div><div style="line-height:120%;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities consist of the following (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deposits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates</font></div></div> Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate. Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Balance represents Cydex CVR obligation, which was determined based on actual amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. Excludes amortization of intangibles For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual $5.0 million amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017. The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees. The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR. The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 75% at December 31, 2016 and 65% at December 31, 2015. Changes in these assumptions may materially affect the fair value estimate. For the year ended December 31, 2016 and December 31, 2015, the Company reported a decrease in the fair value of the Viking convertible notes of $0.2 million and$0.8 million respectively in "Other, net" of the consolidated statement of operations. Investment in warrants, which the Company received as a result of Viking’s partial repayment of the Viking note receivable and the Company’s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. The sum of net income per share amounts may not equal the total due to rounding EX-101.SCH 8 lgnd-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Business Combinations - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Business Combinations - Consideration Transferred (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Business Combinations (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Business Combinations - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Fair Value Measurement (Details 1) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Fair Value Measurement (Details 2) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Fair Value Measurements - Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Financing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Financing Arrangements (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Financing Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Income Taxes (Details 2) link:presentationLink link:calculationLink link:definitionLink 2418405 - Disclosure - Income Taxes (Details 3) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Investment in Viking link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Investment in Viking (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Lease Obligations link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Lease Obligations (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Other Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 2411407 - Disclosure - Other Balance Sheet Details - Contingent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Other Balance Sheet Details (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Other Balance Sheet Details (Details 1) link:presentationLink link:calculationLink link:definitionLink 2411408 - Disclosure - Other Balance Sheet Details (Details 2) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Other Balance Sheet Details - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Other Balance Sheet Details - Investment categories (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Other Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Stockholders' Equity - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Stockholders' Equity - Share-base Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies (Details 6) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Summary of Unaudited Quarterly Financial Information link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Summary of Unaudited Quarterly Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 lgnd-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 lgnd-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 lgnd-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Income Statement [Abstract] Revenues: Revenues [Abstract] Royalties Royalty Revenue Material sales Sales Revenue, Goods, Net License fees, milestones and other revenues Collaborative Research And Development And Other Revenues Collaborative research and development and other revenues. Total revenues Revenues Operating costs and expenses: Operating Costs and Expenses [Abstract] Cost of sales Cost of Goods Sold Amortization of intangibles Cost of Services, Amortization Research and development Research and Development Expense General and administrative General and Administrative Expense Lease exit and termination costs Business Exit Costs Total operating costs and expenses Operating Costs and Expenses Income from operations Operating Income (Loss) Other (expense) income: Other Nonoperating Income (Expense) [Abstract] Interest expense, net Interest Income (Expense), Net Increase in contingent liabilities Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Gain on deconsolidation of Viking Deconsolidation, Gain (Loss), Amount Loss from Viking Income (Loss) from Equity Method Investments Other income, net Other Nonoperating Income (Expense) Total other income (expense), net Nonoperating Income (Expense) Income before income tax benefit (expense) Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax benefit (expense) Income Tax Expense (Benefit) Income (loss) from operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Discontinued operations: Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract] Gain on sale of Oncology Product Line before income taxes Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Income tax expense on discontinued operations Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation Income from discontinued operations Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Net (loss) income including noncontrolling interests: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Net (loss) income Net Income (Loss) Attributable to Parent Basic per share amounts(1): Earnings Per Share, Basic [Abstract] Income (loss) from continuing operations (in usd per share) Income (Loss) from Continuing Operations, Per Basic Share Income from discontinued operations (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (in usd per share) Earnings Per Share, Basic Weighted average shares outstanding (shares): Weighted Average Number of Shares Outstanding, Basic Diluted per share amounts(1): Earnings Per Share, Diluted [Abstract] Income (loss) from continuing operations (in usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Income from discontinued operations (in usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net (loss) income (in usd per share) Earnings Per Share, Diluted Weighted average number of common shares-diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Other Balance Sheet Details [Abstract] Other Balance Sheet Details [Abstract] Other Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Core Technology Developed Technology Rights [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] OMT, Inc. OMT, Inc. [Member] OMT, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of transgenic animal platforms Number of Transgenic Animal Platforms Number of Transgenic Animal Platforms Number of partnered programs added Business Combination, Number of Partnered Programs Added Business Combination, Number of Partnered Programs Added Consideration transferred Business Combination, Consideration Transferred Projected cash flow discount rate (percent) Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate Business Combination, Assumptions Used Estimated Future Cash Flows, Discount Rate Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Goodwill Goodwill Compensation Employee-related Liabilities, Current Legal Accrued Professional Fees, Current Amounts owed to former licensees Accrued Sales Commission Royalties owed to third parties Accrued Royalties Other Other Accrued Liabilities, Current Accrued liabilities Accrued Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Measurement Financial Instruments Disclosure [Text Block] Schedule of investment categories Available-for-sale Securities [Table Text Block] Schedule of other current assets Schedule of Other Current Assets [Table Text Block] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Summary of goodwill and other identifiable intangible assets Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of commercial license rights Schedule of Commercial License Rights [Table Text Block] Schedule of Commercial License Rights [Table Text Block] Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of contingent liabilities Schedule of Contingent Liabilities [Table Text Block] Schedule of Contingent Liabilities [Table Text Block] Schedule of other long-term liabilities Schedule of Other Long Term Liabilities [Table Text Block] Schedule of other long term liabilities. Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Short-term Investments Accounts receivable, net Receivables, Net, Current Note receivable from Viking Notes, Loans and Financing Receivable, Gross, Current Inventory Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Deferred income taxes Deferred Tax Assets, Net, Noncurrent Investment in Viking Equity Method Investments Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Goodwill Commercial license rights Commercial License Rights Commercial License Rights Property and equipment, net Property, Plant and Equipment, Net Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Liabilities [Abstract] Liabilities [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Current contingent liabilities Current Portion of Liability for Contingent Value Rights Current portion of liability for contingent value rights. Current lease exit obligations Short Term Portion Of Lease Exit Obligations Short term portion of lease exit obligations. 2019 convertible senior notes, net Convertible Debt, Current Total current liabilities Liabilities, Current Long-term contingent liabilities Liability for Contingent Value Rights Liability for contingent value rights. Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Equity component of currently redeemable convertible notes (Note 5) Debt Instrument, Convertible, Carrying Amount of Equity Component Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.001 par value; 33,333,333 shares authorized; 20,909,301 and 19,949,012 shares issued and outstanding at December 31, 2016 and 2015, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Quarterly Financial Information Disclosure [Abstract] Summary of Unaudited Quarterly Financial Information Quarterly Financial Information [Text Block] Assets: Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value of level 3 financial instruments as of December 31, 2015 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Fair market value of stock received as partial repayment of note receivable Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements Cash payment received as partial repayment of note receivable Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Viking note receivable fair market value adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Fair Value Adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Fair Value Adjustment Fair value of level 3 financial instrument assets as of December 31, 2016 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value of level 3 financial instruments as of December 31, 2015 Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Other Fair Value, Change in CVR Obligation Fair Value, Change in CVR Obligation Fair value of level 3 financial instruments as of December 31, 2016 Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] CyDex Cydex Pharmaceuticals, Inc [Member] Cydex Pharmaceuticals, Inc. Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2019 Convertible Senior Notes 2019 Convertible Senior Notes [Member] 2019 Convertible Senior Notes [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Viking Therapeutics, Inc. Viking Therapeutics, Inc. [Member] Viking Therapeutics, Inc. [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Payments to CVR holders and other contingency payments Payments to Contingent Value Right Holders Payments to contingent value right holders. Fair value adjustments to contingent liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities Fair value of convertible debt Convertible Debt, Fair Value Disclosures Equity Method Investment, Quoted Market Value Equity Method Investment, Quoted Market Value Leases [Abstract] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Corporate Headquarters - San Diego, CA Corporate Headquarters - San Diego, CA [Member] Corporate Headquarters - San Diego, CA [Member] Office and Research Facility - La Jolla, CA Office and Research Facility - La Jolla, CA [Member] Office and Research Facility - La Jolla, CA [Member] Bioscience and Technology Business Center - Lawrence, KS Bioscience and Technology Business Center - Lawrence, KS [Member] Bioscience and Technology Business Center - Lawrence, KS [Member] Geographical [Axis] Geographical [Axis] Segment, Geographical [Domain] Geographical [Domain] CALIFORNIA CALIFORNIA KANSAS KANSAS Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Payments expected to received from sublease agreements Leases, Operating [Abstract] Lease Termination Date Lease Expiration Date Operating lease obligation, Less than 1 year Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating lease obligation, 1-2 years Operating Leases, Future Minimum Payments, Due in One and Two Years Operating Leases, Future Minimum Payments, Due in One and Two Years Operating leases obligation, 3-4 years Operating Leases, Future Minimum Payments, Due in Three and Four Years Operating Leases, Future Minimum Payments, Due in Three and Four Years Operating lease obligation, Thereafter Operating Leases, Future Minimum Payments, Due After Four Years Operating Leases, Future Minimum Payments, Due After Four Years Operating lease obligation, Total Operating Leases, Future Minimum Payments Due Sublease payments expected to be received, Less than 1 year Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due Next Twelve Months Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due Next Twelve Months Sublease payments expected to be received, 1-2 years Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due in One and Two Years Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due in One and Two Years Sublease payments expected to be received, 3-4 years Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due in Three and Four Years Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due in Three and Four Years Sublease payments expected to be received, Thereafter Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due After Four Years Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals, Due After Four Years Sublease payments expected to be received, Total Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Operating lease obligation, Less than 1 year, net Operating Leases, Future Minimum Payments Due, Next Twelve Months, Net Operating Leases, Future Minimum Payments Due, Next Twelve Months, Net Operating lease obligation, 1-2 years, net Operating Leases, Future Minimum Payments, Due in One and Two Years, Net Operating Leases, Future Minimum Payments, Due in One and Two Years, Net Operating lease obligation, 3-4 years, net Operating Leases, Future Minimum Payments, Due in Three and Four Years, Net Operating Leases, Future Minimum Payments, Due in Three and Four Years, Net Operating lease obligation, Thereafter, net Operating Leases, Future Minimum Payments, Due After Four Years, Net Operating Leases, Future Minimum Payments, Due After Four Years, Net Operating lease obligation, net, Total Operating Leases, Future Minimum Payments Due, Net Operating Leases, Future Minimum Payments Due, Net Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] Purchase of Common Stock [Member] Purchase of Common Stock [Member] Purchase of Common Stock [Member] Statement [Line Items] Statement [Line Items] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net (loss) income Less: gain from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Income (loss) from continuing operations Adjustments to reconcile net income to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Change in estimated fair value of contingent liabilities Non-cash change in estimated fair value of contingent value rights Non-cash change in estimated fair value of contingent value rights. Realized gain on sale of short-term investment Realized Investment Gains (Losses) Gain on disposal of assets Gain (Loss) on Disposition of Assets Depreciation and amortization Depreciation, Depletion and Amortization Gain on deconsolidation of Viking Loss on equity investment in Viking Change in fair value of the convertible debt receivable from Viking and warrants Increase (Decrease) in Fair Value of Convertible Debt Receivable and Warrant Increase (Decrease) in Fair Value of Convertible Debt Receivable and Warrant Amortization of Premium (discount) on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Amortization of debt discount and issuance fees Amortization of Debt Issuance Costs and Discounts Non-cash milestone revenue Non-Cash Milestone Non-Cash Milestone Stock-based compensation Share-based Compensation Deferred income taxes Increase (Decrease) in Deferred Income Taxes Other Other Operating Activities, Cash Flow Statement Changes in operating assets and liabilities, net of acquisition: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Restricted cash Increase (Decrease) in Restricted Cash Other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other long term assets Increase (Decrease) in Other Operating Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Net cash provided by operating activities of continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities of discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of commercial license rights Purchase for Commercial License Rights Purchase for Commercial License Rights Purchase of Viking common stock and warrant Payments to Acquire Equity Method Investments Reduction of cash due to deconsolidation of Viking Cash Divested from Deconsolidation Purchase of commercial license rights Payments to Acquire Businesses, Net of Cash Acquired Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of short-term investments Payments to Acquire Short-term Investments Proceeds from sale of short-term investments Proceeds from Sale of Short-term Investments Proceeds from maturity of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-term Investments Proceeds received from repayment of Viking note receivable Proceeds from Collection of Notes Receivable Other, net Payments for (Proceeds from) Other Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt Repayments of Long-term Debt Gross proceeds from issuance of 2019 Convertible Senior Notes Proceeds from Convertible Debt Payment of debt issuance costs Payments of Debt Issuance Costs Proceeds from issuance of warrants Proceeds from Issuance of Warrants Purchase of convertible bond hedge Payments for Convertible Bond Hedges Payments for Convertible Bond Hedges Net proceeds from stock option exercises and ESPP Proceeds from Stock Options Exercised Taxes paid related to net share settlement of equity awards Payments Related to Tax Withholding for Share-based Compensation Share repurchases Payments for Repurchase of Common Stock Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Taxes paid Income Taxes Paid Supplemental schedule of non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock issued for acquisition, net of issuance cost Stock Issued During Period, Value, Acquisitions Stock and warrant received for repayment of Viking notes receivable Equity Received in Repayment of Note Receivable Equity Received in Repayment of Note Receivable Accrued inventory purchases Accrued Inventory Purchases Accrued Inventory Purchases Unrealized gain on AFS investments Unrealized Gain (Loss) on Investments Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] CorMatrix CorMatrix [Member] CorMatrix [Member] Selexis Selexis [Member] Selexis [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Acquired in-process research and development Acquired In Process Research And Development [Member] Acquired in process research and development. Customer relationships Customer Relationships [Member] Trade name Trade Names [Member] Complete technology Patented Technology [Member] Licensing agreements Licensing Agreements [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] IPR&D Indefinite-Lived Intangible Assets (Excluding Goodwill) Definite lived intangible assets Finite-Lived Intangible Assets, Gross Less: Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Total goodwill and other identifiable intangible assets, net Intangible Assets, Net (Including Goodwill) Amortization expense Amortization of Intangible Assets Amortization expense, 2017 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Amortization expense, 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization expense, 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization expense, 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization expense, 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Five Impairment of intangible assets with finite lives Impairment of Intangible Assets, Finite-lived Income Tax Disclosure [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] California and New Jersey Research Tax Credit Carryforward California and New Jersey Research Tax Credit Carryforward [Member] California and New Jersey Research Tax Credit Carryforward [Member] Valuation Allowance by Deferred Tax Asset [Axis] Valuation Allowance by Deferred Tax Asset [Axis] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Realization Of Excess Tax Benefits From Share Based Compensation Realization Of Excess Tax Benefits From Share Based Compensation [Member] Realization Of Excess Tax Benefits From Share Based Compensation [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Operating loss carryforward Operating Loss Carryforwards Tax credit carryforward Tax Credit Carryforward, Amount Valuation allowance, change in amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred tax assets not recognized related to share-based compensation Deferred Tax Assets, Excess Tax Benefits From Share Based Compensation, Amount Not Realized Deferred Tax Assets, Excess Tax Benefits From Share Based Compensation, Amount Not Realized Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Total stockholders’ equity Equity Component [Domain] Common Stock Common Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Accumulated deficit Retained Earnings [Member] Noncontrolling interest Noncontrolling Interest [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance at beginning of period (in shares) Shares, Outstanding Consolidation of Viking Variable Interest Entity, Initial Consolidation, Gain (Loss) Issuance of common stock under employee stock compensation plans, net Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under employee stock compensation plans (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Shares issued in OMT acquisition Shares issued in OMT acquisition (shares) Stock Issued During Period, Shares, Acquisitions Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Repurchase of common stock Stock Repurchased During Period, Value Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Sale of warrants Adjustments to Additional Paid in Capital, Warrant Issued Purchase of convertible bond hedge Adjustments To Additional Paid In Capital, Derivative Hedge On Convertible Bond Adjustments To Additional Paid In Capital, Derivative Hedge On Convertible Bond Equity component of convertible debt issuance, net of issuance costs Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Net income Net loss in noncontrolling interests Deconsolidation of Viking Noncontrolling Interest, Decrease from Deconsolidation Balance at end of period Balance at end of period (in shares) Payments expected to received from sublease agreements Schedule of Property Subject to or Available for Operating Lease [Table Text Block] Statement of Comprehensive Income [Abstract] Net (loss) income Unrealized net gain on available-for-sale securities, net of tax Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Less:Reclassification of net realized gains included in net income, net of tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Revenue volatility (percent) Fair Value Assumptions, Expected Volatility Rate Change in fair value of Viking convertible notes Convertible Notes Receivable, Fair Value, Period Increase (Decrease) Convertible Notes Receivable, Fair Value, Period Increase (Decrease) Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Public Float Entity Public Float Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Business Combinations Business Combination Disclosure [Text Block] Schedule of Business Acquisitions by Acquisition, Consideration Transferred Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block] Schedule of Business Acquisitions by Acquisition, Consideration Transferred [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Equity [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Revenue Threshold for Revenue Sharing Revenue Threshold for Revenue Sharing Revenue Threshold for Revenue Sharing Range of annual revenue subject to revenue sharing Fair Value Inputs, Annual Revenue Subject To Revenue Sharing Fair Value Inputs, Annual Revenue Subject To Revenue Sharing Average of probability of commercialization (percent) Fair Value Inputs, Average Of Probability Of Commercialization Average Probability of Commercialization Sales beta (decimal) Fair Value Inputs, Sales Beta Fair Value Inputs, Sales Beta Credit rating (non-numeric) Fair Value Inputs, Credit Rating Fair Value Inputs, Credit Rating Equity risk premiun (percent) Fair Value Inputs, Control Premium Market price of risk (percent) Fair Value Inputs, Discount for Lack of Marketability Amount owed to Cydex CVR holders Prepaid expenses Prepaid Expense, Current Other receivables Accounts and Other Receivables, Net, Current Other current assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $8.58 – $138.53 Exercise Price Range Eleven [Member] Exercise Price Range Eleven [Member] $8.58 - $12.53 Exercise Price Range One [Member] Exercise Price Range One [Member] $10.12 - $12.81 Exercise Price Range Two [Member] Exercise Price Range Two [Member] $14.47 - $14.47 Exercise Price Range Three [Member] Exercise Price Range Three [Member] $16.14 - $21.00 Exercise Price Range Four [Member] Exercise Price Range Four [Member] $21.92 - $21.92 Exercise Price Range Five [Member] Exercise Price Range Five [Member] $32.00 - $53.34 Exercise Price Range Six [Member] Exercise Price Range Six [Member] $56.26 - $59.26 Exercise Price Range Seven [Member] Exercise Price Range Seven [Member] $63.58 - $68.62 Exercise Price Range Eight [Member] Exercise Price Range Eight [Member] $74.42 - $74.42 Exercise Price Range Nine [Member] Exercise Price Range Nine [Member] $85.79 - $138.53 Exercise Price Range Ten [Member] Exercise Price Range Ten [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Range of exercise prices (per share), lower Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of exercise prices (per share), upper Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Options outstanding (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Weighted average remaining life in years Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Weighted average exercise price (per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Options exercisable (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Weighted average exercise price (per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Organization, Consolidation and Presentation of Financial Statements [Abstract] Investment in Viking Equity Method Investments and Joint Ventures Disclosure [Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt Instrument [Line Items] Notes Payable, Current and Noncurrent [Abstract] Notes Payable, Current and Noncurrent [Abstract] Principal amount outstanding Debt Instrument, Face Amount Unamortized discount Debt Instrument, Unamortized Discount Total current portion of notes payable Notes Payable, Current Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Sales Revenue, Net [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Partner A Partner A [Member] Partner A [Member] Partner B Partner B [Member] Partner B [Member] Partner C Partner C [Member] Partner C [Member] Revenue, Major Customer Revenue, Major Customer [Line Items] Total revenues Concentration Risk, Percentage Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Income tax receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Tax Receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Tax Receivables Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Deferred tax liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Intangible asset with finite life - core technology Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Income Taxes Income Tax Disclosure [Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Short-term investments Short-term Investments [Member] Bank Deposits Demand Deposits [Member] Corporate Bonds Corporate Debt Securities [Member] Corporate Equity Securities Equity Securities [Member] Commercial Paper Commercial Paper [Member] Agency bonds US Government Agencies Debt Securities [Member] U.S. Government bonds US Treasury Securities [Member] Asset-backed Securities Asset-backed Securities [Member] Municipal bonds Municipal Bonds [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Cost Available-for-sale Securities, Amortized Cost Basis Gross unrealized gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Estimated fair value Available-for-sale Securities Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Contract Termination Contract Termination [Member] Geographical [Domain] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Lease expiration year, Maximum Lease Expiration Year Maximum Lease expiration year maximum. Rent expense Operating Leases, Rent Expense Initial term of lease Lessee Leasing Arrangements, Operating Leases, Term of Contract Annual escalation of operating lease (percent) Operating Lease, Rent Expense, Annual Increase, Percent Operating Lease, Rent Expense, Annual Increase, Percent Renewal term of lease Lessee Leasing Arrangements, Operating Leases, Renewal Term Rent expense, net of sublease income Operating Leases, Rent Expense, Net Adjustment for accretion and changes in lease assumptions Operating Lease, Adjustment for Accretion and Changes in Lease Assumptions Operating Lease, Adjustment for Accretion and Changes in Lease Assumptions Financing Arrangements Debt Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development expenses Research and Development Expense [Member] General and administrative expenses General and Administrative Expense [Member] Share-based compensation expense Allocated Share-based Compensation Expense, Net of Tax Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Balance at beginning of period Unrecognized Tax Benefits Additions based on tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Additions for tax positions of prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Balance at end of period Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Net proceeds from debt issuance Proceeds from Debt, Net of Issuance Costs Convertible debt conversion ratio Debt Instrument, Convertible, Conversion Ratio Debt conversion price per share Debt Instrument, Convertible, Conversion Price Interest on debt instrument (percent) Debt Instrument, Interest Rate, Stated Percentage Number of trading days Debt Instrument, Convertible, Threshold Trading Days Number of consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Stock price trigger threshold (percent) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Debt threshold trigger price (percent) Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger Debt Instrument, Convertible, Maximum Threshold Percentage of Debt Trading Price Trigger Carrying value of equity component Proceeds from issuance of debt Proceeds from Issuance of Debt Discount rate (percent) Fair Value Inputs, Discount Rate Convertible debt, noncurrent Convertible Debt, Noncurrent If-converted value of debt in excess of principal Debt Instrument, Convertible, If-converted Value in Excess of Principal Debt issuance cost Debt Issuance Costs, Gross Unamortized debt issuance costs Unamortized Debt Issuance Expense Debt issuance costs, net Debt Issuance Costs, Net Term of debt (duration) Debt Instrument, Term Warrants to purchase number of shares (shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price per share of convertible bond hedges Exercise Price of Convertible Bond Hedge Exercise Price of Convertible Bond Hedge Payments for convertible bond hedges Exercise price per share of warrants (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Commitments and Contingencies Disclosure [Abstract] Litigation Legal Matters and Contingencies [Text Block] Schedule for accounting for share-based compensation Schedule For Share Based Compensation Expense For Awards To Employees And Directors Table Text Block Schedule for share based compensation expense for awards to employees and directors. Stock option plan activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock option plan activity, by exercise price range Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Stock option weighted average assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Restricted stock activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Metabasis Metabasis Therapeutics [Member] Metabasis Therapeutics [Member] Revenue royalty payable on all Cydex-related revenue (percent) Revenue Royalty to Acquiree Shareholders, Percent Revenue Royalty to Acquiree Shareholders, Percent Cydex-related revenue amount that triggers royalty payments Threshold Revenue Amount to Trigger Royalty Payments Threshold Revenue Amount to Trigger Royalty Payments Additional revenue royalty payable when higher threshold of Cydex-related revenue met (percent) Additional Revenue Royalty to Acquiree Shareholders, Percent Additional Revenue Royalty to Acquiree Shareholders, Percent Cydex-related revenue amount that triggers additional royalty payments Threshold Revenue Amount to Trigger Additional Royalty Payments Threshold Revenue Amount to Trigger Additional Royalty Payments Contingent Liability [Roll Forward] Contingent Liability [Roll Forward] Contingent Liability [Roll Forward] Commercial rights, beginning Business Acquisition Contingent Consideration Potential Cash Payment At End Of Period Business acquisition contingent consideration, potential cash payment at end of period. Payments Fair Value Adjustment Commercial rights, ending Lease Obligations Leases of Lessee Disclosure [Text Block] Schedule of assets and liabilities measured on recurring basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Significant unobservable inputs used in determining the fair value of contingent liabilities Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Reconciliation of the level 3 financial instruments Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Dilutive potential common shares: Earnings Per Share, Basic and Diluted [Abstract] Restricted stock (shares) Weighted Average Number of Shares, Restricted Stock Stock options (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 2019 Convertible Senior Notes (shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Shares used to compute diluted income per share (shares) Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Equity Method Investee Equity Method Investee [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] IPO IPO [Member] Derivative, by Nature [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Debt Debt [Member] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Viking Variable Interest Entity, Primary Beneficiary [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Number of programs licensed Variable Interest Entity, Number of Programs Licensed Variable Interest Entity, Number of Programs Licensed Aggregate value of shares received in Viking IPO Equity Method Investment, Value, Shares Received, Licensing Agreement Equity Method Investment, Value, Shares Received, Licensing Agreement Convertible loan facility extended Variable Interest Entity, Financial or Other Support, Amount Loss recorded (percent) Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded Variable Interest Entity, Qualitative or Quantitative Information, Loss Percentage Recorded Shares sold in Viking IPO (shares) Stock Issued During Period, Shares, New Issues Aggregate offering price Stock Issued During Period, Value, New Issues Initial offering price per share (in usd per share) Sale of Stock, Price Per Share Shares of Viking stock purchased (shares) Equity Method Investments, Shares Purchased Equity Method Investments, Shares Purchased Purchase of Viking common stock Interest rate on note due from Viking (percent) Note Receivable, Stated Interest Rate Note Receivable, Stated Interest Rate Extension of lock-up period Loan Amendment, Lock-up Period Extension Loan Amendment, Lock-up Period Extension Amount of loan to be repaid upon consummation of first capital financing transaction Note Receivable, Amount Due Upon Triggering Event Note Receivable, Amount Due Upon Triggering Event Amount of loan to be repaid in cash upon consummation of first capital financing transaction Note Receivable, Cash Due Upon Triggering Event Note Receivable, Cash Due Upon Triggering Event Repayment in equity (percent) Variable Interest Entity, License Agreement, Repayment in Equity, Repayment Percentage Variable Interest Entity, License Agreement, Repayment in Equity, Repayment Percentage Warrants purchased (shares) Equity Method Investments, Warrants Purchased Equity Method Investments, Warrants Purchased Shares received pursuant to MLA amendment (shares) Equity Method Investment, Shares Received, Licensing Agreement Equity Method Investment, Shares Received, Licensing Agreement Warrants received, licensing agreement (shares) Equity Method Investment, Warrants Received, Licensing Agreement Equity Method Investment, Warrants Received, Licensing Agreement Value of consideration received for repayment of convertible notes Other Significant Noncash Transaction, Value of Consideration Received Aggregate ownership, percent Equity Method Investment, Ownership Percentage Decrease in equity method investment Increase (Decrease) in Equity Method Investment Increase (Decrease) in Equity Method Investment Other than temporary impairment of investment in Viking Other than Temporary Impairment Losses, Investments Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Risk-free interest rate (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Forfeiture rate (percent) Share based compensation arrangement by share based payment award fair value forfeiture rate Share-based compensation arrangement by share-based payment award fair value forfeiture rate. Revenue Business Acquisition, Pro Forma Revenue Net (loss) income Business Acquisition, Pro Forma Net Income (Loss) Basic (loss) income per share (in USD per share): Business Acquisition, Pro Forma Earnings Per Share, Basic Diluted (loss) income per share (in USD per share): Business Acquisition, Pro Forma Earnings Per Share, Diluted Pro forma adjustment for share-based compensation expense Business Acquisition, Pro Forma Information, Nonrecurring Adjustment, Share-based Compensation Expense Business Acquisition, Pro Forma Information, Nonrecurring Adjustment, Share-based Compensation Expense Pro forma adjustment for additional amortization of intangible assets Business Acquisition, Pro Forma Information, Nonrecurring Adjustment, Amortization of Intangible Assets Business Acquisition, Pro Forma Information, Nonrecurring Adjustment, Amortization of Intangible Assets Pro forma adjustment for platform license fee paid Business Acquisition, Pro Forma Information, Platform License Fee Expense Business Acquisition, Pro Forma Information, Platform License Fee Expense Pro forma adjustment for revenue of OMT, Inc. prior to acquisition date Business Combination, Pro Forma Information, Revenue of Acquiree Recognized Prior to Acquisition Date, Actual Business Combination, Pro Forma Information, Revenue of Acquiree Recognized Prior to Acquisition Date, Actual Schedule of major customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Summary of computation of basic and diluted net income (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Shares [Rollforward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Balance at Beginning of Period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Balance at End of Period (shares) Exercisable at December 31, 2016 (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options vested and expected to vest as of December 31, 2016 (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Balance at Beginning of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Balance at End of Period (in usd per share) Exercisable at December 31, 2016 (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options vested and expected to vest as of December 31, 2016 (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable, Weighted Average Remaining Contractual Term in Years Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Exercisable, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options vested and expected to vest, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract] Effective Income Tax Rate Reconciliation, Amount [Abstract] Amounts computed at statutory federal rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State taxes net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Meals & entertainment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount Imputed interest Income Tax Reconciliation, Nondeductible Expense, Inputed Interest Income Tax Reconciliation, Nondeductible Expense, Inputed Interest Section 162(m) limitation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Amount Contingent liabilities Income Tax Reconciliation, Contingent Value Rights Income Tax Reconciliation, Contingent Value Rights Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Expired NOLs Income Tax Reconciliation, Expired Net Operating Loss Income Tax Reconciliation, Expired Net Operating Loss Research and development credits Income Tax Reconciliation, Expired Tax Credits, Research Income Tax Reconciliation, Expired Tax Credits, Research Change in uncertain tax positions Income Tax Reconciliation, Change in Uncertain Tax Positions Income Tax Reconciliation, Change in Uncertain Tax Positions Rate change for changes in state law Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount APIC Excess Tax Benefit True Up Effective Income Tax Rate Reconciliation, APIC Excess Tax Benefit True Up Effective Income Tax Rate Reconciliation, APIC Excess Tax Benefit True Up Increase in deferred tax assets from completion of 382 analysis Income Tax Reconciliation, Change in Deferred Tax Asset From 382 Analysis Income Tax Reconciliation, Change in Deferred Tax Asset From 382 Analysis Avinza true up Effective Income Tax Rate Reconciliation, Purchase Agreement, True-up Effective Income Tax Rate Reconciliation, Purchase Agreement, True-up Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Income tax expense from continuing operations Deferred rent Deferred Rent Credit, Noncurrent Deposits Deposits Liabilities Noncurrent Deposits liabilities noncurrent. Other Other Sundry Liabilities, Noncurrent Other long-term liabilities Deferred assets: Deferred Tax Assets, Gross [Abstract] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Research credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Fixed assets and intangibles Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets Deferred Tax Assets, Property, Plant and Equipment and Intangible Assets Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Contingent liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Deferred revenue Deferred Tax Assets, Deferred Income Present value of royalties Deferred Tax Assets, Present Value of Royalties Deferred Tax Assets, Present Value of Royalties Deferred rent Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent Capital Loss Carryforward Deferred Tax Assets, Capital Loss Carryforwards Viking Equity Method Investment Deferred Tax Assets, Equity Method Investments Other Deferred Tax Assets, Other Deferred tax assets Deferred Tax Assets, Gross Valuation allowance for deferred tax assets Deferred Tax Assets, Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Retrophin fair value adjustment Deferred Tax Liabilities, Fair Value Adjustment Deferred Tax Liabilities, Fair Value Adjustment Convertible debt Deferred Tax Liabilities, Financing Arrangements Identified intangibles Deferred Tax Liabilites, Finite-Lived Intangible Assets Deferred Tax Liabilites, Finite-Lived Intangible Assets Identified indefinite lived intangibles Deferred Tax Liabilites, Indefinite-Lived Intangible Assets Deferred Tax Liabilites, Indefinite-Lived Intangible Assets Total Deferred Tax Assets, Net Total revenues Total operating costs and expenses Income tax (expense) benefit (Loss) income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income from discontinued operations Net income (loss) (in usd per share) Net income (loss) (in usd per share) Weighted average shares—basic (shares) Weighted average shares—diluted (shares) Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Asset Class [Axis] Asset Class [Axis] Fair Value by Asset Class [Domain] Asset Class [Domain] Cash Equivalents Cash Equivalents [Member] Notes Receivable Notes Receivable [Member] Investment in warrants Warrant [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Current portion of contingent liabilities - CyDex Current Portion of Liability For Contingent Value Rights Company [Member] Current portion of liability for contingent value rights company. Current contingent liabilities-Metabasis Current Portion of Liability For Contingent Value Rights Company, Metabasis [Member] Current Portion of Liability For Contingent Value Rights Company, Metabasis [Member] Long-term portion of contingent liabilities - Metabasis Long-Term Portion of Liability For Contingent Value Rights Company, Metabasis [Member] Long-Term Portion of Liability For Contingent Value Rights Company, Metabasis [Member] Long-term portion of contingent liabilities - CyDex Liability For Contingent Value Right Company One [Member] Liability for contingent value right company one. Liability for restricted investments owed to former licensees Liability for Restricted Investments Owed to Former Licensees [Member] Liability for Restricted Investments Owed to Former Licensees [Member] Assets, fair value Assets, Fair Value Disclosure Liabilities, fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Convertible Notes Receivable, Fair Value, Period Increase (Decrease) Schedule of the components of income tax benefit Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of unrecognized tax benefits Schedule of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns Roll Forward [Table Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash Equivalents and Short-term Investments Cash, Cash Equivalents, and Short-term Investments [Policy Text Block] Cash, Cash Equivalents, and Short-term Investments [Policy Text Block] Accounts Receivable Allowance For Doubtful Accounts [Policy Text Block] Allowance for doubtful accounts. Inventory Inventory, Policy [Policy Text Block] Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Acquired in-process research and development In Process Research and Development, Policy [Policy Text Block] Commercial license rights Commercial License Rights [Policy Text Block] Commercial License Rights [Policy Text Block] Contingent Liabilities Contingent Liability Reserve Estimate, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Preclinical Study and Clinical Trial Accruals Preclinical Study and Clinical Trial Accruals [Policy Text Block] Preclinical Study and Clinical Trial Accruals [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Share-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Income Per Share Earnings Per Share, Policy [Policy Text Block] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Cash consideration Payments to Acquire Businesses, Gross Actual number of shares issued (shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Multiplied by: Ligand closing share price on January 8, 2016 (in USD per share) Share Price Total share consideration Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Total consideration Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Shares [Rollforward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested at Beginning of Period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Nonvested at End of Period (shares) Weighted-Average Grant Date Fair Value [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested at Beginning of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested at End of Period (in usd per share) Current expense (benefit): Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Total Current Income Tax Benefit Current Income Tax Expense (Benefit) Deferred expense (benefit): Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2002 Stock Incentive Plan Two thousand Two Stock Incentive Plan [Member] Two thousand two Stock Incentive Plan. Amended ESPP Amended ESPP [Member] Amended ESPP [Member] Stock Options Employee Stock Option [Member] Increase the number of shares under the 2002 Stock Incentive Plan (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Shares available for future option grants (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Weighted-average grant date fair value per share of stock options (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Weighted-average period in which cost is expected to be recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Cash received from options exercised Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Unrecognized compensation cost, restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan [Abstract] Shares allowed to purchase in employee stock purchase plan (shares) Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee Percentage lesser of fair market value taken as purchase price of share Percentage of Purchase Price of Stock Percentage of purchase price of stock. Common stock issued under amended ESSP (shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Corporate Share Repurchase [Abstract] Corporate Share Repurchase [Abstract] Corporate Share Repurchase [Abstract] Shares repurchased in period (shares) Shares repurchased in period, value Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Stock repurchase program, period in force Stock Repurchase Program, Period in Force Stock repurchase program, remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Lab and office equipment Office Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Computer equipment and software Computer Equipment And Software [Member] Computer equipment and software. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, useful life Property, Plant and Equipment, Useful Life Property and equipment , gross Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Depreciation Depreciation Basis of Presentation [Table] Basis of Presentation [Table] Basis of Presentation. IPR&D In Process Research and Development [Member] Metabasis Therapeutics Title of Individual [Axis] Title of Individual [Axis] Title of Individual with Relationship to Entity [Domain] Relationship to Entity [Domain] Director Director [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Vest 1/8 on the six month anniversary of the date of grant Vesting Period One [Member] Vesting Period One [Member] Vest 1/48 each month for forty-two months Vesting Period Two [Member] Vesting Period Two [Member] Basis of Presentation [Line Items] Basis of Presentation [Line Items] Basis of presentation. Working capital deficit Working Capital Deficit Working Capital Deficit Mezzanine equity excluded from working capital deficit Mezzanine Equity Mezzanine Equity Days after threshold consecutive trading days to complete payment of principal Debt Instrument, Convertible, Days after Threshold Consecutive Trading Days to Complete Payment of Principal Debt Instrument, Convertible, Days after Threshold Consecutive Trading Days to Complete Payment of Principal Royalty revenue (percent) Maturity period of cash and cash equivalents, maximum Maturity Period Of Highly Liquid Securities Maximum Maturity period of highly liquid securities maximum. Write-downs related to obsolete inventory Inventory Write-down Goodwill impairment Goodwill, Impairment Loss Impairment charge Asset Impairment Charges Royalty revenue Mr. Aryeh's ownership percentage in CorMatrix (percent, less than) Related Party, Ownership Percentage Related Party, Ownership Percentage Number of contingent value rights Number of Contingent Value Rights Issued Number of Contingent Value Rights Issued Sales/revenues from partners reporting period Revenue Recognition, Licensee Sales Reporting Period Revenue Recognition, Licensee Sales Reporting Period Restocking fee (percent) Sales Returns, Restocking Fee, Percent Sales Returns, Restocking Fee, Percent Share-based Compensation [Abstract] Share-based Compensation [Abstract] Expected dividend rate (percent) Fair Value Assumptions, Expected Dividend Rate Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award vesting right percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Award expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Gain on disposition of product line Gain (Loss) on Disposition of Business Provision for taxes on gain Schedule of Quarterly Financial Information Quarterly Financial Information [Table Text Block] Summary of carrying values and coupon rates on financing arrangements Schedule of Debt [Table Text Block] Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] EX-101.PRE 12 lgnd-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 stockperformancegraphv3.jpg begin 644 stockperformancegraphv3.jpg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

0?L&?L'>)O"7B2^_:S_:NNSXT_:A M\?%]8M[35TM;VW^&5IJ$:D11PI%]BC\5FR?["3:1K9^&K!O['TL"074[_1Y? MEV&PN%CG6Y?]W3ZU9;ZK?V:5^:27:VY\??L'^(/V)? WB.\_:K_ &KOVX_V6_'W[4?C MJ6768EUCX]_#+4+?X:PZC%_JK?=XB^S+XI^SN+222S2.P\.V>='T=$/VBYD_ M6X?\%%OV AG_ (S6_97_ ^//PRXX&<#_A).?UZ?6OL3[':#&;6UST_X]X^? M_'>/>E^QV?\ SZ6W_?B+_P"(KRLQS'$YIB9XK$RL[1IT:,/=HX;#P5J-"A!: M0ITH>ZMY-WE)N3E)X5:TZTG*3T^S&[Y81UM&*Z)7=OO=W=GQV/\ @HO^P'S_ M ,9K?LK]>/\ B_/PR_KXE%+_ ,/%_P!@+_H];]E?_P /S\,O_FEK[#^QV?\ MSZ6W_?B+_P"(H^QV?_/I;?\ ?B+_ .(KA,CX\_X>+_L!?]'K?LK_ /A^?AE_ M\TM'_#Q?]@+_ */6_97_ /#\_#+_ .:6OL/['9_\^EM_WXB_^(H^QV?_ #Z6 MW_?B+_XB@#X\_P"'B_[ 7_1ZW[*__A^?AE_\TM'_ \7_8"_Z/6_97_\/S\, MO_FEK[#^QV?_ #Z6W_?B+_XBC['9_P#/I;?]^(O_ (B@#X\_X>+_ + 7_1ZW M[*__ (?GX9?_ #2T?\/%_P!@+_H];]E?_P /S\,O_FEK[#^QV?\ SZ6W_?B+ M_P"(H^QV?_/I;?\ ?B+_ .(H ^//^'B_[ 7_ $>M^RO_ .'Y^&7_ ,TM'_#Q M?]@+_H];]E?_ ,/S\,O_ )I:^P_L=G_SZ6W_ 'XB_P#B*/L=G_SZ6W_?B+_X MB@#X\_X>+_L!?]'K?LK_ /A^?AE_\TM'_#Q?]@+_ */6_97_ /#\_#+_ .:6 MOL/['9_\^EM_WXB_^(H^QV?_ #Z6W_?B+_XB@#X\_P"'B_[ 7_1ZW[*__A^? MAE_\TM'_ \7_8"_Z/6_97_\/S\,O_FEK[#^QV?_ #Z6W_?B+_XBC['9_P#/ MI;?]^(O_ (B@#X\_X>+_ + 7_1ZW[*__ (?GX9?_ #2T?\/%_P!@+_H];]E? M_P /S\,O_FEK[#^QV?\ SZ6W_?B+_P"(H^QV?_/I;?\ ?B+_ .(H ^//^'B_ M[ 7_ $>M^RO_ .'Y^&7_ ,TM'_#Q?]@+_H];]E?_ ,/S\,O_ )I:^P_L=G_S MZ6W_ 'XB_P#B*/L=G_SZ6W_?B+_XB@#X\_X>+_L!?]'K?LK_ /A^?AE_\TM' M_#Q?]@+_ */6_97_ /#\_#+_ .:6OL/['9_\^EM_WXB_^(H^QV?_ #Z6W_?B M+_XB@#X\_P"'B_[ 7_1ZW[*__A^?AE_\TM'_ \7_8"_Z/6_97_\/S\,O_FE MK[#^QV?_ #Z6W_?B+_XBC['9_P#/I;?]^(O_ (B@#X\_X>+_ + 7_1ZW[*__ M (?GX9?_ #2T?\/%_P!@+_H];]E?_P /S\,O_FEK[#^QV?\ SZ6W_?B+_P"( MH^QV?_/I;?\ ?B+_ .(H ^//^'B_[ 7_ $>M^RO_ .'Y^&7_ ,TM'_#Q?]@+ M_H];]E?_ ,/S\,O_ )I:^P_L=G_SZ6W_ 'XB_P#B*/L=G_SZ6W_?B+_XB@#X M\_X>+_L!?]'K?LK_ /A^?AE_\TM'_#Q?]@+_ */6_97_ /#\_#+_ .:6OL/[ M'9_\^EM_WXB_^(H^QV?_ #Z6W_?B+_XB@#X\_P"'B_[ 7_1ZW[*__A^?AE_\ MTM'_ \7_8"_Z/6_97_\/S\,O_FEK[#^QV?_ #Z6W_?B+_XBC['9_P#/I;?] M^(O_ (B@#X\_X>+_ + 7_1ZW[*__ (?GX9?_ #2UY_\ %G_@H%^PKKWPK^)> MAZ+^V-^S)JVLZU\/_&6DZ1I6G?'#X<7NH:GJ>H^'-2L[#3[&SMO$4EQ=7EY= M316UK;01O-//(D42,[JI_0/['9_\^EM_WXB_^(KR_P"-]G:CX,?%QEMK=2OP MP\?G(MX3_P RGJX'5>Q(/!&<8/!H Y']D963]E;]FZ-E*O'\"OA1&ZL"&1T\ M#:&KJP/1E8$$=017\F7_ >"?\X\/^[M?_?9:_K*_9"!'[*?[-F>2?@3\*&) MY.=W@;0SR6))(& 222:_DU_X/!/^<>'_ '=K_P"^RT ?T_?\$UO^4<_[ ?\ MV93^RO\ ^J+\"5]K5\4_\$UO^4<_[ ?_ &93^RO_ .J+\"5]K4 %%%% !11F MC- !7Y>_'7_E+/\ \$]O^S7?V_?_ $]?LFU^H5?E[\=?^4L__!/;_LUW]OW_ M -/7[)M 'ZA4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,W-C/'0^N>_3_/KC M-?GO^W?^WCX6_9)\*6N@Z#9Q>-_CWXYC^Q_#;X<67F7ET;F\[;&Q78+FZMY/V[/VZO"G[(G@^'2M*BC\9?'/QK"UG\- M/AS9*;N]EO+IC9V^OZ_:6H>Z@T2"\=%L[:)!>:_?*-/TY"/M4UKX%^P;^PIX MJT?Q3=?M?_M=W$_C3]ISQU,->TK3->V7/;A]>T^SUDI>0?#"RU*%&AC6V=7M;;Q7#:-]BCBM=UIX4T[& MD:7BX^V74OZ]A>,$GO\ SZXZ'/7DU>1 MF.98K-,2\3BG37N^SHT**Y,/A:$-*=##4XVC3IQ6Z23<_>DW)RD\:U6=:?// MHN6*6T8JUHI=+67KN&!G/_ZJ6BBN(R"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_C?_P D M6^+W_9+_ !__ .HIJU>H5Y?\;_\ DBWQ>_[)?X__ /44U:@#A_V1/^34_P!F MO_L@_P )O_4$T*OY,_\ @\$_YQX?]W:_^^RU_69^R)_R:G^S7_V0?X3?^H)H M5?R9_P#!X)_SCP_[NU_]]EH _I^_X)K?\HY_V _^S*?V5_\ U1?@2OM:OBG_ M ()K?\HY_P!@/_LRG]E?_P!47X$K[6H ^/?VW?VHF_9)^#=C\1;'PYI'B?Q+ MXL^(_P ._@]X(LO%/B9/!'@*Q\:_%/Q%#X9\/:U\1_&LEEJ?_")^!M+N[C[1 MK&JP:9?W\[BUT;2[6;4M5M$KP[X6?M(?MF?$7]F'0?BUJ?P8_9V^''C/3M.M M/%7C36?'WQA\8V'P+\3_ PO? .D^/+/XJ?"WQ/X7\#>,_%MOHXM]4DL-;\. M?$#0- U'PY>Z/K47]I:Q90V.J:E]+?M,-&UOPA!K M-C;P^(-.6SN#?6?X^_ C_@G_ /M1^#O^"^&'P\_:.E7Q@IU70M+UCXI:+I?Q-\=2?#_P#O\ M"6@:OXBM]+T;43>7NH74(!],?!W_ (* ?M+?&GX=_L[V_AS]G7X4Z=\?/VG- M!^+_ ,7OA]X9UOXM^.K'X66?[,OPSU'0M/\ #WQ:\2^*IOA%'XTTO5?B\WBS MP7=^"_!0\!27&GZ=XLM+SQ#J5HVEZE;#6T__ (*0>,OBYX:\+:K^S-\"],\7 MZ]8_LYZO^TU\9/"OQ.^(5_X(G\'^&O#?CGQE\,KWX4>#]2T'P=XNM_%/Q5UO MQS\-?B5I'AZYU8>'? HMO!_]J:GKMG#KUBH]>^/GP8^*W@?XX?L\_M*?LT_# M#PW\4+SX/?"3XG_L\ZU\&[[QGI/PQFN/A[X_D\ :]X;UGPOXIUG2]1TFS?P? MXD^&>B66I:+>);?:_#>MWMUIYN-1TJUTZ\^+O '[#/[4G[)VB:7>?!GPQ\.? MC7XT^+'[*'B']G_XQ37OC>'X=:+X ^*FO?%WXK_&33/BA83ZMH-_=^,_AMI. ML_'7QOH>JZ'8VMEXOGTOPWX;O--TVZN=5U&"P /V;^$/Q/\ #'QF^$_PV^,7 M@^6Z;PA\4_ /A'XC>&)+^'[->_\ "/>-- L/$>D_;;?_;]#2"-]@(UO]DL$%L8!!= ?V MYO$?B6'_ (6=\8/.O]7T'6OV8CI%Q'=GQ^;JP2R.MZMBVTZ:SM;D7\AO8;@V MNG_9 #^@2BO@O_AV1^Q+_P!$@U3_ ,._\31_P[(_8E_P"B0:I_X=_X MX?\ SR: /O2BO@O_ (=D?L2_]$@U3_P[_P 31_P[(_8E_Z)!JG_ (=_ MXX?_ #R: /O2BO@O_AV1^Q+_ -$@U3_P[_QP_P#GDT?\.R/V)?\ HD&J?^'? M^.'_ ,\F@#[THKX+_P"'9'[$O_1(-4_\._\ '#_YY-'_ [(_8E_Z)!JG_AW M_CA_\\F@#[THKX+_ .'9'[$O_1(-4_\ #O\ QP_^>31_P[(_8E_Z)!JG_AW_ M (X?_/)H ^]**^"_^'9'[$O_ $2#5/\ P[_QP_\ GDT?\.R/V)?^B0:I_P"' M?^.'_P \F@#[THKX+_X=D?L2_P#1(-4_\._\31_P .R/V)?^B0:I_X M=_XX?_/)H ^]**^"_P#AV1^Q+_T2#5/_ [_ ,31_P[(_8E_P"B0:I_ MX=_XX?\ SR: /O2BO@O_ (=D?L2_]$@U3_P[_P 31_P[(_8E_Z)!JG_ M (=_XX?_ #R: /O2BO@O_AV1^Q+_ -$@U3_P[_QP_P#GDT?\.R/V)?\ HD&J M?^'?^.'_ ,\F@#[THKX+_P"'9'[$O_1(-4_\._\ '#_YY-'_ [(_8E_Z)!J MG_AW_CA_\\F@#[THKX+_ .'9'[$O_1(-4_\ #O\ QP_^>31_P[(_8E_Z)!JG M_AW_ (X?_/)H ^]**^"_^'9'[$O_ $2#5/\ P[_QP_\ GDT?\.R/V)?^B0:I M_P"'?^.'_P \F@#[THKX+_X=D?L2_P#1(-4_\._\31_P .R/V)?^B0 M:I_X=_XX?_/)H ^]**^"_P#AV1^Q+_T2#5/_ [_ ,31_P[(_8E_P"B M0:I_X=_XX?\ SR: /O2BO@O_ (=D?L2_]$@U3_P[_P 31_P[(_8E_Z) M!JG_ (=_XX?_ #R: /O2BO@O_AV1^Q+_ -$@U3_P[_QP_P#GDT?\.R/V)?\ MHD&J?^'?^.'_ ,\F@#[THKX+_P"'9'[$O_1(-4_\._\ '#_YY-'_ [(_8E_ MZ)!JG_AW_CA_\\F@#[THKX+_ .'9'[$O_1(-4_\ #O\ QP_^>31_P[(_8E_Z M)!JG_AW_ (X?_/)H ^]**^"_^'9'[$O_ $2#5/\ P[_QP_\ GDT?\.R/V)?^ MB0:I_P"'?^.'_P \F@#[THKX+_X=D?L2_P#1(-4_\._\31_P .R/V) M?^B0:I_X=_XX?_/)H ^]**^"_P#AV1^Q+_T2#5/_ [_ ,31_P[(_8E M_P"B0:I_X=_XX?\ SR: /O2BO@O_ (=D_L2_]$@U3_P[_P ;_P"OQ)IC_P#! M,S]B1!EO@_JV,XR/B_\ &\CZG_BY/ '#Z@<#ZG^M? 7[<_[;_AK]DCPE;:;H]DGCCXY>.D-A\+_AAIZRWNHWU[ MT^"5[XV^-/C13:?#/X:1?%_XZSSZE>RRBUAUK78[+XE&^MO#MM=NL/EVX M2^UN\*:7I;++))Y3YY'91I0A#ZQ75X*SA M2>DJVO3JHZ6;=O+J>U_L*?L'^,-/\83_ +8/[8DTWC3]I7QI,=:T30]:"75M M\+;6Z1S:;[9C)9P>*(+5UMK6RM4%AX/M2;"PW7S7%PO[#*N&)([<'TR22,]R M26)/ '&.M?!W_#LK]B@[2?@_J)ZY/_"W?C?GGN/^+DA;.<=.*!_P3)_8G M[_"#4_P^+_QP_G_PLFO*S+,L3FN)EB<3*S25.AAZ:MA\)03O'#8:#?N48JR2 MM>Z;OS-M\]6K.K-RD_));)=$E;_A[)OR^]:*^"_^'9'[$O\ T2#5/_#O_'#_ M .>31_P[(_8E_P"B0:I_X=_XX?\ SR:X#,^]**^"_P#AV1^Q+_T2#5/_ [_ M ,31_P[(_8E_P"B0:I_X=_XX?\ SR: /O2BO@O_ (=D?L2_]$@U3_P[ M_P 31_P[(_8E_Z)!JG_ (=_XX?_ #R: /O2BO@O_AV1^Q+_ -$@U3_P M[_QP_P#GDT?\.R/V)?\ HD&J?^'?^.'_ ,\F@#[THKX+_P"'9'[$O_1(-4_\ M._\ '#_YY-'_ [(_8E_Z)!JG_AW_CA_\\F@#[THKX+_ .'9'[$O_1(-4_\ M#O\ QP_^>31_P[(_8E_Z)!JG_AW_ (X?_/)H ^]**^"_^'9'[$O_ $2#5/\ MP[_QP_\ GDT?\.R/V)?^B0:I_P"'?^.'_P \F@#[THKX+_X=D?L2_P#1(-4_ M\._\31_P .R/V)?^B0:I_X=_XX?_/)H ^]**^"_P#AV1^Q+_T2#5/_ M [_ ,31_P[(_8E_P"B0:I_X=_XX?\ SR: /O2BO@O_ (=D?L2_]$@U M3_P[_P ^&'Q'U_2?A+J,&J:'X"\8:QIL\GQ8^--S'#?Z9X>U&]LY7MKKXB3 MVUPL=S!$[0W$,L$J@I+%(C,I /JC]D,@_LI_LUX(./@1\)@<=C_P@FA<'T/L M>:_DT_X/!/\ G'A_W=K_ .^RU_69^R*7;]E;]FYW3P/HC MN^T9"[V8DJ#L7H@"\5_)G_P>"?\ ./#_ +NU_P#?9: /Z?O^":W_ "CG_8#_ M .S*?V5__5%^!*^UJ^*?^":W_*.?]@/_ +,I_97_ /5%^!*^UJ (Y(EDR'R0 M1M9>S*@'7\/ MSYK\O_CK_P I9_\ @GM_V:[^W[_Z>OV3:_4*OR]^.O\ REG_ .">W_9KO[?O M_IZ_9-H _4*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHIA(YR2,'UZ\?RHUTT_X "N3M.!D]@> M,_CV^O:O@O\ ;D_;H\$_L?>![?%O%XO^,GC"*2S^&GPTM)6EO=2OY7^RPZ[K M<-L6N[7PS97;HKO'&+S6;H)I>DI)662T^3_V& MOV(?'.N>.;G]M7]M$MXJ^/WC.:#7/"'A#68EEM?AK8NF=.NY]+.ZRL-=\\+/VA?&#C5_"7A760DUI\-+&9 VG7$NG/OMK'Q#:V;I#HVC6RB MW\'V;; KZP9IH?V3"KC<223GGU!.X8X]._<$[L]DBC7YB1D[L%LGDX&<=R 3 MC)Y)&3S4V!Z?GS_.O*S3,\3F^*>*Q+AI!4:%&DG&AA,/!*,,+0@G94Z25E+2 M4GS2E>4FWA6K3K3YY66EE&*]V*T22[62MZBT445P&04444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !7E_QO\ ^2+?%[_LE_C_ /\ 44U:O4*\O^-__)%OB]_V2_Q_ M_P"HIJU '#_LB?\ )J?[-?\ V0?X3?\ J":%7\F?_!X)_P X\/\ N[7_ -]E MK^LS]D3_ )-3_9K_ .R#_";_ -030J_DS_X/!/\ G'A_W=K_ .^RT ?T_?\ M!-;_ )1S_L!_]F4_LK_^J+\"5]K5\4_\$UO^4<_[ ?\ V93^RO\ ^J+\"5]K M4 >5?&?XR?#/X!^ -7^)_P 7/%EGX-\%:')86]YJMU!?W]S=:AJM]#IFC:'H M6B:/9ZEKOB3Q+KFJ75KIVA>&M TS4M9UO4)H;+3["ZN)%B;P_P !_MY_LK_$ M'X%V'[0?AKXDW-SX O-#]/\(WVM7>B'_A(M/M;SP\R:J_GO_!2W3O@O=_L[Z7J?QQ\1_%; MX?>&O"GQ@^%7C#P[\8/A#I2ZKKGP0^(/A[Q%]K\%_%7Q-]JT/Q/H>F?#K0=4 M/]G^.]9\6>&]:\(Z?H.LW#^(K6'36FU"Q_!?X">)O'?Q5\$?L;^-_BM\8;'3 M/V7?V?/B_>^$_'G[-/%EH^LZ?I>H_#3Q M[>W?[/GB?]H#P3J6FZ!-J,&F:7I.J>'+R[U.&V /Z+[G]O;]DR#X8^%/B[!\ M68]9\'^-O$7BCPCX9MO#'@KXB^+?'NH>*O O]IGQ]X:E^$WA?PAJ_P 5M-UW MX?#1M4;X@Z3JO@NROO JV4S>+(-'7:6U?'_[;W[+'PST+X?^)_%/Q?T9_#_Q M/\+2^//!FK^%-'\5?$*RO?AY:Q:?-?\ Q+U6;X?Z#XG'A7X8Z4FJZ=_;7Q)\ M6?V)X&T5KR"/5M?LY&VU^,OP*^)]G\(?V@_@O^TC\=?&,-A^RI97G_!0'X1_ M!?\ :.\;65KIUGXUT?Q'XR^!?C'X6^/_ (@^+K;3K&WU_P 3_$SPO\/?B'H? MAGXG:U'_ &S\7X_#-E=SW^JZ[X@LO[6\J_9MU"T_9.\/W/B#]I^PU+P#X>^/ M/_!.SQSX5^"6B^+M#OK2]US7+W]IK]ICXD0? ;1M,%O+J,WQ+\1> /C'\);_ M $7X;O!#XKUA;N72M/T66Y\.:A;6(!_4?9ZA8ZA9VNH6%[:WUA?VT%[8WMG< M17-I>V=U&DUM=VES SPW-M6PN&61M\UM(_F;F)/Y=?''P) M^VU?%O_"M_V_O^CM?V9/\ Q"/Q_P#_ $;5 M,?X<_M^J 3^UK^S+U _Y,A\?D?C_ ,9LG ]^/0._$,\=OX'^%>E_L;>/-.UOQ41.B7=U<7R_MDZM)H6B6Z[HGU>72[ MWS;QH[*QLM0O&$"^+_L^?L"?M=?%/QWHW[;'QJ^+/PU\,?'#Q"\^M:+X%^,/ MP+U[XS:;X0L+F.!_#5[;:1I'QJ^$=MX0U;1KAAI*#<:%+_F*KJRC_ XM3E== M5&G%0^L5=*<9+EIM^_4?2R_E7VGIVT/:?V&_V(_&_BGQPW[;'[:3W'B[X]>, M)(]<\$^#-=A!LOAM8.J_V7>W.DN9+>SUFTM&2+0-#C3[)X3L'C+1_P!N33SV M_P"S\:L"20>5&22"N?^&V>_)Y[@?,14G_"M_V_O^CM?V9/_$(_'_\ ]&U7F9IF>*S;$O$8AQIQ M@HT\-AZ2Y,/A<-!)4\-1I[0C"*LW;GG*\Y2DVV95:TZTN:6D?L06U./\J[*_ M^;;9]I#/?KFEKXL_X5O^W]_T=K^S)_XA'X__ /HVJ/\ A6_[?W_1VO[,G_B$ M?C__ .C:KSS(^TZ*^+/^%;_M_?\ 1VO[,G_B$?C_ /\ HVJ/^%;_ +?W_1VO M[,G_ (A'X_\ _HVJ /M.BOBS_A6_[?W_ $=K^S)_XA'X_P#_ *-JC_A6_P"W M]_T=K^S)_P"(1^/_ /Z-J@#[3HKXL_X5O^W]_P!':_LR?^(1^/\ _P"C:H_X M5O\ M_?]':_LR?\ B$?C_P#^C:H ^TZ*^+/^%;_M_?\ 1VO[,G_B$?C_ /\ MHVJ/^%;_ +?W_1VO[,G_ (A'X_\ _HVJ /M.BOBS_A6_[?W_ $=K^S)_XA'X M_P#_ *-JC_A6_P"W]_T=K^S)_P"(1^/_ /Z-J@#[3HKXL_X5O^W]_P!':_LR M?^(1^/\ _P"C:H_X5O\ M_?]':_LR?\ B$?C_P#^C:H ^TZ*^+/^%;_M_?\ M1VO[,G_B$?C_ /\ HVJ/^%;_ +?W_1VO[,G_ (A'X_\ _HVJ /M.BOBS_A6_ M[?W_ $=K^S)_XA'X_P#_ *-JC_A6_P"W]_T=K^S)_P"(1^/_ /Z-J@#[3HKX ML_X5O^W]_P!':_LR?^(1^/\ _P"C:H_X5O\ M_?]':_LR?\ B$?C_P#^C:H M^TZ*^+/^%;_M_?\ 1VO[,G_B$?C_ /\ HVJ/^%;_ +?W_1VO[,G_ (A'X_\ M_HVJ /M.BOBS_A6_[?W_ $=K^S)_XA'X_P#_ *-JC_A6_P"W]_T=K^S)_P"( M1^/_ /Z-J@#[3HKXL_X5O^W]_P!':_LR?^(1^/\ _P"C:H_X5O\ M_?]':_L MR?\ B$?C_P#^C:H ^TZ*^+/^%;_M_?\ 1VO[,G_B$?C_ /\ HVJ/^%;_ +?W M_1VO[,G_ (A'X_\ _HVJ /M.BOBS_A6_[?W_ $=K^S)_XA'X_P#_ *-JC_A6 M_P"W]_T=K^S)_P"(1^/_ /Z-J@#[3HKXL_X5O^W]_P!':_LR?^(1^/\ _P"C M:H_X5O\ M_?]':_LR?\ B$?C_P#^C:H ^TZ*^+/^%;_M_?\ 1VO[,G_B$?C_ M /\ HVJ/^%;_ +?W_1VO[,G_ (A'X_\ _HVJ /M.BOBS_A6_[?W_ $=K^S)_ MXA'X_P#_ *-JC_A6_P"W]_T=K^S)_P"(1^/_ /Z-J@#[3HKXL_X5O^W]_P!' M:_LR?^(1^/\ _P"C:H_X5O\ M_?]':_LR?\ B$?C_P#^C:H ^TZ\O^-Y ^"_ MQ>R0,_"_Q_U./^93U<]_8$_0$U\^?\*W_;^_Z.U_9D_\0C\?_P#T;5>??%GX M>?MUP?"SXE7&M_M4?LWZEHT'@#QG-JVG:?\ L9>.=*O[_3(_#FI-?V5CJL_[ M96KPZ9>75H)8+;4)M)U2*SFD2XETZ^2-K64 ^B_V0SG]E/\ 9KQ_T0CX3C\1 MX%T,$?@017\FG_!X)_SCP_[NU_\ ?9:_K-_9&V_\,K?LW; RQGX%_"ED5FWL MJ-X'T0JK/M7>RJ0&?:-S9;:N<5_)E_P>"?\ ./#_ +NU_P#?9: /Z?O^":W_ M "CG_8#_ .S*?V5__5%^!*^UJ^*?^":W_*.?]@/_ +,I_97_ /5%^!*^UJ ( MY(HY05D4.K(R,C ,C(XPRLC JP9258$$%6(((-5;'3;'3+.RT[3+6VTW3M.M M+?3["PL;:"TLK&PM(4M[6RL[2"-+>UM+:".**WMX(XX88HTCB1$&VKU% #-G M+$,P9AR>#TZ'!!7([3 MG'T]!Z#H.V*_+_XZ_P#*6?\ X)[?]FN_M^_^GK]DVOU"K\O?CK_REG_X)[?] MFN_M^_\ IZ_9-H _4*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH ***,T 1E\(3'XB^(?B**:U^'7P[MI]NJ>)-4 M.(5O+Y(M\VG^&]/G=/[2OF1C,V+"Q%Q>3*%^)OV*OV+OB-\3_B*/VY/VW&EU M_P"+?B)X=;^&?PTU:$C3?AYI?$FB7M_H\I:WLKZPB?=X7\/;2NA)(FHZD9]= M9FL_HLKRK#T\++.$??;Y> MNA1@H^WQ-XT?^7&A'Y7AB'_3+]7\0D MO9?M6(]PW,S$L ,<8&#VR,\X'7(XRN,TU.ZODL,CIT&"?7G P >^,U,G"C'3 MG^?U.*\S,\TQ&;8KVV)]G!*"AA\-0CR8;"T*;4:=+#4XJ,:<5&W/9*4IWE)M MMF5>K.M/FE97_&_P#Y(M\7O^R7^/\ _P!135J .'_9$_Y-3_9K_P"R#_"; M_P!030J_DS_X/!/^<>'_ '=K_P"^RU_69^R)_P FI_LU_P#9!_A-_P"H)H5? MR9_\'@G_ #CP_P"[M?\ WV6@#^G[_@FM_P HY_V _P#LRG]E?_U1?@2OM:OB MG_@FM_RCG_8#_P"S*?V5_P#U1?@2OM:@!"P&,]3T&"2?7 )..OTR>@-,26* M14>-UD25%DC>,^8LD; %9$9-P:-@RD."5(((.#7PE_P49^&GQ@^+7[.,_@SX M,:K8+K-U\0OAWJ/C3P/?_$2_^$9^,?PIT?Q#%J'Q'^#NG_$[2H9]3\%ZAXX\ M-0W<":G9QJ+RWLKC1+^XM-+U6]NH?QF_9\\ ^)/VC_V)?@Y^SC^SQX2\=^$M M6\!_M ?!#Q?^T-^S7^UI\;/$?@31_A[X2;X#:?\ $FS\(?#;QE\+8?%_B_QE M\"?B;JEWX<^(/AW0="\0ZTL,6LZW8W9T+2-,N_#-@ ?U$;@21GD/3/'&??'?T-?SV_#:/X>?M$?'7X&_L2ZYX%U+X>?! MKX3:-^VE;?&3X0^#?B7\2D\&>*OV@_@QXP^"'A>RU'0OB#+K7A_X@^,/ UCI M/QG\^#Z'K7Y? M?'7_ )2S_P#!/;_LUW]OW_T]?LFU]1?L7?$KQ9\6_P!C[]EOXJ>/GDN/''Q& M_9X^#WCKQ?<-!#;&_P#$?B;X?Z#K.M:BEO"[6]N-2O[NXOX[:-PL"7*QG9M" MC\I/C?\ M4^)I?\ @J!^P_XC_P"&-_VQX[CPU^SW^W3HEOX>?P3\(1K/BF'4 MM<_9?637/#(_X7A]@N-&TC^S4.L2ZK>Z1>P_VSH/V*QU 7EX=- /W[HKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&H_X;6\8_]&$_MV?^$/\ K_Z(:@#[LHKX3_X M;6\8_P#1A/[=G_A#_ K_ .B&I/\ AM?QC_T81^W;_P"$-\"OZ_M#8_.C<#[I M/7_ !WX@BFL_AS\.;2< M+J_BG6%4HES<(NZ2Q\/6,TD3:IJ;1'!V6EDL]_/##7S9\>/^"JWASX%Z%'/X M\_97_:B\ >)/$%CJT?@&Q^)OASX7Z1H7B+7-/A26*TO;_P )?%CQOK.F6!ED M@674#H,EMYCQ6OF"[FMTK\_?V=/"'QC\2_'+4/VOOVS?V2/VM_C?\0]0EL-6 M^%6A^#_ _P )[_X9^&-%EMHM0\/ZK9V?BOXU>&=44Z3%&M-_LJ[ MBDUJ^6]U6Y@FM?H\IRG#0P\LZSJ4Z654VX8?"P?+B,UQ2VP]).SCAKZ8G%)/ ME2<(-SUAV4Z)<$P6-S80,C>&?#LL+ M+I'F?VUJ7F:[<_Z)^VD88,2P.6 R#M W$<%LD5\*#]M'QB#G_A@K M]NSJ2?\ BAO@2">1W'[0XZ8 YSD 9R1FI?\ AM;QC_T83^W9_P"$/\"O_HAJ M\S-,SQ.:XE5ZZA3ITX*EA,)13CAL%AU;EH4(=$DM[>\[MN[2,:]5UIU&V?4]3>R^/M[=II]@LINKQK6SN MKE;:*0P6T\H6)@#ZA_9$_P"34_V:_P#L@_PF_P#4$T*OY,_^#P3_ )QX?]W: M_P#OLM?UF_LC +^RM^SHQ_#N!?A_'IVE7&G>&[7P4\OAJ MQT*UTIS;U^@%% 'QGXB_8,_9[\0>#O!GA.&R^('A34O ?B#Q9XMT/XG>!/BG MX]\%_&:;Q1\0K&33_B7X@UWXL>']=LO&OB/5?B9!)O\ 'MSK>K7Q\1W4%C>W MB_;-+TR>S@\=?\$_?V8O'6A?#WPR/"7B/P)H'PV^'MY\'M(TSX4?$'QQ\,(= M=^#.J26,VM?"#QS)X,UW2;CQQ\.=G01VEAI>EZ9;16>G:?86L")# M;6=C:016MK;QH(H;=%B10@Q7YG_'5!_P]G_X)[#G'_#+O[?G';/]M?LHC/3@ MD2-G'MZ5^HM?E[\=?^4L_P#P3V_[-=_;]_\ 3U^R;0!^H.!Z#\J,#T'Y4M% M"8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2 MT4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]! M^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J, M#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/ MRHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@ M>@_*C ]!^5+10 F!Z#\J,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5'.> MG'2<8_ST_SWZ]J5]]'H[?E_F [ ]!^5&!Z#\J^1_P!KG]K_ .&O['GP MUG\<>.YI-5U[4C-9>!/ >G74<>O^--8C1I&M[42*PTW2[)6CFUC6KI&M-/MP M% GNY[.TN-[]G7]K#X._M*_#/1OB;X'\4Z;96U]&+37/#>NZE96'B#PEX@A1 M&O\ 0=;L9YHY([BW9PUK>1*UIJ5FT5[:R-%*H7N_L['_ %&&9?5*_P!1G5]A M#%*G)T95DDW3C-*S:[_"VFD[IHU]C5]FJRA/V3=HSY7RN6ETO2^_?0^FL#T' MY48'H/RKF_\ A,?"G_0T^&O_ =Z;_\ )54+GXB> K.017GCKP9:2L"ZQ7/B M?18'="2WRN5![@ <>G7FC2J2=E3FWO\$GV[)]UY$*,G]E_<_+R\[G9X'H M/RHP/0?E7"?\+0^&W_11/ ?_ (5V@_\ RPJ&7XI_#*&-Y9?B5X#BBC&^21_& M'A]451R2S-J& ,=\BG["O_SYJ?\ @$EV\O/[_O3]G/\ E?W/R\O/\'V/0<#T M'Y48'H/RKR4?'?X)?]%B^%Q_[GWPSP/<#5>/QQ2_\+W^"7_18?A?_P"%[X:_ M^6M4L+BFDUA<2T^L:%62Z;-1UW_#S%R5/^?<_E%V_K_+T/6<#T'Y48'H/RKQ M2[_:2_9\T^7[/??'/X1VD^T.(KGXA^%(I"AZ-L?54/X@?@,U6_X:?_9O_P"B M^_!S_P ./X1_^7%5]3QG_0)B?_!%7_Y ?LJO_/JI_P" /R\O/^KJ_NF!Z#\J M,#T'Y5X)>/^)R>V,>OM1]2QO3"8E_\ <"K_ /(![*K_ M ,^JG_@#\O+S_K2_TI@>@_*C ]!^5?-3?ME_LE $_P##3'P(&.N?BIX+Q[_\ MQG_#WQ6;VDEN'Y[I&U:K*NH>PK],/7?9JE.S]' M8^N<#T'Y48'H/RKXQ_X>%?L4_P#1ROPR_P#!Q7]WS?W>9]G8'H/RHP/0?E7PY/\ \%(_V&K69X)OVE/ 9D0@'R1KUS'TS\LU MMH\L3YZY21ACO4/_ \M_85S_P G(^"<<#/D>)#V_P"P%WYYZ9H_L7.NF3YH MWV^HXF[]/W6K\OGMJ2\-B+7]A6W_ .?4UV_NZ[['W00 ,X';K@=_6OCC]LK] ML;X<_L>?#"?QCXME35O%^LKK^+M>C4*JD#<]CH=A+)#-K.JO M'Y=K"RP0BXO9K>WE_+G]IG_@MCI_@_XL>'="_9PT/1/B9\.?#K7,WCGQ%KHU M'2H/'%Q>:?,MKHWA">2UBOM(L]&F=+VXU^YL)_[2OH186UD;&-I+W=_8,_9N MUS]L3QK'_P %!OVK?$&D?$2^U?5;Q?A!\.;>5;WPOX0MM!U*>UMWU#26>:TL MHM"NH'&B>&[@3W"WPD\0:V\NI30X^@H\+5,LPM#/.)Z$\+E>LZ&%DW'%9AB4 M[0R]TTO:8=5$E.M4:C*-)KE?.VH=<<"Z*C7QB=.E9.$?M3GO&-M+7^U=Z+^5 MW:Z[]C#]C3XC?'?XC6_[='[N-;:Q\)?A5JUNZZ/X*T:-S<^']4U#0 M[H-'IZ6,4JR^&?#DD?F6KO\ V[K1GU>Z1+;]NQ$F2Y)!W?>'7DF/3TKY[-,UQ.;XB.(K6I M4J<52P>$I+EP^"PR^"C0I[+D5ES/WIR]Z3N5HI)1A".D81C9))+ M3HKO6[^21@>@_(48'H/RI:*\XQ$P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,# MT'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* M$P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*E MHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z# M\J6B@!,#T'Y48'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48 M'H/RI:* $P/0?E1@>@_*EHH 3 ]!^5&!Z#\J6B@!,#T'Y48'H/RI:* $P/0? ME7EWQP4'X+_%WC&/AAX_(QE3G_A$M77J,'HQQZ'D, ]#GD9'&,YQVQD=P*^(?\ @H1^T;XV M_9;_ &>+CXF^ ]-T0:K?>/\ X=?#_4?'OB[1/$'B7P#\%?#WC[Q/:^'M6^-' MQ!T'PN]OKFJ>$/ <5TEW?VEMJ&D6;W=SI[ZSK6D:)'J.I6OS_P#L\?MI_$*S M_8+M?VE_CCKWPA^.^MZCIOAB+X->)/V<]3LF@_:9UWQSX>\.MX$\(6?A&UU+ MQ%8^!_BKK7CW6;CP!XA\/:=X@U[1=,N-+N?%;R:+H:W^EZ, ?J\LB-T8'\_0 MG^ASZ$$'D8H\Q,$[L@=< DC\ ,].3QP/F/'-?B?\ _VX_P!JC]IWX7?L2^$_ M#EK\%/A+^TG^TI\&?C=\<_BAKNK^%O$WQ&^&GPUT'X,^--,^'\GAGPOX*M/' M_A#7/$=_XD\7^*?#>E?V[>^-;6STW2=.\2:U#::E"O\ @H)^T1^T MMH.EQ_L_Z-\(OAWXT^'O[+FN?M&_&K3/B)H_B+XA:/KOC+P]\4OB?\'X?@CX M/?0O&7@F^\(Z1XB\4?!;XA:I-\3=6C\27^AZ%>>$O+\#ZM>W.J+:@'[;@@]# MFOR^^.O_ "EG_P"">W_9KO[?O_IZ_9-K[@^ 'Q>TCX]_ OX/?'/0;&?2]%^, M'PP\"_$W3-)NYX[FZTBS\:^&=,\1II5Y>%?L^GWMUK7[*AM;2]E_ MM;9:W%T;:X%M%.8WN/LUV85<6ESY0!^PM%>5?\+V^"'_ $63X5?^'#\(_P#R MWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_ MX7M\$/\ HLGPJ_\ #A^$?_EO0!ZK17E7_"]O@A_T63X5?^'#\(__ "WH_P"% M[?!#_HLGPJ_\.'X1_P#EO0!ZK17E7_"]O@A_T63X5?\ AP_"/_RWH_X7M\$/ M^BR?"K_PX?A'_P"6] 'JM%>5?\+V^"'_ $63X5?^'#\(_P#RWH_X7M\$/^BR M?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_X7M\$/\ HLGP MJ_\ #A^$?_EO0!ZK17E7_"]O@A_T63X5?^'#\(__ "WH_P"%[?!#_HLGPJ_\ M.'X1_P#EO0!ZK17E7_"]O@A_T63X5?\ AP_"/_RWH_X7M\$/^BR?"K_PX?A' M_P"6] 'JM%>5?\+V^"'_ $63X5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^ M6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO M0!ZK17E7_"]O@A_T63X5?^'#\(__ "WH_P"%[?!#_HLGPJ_\.'X1_P#EO0!Z MK17E7_"]O@A_T63X5?\ AP_"/_RWH_X7M\$/^BR?"K_PX?A'_P"6] 'JM%>5 M?\+V^"'_ $63X5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ M"]O@A_T63X5?^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO0!ZK17E7_"]O M@A_T63X5?^'#\(__ "WH_P"%[?!#_HLGPJ_\.'X1_P#EO0!ZK17E7_"]O@A_ MT63X5?\ AP_"/_RWH_X7M\$/^BR?"K_PX?A'_P"6] 'JM%>5?\+V^"'_ $63 MX5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5? M^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO0!ZK17E7_"]O@A_T63X5?^'# M\(__ "WH_P"%[?!#_HLGPJ_\.'X1_P#EO0!ZK17E7_"]O@A_T63X5?\ AP_" M/_RWH_X7M\$/^BR?"K_PX?A'_P"6] 'JM%>5?\+V^"'_ $63X5?^'#\(_P#R MWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_ MX7M\$/\ HLGPJ_\ #A^$?_EO0!ZH3@9/ I-R]<\?C7E9^.WP0Q_R6/X5GM@? M$/PADYXXSK 'YUY]\5OVO/V;_@UX'NO'WCCXN^"8="C>:WL8]!UW3O$VK:Y? MQQ>8--T+2=#NKV]U/4"",Q0)Y=NC"6\FM[?=*NM"AB,56IX?"T*N(K59*-.E M1C*I5G)OX84H)RDUN]E;KHQQC*)O ?[-/P0 MM[R?1?%7Q:\%G1+FW:M"ZM_8/A.RN=7CCE>/4M?T^ M)P#]J?LG?LB?L+?LQ2VWB^\^+'PO^*_QD,K7E_\ $_QUX[\&7]W;:E*YEN+C MPSH\^N7=IH;M,3(FHO)?:[([&:?4]Y\M/H_['R[*8JKQ!7]MB8V<^'KKX M\>/?B(_Q.O+5;SQ'9?#_ %?PYIOA?1YKC$L6BV1U3PQK=WJ4NEJQM[K5GNHX M[V?S)(+=(=CR?L\OQQ^""L6_X7+\*VYSEOB'X1)QR<<:N.0> 3DXZDYQ4O\ MPO;X(?\ 19/A5_XNBMQUGKPU+ 8"K3RO X:=\/2P5/VWP0_Z+)\*O_#A^$?_ );T?\+V^"'_ $63X5?^ M'#\(_P#RWKC_ -;^)_\ H=X__P &^GEY?UAK]-/^%[?!#_ *+)\*O_ X?A'_Y;T?\+V^"'_19/A5_XD^+N)7J\ZQUU_T^?2W^7XL/[1QO_056Z?;?0_.-O\ @BA^Q"3D:3\3!]?' M]R>^>/\ 01CJ?_K<4W_AR?\ L1?] KXE_P#A>W'_ ,A5^CW_ O;X(?]%D^% M7_AP_"/_ ,MZ/^%[?!#_ *+)\*O_ X?A'_Y;UF^*N(V[_VUC_\ P>_+^OF+ M^T,;_P!!-7[T^W5J_3OU9^>=G_P1>_89MHC'/X2\>W[[F/GW7Q#UN.3#=5Q8 MO:1;>G!C[?E_5E:?KN+_Y_ MU/\ P+^NW]79\!0_\$:?V$(I4D;X?^,)U0DF";XC^*UBDXZ2(92/99!6F M/^"._P"P/W^$^O\ _ASOB&?U_P"$E'\J^ZO^%[?!#_HLGPJ_\.'X1_\ EO1_ MPO;X(?\ 19/A5_XD^(\_>^/B=\0QR#D<_P#"2UJV7_!([]@JR@$ ^"TU MP [OYMYXY\<7MP2Y!8-/<>(&D*@_=7. .@'-?:W_ O;X(?]%D^%7_AP_"/_ M ,MZ/^%[?!#_ *+)\*O_ X?A'_Y;U/^L.??]#G-/_"[$_\ RP7UO%?]!%;I M]M]+?Y?BSXV'_!)G]@L?\T0B/_,;B ^[P2Z\\3GM\PZ5]A_P#"]O@A_P!%D^%7_AP_"/\ \MZ/^%[? M!#_HLGPJ_P##A^$?_EO2_M_/'J\YS1_]S^*U^ZJ@6*Q7_016_P#!DOT9\J?\ M.MOV#LY_X9Y\+?\ @P\1_P#RXH_X=;_L'CI^SSX6Y&#_ ,3'Q&.,>HUC/Y=* M^J_^%[?!#_HLGPJ_\.'X1_\ EO1_PO;X(?\ 19/A5_XL_[:SG_H M;9E_X6XCR_Z>>7]65AXK%/?$5O\ P;/_ #/FNT_X)H?L)VL"P#]FCX>RB/.) M+F+5;F9\G)+S2ZF9&P3@%CG%3_\ #MC]A;/_ ";+\-L9'_+E?\?3_B89_6OH MW_A>WP0_Z+)\*O\ PX?A'_Y;T?\ "]O@A_T63X5?^'#\(_\ RWI?VQF][O-< MR=N^-Q&GI^\T^7=]"?K&(_Y_UO\ P9+R[M]E]Q^9/QE_X(R_LY?$'XD_#_Q7 MX$27X3^"],O"OQ*^'_AA;@Z?XPTFUC,UDNA7$]T\GAK5[NYBBT_6;R)YH+C2 M)IFMK>WU&..X?]8O!W@[PWX!\-:+X,\':#IGAOPKX;T^WTK0M$TFVCM-/TVP MM45(;:"WBP,8R\LK$RSS-)-.TDKM(W)_\+V^"'_19/A5_P"'#\(__+>C_A>W MP0_Z+)\*O_#A^$?_ );T8W.,SS&EAZ..QE?%4\)&4:"K3G/7E MYYN4E%**=AU<16KPA"K4E4C3^%2UM_F_-ZGJ@S_GK^/O2UY5_P +V^"'_19/ MA5_XC_A>WP0_P"BR?"K_P .'X1_^6]>:8'JM%>5?\+V^"'_ $63 MX5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5? M^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO0!ZK17E7_"]O@A_T63X5?^'# M\(__ "WH_P"%[?!#_HLGPJ_\.'X1_P#EO0!ZK17E7_"]O@A_T63X5?\ AP_" M/_RWH_X7M\$/^BR?"K_PX?A'_P"6] 'JM%>5?\+V^"'_ $63X5?^'#\(_P#R MWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_ MX7M\$/\ HLGPJ_\ #A^$?_EO0!ZK17E7_"]O@A_T63X5?^'#\(__ "WH_P"% M[?!#_HLGPJ_\.'X1_P#EO0!ZK17E7_"]O@A_T63X5?\ AP_"/_RWH_X7M\$/ M^BR?"K_PX?A'_P"6] 'JM%>5?\+V^"'_ $63X5?^'#\(_P#RWH_X7M\$/^BR M?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_X7M\$/\ HLGP MJ_\ #A^$?_EO0!ZK17E7_"]O@A_T63X5?^'#\(__ "WH_P"%[?!#_HLGPJ_\ M.'X1_P#EO0!ZK17E7_"]O@A_T63X5?\ AP_"/_RWH_X7M\$/^BR?"K_PX?A' M_P"6] 'JM%>5?\+V^"'_ $63X5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^ M6] 'JM%>5?\ "]O@A_T63X5?^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO M0!ZK17E7_"]O@A_T63X5?^'#\(__ "WH_P"%[?!#_HLGPJ_\.'X1_P#EO0!Z MK17E7_"]O@A_T63X5?\ AP_"/_RWH_X7M\$/^BR?"K_PX?A'_P"6] 'JM%>5 M?\+V^"'_ $63X5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ M"]O@A_T63X5?^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO0!ZK17E7_"]O M@A_T63X5?^'#\(__ "WH_P"%[?!#_HLGPJ_\.'X1_P#EO0!ZK17E7_"]O@A_ MT63X5?\ AP_"/_RWH_X7M\$/^BR?"K_PX?A'_P"6] 'JM%>5?\+V^"'_ $63 MX5?^'#\(_P#RWH_X7M\$/^BR?"K_ ,.'X1_^6] 'JM%>5?\ "]O@A_T63X5? M^'#\(_\ RWH_X7M\$/\ HLGPJ_\ #A^$?_EO0!ZK7E_QO_Y(M\7O^R7^/_\ MU%-6J+_A>WP0_P"BR?"K_P .'X1_^6]>;?&7XV_!F^^$'Q5LK+XN?"^[O+SX M;>.K6TM8/'_A.6>YN9_"^JQ000Q)JS/+++*Z1QQHK,SL H)(% &M^R)_R:G^ MS7_V0?X3?^H)H5?R9_\ !X)_SCP_[NU_]]EK^LS]D0_\8J_LVC# K\"?A."& M4J01X&T,88'[K#'S(3N0\-@U_)G_ ,'@G_./#_N[7_WV6@#^G[_@FM_RCG_8 M#_[,I_97_P#5%^!*^UJ^*?\ @FM_RCG_ & _^S*?V5__ %1?@2OM:@#P']I# MPQ\=_%?PZ-E^SE\1/"7P[^)FGZ]HNM6TGC[PP_B;P/XTT*PN'.O_ Z\6&S5 MM?\ #6C>+]/DDL7\9^$@WBCPQ=QV>HZ;;WZ)!_B=<_$#PI\5-&\,?L;^/_B-\%?AY\+?%_AWX$:%\!+K5M$U?PS=> M$]3\;>,?&7AK2M1UGQ]XPUK0M.CU3Q)K]_=:7HMI)'_:%_\ MM@9S@9]<<_Y MYH*@G) SZX].F?7';/3M0!^*7P+_ .";_P <_P!DWX:_LLZC\$_BKX*\W.L>-?"\O@[Q)X4\& M:OI6G6]C/I&I,GBBSF72Y=8CU:VU=%_X)S?&KX$:!X:M/V9?BM\.)_$WB;]F MC7?V:OCGXB^+FA>)XH[Z37_B-X\^*[_&[P#IGA.6\+>*M"\8_%SXG/8^ O$= M[%HNJZ/J?AS3KCQ?IW]@O<:E^R^Q7?!3X4>'_@C\&OA9\%/"\MY<>%_A-\./!GPTT"YOV0ZA=Z/X+\-Z M=X;LKN_:+]VU]=V^G1W%V\85&N9)&4=*_)?XX_LK?LOQ?\%3OV$?#J?LV_ ! M="\2_LW_ +=NL>(M('P8^&PT[7M6TK6_V6CI>J:S9CPR(-3U#33J6I?V?>7D M>&XH(P ,!6<.[$+&KL<'YP_:D_P""IOP:^!^I MO\./A9:7'[07QQO+C^RM/\%>!&DU#1=/U9R8X[;6]&_V'_VNOVZ_$&F?$O]OCXAZG\/OARL\>I^'OV>?!DXT^>" MU.##!?V4,MSIOAN3! EO]2?Q#XK8*!+/8R,HA^APG#U14:>.SK$2R; S2E3E M6I\^.Q*:4DL)@+IU(SBG^_J.%&%U+FEL==/#>ZJE>:H47]J2;E+9\L(K6[\[ M;=GKX[\6_CK^SE\7_%]W\$_^"=O_ 3^_9Y^+7C-F>WO/BOJ?[-_PP'A#0H_ M,$3ZKI6G:AX4MK>2R@W+(FO>+)M-T//B!J^H1Z_>?#[P-X9T/P;\+-/U1D0J^K:?X9TG0;;Q;=VNQ(D1+#3 M="ACACM_L-]!#"R?KU\(/@I\+/@1X3L_ _PD\$:)X'\.6P0RVFE6JK=:A<*, M-?:QJM =!_D\_P ZVK\04\'3EA.'M55M M^;[*\H[/9K4^<;[]CS]DC5[J>_U7]EO]G/4[ZYD,EQ>:A\$/AE>W<[D*-\]S M<^&)9II" 7DD=B ,G@53'[%/[&_)/[)G[,S?7X#?"O/X_\ %*V%_9>&M3N;.]L[J M#PNDUM=6MS%'<6\\+I+#-ⅅ*Z@C[>KR_XW_P#)%OB]_P!DO\?_ /J*:M0! MP_[(NX_LJ_LW.S.[R? KX42.SL69G?P+H3.Q)R268ECZL2>IK^3/_@\$_P"< M>'_=VO\ [[+7]9G[(G_)J?[-?_9!_A-_Z@FA5_)G_P '@G_./#_N[7_WV6@# M^G[_ ()K?\HY_P!@/_LRG]E?_P!47X$K[6KXI_X)K?\ *.?]@/\ [,I_97_] M47X$K[6H **\+_:'_:%\ _LS?#I_B-\0(?$>IVUUX@\/>#/"OA3P7HK^(_'' MC[QWXOU!=*\*^!_!>@K/:)J?B/7K]O*M4O+[3M,M+>*ZU'5M3T[2[*\O8/F' MP-_P4G^$?CKX*>$_BMI_PR^/$7C/Q=X\TCX5:?\ L\#P%:7/QKD^).L>$(/B M#!X?MK-=?B\!7.C?\(!,?',?CYO'EMX!E\+JMT?$46I2+I5 'Z)45\'S_P#! M0WX+7G@3X;>*_ WA3XO_ !3\7?%+6/B-X=T#X'_#_P %V5[\:=,U_P"#%Q<: M?\:=(\5^&-?\0^'=$\,WGPGUF!- \6_VGXHBAGUV_P!&TSPQ-XBN-=T5;^KX ML_X*/_L]Z)X;\!>*O!VG_$_XT:7XY^%E]\=KI/@_X)/B34O 'P0TB];2]<^* M/Q$TO5]4\.WV@Z)HVLP:AHESX?M(=5^(%[K.B^(-.T3P;JMSX?UA+( ^^J_+ MWXZ_\I9_^">W_9KO[?O_ *>OV3:_2'PUXJ\/^,?#>@^+_"VJ6FN^&?%.BZ3X MC\.ZWITJSV&LZ%KMA!JFCZI8S#'FVFHZ?=6]U:R$+YD4T9P":_-SXZ-G_@K- M_P $]B/^C7?V_,_W0#K7[*!!+=#RA! R5)&1@T ?J)1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !129XR>/7_(S_GTIC2;>=N1Z@C 'J>XX[8)^G)H_K_A M^WS ?QGWQZ=J:74< Y//']?I].O..AQYY\3?BS\-_@UX3O\ QU\4O&.A>!_" MVG(?.U77[Z&TCGEP2MII\!9KO4]0FZ6VGZ?;W-[<-\L4#'('XJ^,_P#@H'^T MW^V9XCU3X4_\$[_AEK&D>'(YFL?$7[0'C"SBT^'2H9':-[FP>^2;2/#*O%ND MMWNQJWB>0#S;#1;>4^;#ZV6Y'C\SC.M2C##X*B[8C,<6_98+#[:2K2LI3MJJ M5/GJ-M-0:N=-#"U:ZE-(1A9H3I^L^)6 MFB3<8[ :%X19I522\U+R6=_J_P#9A_X)3?"_X6ZW%\5/C]K=S^T?\E_9Q>VSLW=K=: M:'QE^RU^PA^S]^R9IL/_ KWPI'J?C9X!#JWQ-\4K#J_C/5#MQ/]FNWC6#0+ M*:1I"+#1HK6$(Q6X-T^96^TD&%4>@_STQ^%*<]NOOG'Z4HSWZ^U?-XC%8K&5 MIU\76J5ZLWK.K4E-VLK1BI:0@ME"-HKHK').I.H^:;N_Z_KL%%%%8$!1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%'-*Z6^GJ 44SIP.WK@=\5?,K M7NE;>[M:W=/5?/=:K0=O3[U_F245ESZUI-KG[5J>FV^/^>]_:0^H.?-E3&&& M.OKWXKF=1^)_PYT@9U3QWX/L!_T]>)-(B]N=UV"!G@GH#QZXYZN-P=&+E6Q> M%I);NKB*5/\ ]*FB'."WG#_P*/X:Z_([JBO#;[]ICX :<&-S\7O ;;>HM/$% ME?N#Z%+&2X<-P?E*Y]JXB_\ VV/V8]/R'^*.G7+#'RV6D^(;H'.?NRQZ28&Q MMQ@2[B2 ?<^J:,U\,ZC_P %$?V;+!ML6L>)]2^[@Z?X;N&#;R0H NI[5LD]1CC(SUKE M;S_@I!\)SG^Q? _Q+UK! 'E:-:6VXD8_BO9N-Q53P>6!QQBO*K^)' N'_B<3 M98^MJ52IB&_18>G5;^2>FJT(>+PR=O;4V_[KY[>O)>V_4_0UF(.!W]?7_/?I M1O&<$<^F0>A ]NA_H:_-M?\ @H)J.JKGPO\ LY?$[5)"=B&8 "0ABIP+2PNG M.#UX)QG I/\ AK?]IK5G*Z!^R1XE1"Z^7-J9\0Q(P8,NXEM M86"O@MBX(P" M.N,<7_$3^$)W>$Q689AV^H9'G%5RVU4_JD8R71.ZVZ(GZ[A^DY/TI57?KT@? MI(,?WC^!Q^0/^>U+D#^+KR-W(P.<^WXXYQ7YN-\9?V^]7*G1_P!GOPUI43$! MCJDD990>C'[9XKTN3CDG;;OQQM.:4WW_ 4AUM04T[X9^%@Z9PYT@M"3O7GS M9-<'RG;(/]8.@SU%+_B(V#J?[IPUQIB6[6<>&\71B]O^7F)E2BKK[4O=\P^N M1=E&CB97T5J35WI_,XK?OVM>Z/TB#9SR#C'3([9X)X]._3KBDP6. >,! M!^RU^UWJI;^WOVL]1BAE WP:4-;VJ#A7"!I+1!E0"NT !BQ]R?ZYYU5_W3P\ MXKKWV>)_LC PMHKN>)Q\9)Z_"H2=KMZ78?6*E_=PE?I:_LX]M;^TT=_)]?5? MI(2 OWAP#G/7WZD8^AJA-J.GVPSO&,MT]%%27_@7W6N?<>H?$'P M%I0)U/QKX4L-H9B;K7]*@("J"VY7NA@ $,3V!'3-<+?_ +1OP&TP/]K^+WP_ M5HMV](O$FFW4R%" =T-K/-*""R_PY)Z \U\]Z=_P3G_9VL0@N8O&>J[*,Z5:I2X>X6PTH4W M.G2JYQC,9.K46T/W6%PT4W_B2OUW%?&N]J>&CM92G.3NK=5'6]M].ESEM(_; MD\"7WQ]U3P//KNC6_P +%T"*WTGQM=.+2RD\6PN;J\GGOKIHUBT>ZMYQIMI) M($7[9:&4$0R&2OM#1O'O@KQ$BS>'_&'AC5XVVX;3M;TV\5MQ."/(N7)R0VW' M7IZX_)-?^"9/Q,')^*'@5L@!Q_8OB !O[V0)\ -SM4 >6.%-?2D__!.7X-7= ME83P:CXL\+Z]'96PO)O#FN&?3!J7D1"ZELH]8LKJ_2U^T([6L9NXW2,@-ABV M?E.%/KXG#+%9M1P=58?$RO\ 5,-5@\=%T,-M15>"J.+2 M<]$ESX>MF;%2T_P ,_P!J/QOI+C/EP:N=3\F- ,*CRVFJ M7!D4="!;1IM'W*0^!?\ @HAX+*KH_P 3?!'Q LX!DKJR62W5P%' #:EI,5T7 M<\_\A"(8QDYKZY\8\083_D9^'_$5.,;*5?*\3EF;4+JSDU"E7HXGE2UYO8)= M-&SH^LU%\>$KI_:<'3G#I>UIIOR]W;MJ?I)N7(Y ST^48_//\OPJ0,/7GZ&O MS6_X7S^W%X.5O^$P_9RTWQ5!%C,_A9KE9I0N07QI6I>(V+G&0/L40]AC%6+? M_@H.FBSQVOQ$^ _Q)\*3KQ<31P+<00XQD^5?VNF3G&"3NP<#G'4$?$WA6DTL MQEG&32ORM9OD^:8:"E9?\O/J]6E9/1R4^6^_5E+&4.KG3:M=5*[:R M;MON?I'17Q/X?_X*!_LUZXPCNO$FM^'),X<:]XX:!^T5\#/$YB71?BIX)N99SB*VFURTL+MSQP+2_:VN0>0,&(')P1GB MO?P/&?">966"XDR3$3:O[.&8X6-5>4J,ZD:L'_=G",O(M8G#O_E_2[V=2*>U M]4VFM'M:Y[116=9ZMINH('T^_LKY6 8&SO+>Z&UL%6!@DD!!!!R.W/-70Y)( MV\CL2,GZ#K^E?20G"I'FA.$X_P T91:[[I_U==S;2U[JW^)?YZ_J245'Y@]# MU]L?KBEW'T'_ 'T*JZ>B:^]#LU:_7;\/\Q]%,W?3/IG/\AC/XT[/'0C\#2O_ M $DW^0KBT4G/_[)?X_P#_ %%-6KU"O+?CBVWX+_%W./F^&'Q R0HR/"6 ML-U.!C"G)[=3QD@ XG]D3_DU/]FO_L@_PF_]030J_DS_ .#P3_G'A_W=K_[[ M+7]9?[(9_P",5/V:_;X$?"8=#V\"Z&.X![=P*_DT_P"#P3_G'A_W=K_[[+0! M_3]_P36_Y1S_ + ?_9E/[*__ *HOP)7VM7Q3_P $UO\ E'/^P'_V93^RO_ZH MOP)7VM0!\,?\%#O#W@GQ+^SQ):?$3X&?%3X[>$=.^(/P_P#$&IV/P/O=;L_B MW\+)-"UQ-2TWXY^!%\(ZEIGQ O\ 5_A=JMO8ZU/IOPXDO/&]UI;Z@-)TG6(U MN]-NOS>_8-^+/Q]^'W['MOH_QB\.?ME?%_\ 9JU#4_AY\+?A;\7[CP!XB\.? MM2^!?A=JOP"\/S>*O&5SX&\ >%M ^.'BKP)X7^,IU7P+\._'NE>!HOBC_8%S MIOBB\L=1\/:-%XEN?Z"/PZ=/:B@#^=']G'X??$;]DSXB? [X]>+/A5\;=6_9 MN\--^W/\*_AI9:%\+/B!\1/CSX<^&7QE^(GPM^+WP<\;?&;X>^&_#VM?%?5/ M%?Q!U/P-XZT_Q#XN\4Z-/XZ34]?\)W'Q9>PU;4=2O+'G_@'\*OC5^QGI$OB+ MXG_!+XO>*[WX_?L-^+_AWX;\(_#;P'K_ ,5+[P9\9]1_:,_:)^,FA_!?QH/ M^DZO8> 1K?AW]H7P[8+XL\47FG_#?3]=\,>,8M7\6Z?!:VLU[_2;@>GY!=#T+6H;*[6-$N;*VU*QN+>RE5 LEK#"<,,$_E/\ '']GWXP)_P %2?V& M=);]MW]HV34=:_9U_;HU+2?$C^"_V3#J_A"RL-:_9B%YH6@PK^S6NAW6FZX- M1M1J<_B71?$&LQ?V)IG]E:KIQFU4ZA^]84*,* !Z 5^7WQU_Y2S_ /!/;_LU MW]OW_P!/7[)M 'M__#,'QY_Z2)?M6_\ A ?L0_\ T(M'_#,'QY_Z2)?M6_\ MA ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X0'[$/_T(M'_#,'QY_P"DB7[5 MO_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ A ?L0_\ T(M'_#,'QY_Z2)?M M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X0'[$/_T(M'_#,'QY_P"D MB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ A ?L0_\ T(M'_#,'QY_Z M2)?M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X0'[$/_T(M'_#,'QY M_P"DB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ A ?L0_\ T(M'_#,' MQY_Z2)?M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X0'[$/_T(M'_# M,'QY_P"DB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ A ?L0_\ T(M' M_#,'QY_Z2)?M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X0'[$/_T( MM'_#,'QY_P"DB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ A ?L0_\ MT(M'_#,'QY_Z2)?M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X0'[$ M/_T(M'_#,'QY_P"DB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ A ?L M0_\ T(M'_#,'QY_Z2)?M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^U;_X M0'[$/_T(M'_#,'QY_P"DB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M6_\ MA ?L0_\ T(M'_#,'QY_Z2)?M6_\ A ?L0_\ T(M?:=% 'Q9_PS!\>?\ I(E^ MU;_X0'[$/_T(M'_#,'QY_P"DB7[5O_A ?L0__0BU]IT4 ?%G_#,'QY_Z2)?M M6_\ A ?L0_\ T(M'_#,'QY_Z2)?M6_\ A ?L0_\ T(M?:=,=L8Y(R>W\J /B M_P#X9@^//_21+]JW_P (#]B'_P"A%H_X9@^//_21+]JW_P -_P#L0_\ T(M? M:!;) &<]>#C\/Y?C[U\ ?M8?\%&OV??V5$N=#U76W^(7Q5<)%I?PJ\$7$&HZ MY]ME.VWB\0WD7G67AJ*5SE8[POJUP/\ CRTJY7!7JP>"Q>/KPPV"H5,17J?# M3I06XN;J?]DJ*"&")%9GE>1(U4%F M; -?D)\?_P!L7XGZ=XK3X-?L>_ML?M=?M.?&B\N_L=I<:)\-/V,[_P :==( MX20++I?[)]I?^*1"P;[1+87>GZ"ENLDIUYE^9/3+3X(?MZ_\%*[NWU_]HKQ' M??LQ_LS7CW!BO+WSXV7_B;^,WCA59#+8>&E MA;RS^P'[.O[*_P #?V8/#?\ PC?P?\#6/A]I84AU?Q'K*,E>5'#M&'\.#OM4F[6*1^'O"GPWN?"$L_@I]T3RRNNM^&_$?PZL M9)U7%[X?T7P?>6#17,T$VH.H$=?H1X/_ &*_B/\ #WPWIOA+P'^W5^TEX/\ M"VD0B#3-"\.?##]AO2],LXQC.RWMOV1D\R63 ,MQ,TMQ,WS23.W-??NU<8VC M'I@8HVC&,<5Y699SF&:^SCBJL88>C_ P6&@J.#P\59)4J%/ECS)*WM9\U62T ME-HPKXFK7:YK*$=(4H+EIP79+5_-W?F?%O\ PS!\>/\ I(C^U<.G'_" _L1' MI]?V1S^)ZGN3Q1_PS!\>?^DB7[5O_A ?L0__ $(M?:=%>6?^DB7[5O\ X0'[$/\ ]"+1_P , MP?'G_I(E^U;_ .$!^Q#_ /0BU]GJ2>_3\_U!_#I2X/;MEJY6ERVW M;346I6ZI7#7JFO-JRZ=?G^#/C+_AF#X\_P#21+]JW_P@/V(?_H1:/^&8/CS_ M -)$OVK?_" _8A_^A%KZ8U_XD_#_ ,+1M-XD\=>%-"C7.6U3Q!IEI@C(QMEN MD;=GC&.HP!GBO#O$G[:G[-GAM7$_Q+T_5+B,'%OH%EJFK&0#D>7=6]H;!N.K M&\"^_!KQL;Q+D&7:9AG.68*6ON8G'8:C5^5*=55'==%%OR(E5I1^*I!=[R6F MWG?KKH=ZG_P4<^&DC^7X*\!?$;QK*Q"Q_9M/M]/B=FX1@3+>2-&6(!(4GG@ M>F6?VK/VJ_&&Z/X=_LN:G91S8^R:AXH_M8P-GCYC<1:#98RRDG[>J@ G=@DC MYFKXH<'*;I8/'8O-JZT]AE.5YCCIN5[5!XAN1UP2NH[LKP^>K?^&.?VA/%YQ\3?VIO$\\,N0]IX?\ [7*(KY9H8S+? MZ=&BAB0K(HXZ+6:XWSC&)+*. N)L0I_#5S.G@<<7BU63NM(^SORWE MMNUB)/X<-7<;K5\D+_*C:;7?^"G'[1VCQQYWOJ7A?\ M83LU3CHWVG]E!,$=?QKQ/Q#KFE>&MXO_ /@K-^T75HO@']B_7F=U!)0 M/H_['M["K'!'[R6-0< L#P?6]'_X)R_!B&5+GQ3XB\>^,KTX\Z2_UF*TAFYY MRL%J]^,C@G^T6W^&_V/\ ]F_PV8C9_"O0[V6$YBN->:\U^=2I'S*^ MJ75VJ9[A0!S@* 2*3QOB?C_X&3<*Y%>R7]I8_&9G..WO*GE]'"PG:VL?:QZ> M_IJE+&R_Y=4*:[3J2D[:+>"MZ'YBZO\ 'ZY@:6+PU^WG^W;XQN(FQY>F?";] MARTAD'0,L]U^RF[@'J-UJ#C&0#Q6"OC#]NCQSDW*^F_X+I_+_J?QC^/ MG_"1:)>?%'XW^)/B+XV^&VOWDGAWQ!XBTKX8:)>^'K^.\5;FPCLOAAX3\'>$ M]2DC>W2UDO)='N+FZ0FWFO#;8B7])?AWHW[;7QN\(Z/XYT+]H3PG8:#KL#2V MSV-I#;W%O(LKBZL[NWTK1(U@O;*X#VLT3N7&W=&WD&'/Z5GX=^ &9F/@;P@6 MFV5O M8VJR2)M2D27Q%^TS\2]18Y,L<(NX@6^]E9)?$+;E&T'/'6OKX^&'";?^T4,C)V5VX5\=*.^ME^K.GZGA]; MQE)O=RG-MZIZOF^X_.F#_@G!\+K@'_A(/'_Q.UMF. S:KIL0!5MPP+O3M1/W MR9,,2">O<5P^M?\ !*/X6:GO&F?'3]H3PQN5%_XDUU\&Y]JHTC!5_M[X/ZSD M$R?,&W [$/!!)_4[ Z8Z=*7KU%:T_##@*E*,H\+Y5-Q=U*O1J8B:?=2K5JEG MO\G;U:P>%6U"'3OTMY^1^0=E_P $B_#6GG,?[8/[5%Q\SG&HZ#^R1J2_.E+#/."2/QKL['_@F)8:<5:T_:L^.BN%*B:;X5_L2W4NTD':9)_V3I2? MNC&OI^I&!Z#\J,#KC_(_S_G KVZ7"/"M!ITN&\BIVZQRC+D]T_B^K7OHM M;W*CAL/'6-"FGIO%2[=UO=;GYY:?^PAXMTH!--_;.^.]FH)8"/X,?L&$Y/4A MIOV/)"">,D8[=#S756W[)?QBL!_H7[?G[35B.F+/X7_L*VO&0<8M_P!D!!C( M!QTR >O-?K0R[ 89?[-@,#AK--*AA26_GN?%(_9B^.W_21']J[\? /[$GY\?LD=__ *V,8I?^&7_C MR>G_ 42_:M Z_\ (@?L2'^?[)']*^U>G04?A79J]U&_WK\HE>A\5?\ #+_Q MY /_ !L2_:N/_<@_L1_S_P"&1_QZT#]F'X\-T_X*(_M7>^? /[$>/IQ^R0". MG8U]JTF!Z#\J-7J]+;6;:^>BVZ!_6W]?UZL^*S^R_P#'K_I(C^U;UZ#P!^Q' M_7]DC\/7N?^DB7[5O\ X0'[$/\ M]"+7VG13 ^+/^&8/CS_TD2_:M_\ " _8A_\ H1:/^&8/CS_TD2_:M_\ " _8 MA_\ H1:^TZ* /BS_ (9@^//_ $D2_:M_\(#]B'_Z$6C_ (9@^//_ $D2_:M_ M\(#]B'_Z$6OM.B@#XL_X9@^//_21']JW_P (#]B(?R_9&&?H>/44G_#,'QYR M<_\ !1#]JT@C'_(@?L1#_P!]( _3O7VI1CV_2C^OZOH._P#7S/BG_AF#X\$C M_C8A^U>,$?\ ,@_L2?CG_C$GG\<_G3)_V6OCE<1M%H'Y5$X*<7&<8U(O1QG%U M]4^VPGKOVM\OZ1^<.O\ _!/W7/%2E?$/[8WQVU16R'\_X/?L)Q.^.E3@L'VR1>&? MV;]%N@ 0,"*ZCP.*_6G ]!^5)M4]OZ?RKP\9PMPWF$91QV0Y1B5+5NIE^&=2 M[M=^U]FJE]-TT[:&,L/AYN\Z%*3>[E3A)OYM7;T[GYO2_P#!.3P?I<$0\$?% M_P")WA:YBC"M=/>6-S)/,H4-<2)H\7AN$/(J#S%C18R>0@X%5S^S%^USX.PW M@+]J"YU2TMU86^G>)$U >8,@JK"?^UK5'.T ERXP6&<9S^E.U?3_ #T_S^?6 ME(#=1G'(KYV7AAPA!\V P>+R>>KC/*,TS' N$G;WHPI8KV;>CTE!QU^$S^IX M=6Y8RAYPG)-;7MK9>B5NA^.GQ(\#_P#!56X5#X=^-6HZ!%& &/PX\._L^ZO/ M*B')W)\2OACK++*XX)42''W06W9\9_X2/]OWPJ2OQ#^,W[:2P0Y-QJ'A_P"' MG['1CVC&3&6_9 U&QSGL;YSR>,V/IQ4O@G-\-_R*>/N*<)R M_!2QSR_.,*EII*EB\)&M/:U_K4=/-W2>'JQ_AXJK%[7FHU5;MRR27SWOL?A) MIW[0&M?*OBO]MS]OCP;,75'6^^%'[#%_&CD\AI(?V4;1L ?W('/7O7L/A_QM MH?B(1"#_ (*M_M.Z9+)C,&N?##]C?2?*W8P)KJZ_8Z%@G!Y/VPK@$YP":_5_ M5O#7AW7%(UK0=&U<;2#_ &GI=E?_ "]Q_I4$O&.*\8\1?LL_L\^)3+)JGPF\ M(?:)L[KO3]._LFZ^8$96XTQ[25#CIAA@X(&0,+ZCXFX/W<-GW"V;\OO-9CD^ M,P-6I&ZBHIX+&5:5/1=(-_P""IWQ^UI6&Y#IN@?L&W)92<9"Q?LHLSC1#D?NCTJWXA1PO\ R..$ M^+\I>MW+*/[0I12M=SK976QE.,?[S=OOL5]9Y5>K0K4_^W5473K3J_ M\,P?'G_I(E^U;_X0'[$/_P!"+1_PS!\>?^DB7[5O_A ?L0__ $(M>4K^WSXG M\.M'!\2OVI/>TE*.FFOO)+6^VYM M?\,P?'G_ *2)?M6_^$!^Q#_]"+1_PS!\>?\ I(E^U;_X0'[$/_T(M>@?LU?M M!:;^T#X6UC6XK6/2-7T+Q%J.E:CHJSF9HM/DGEG\/WY) ;-]IAC\PK^[^U07 M0! V ?2=?595FF!SK 8;,\MQ$,3@\7356C5@TTXNZ:=F^6<6G&47K&2:>QO& M<9Q4H24HR5TT?%G_ S!\>?^DB7[5O\ X0'[$/\ ]"+1_P ,P?'G_I(E^U;_ M .$!^Q#_ /0BU]IT5Z!1\6?\,P?'G_I(E^U;_P"$!^Q#_P#0BT?\,P?'G_I( ME^U;_P"$!^Q#_P#0BU]IT4 ?%G_#,'QY_P"DB7[5O_A ?L0__0BT?\,P?'G_ M *2)?M6_^$!^Q#_]"+7VG10!\6?\,P?'G_I(E^U;_P"$!^Q#_P#0BUY_\6/V M;/C?I_PK^)=_??M^_M0:[96/P_\ &5Y=Z)J7@3]C*'3M8M;;P[J,UQI=_-I' M[*FEZK%9:A"CV=U)IFIZ?J$<$TCV5]:72Q7$?Z)UY?\ &_\ Y(M\7O\ LE_C M_P#]135J .(_9&*G]E?]FYU01J_P*^%#"-2[*@;P-H;;5,C.Y W8#.[NP +L MS9)_DR_X/!/^<>'_ '=K_P"^RU_69^R)_P FI_LU_P#9!_A-_P"H)H5?R9_\ M'@G_ #CP_P"[M?\ WV6@#^G[_@FM_P HY_V _P#LRG]E?_U1?@2OM:OBG_@F MM_RCG_8#_P"S*?V5_P#U1?@2OM:@ HKC/B%\1/ OPG\&^(/B'\2_%WAWP'X% M\*:=+JWB7Q=XLUBRT+P_HFGQ,B&YU'4]0EAMH%DEDCM[="YEN;J6&UMXY)YH MXV\4L?VU/V3-1^"&B_M*0?M#_"6+X"^(KFPT[1OBG?\ C31]*\*7NM:G"-1^)WQH^&'@+3?B7=VME\/ MM1\5>-_#VC67C2>^BM9[5O#5U=W\<&KVLL%[93?;K61[)(KVSD>X"74#. >V MU^7OQU_Y2S_\$]O^S7?V_?\ T]?LFU^GT4BRHLB$%7 92K*X93R&5E)4JPY5 M@2&4@CK7Y@_'7_E+/_P3V_[-=_;]_P#3U^R;0!^H5%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M&:3$_'O\ :2^" MW[-OA8^+OC%X[TKPG8D2'3--DD^U^(?$-PJ$K9^'] MO,U+5;AFPK&"$6T!. M^ZN((E:1?RN^+'_!4+Q[\8_%UW\$_P#@G9\,]5^*_C2;S;.]^+6IZ1+_ ,(C MX?5I?)_M33;#4!:V;6<.\7*Z]XLN+'3F7]Y%I.HHT:R=-\!O^"4L>M>+!\;/ MVY_'NH?M$?%Z^>.]?PSJ&H7UWX#T)T9)8;*Z>?R+GQ#%:.2B:7##IWA:#;LB MTV[14E'T\,AH8&G'$\18EX*,E&=+*Z$HRS7%0?5QLX8*G+^;$VG;3V6MUV?5 M(THJ>,FJ5]8T(N]:=K6T7P)OK*ST:LFCQG5/VF_VY?\ @HYJ-YX1_9&\(:C^ MSY^S]-QH1C0H.RE"G=.IM_$FWS M2UOHK)WUNA@7)!PWOS]1SZ\=L=/6G8.[/;T_#'I]:=17SZ5E9:)=%ZW_ *_S MU./^EOIZ?\&^X@SS]:6BBA*RLEH@"BBBF 4444 !..M-W+Z_S_PII<;3U!'; MC1_M*#C/UQ+E;^6R^)N5K/LU9VZ/5_\%^? MZDN1_D&@L!U/Z'_"N/\ $/Q"\">$XI)_$_C+PQH$<7RRMJVNZ=8"-B< ,MQ. MC!L\8(S[5\Z>*_VX?V:_"PE5O'O]OW,+,K6WAG2]0U4L02/W=VT%KITN2, I M>MV) 4ACXF8<3^,=_P 0,X_&OR0^-'_!0S3O M$'@S7?#GPT\*^+=#O?$%E+I]AXSUB2VTY;*":18KJXTZU@::1[Y;<7)U\-2I.%*>0JH_$U^:X^$_\ P4!\ M<$CQ+\;O#7@.)\-Y/ATQ^;"">8R=$TFQE8XR!YE]-CG]Z1@5-#^P'KGB"87? MQ,_:)^(7B>:0M]JM;*6YA@E!4;@);_4[Q2&(/#6.!QUKTO\ 7'B?%I?V5X>Y MW)2^&MG.-RW):*6CYJD*E?$8N*L[V^K76N[5C1UZ\E>GA9Z_\_:D:=MO)N_E M;?KN?;WB/XQ_"?PFK?\ "2?$?P7HS ?ZJ^\1:7',R(A8GH#BO M O$W[=G[-/AP,5\>^6ZD=N 2[DMGGWI^T\4\;_#H\'9'&35 M_:ULSS>O"+L[TY4Z>$P\WVYN75-V2L%\9/6V'I+LW.J_6Z]FK>7EO9GR3>_\ M%$_#FH3-;> /@_\ $?QB\@"VDYM8K*&1V.$W0V\>HSA6ZXC+G)/' JH/VB/V MU?&G'@C]FB'PY&_^KN?%?VU5\LG_ %Q.KW/AB+A<$*@F)R,;LXK]&;'2]/TR M$6^F:?9:?;+C$%C:06<0*\<1P)$N.@ P.!CM5T\C&5Z\94G'.<8''Z_B:G_5 M;B_%O_A4\0\PHTWRM0R3*E?8#=VP;((#Z9I=U>@J#D M8U>0@C@@XH7]AGXI^*2DWQ._:>\;:Q+G]_!I1U-H9D.08S)>ZO" H4D+FU< M8&PBOTKHJEX99!7:GFV.XCSV:W_M/B#,I4IZ6M+#86OA<,XOJO96^0+!4OM3 MKS\IUZC3\FE))KR:L?!6@_\ !.KX!:8_GZT_C7Q;Z!&<%KC4Y M+IB>N3WXR*^A:*]K!<"\'9=9X3AK)Z\VY/JS6.' MH0=U1A?NU=KYN_\ 7F8>E^'-#T-0FBZ+I&CH%"E-,TVSL$*C^ BT@AR!V!R. M*V<'/);_ (#@#]3_ $ZT^BOIJ=&G1BH4H1I0C:T*453@K66D8**O9)7MMMT- MEI:UE;:R2_0CVGKD^_K_ #QSCU%. /7YNO3(Y_I^M.HK2SO>^G9)+HMW:_3O M^MS^MO\ (CVD=B>^00/TIRYSSG\3G^G]:=11RI=_O?\ GY %%%%, HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "F[E]?Y_X4IZ'Z&F@!1SC.>_K MV&30 [<,9SQG%&X'/!6@:QXK\7 MZYI/AGPSH%I)J.N:]KE];Z;H^D6$"KYUYJ%_=-';6ENA9=\TSJJ[N6H=TG+W M4HKFDY.UHK=^7>[LOO'",JDXTZ<9SJ3<(QIPA*4Y2J35.$(I+6V?PKY93]M[]CQRB)^T]\#',C*J+_ ,+,\*EF9SM4#_B9 M\$M@ $=^OK]-Q3QW$<VC#F<;ZV MO;JBYGZ_D3_*BHLCT&>.W_V)!YR>#[=>*3DYP. 1Q^F>..<=N15IWUL_NEY? MW?/^NG-YZV\E_FTNY-14.7ST;\B>ZD\GKT&.I)VX ]SP M>QQ1=_W?F[=%W73OL3?R?W7_ "OZ$E%9TNHV$./.O;.#=\J^9>6\:L?1=[KN M]P*RIO%OA:T\P7'B;P];^5Q+Y^MZ9%Y7&<2>9=+L.#GYL=CTZKGA_/#M\E&HU]ZCZG2@@]/Y&DW+Z_SK@+CXH_#2R8+>?$/P+:,RLZ+ M<^+M B+("064/J"[AVSC@@CBN/U#]I3]GK2XVEU+XX?"BTB201L\_C[PRBK* M7*B//]I$AB58!<#Q@9NO1C?GJTXI/63G!12TU;<[+?=M+5'32RO,ZUO8Y M;F%7F^'V>"Q,V_\ "E2N]G:VY[C1_GH?Z5\NWO[:W[(6F230W_[2OP2MIH$$ MDL,GQ%\,^:J$9!$?]HL[9'*A02W0#-?\ !0K]B6Q$9G_:6^%+"0$K]EU] M;X@!0QW_ &"*<1\'C>5![9-8RS# 1U>-P:_Q8FC'\YGHT.%.*,5IAN&\_P 0 MU:ZHY-F-5J_=4\/)KR[GV5O7IS^7%.R,=L?Y_P#KU\ W_P#P5!_8+TY9GN/V MB_"KK;R>7(++1_&&H.S"3ROW,=AX>N9;A-X/SP+(A7]X"8OGKD[[_@KC^P%9 MN43XXK>@(7WV?@GQVRC )\L"Y\-VTI<\@ )C/)89S64LWRF-N?,L##UQF';> MVJM/35->>ESTZ/AWQ_7_ (7!'%<_..0YHUTZRPD(IZWLY7M^'Z49']W/ICV] MB![<#^E)DC^\/;:/_K</QSXPO]TA0QV'@352Z#G] M\XN7ME\LD$85FESUC%_\ !^7IOJ=4?"WQ&DTO]2N) M(MM).KE6*H+6WQ.K",8*[U;E9+5M(_8U6#< MUQSZ^W!Q_3UI,-DCN94Y>E&J^VFE.2?WK\#T:7@UXH55>'!V.CHK*KB(_BAX(M?#GPJ\' M^ (-:U'5H;C7M?U5++1-0M-,LT,D=MI]W;Z3=73S:C<[([F3?$$M(98^/]8_;Q^%.F:SX_\ '6MZ7=^&_B8M[INL^,O$6L:?(I#L)']BM7X<99E.4IAXQCBY5H1I7_&__DBW MQ>_[)?X__P#44U:O4*\O^-__ "1;XO?]DO\ '_\ ZBFK4 '_=VO_OLM ']/W_!-;_E'/\ L!_]F4_LK_\ JB_ E?:U?%/_ M 36_P"4<_[ ?_9E/[*__JB_ E?:U 'YX?\ !3+PQ\*/%7P \*VWQ6^-:?L^ MKI'Q[^"?B;X;_$W4O"47CCP?IGQ?\/>+XM2^'FE?$3PUJ*0^'+WP1XBU6&30 MM1E\5ZWX4T*QU"_TJ]'BO0M6M]+NQ^2G[)G[7'P*^&O[/.A:S\>?@G^S7\0O MVEOAO\:OA5X0^ 'B#X(W^CZ=X7_:7_:=\8_LG>$;J#Q9H'B#XF7%IH7PV^*O M@3X7WMSX-_:*\9ZAXDUS2_AWI^@ZQJ3>(;M[RPT&7^F'Q#X<\/>+M#U7PSXK MT'1O$_AO7;*?3-;\/^(=+LM:T/6--ND\NYT_5=)U*"YL-0LKE#LGM+NWF@F3 MY9(V'%>5K^S1^SFO@3PO\+S\!/@S+\-O!"/'X.\ W'PQ\%W/@[PL)4V3MH'A MNXT672-)DN%)^TS6-I#+?AUX<_9A_:5_95\4?''XI_!+ M4_#GQ/\ #?\ P41^+/BGQ9X.UG1M/_9O\#_M-?&WQM\'/''B3X !\-_!P\$KK@8N-97PH-&_L)=6#DL-1%@+S<<^=FNG\4_#?X=^.?^ M$?\ ^$V\!>#/&/\ PB6J6^M^%?\ A*O"^A^(1X9UJTV_9-7\/#5[&\&BZI;; M$%OJ&F_9KN$1H(Y5"+@ \"_89L?'&B_L5_LDZ/\ $>+4(?B#IG[-/P1L/%\. MM?:O[8@\2VOPV\.0ZE:ZT;R66Z.L07:/;ZJT\SS/J*W&\ACBORP^-][^WV?^ M"GO[$$DV@_L9#QE% 'P7]N_X*>_]"Q^P;_X7'[0O_SNJ/MW M_!3W_H6/V#?_ N/VA?_ )W5?>E% 'P7]N_X*>_]"Q^P;_X7'[0O_P [JC[= M_P %/?\ H6/V#?\ PN/VA?\ YW5?>E% 'P7]N_X*>_\ 0L?L&_\ AE% 'P7]N_X*>_]"Q^P;_X7'[0O_SN MJ/MW_!3W_H6/V#?_ N/VA?_ )W5?>E% 'P7]N_X*>_]"Q^P;_X7'[0O_P [ MJC[=_P %/?\ H6/V#?\ PN/VA?\ YW5?>E% 'P7]N_X*>_\ 0L?L&_\ AE% 'P7]N_X*>_]"Q^P;_X7'[0 MO_SNJ/MW_!3W_H6/V#?_ N/VA?_ )W5?>E%%P/@O[=_P4]_Z%C]@W_PN/VA M?_G=4?;O^"GO_0L?L&_^%Q^T+_\ .ZK[TSV[T4 ?!?V[_@I[_P!"Q^P;_P"% MQ^T+_P#.ZH^W?\%/?^A8_8-_\+C]H7_YW5?>E&?\_3K0!\%_;O\ @I[_ -"Q M^P;_ .%Q^T+_ /.ZH^W?\%/?^A8_8-_\+C]H7_YW5?>>1ZBHYI(XHVEF=(HD M&YY)'6-$'3<[N555&>22*-7MUVTO^0+6W6_;KZ'PA]O_ ."GO_0L_L&_^%Q^ MT+_\[JC[?_P4]_Z%G]@W_P +C]H7_P"=W7T=XR_:$^!?P]B>7QS\8_AGX46/ M.Y=<\;^';"3C/'E37ZS&1B#MB6,L3\J@G KY&\;?\%7OV%? RS++\;+?Q1=P MD@V7@SP_XAUUWQS^ZO?[.MM'E'(VF/4CNZ*>#7=0RS-,8_\ 9,MQM=:>]1PU M6K&VFKY%[B?\TG;6W4UA0KS?NT*DUW49>7E;_A^]K]4=0_X*=CKX:_8,_P#" MY_:$Z] /^2=>O%1C5/\ @IR5W#P[^P0R@-EU\=?M![!L)60[A\/&7:C*RO\ M-\A4AB#G;^:7[3/_ 6DM/%_PXUSPW^R5X)^(UOXCUFWGL[CXI^)/#8MK3PA MI$EN?MVJ:/IUA-JZOKPB)33[V_N8K'3&62^:.>XBBB3X!_8PL_VU_P!KBVN_ MV8? 7QD\>^'O@2=;N?%'Q0\7/+P_^QS\<_'ESJXTC5? _P $/%_Q[US6=+8C8T8U>[^'1\.7 MNKQSO'&?#]M?O?';/'=26+JN[S;QO^Q-_P %*_VWV\/_ !,_: \6?#+PQH*Z MQ#J-A^SKXYUSQMX4T6TT!H_.C7R?AU8Z^_A[6#*L,5Q=:W'KGB$VK2Q27FFW M&-GZ^_LK_L)?L]?LDZ7%_P *Z\*)J?C62W^S:O\ $OQ.L&J^,]2+JOGI;7?D M);Z'ITC[O^)=HT%C!Y;'[2UU,SSR?98 (.?4=LG(S@Y[]6(R>/T/!/.L!E7[ MGAS#359+EJ9SCZ<*N-FW92EA,-[U+!4F^91E'GQ%N7FE=&#Q-*A&V$BN?_H+ MJ*\M&OX<7I!?^3=[,_,'X3_"/]N;X%^%;?P5\(O@]_P3O\"^&K?8?L&C>+_V MAA->2(K*MSJVI3_#V;4]9O<,V;W5+N[NCD_O:]/^V?\ !3L'(\,?L'9P!_R/ M/[0W0$G_ *)WCJ3]>_05]ZCWZ_UQ2YKYFI4J5IRJ5ISJU)RYIU*DG.F:AFN+>VC::XFA@B7EY9I$BC7/0L[LJC\364IQ@N: M325UK)\J^;]!'PB;_P#X*>_]"S^P:/KXX_:%_P#G=B@7_P#P4\(_Y%K]@TGV M\5])>*?CW\&O!N]?$GQ-\(:=+$<2VPUNRO+T$ L5%C8/=73.5S MA5@+=1UKYS\1?\%"_P!G[1YFM-!NO%/C6[9&^SQZ!H%S'!.ZG;M674S97"Y; MC<+1^S [ @'PS^P;D]!_P )S^T)S_YCJG?; MO^"GG;PS^P=_X7'[0G_SNS7$?\-H?&SQNVWX2_LQ^++^"4%8]3\0?VC]FC93 M@22_8]/@LP&R"B2:A#DCAN] 3_@HQ\00-\W@3X56,Q^=0-,^VQQMRHCV'Q-= M[U&-S"ZMVYP1G(KP/^(EY1B&XY)E/$W$#O:,\LR+&/#3VU6,QBPF'IJ]U>I/ M5IVT,EBZSA5J_WH0:@W?HY67W-[IWM<[,ZE_P4[52[^'/V"50<[V\=?M" M*H ZDD_#P =SNP.^*\\\2_&W]NKP\0,=_R+N"<+ET79*>?YS14X:II%Z=+QIW?7OJ?&GB#]O[]J#0598M6_85\0W0)5 M;7P_JW[45R7D_A47-S\++6S(8X&Z*>;!/W<\5K_"W]O+]M7Q9>7<&M_LU_## MQ%;!VCL;OX5ZS\8=3:0E1Y%_@7\&_! MO'AKX:>"]+<87SDT&RFN&V\[FN;N*>9W)&3(7WGJ23R?5(XHX$2.%(HHHP%C MCB 2.-1P%2- J@8 "@ #ITI?V-XB9@G+,.,G+65#AW(J=1TUI>/US-\ M5B:O-JTYPA%)V:@@]GBZEKXBE3\J4+MVM=)S;=WNM#\WCXG_ ."B?C_<=*\' M>!OA98RM^YGU'^S#>I$W4R#4+O7[C>O4$:9:2>B9R1Y7\3OV4?V_?&.CI)H_ M[17@"_UF<&2YT3QMJ_Q)TSP]!O;YA!+X(@@FV;?E#);1JNXC!7 /Z]D CHO7 M/J.G4XQS[GIQS32N.2%/YGTZ \'UIP\.GA:FS?- MA#HI7OHXS=G\3221]3@_XM;$5>T9U'RI:;*/+Z^?4_"G0?V!_VOK.7[5X MF\+?L;>.KY@OVF?5_BO^TS817#XR7*Z;X)2\^;H1+J5P"O!]*]W\,_L\?MA> M#W27P_\ +_@F[:S1[=MQ=^)OV@M7NOD^Z6NM7^'E].Q7L6D)!YZQ+ZXZ M^V,_SS]:HWNK:7IJEM1U/3]/4=6O;RVM5&>F3/(@&>HS7M9?P/P=E/OX+AS* M*4]/WU7"4L57OO\ [QBU7K7OO^\U^2-J.#I1?+0PZ_B MU^RQ^W-\9-9TS6/%7A_]C.P_L;3#I6F:5X;^)7Q\T?1K."2:::XFBL(OA=)& MMS\CA7X8P;+U%EEA:6^0D6SR[]M'_ (*YZ]^S'\>=5^#_ M (,^$_@SXGZ+IGAGPSK:^+9/'][9?:;_ %VWN+B?3_)T?1-7LD.G>4B/NO?M M,OG)^Y48)ZC]CO\ X*^> /CC<>/XOC^OPU_9WC\,0^'I?#,^H^/9KN+Q8VI_ MVL-6A@&K:9I;+)HJV-B9?($Q8Z@BR+$ZA6\NEE_A_A^))YA3P>5TN)83E.>- MY9TZ].;@XSY:\W[&G>#E!QBXQ>W*W9+]*7@UQ^N'J/&-+A:K5R?%4,-B:.*P MT\-B\95IXMQC2:R_#U9X]7YE>U'FA&\JBC!-KZJ^V_\ !3H<_P#",?L&8)S_ M ,CQ^T*>?_#=_H/RI?M__!3G&/\ A&OV#OI_PG/[0Q_G\//\GWJU?_\ !2S] MA?3_ "_M'[2/@B7S&D"_V>FN:B3Y156)73](NG1"6&R4A8W_ ('.#7 WG_!6 M_P#8#LP-OQVCO>&+?9/!/CXB/;R=[7/AJU0;\_NV#%7!!!PRX+XJJ*3LI1R+,U![=9X6ROJ[-Z]-6 MCLQ?_P#!3KI_PC'[!O7C_BN/VAL_G_PKK-/^W?\ !3W_ *%C]@W_ ,+G]H7_ M .=UFO"]2_X+5_L(6.T1>-/&NH[O,S]@\"ZCF/R^GF+>W%D1YI&(B$8$D9V\ MUPTW_!<[]C=\?V5H7QMU=@61O(\"Z=&IER D88>(YRS2=5( .#RF2 ,99[DL M=?[1PME;:HJCO=+[*;OTMOU/2I>%7B-5E&$."N((.5K*OE];#1Z:\U>-&*5E M:[=NFY]5_;O^"G8/_(L_L'#/_4\_M#>G_9._P_SB@WO_ 4[[^&?V#?Q\<_M M#?\ SO.>/I7QG>?\%QO@P?\ D!_ /X^ZY]]0%T/3[0>:/N1',]SAY..!R,C( MQ69#_P %JKC5PG_"-_L1_M!ZHSS-;JS"W1?M& 8H@+72;AF=L@E0<@'DUC+B M3)4[?7HO;X:.*EVZQP\D][:-GH+P8\3;*4N%J]!6NWB=_UKX@/_!5C]I_5=A\+?\ !.CXQ7X9GA_TF/Q0V;CD1HAM?![C']]3 MA\ E0>,LM_\ @H9_P4AUP1C2?^";GB&Q,LCP*VKS>-K91)R$DD74/#VCO'%& M>6:14B?E4G!(H7$6725Z;QE7^[3RW'2F]OA2I6>B=E>^_9D_\0AXSIR4<5#( M<"W=WQW%/#N&44K7=/^$:_ M8,S_ -CQ^T+C_P!5U_7\Z=]O_P""GF/^19_8-_\ "X_:$Q^?_"NZ^(?L7_!= M'6PI34_@%X7+)+;_ #?\(Q^[?+ 7LHDT;7"W&&B$6$# ![4@U%;_ :_X+?: MX(AK/[27P@T#>)+>5K"R\-R>5'N?%RQTSX=6>^5U*[1%M>#: )'R6JEGDI+F MIY1G,K6TG@71[=*M1-^;C=;KN8?\0WP]*7+B_$/P[H);^RSS$8R2VVCA,!64 MM;W:DO)6:O\ <7]H?\%//^A:_8,_\+G]H3_YW=+]O_X*>]O#'[!O'//CC]H7 MI[?\6ZZ_3)]J^(A^QO\ \%;M5&!'%_P3E_X*$:HJ+XK_ ."E'C>3.0YC;2W-+!TWVUC/%\\?5QOU-5P#PM#E]OXL< M'1YE=QPV XJQ-P9E!YY& #9LO^")FGNL:^ M(_VR?VA==7:T=RHO9K,3PD$"-//\1:IY2J2"0PF4C*EFLN13G_P" QEVM;4R_U4\/J,U'$^*6&J15N9Y?PGGV*_\ 9U7A(=[ MW6FG<^O[CQO_ ,%%[49ND_X)W6PQN)N/BC\!%X]^E)?C#\?\ Q"=KI/N\3Z':I,I)*(JW.A:GY:H.JDR!CD\$[:Z32O\ @AU^ MQ3IR1BY?XLZOY8+XA<7; M)\%%I.W-FK>ZTLHX/5W[M72=G=FLLA\):?*GXA<1XF5]8T.!G2A\JV)SZ#=F MM8^QORMR3?+RO\O;K_@N1^V''>7D,?A7X"B.&[O(H]OA7Q?*ABMYGB1TF/CR M+S(Y"FZ*1DC+QLCNL9+!?O+X6?\ !2;]H/QQ\-/"WCC6/BE_P33\'7>M:<;J M]\-?$+XK?%;PIXZTF6.]N;(V^O\ A+3=$\21:3>R&W%PEO;:OJ,;6L]O<+*% MF"+\L3?\$$_C09Y6A_: ^%:0>?,]LC^$?%YECA\UVMHW9;[YGCBV([C.\JS M$'%?H;\#?^".O[*_A'X;^%M)^,G@;3_B5\4K/3IH/&/C33O$/C;2]%U[4&U" M\GAN]-T&374ATI8=/EM+-XX;:#>ULTI#-*S'Y[)*?&M+%8J6/C3E1<)+OVJ+^,*21DRV7PAN(AR"-K.&R.17VC8?\$M/V#K&)HH_P!G MWP[TJ>)U;17E1APQ1>#6'=?\%@O&MM"\R_%;]@NZV$XBMK M?]LHS28(&8UE^"<2N3S746'[&7[*&G3MEF"F&RM? MVKVF0,,J["Y^%UK%L['9-(X/&SI7-7W_ 7'^(=E*D<9867[29 M5&,GEK&XO/!-FY8GGY%= ,9<$D#][K#]F7]G;3!(MC\#/A-;";_6^5X!\-9< M^[-IK'ICOZGZ[L'P-^"EK$+>#X0_"Z&$$GRD\ ^%0N7'S$C^RL$L>I(Y'7M1 M&EG\G:6.RZ"WO#+ZS;=UI[^,:M:_2Y,\T\(X+]UPIQI7=TK8CBC*Z,;;N5Z. M0SES7LN5WBUJW<_GAD_X+E_&<,?LOA#]G"\C;:8)%M_VBH/M =5*[$;P1*^!H$A $*P^$_#\:Q!3\HC6/3AL"\8" 8]JV8 MO#'AJ"198/#^A0RH04ECT?3XY$.,95TM@RG'&01Z#BIE@\_DTUG5""ZJ&5TI M:7[SKM^7_!+7$7A5"UO#C.:]DDW7XUQ$6WHF[8?*J4;=6^5:WM9:'\PL_P#P M7*_;8\K=IO[)_P "M5G#*'MHO%?[04!16_C:4_!R=5 /!#*IX].:O:7_ ,%L MOV_=1262']B#X2WB)\OF:;XP^/4\:2\DI*TGP7C4?+A@58]<'!!K^H*"WMK8 MDV]O;0%P YBA2-F Y&XHJD@')P<\YQ5L$GTZ]1_]<&C^S\]LN;/[?XI_G8I<6>&$-(>$U:>B][$<=9U>3T=^6G@8QZ[)^MM4?S7Z=_P6"_X*"7EG M%<']@'PU.TICYLGM^ M.?KP>/T'MFG_ &?FNG-GU57MHL%@UT6V^OW^:?67QGX?V_=>$N6Q>MO;<5\2 MU;/II[:FFEU77HT?A)'_ ,%)/^"AU^[6UA_P33\:07!^Y+?+\0$MTV\L)6G\ M'6,8+#&P&X0GG(JTG[=O_!4;5@!I/_!/&6P:)OWQU.;Q(%D5Q\@B^UOI?S Y M+;6E&.RFOW/)QQMQ^/'Y#CZBD &1D#D#CDG'3@^^!W]!Q3>5XZ5^?/2:MTY4V[>];19PXZX6I?P?"OA+>_^T8[B3%N[23TJ9O%VZI?[094QOD7[7XTTZ3RFR1&/ ML_;[Y'-0-^T!_P %N;MS);?LE_"*TMIV#0)=3:09K>-LX\XR?&6*3>G5B]K& MP./W1&:_=<]0!TQ[C&._H<<>OOQFDPGM]>._U'IQSTZ5*R?$]<]SEJVT:F"5 MMGO]4O\ \/VWV?B1DRLJ7A5X=1LU=U<+Q!6;7SSZ.K[_ (:W/PM/Q"_X+D:@ MHMU^$'P/TDW#<7C/X=_T('G)5O&M\I*_?\%"]0N/B/+HO\ PC1UB[\-K+:QWD.F&V^U70NWOX=:9M(>ZLF!4AE$\+$\<@!LY[\L"" M<;_ES7]2ND? /_@LYK6DZ3&?VJ?ACH6D/I]C-:RV-OIRW$%N;2$V5N_V#P1# M(Z_9C&K$3-ND#,YD&UC^RZ_!;X/;0?\ A4GPQ# [@R^ O"V!]/\ B4@@^_!K MTN..-4$:(B(BJBH@"H(T 5550H554!55 H"J% Z5Y64\&4LN]JJV88VJJUD_ MJ]:KAHK?>5.I*=]7:2DFK/2TF?>>('TD<3QC_9$LOX-R'!SRUX^4WG^"R[B* M4XXV=&4(X:&+P=*.%='D:K75156X-\K@D_PN/[&G_!6[64,VI_M]Z+H\MRI2 M:#3$UQ4M@,IYEN]AH]HN_8-X$:1_,>3D$USNJ_\ !/'_ (*E7@@"?\%(KBZ6 M/S,_;[WXD0E=RX!46=R Q.,L9.G\..*_??8?7]3_ (48Y^Z#VZ^_O]0.?Y'% M>M_JW@&K2JYG43MI/-LQLK)=%62ZM=[ZGYO_ ,1>XH4HSH9?P;A''9X?@KA: M+NTE?FGEE62TTLFNM[VN?S9:Y_P2W_X*EZI#>*/V]?!E_P#:;D2[=2U[XZ11 MS]Q+<&QU ,DHY $7[K'O7ENI?\$>?^"H.HW8GG_;#^"EZHC2)FNO%7[3,4KQ MC@QLMMJ?D<@L Y1F[D-BOZG\'L@'Y?GTSGOG.I5NO1:7Z;DU/&/CR37)C\JP[2LOJO#O#V&5DUK:CED8N7G* M[M9;;?RQ)_P1?_;VF;&L?'7X$:Q$J@K%)\1OVD(!',!_KD:;1K]58]RJ+(.G MF8XJY'_P1)_:=N$5=<\1_L]ZT9,_VB9/B]\>85U D_QI<_#/4 IV!$S(;ECM MZ]A_4EMSC.!CTSR*7:OI5?ZNY*M98",V[7?/5;=K;WJ=M?7>^A'_ !&?Q/4F MZ?%F-H7M_N]+!8>*5E?EA2PL8PV=N6UGK=-W/YAK'_@B/\8+1&27PO\ LRZ@ M6=762Z^-OQ]ADC 7;Y20XX%=I9?\$@R^3\Q+'R]N6))ZG/[X45O'*,JCHLMP/;7"4'V[P?9' MDUO$#CNNVZO&7%$FW=VSW,X+7^[#$Q2]$K):+0_#.W_X)W_%.U,9B_8Z_P"" M7^!;@3OM_Y:3>9(6^/>)-BM\;7&]3D-^]^&;\@U^TM%:K+LOC\. P4?3"T%_P"V'#/B M[BRI_$XGXAJ7T?/G693NNWO8EGY*67[-G[5NG.TEE^S%_P $M+=W18V98OC M247[J_/\*6QCVP?>NIM/A#^VQ8"(6/[/_P#P3"M/(.Z$P+\78VB;D[D9/A.K MJWS'Y@P;D\\U^H5%:QPV&A\&'H0Z>[1IQ_**[+[C@KYSG&*TQ.:YEB%>_P"_ MQV*JZ[7_ 'E66OF?F_:^$/\ @H'9!ELOA)_P3AM [!G%KJOQMMP[#@,PB^%R M!F X!.2*Z&#_ (>86N/LO@S]@*V*KL!@\8?M 0D)Q\H\KX<(0O X!QP.*^_Z M*VLNR^XXI5Z\[J=:K-/1J52V\*VGQV^$'["?C2'P5?:!"8%:#RV9RW[!45%6E2KTW2KTX5J.]!MM4M-(UJ;XZ_MCZZEG M!K=A-I>I@:9KVAZEI[-\TSC M-L[Q*QNVQ$ZE3V<.:7+#FY8\SLM6?!?V M[_@I[_T+'[!O_A M:?!?V[_@I[_T+'[!O_A M;P)XO779-)\:_'R75DT;_A'M1.J/I<5YX @M9=12P%PUE'6.,L MX_3"O+_C?_R1?XO6/ ^AA#(!@"3:!O X#9P<8K^3+_@\$_P"<>'_=VO\ [[+7]9?[(8 _93_9 MK _P"%#_";@#'_ #(NA'M[DGZFOY-/^#P3_G'A_P!W:_\ OLM ']/W_!-; M_E'/^P'_ -F4_LK_ /JB_ E?:U?%/_!-;_E'/^P'_P!F4_LK_P#JB_ E?:U M!13&D"D+@DD9'7!YQC.,9/8'J 3VIGFX W(5)QQD=/>@":OR] M^.O_ "EG_P"">W_9KO[?O_IZ_9-K]0%;<,XX.#USU_E7Y?\ QU_Y2S_\$]O^ MS7?V_?\ T]?LFT ?J%1110 4444 %%%% !1110 45&9%'OQTSR3Z8./S-,\[ M W%"!GKU./7 Y.3P .>]"UVN];72=OOV_$/\TM%?65K+2^]T3T5$)5()'.#C MC/7N.G^1S1YG8C!R1C()XZ].,^Q(YHNE>[2MO=I6O;=-Z;K[Q77=='NOM;6[ MW):*87P.A)]!S_\ 7_3ZUGZAK&F:1!]JU:_L=+MAG,^HWMK8PJ ,DM+=2PQ@ M#/.&.*<5S_#[SZ)6;?HEJ_D59_/MUMW2W:\UH:=%?,GC7]L_]E'X=F:/QA^T M%\*=)N( 3+8IXPTO5-2&W=D)IFD37]_*V5("QV[$L, $U\@^-?\ @LW^PSX2 M=H=+\9^+_'L^6CB3P?X)U4I+*"%5%?Q(?#K,&8\/%'*"H+('&,^IA4'K9VGRNFM]F;PPN)J?!AZTO/V"?A- MIUTK;;_QTZI?V =%>)BGBKQ'H\_F!O,1MWABZY8>9%&017?_ *I9M!I8NIE^ M7QV<\=F6!HVVU;A7J3BD[7O3UNMV]-O[/Q$4_:>SHVZU*M.UM/Y9R;=GLE<_ M<[=G'W>3C!R>0<8&!C/MUJK=7EM8Q/<7MU!96R??N+J>*UMUSZRS.B+WZD>M M?AM-^S7_ ,%A/BB'D^(O[8/@?X164A+-;>""(9H8FX\GSO"OA_P^6<*3]_46 M0$8:>4X)H)_P20L_$MC9O36]:7L*+2M:ZEYV2$\/AH M)>UQM-:WM2A.H[63U;48I>:D]^A^LWC;]J7]FWX_(I=ECL8;Z6\EE"@D11V[RMT"'I7R!XY_X*^_L)>"//$7Q2U7QG-;A M@\'@OPAKVH988"K%=:O;:+ITV[(*O#=20-P1)FO'_#?_ 30_P""7WPX$5CP#G 'G5\_\ M,\N7^T9]5QU6QTGQWI%I;0 ^7I_A_PGKM MM;8"!@(8K31+>TY4@*OF ' '4&N%^7R;P]3A?W=WF.?O,T_AU]E0K8>&ZM:UW MMIJG*S/+;_N*.'G)6_BUO;KH]%&Z>OF]MET^%V^"O_!:?XK;T\7?M$_"_P"" MNFW(++;^%H]-.H6:R<,GF^&/#!O1(BG*,?$5SM8#YE/--B_X)$_%[Q]*E]\? MOV[OC%XRN7/^G6.AR:NEI9H_P .?BQK2[=XV>'D@7:HS,2PN+D*(N[\O+:%)=F"Y5(K.0[0C*3T?+ !6->/4^D#PCAW_ +'GN38*;LHQRO(Z MJFM8R]RH\#7G=;)^T3:U5RGF\^7]U"$(VUGA\"_=U7_+V-*2A;:[DMVNQYSX M-_X(J_L3^''6XU[3/B-\0+K/F7$GB?QQ=6<,\S$,\C1>%+7P],R%@2(KBYG! M!(=I ,U];>"/V$OV//AY)!-X7_9V^&%M=6PQ%J.I>'K?7[_C _>76N_VC.Y/ M).YR,\\L3GYZF_;@^-ETS-H_[-LL,66'GZQXCFM8HQ]Y/.8Z?#"K%&4['E1@ MW&!@5CWO[7W[4%R6BL_AM\(]!^,-*SL(^=W$2Y(7( M(KR\3XX8/&KF6.XKS&G*226#RC.)TY-O3E4*-.F[WT2A^1/UK'8B2A3I9IBG M)_#AL)BZCNVK75.BU9NROM=QZM'Z7V7A/PII.FW>DZ3X8\-Z;I-];36E[I6G MZ+IMCIUW:3QM%<6MU:6UM';SV\L+NDL$D;1R(Q1@58BO./@+\/\ X)_#CP0- M&^ >A>&="\"76N:_J#0^%\O:W6O2ZM\BDLHDFE=;.SM[>S MLMEC%!&OY1?$7]MK]H^UM+70KO5_A7 WBO2];C#_ [O-#\4W>E6UK':V]TU M_=Z3XDU]-%NY/[0C&ER32J]S)'<26NXV75I9M;N$BLK>*WECC6\9)GP2V?@ M,'ALYH<-C&LIJ5,;3Y?J$91Q]:&'G3@IU6YUYP]BJG-"[4D M8RAFOUZAE<,IS>6+Q3M3PL\+55:K47P05.24O:35_9TW:I4E:-.$I.Q_25?: MCI^FKY^H:A9:?"!GS;ZYAM8@%!)_>3NBX'7J,5XMXI_:;^ 7@\RKKOQ5\)Q3 MPY$MIIU\=:NT(_A>TT9+^X!/0 QC/&*_#+6?C5_P3QMI9[GXH?MG?$[XMW:L M7NK/PYX9\7I!).@!98;G7M*N[>="2<2P2QJ0=HD1U.(=._;S_P""6OA5G3P; M\#_BW\3]0@_=K+J_AQKY+J2,94)#?>(KB!.S(#I< !8L(QG->O/B[C#%K_9L MOX6R.F_AK9IGLLSG&+:Y4\+DU*TY)*S_ '[BO*UE]IA?##Q1Q\HQP_ ^>4%- M>Z\?E^(P5MOCEBX8>G!IIZ3J)O;J[_J5K_\ P42^"MI)+:^$M%\=^.[V%\)% MI&B_8[><= Z2W<_VG:3T#V"\XXR:YK_AJG]J+QR7'PO_ &7M5M+:;_CUU7Q> M=1$)#'"%S,F@:=D*5:0?VB=@QD;2"/B;0O\ @K5I2*UG\#/^"?/Q3N9H=T-M M-;:-:::K@C;#_P @3P[=W2AF(WYF8[22I9AST\?[?W_!2OQF9(_ O_!.G6M( MC?!@N_%K>+8U;.?+D<:I9>&K;8-\9)2Z*DK(6.U@4YY+B/'O_;^/<90A+_F# MX5X7E0F_!/Q$IRIK-991D,9;_VEQ%PQEU)62OS MRQ&85Z\$^CA!RU6D>GUD?!__ 4-^(9*ZSX_\%?"JPN!EH-'6T>]M/XL*=,M M=1OEPORJ!KCY(!8DPDL7 &..M?*"_$K_ (+A^-@4T_X,?!?X9PR-MCFOSX>::-&X#O\ ;/&W MBECY:R DM81L3$P^SY()B'P+_P""UOC@M'XH_:=^%O@"WE;[GAZ+2?/MHR,@ M!M \$VDQ*DD8^V3$XSYG0"H\(9#B6YYE@N->(IN*I%JU^:CE."Q4;:6YE9+1 MW8DQS^\L;'^S],//4"S4-_% MD=??]'^'/PH\ 01G1O!_@;PK#$3(DL.E:/I[*P& XNIXDD!7;G(EZ\[NIK\< MA_P35_;R\8L4^)W_ 4<\:SVTSMYUIX<_P"$L:.)7PLD,"3ZWIEN@5'G4*(U M#,8SP$-7K#_@B/H&I,S_ !'_ &N/CYXX\[Y[B(7?]GH[OS+M.HZQX@7:6:3: M?)& XRI *GZ3+Y^N^N?&SX.^%HGG M\1_%?XM?'_AW_@A[^Q3HS^;JP^*G MBV5W,D[:WXU@M1/(Y#2,QT#1-&E^9@<%IGDP#QZKK%S&48Y)0($_V0.*][VO$516A@LLPVJM M[;%5:SM=;^PHT4VDO+RON:_V?X.8.2=7B/CS.(_:^H/*\/>"?%4C.T9^9(FU?3=)A M?9Q?9^]".(P%-NZU?(G9V5E=/\ "Y?%_P#P7+\<*%M_AW\# MOA>K_P 5RWAHM'G+#(G\2>-R6'E*I8 X\\?(=I"I'^SC_P %G_' \5_M=?# MKP('W!CX;M[?=$KPX SR.,D__ %L].W I MP7C! Z]L_P!>:;R-3_C9IF]9=GC%3CTTM1IP>OKIT#_B*.)HN+RW@KP[RSE3 M2E1X5PV,GK;5SS6MCY2M9?&W=W,5V_%7_@HS\1[\.-LL M?A__ (2F2/ Y"K]MU_3R0-J<$H,Y(VD*!H:=_P $0OA_?!?^%B_M/_M >.=V M?/!U2#35F8\9VZE>>)@H& <$.2..GRC]R/+&>F,=,>_7U_G^'>E*@X]L>G;Z MBC_5O)YJU6A7KW=W]9Q>,J6\[2Q#7>[:;LR9>,/'\9)X/-L)E"BN6*R3),DR ME*.FB6"R^BXI6TC&5NJLS^6OX_?\$1/BY9_$:XM_V9+CPQ=_"9-#T9;2?XG> M/6M_%TNO^5-_;[WD>E^#ELVLGG$#6"PB%?*+J\:D GZ"_8C_ ."/'_",7OQ$ MF_;3\"> ?&EI=1>%C\.[;PUXTU_4!IMQ:RZPWB1KY;*T\.#R[Q)-%C2.X^VJ MXMI0HA7_ %G]!QC;!"E5^8'@<>_X^GI3MIYSCD\=>/;MV^G:N>CPCD5#%_7( M81-WNJ-3EJ48OELVZ4TXM:MJ[;4D>UCOI >*&99!_JYB<\Y*"IX:$LSPU)X; M.I*A*,E_PJX>I2Q,YR<(QQ$I).K!RC*ZE(^&;'_@FI^PKIP(B_9J^'5SND24 MF_L[W4?G7[JC[9>S8C/.8^$;G_G.836ZTUQ#=FUKZ7WV\1T[]FW]GW M2 5TWX(_"FS!G6X81> _#!)E3GS/GTYB'!'TQU!Z5UME\+/AEIH_XE_PW\!6 M $JR@67@_P .VH#KC;)^XTQ,2J "'ZC@ @XZ_F7>OB\36;7N[RJ5 M6];:V?;MICV>CZ38<6.E:98KYGFA;33[2W_>\ 2_N88QYA'&_AL #-:^2HR3 MD^G;^7I2 ,.F.?4D_P!!3NHY _I^M;)625DO38XI5*E36I*4Y=Y.4FM%UDY- M_>+1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O\ C?\ \D6^+W_9 M+_'_ /ZBFK5ZA7E_QO\ ^2+?%[_LE_C_ /\ 44U:@#A_V1/^34_V:_\ L@_P MF_\ 4$T*OY,_^#P3_G'A_P!W:_\ OLM?UF?LB?\ )J?[-?\ V0?X3?\ J":% M7\F?_!X)_P X\/\ N[7_ -]EH _I^_X)K?\ *.?]@/\ [,I_97_]47X$K[6K MXI_X)K?\HY_V _\ LRG]E?\ ]47X$K[6H ^&O^"ANG?M%ZI^SE>VW[-4?C"X M\2GQW\/9/B/I_P ,?$^@>"OC!JWP,C\26Q^+.G?!_P 7>*+S3-"\/?$67PT9 M9-&U&[U?1+H6L6I6^B:WI'B"XTJ_@_//]CKXB_%;XD?\$VO'.G?LO_M.>.H? MBOX0T/0X-7N?VPOAIXTU?XT_LI6.I_"'PYXLUOPL^G>*-3LM9^+.KPVUW+XV M^"/BWQAK>K>$KW1_$FD+<:YXIT#1(K"?]=OVB_@+H/[1?@&'P+K7BWXB_#^\ MTOQ)H'C;PEX]^%GBB7PIXS\'>,_"UT]WH6NZ=%O%FC> M(/"'B+2[R[TW7]!U&UF$8\B_9G_8F\"_LU?"GQI\/HO&?Q"^*/B;XJ:/I&F? M%3XM^/;[1!XV\6+X?^'NE?"_PS9V5CX;T71O"?A7P]X2\&:18Z)X0\.:#H5O M8:/;0O<7CZIJ=UJ&IWX!\%_##QM\4OVC](_X)?? /Q?\9/C!X;T?XL?\$^KG M]I;XQ?$#X=^.-8^'_P 4OB7X_P##'@_X$>&-(74?B)X:DLM?TZW?7/BCKOCO MQ!I^C7=E#K^M6>E6VM+?Z''=Z7>^'? SXV?'_P#;.T.3PWXT^.WQ5^'>J? ; M]B?Q/\4+3Q;\*?$5Q\.+GXA_'+2?V@OVAO@OH7Q/\:-H$=K8^-/#NFZ%^S]I M>K7GP]U*UD^'&LZ[XL\2G6O#%_:Q:1!I_P"K&J_L+?#X^ /V)?V5OAU'\*?A/\7_ .K>"C\3(OA[-X-T?P-KOA;Q)-XR\!^+?!/B*R\1Z; MX=T'4]3^U>#8I['Q-H.C^(_#SZ+?V44M^ M!=AX/^#>J?L\ZU)_BQ\"?A7\1_$MO:6QM;*+7O%O@?1=>UD:?:$L8;"34+VXDL(]QQ:R1$9' M%?E!\%?#&@6$933]$\.Z!IMOI.CZ191MDI:6&G6EO M:0H6OP7_P"A _; _P#$"_VUO_G"4?\ #>OP7_Z$#]L#_P 0+_;6_P#G M"5]J44 ?%?\ PWK\%_\ H0/VP/\ Q O]M;_YPE'_ WI\%_^A _; _\ $"_V MUO\ YPE?:E% 'Y%_ME_MX^%E_9?^-#?"C3_VK? 7Q%'A&3_A$_&.L?LD?M5_ M##3M U0ZC8 7MW\0/&_P>\/^%/"R?9Q/ -2US6=/M%>58//\V>*-_P =+/XL M?MPZE\,_#%WI_P"U/\8K?QS-J4&NZ@-5\>:C%9MHMWM8:3<-Y,NV2UM5M[G8 ML8-Q+)/ S*'.W^J3XZ_";2/CI\)O&_PEU^^N-.T?QQI4>E7UY:PQW$UO'%?6 ME^C)!*Z1S!IK.-9(I&5)(V="W.#\!2_\$P?#\BF)_B]X@:-T\N6(>$]'"-%E M_EV?VD (RKE#& 5*C:1TK\6\4,LX_P ?F.1U.#%B(X?#1C/&U(8U8>@Y>V2M M/"N'\APN693E64U\>N)O[9QN89CE^78^53 0R MZC@Z.5^SQN&JN6'=55\15@JM.+J*A->\I'GNO?\ !4?Q$;:&U\"?!O03=K L M2W?C7XAQE;B6-,--]F\-:/>S/O.'>+SD=F+@.!M-?.OB_P#X*"_MGZYYRZ)K M_P &OA]:N2J2:#\._$OB;4+5W V*;SQ'JUS9R.>@WZ/%D\G*XQ^\FB_#?P78 M6%C!/X2\(W5[9VT%O-J2>$M#L6O)XH42:[6VALMEI]H<-+Y$3&.(N40E0*ZJ MTT'0[%/+L]&TFTCW;REKIMG;H7_O[(847=T^;&?>OJL-E/B.HP=7CC+WUS]K[XQ(SQ,UQIG@'PC'X1MVMF38_FP>& MM-LV,9DRN/*.5P!R-09O%VK?M._$:;4FS#)=Z9\0-:AE:1MKC M['=:%JT)/FJTGEJJH-P88;FO[.,?7\S28^OYD_S->BLN\0^GBIG>$7_4IR7) M,K:VU3HT)^\DK*33=K+9'I4L7@X)1=+-4M.94'4A8QHGA3]AJ'S4;RQ$)H+Z7P?J6H$ MS8W"Y>3SDD!DB= :_JBP#U _*C:/3'TR/Y8KSL5P=GV9-O-O$[Q"S%R^+VF= MO#J6B7PX.GATEILK*WS;VCCLK3_>Y9B\;!?##'YWC9VVOK@H8"]VGM&*2MU5 MW_*OK7[9W[?%NIM+7]G+_@H2L-O&1'!H'[/'Q/TJS1%!;RH(=$\!O;[6)QLM MUWDG*CN?+;S]JO\ ;PU]IDNOV9?^"@*B)8C_ ,5!\#/VGX4G*IB,*=)^&-R9 MO);'^M2(D;L%AP?Z^Z*\J7A+DE;7%YWQ9C'M_M&?XR2MUNDU>[UW6N]SJIYK MPY3<9?ZBY'7E':6*S/BRK*.WPJ'$%>VE3FO(_CB?QY^VAK;1K+\ /VDK!; M@;W;7?@'^VUJ"V[8+N)XX?@EY+'$8D7G(ZUERZ5^U_JV9&^%?C.S?<4SJ M/[)'[9UN9Z6O-2 M[[ZG\;T?PP_:>NWD%Q>_$+0H_+)26S_8*_;=U!VD(&$"2_LXNT6P9"NS/[JP MZ;4/P*^.VI0I'J7QD^,>DB;BX^R_\$W/VZ9Y;;&"K12VG[/%N)'!4'*!6[YP M:_L'Q]?S-'^>]=M+PFX$H[9'0FU:TJK]I)6MHG):+39+?6^MEZ%#Q'S#"V^I M\-<"8;EV:X/R>LT[)7MB:%:#M;[<9^;?3^0O3OV8O'D#2RW?[4?[4T$KLIC_ M +)_X)Q?M_F)L<_OH[KX*J(@&)VB%.3VVFNHB_9:M;Q%BUS]J3]NJ2U),LL5 MA_P3<_;9\S[0.=\9N/A$@*%B;?YW_E#C_8^^%\SBXU M']J+_@I-+-(0MP=/_P"">W[;%I%+ K#]U'L^'$8CW(&4L8<9.2K %3TD'['? M[,LY;^W/C=_P5 U9$&;16_8A_;0MA;-U9D\[X*WW!'E[5A6 J4SEC]W^I?'U M_,_XT8^O'N?\>?QKU*?"_#])6IY91@NT95%?;KS7\]&ONWA>,7B3%WI\2N@[ MMKZME.2X9)O^7V.7P:MJE:1_+S'^Q'_P3_G"C7=5_P""G.M*^#>+)^QG^UM$ M;J;);SF-S^S#?%6+98^9Y[$_>9JV[#]B3_@F%:(%D\'?\%(]18RM(9KS]C_] MKM7"L"AB46/[+-E&J8R=P0R@_P#+3' _IL_SW-%:+AS(XNZRS"/OSTE4OLUK M.\KIJZUT%/QD\4JFCXYX@C&UN2CBUAZ?SIT*=.#\KK1V:LTC^0C]J/\ 9*^$ M$0\$G]B7P#^UMX>8OKG_ LA?B%^RY^W3IIOHU32QX7;2VA_9VN1*]O,==DO M!Y<6#-;D,P 5>4_95_9QOO"_QJT'6?VI_AO\>?'7P6BT;Q+;>(/"]I^RO^W? MXBEO]5N]-:+P](VDG]GK3%G@L]2"3S-)=JL: EXY!E:_LAQSGG\S1CZ_F?\ M&O/EP7P_+,*>8O!0]O2G&I&'+3=#FBE&_LI4VM4DG=N_SL>@O&OCEY'7R/$8 MK XQ5Z56E+.,5E^'K<0)U9.:JPSEP6,A6H.36&J1GST$H\DE8_(#PWJ7_!-; MPDZ2:!^QA\8["6)@5G_X=M_M?7U_9VB?/&<[B?>OT0 QC';ZFE MKZ.GA,+235+#4*2>_LZ-."MVM&"6_P#GN?G&*SO.\=;Z_G&:8ZSNO;XF3]O#X*Q@*O@']K]$4 *B_L%?MJHB@= BCX"A0/]D# M&.@IW_#>?P8SQX#_ &P#[?\ #!O[:A_]X,!^=?:]&,>OYD_SK=*W:VUK)=NU MNW2QY6M^ZO=[W=]_>O>[?7_ASXH/[>?P8/\ S(7[8(X(_P"3"OVUN_K_ ,6% M(_S]:0_MX_!_??K_6R/BD?MY?!88/_" ?M@$C R?V#/VUNG..#\!3TSVIW_#>OP7_ .A M_; _\0+_ &UO_G"5]J44PV/BO_AO7X+_ /0@?M@?^(%_MK?_ #A*/^&]?@O_ M -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T('[8'_B!?[:W_P X2C_AO7X+ M_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ ]"!^V!_X@7^VM_\ .$H_X;U^ M"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ /0@?M@?^(%_MK?_ #A*/^&] M?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T('[8'_B!?[:W_P X2C_A MO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ ]"!^V!_X@7^VM_\ .$H_ MX;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ /0@?M@?^(%_MK?_ #A* M/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T('[8'_B!?[:W_P X M2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ ]"!^V!_X@7^VM_\ M.$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ /0@?M@?^(%_MK?_ M #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T('[8'_B!?[:W M_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ ]"!^V!_X@7^V MM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ /0@?M@?^(%_ MMK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T('[8'_B! M?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ ]"!^V!_X M@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ /0@?M@? M^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T('[8 M'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ ]"!^ MV!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ /0@ M?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^"_P#T M('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]?@O\ M]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO7X+_ M /0@?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X;U^" M_P#T('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_^&]? M@O\ ]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /BO_AO M7X+_ /0@?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@#XK_X M;U^"_P#T('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH ^*_ M^&]?@O\ ]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U** /B MO_AO7X+_ /0@?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM2B@# MXK_X;U^"_P#T('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K[4HH M ^*_^&]?@O\ ]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA*^U* M* /BO_AO7X+_ /0@?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\X2OM M2B@#XK_X;U^"_P#T('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK?_.$K M[4HH ^*_^&]?@O\ ]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[:W_SA M*^U** /BO_AO7X+_ /0@?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^VM_\ MX2OM2B@#XK_X;U^"_P#T('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(%_MK? M_.$K[4HH ^*_^&]?@O\ ]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B!?[: MW_SA*^U** /BO_AO7X+_ /0@?M@?^(%_MK?_ #A*/^&]?@O_ -"!^V!_X@7^ MVM_\X2OM2B@#XK_X;U^"_P#T('[8'_B!?[:W_P X2C_AO7X+_P#0@?M@?^(% M_MK?_.$K[4HH ^*_^&]?@O\ ]"!^V!_X@7^VM_\ .$H_X;U^"_\ T('[8'_B M!?[:W_SA*^U** /BO_AO7X+_ /0@?M@?^(%_MK?_ #A*\_\ BS^W'\'M9^%G MQ+T>U\"_M96]SJWP_P#&>FV]QJ?[#G[8NCZ;!/?>'-2M89=1U?5_@?8Z5I5C M')*KW>I:G>6FGV, DN;VZM[:*69/T4KR_P"-_P#R1?XO?]DO\?\ _J*:M0!P M_P"R,&7]E?\ 9O1@H,?P+^%$;;7#KN3P/HBL%=20Z@CY7'RR*0Z\$5_)G_P> M"?\ ./#_ +NU_P#?9:_K+_9# 7]E/]FO _XL1\)CP,<_P#"":%SQWK^33_@ M\$_YQX?]W:_^^RT ?T_?\$UO^4<_[ ?_ &93^RO_ .J+\"5]K5\4_P#!-;_E M'/\ L!_]F4_LK_\ JB_ E?:U !1110 4444 %?E[\=?^4L__ 3V_P"S7?V_ M?_3U^R;7ZA5^7OQU_P"4L_\ P3V_[-=_;]_]/7[)M 'ZA4444 %%%% !1110 M 4444 ,QQC;D9SC//IV&/UHVYY/Y>^?4#ICZT^BIY=4[MM.Z=[6Z6TLK>J8? MGWZ_TAOS8/ 'H*49 YY-+15+0 HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH *\O\ C?\ \D6^+W_9+_'_ /ZBFK5ZA7E_QO\ ^2+?%[_LE_C_ /\ 44U: M@#A_V1/^34_V:_\ L@_PF_\ 4$T*OY,_^#P3_G'A_P!W:_\ OLM?UF?LB?\ M)J?[-?\ V0?X3?\ J":%7\F?_!X)_P X\/\ N[7_ -]EH _I^_X)K?\ *.?] M@/\ [,I_97_]47X$K[6KXI_X)K?\HY_V _\ LRG]E?\ ]47X$K[6H **** / MRW_X*&_MT?$7]F#Q#\&?A1\'-$^#O_"T?C1!XDU[1/%'[0OBK6?"?PIM](\$ M^+/AQX8U;PG82^'8FUKQ-\2?$EW'B"VBO=;^PZ?8 M_P""F?P/^.WQ[^&VB^!/ ?[/_P OVIOA5J]S:V_Q)^"GQ*FU.U\: M>#=6T/QCX&\?Z]IOB/PK8Z5;^&].\9^%?'&@7>A6/B*_TOQ1;ZMX6\1PW6EW M.@:[\S_#;]AW]L/]F[POX9O/AS'\,/B[X_\ B!^R/J/[*WQ*A\7?$OQ3H>D? M!Z>V^)OQ+^(/PG\1^&O$VN^&_%_BWXL^!?A+H7Q>U[X#?B1X;6^C$ M-[%H?C;P]I_B/3(;^%6817L%IJ4$-[$&_=3),JEMM? ?[0-U;Z?_ ,%6O^"> M^H:A<0Z?9C]F']OV$WM])':V8F.M?LF8A-Q.\5C>Y959@-S?,/B3_@E)_P $Y/&5_P#VIXP_8]^"WBS45>]DBOO$ MWAQ]>NK:;_\D5^?7_#G7_@EQ_T8I^SG_P"$!I_^-'_#G7_@EQ_T8I^SG_X0 M&G_XT ?H+_PF'A3_ *&?PY_X/--_^2*/^$P\*?\ 0S^'/_!YIO\ \D5^?7_# MG7_@EQ_T8I^SG_X0&G_XT?\ #G7_ ()%,'_ M (J?PY_X/--_K<"N L?CS\,+_P"*/B'X01>*M*_X3/PQX \&_$K586OK!-,3 MPQX[\1>.O"^@26^I&\,5S?OJGP[\1K>V<:;[.W73YY6"W\*GXY/_ 1V_P"" M6_?]A7]G+\? &G]_Q[X--_X&.221XH6:;_\ )%'_ F' MA3_H9_#G_@\TW_Y(K\^O^'.O_!+C_HQ3]G/_ ,(#3_\ &C_ASK_P2X_Z,4_9 MS_\ " T__&@#]!?^$P\*?]#/X<_\'FF__)%'_"8>%/\ H9_#G_@\TW_Y(K\^ MO^'.O_!+C_HQ3]G/_P (#3_\:/\ ASK_ ,$N/^C%/V<__" T_P#QH _07_A, M/"G_ $,_AS_P>:;_ /)%'_"8>%/^AG\.?^#S3?\ Y(K\^O\ ASK_ ,$N/^C% M/V<__" T_P#QH_X:;_P#)%'_"8>%/^AG\.?\ @\TW_P"2*_/K_ASK_P $N/\ HQ3]G/\ \(#3 M_P#&C_ASK_P2X_Z,4_9S_P#" T__ !H _07_ (3#PI_T,_AS_P 'FF__ "11 M_P )AX4_Z&?PY_X/--_^2*_/K_ASK_P2X_Z,4_9S_P#" T__ !H_X%/^AG\.?^#S3?_DBOSZ_X'"Y_Z^/_U]*\Z^%GQ_ M^%GQA\'P^.O!OBO2Y?#]SK_C?PU#)J=[8Z;=G4_A]XW\1?#WQ&IM)KII/LZ> M)/"VK)8W()BO;%;:]B/EW"U\?C_@CM_P2X!!'["O[.8(.01X T_((]#GJ#4< M7_!'#_@EE @AM_V#OV;+>)2S"&W^'6E6\2M+(\LCB*$(@:::26:5@H:6:226 M0M([L0#]"?\ A,/"G_0S^'/_ >:;_\ )%'_ F'A3_H9_#G_@\TW_Y(K\^O M^'.O_!+C_HQ3]G/_ ,(#3_\ &C_ASK_P2X_Z,4_9S_\ " T__&@#]!?^$P\* M?]#/X<_\'FF__)%'_"8>%/\ H9_#G_@\TW_Y(K\^O^'.O_!+C_HQ3]G/_P ( M#3_\:/\ ASK_ ,$N/^C%/V<__" T_P#QH _07_A,/"G_ $,_AS_P>:;_ /)% M'_"8>%/^AG\.?^#S3?\ Y(K\^O\ ASK_ ,$N/^C%/V<__" T_P#QH_X:;_P#)%'_"8>%/^AG\ M.?\ @\TW_P"2*_/K_ASK_P $N/\ HQ3]G/\ \(#3_P#&C_ASK_P2X_Z,4_9S M_P#" T__ !H _07_ (3#PI_T,_AS_P 'FF__ "11_P )AX4_Z&?PY_X/--_^ M2*_/K_ASK_P2X_Z,4_9S_P#" T__ !H_X%/^AG\.?^ M#S3?_DBOSZ_X#/%'CSQ+)IVH6.HZA'X?\ M'Z'?>(=9>QT^*Y66^O$T[3KEK6SC827,X2%"&<5T>E?$'P;J^G6&J6GB?P^; M/4[&TU&S>36M-CD>UOK>.YMV>+[2QC:;_\D5^?7_#G M7_@EQ_T8I^SG_P"$!I_^-'_#G7_@EQ_T8I^SG_X0&G_XT ?H+_PF'A3_ *&? MPY_X/--_^2*/^$P\*?\ 0S^'/_!YIO\ \D5^?7_#G7_@EQ_T8I^SG_X0&G_X MT?\ #G7_ ()%/^AG\.?^#S3?\ Y(H_X3#P MI_T,_AS_ ,'FF_\ R17Y]?\ #G7_ ()%/^AG\.?\ @\TW_P"2*/\ A,/"G_0S^'/_ M >:;_\ )%?GU_PYU_X)%/^AG\.?^#S3?_DBC_A,/"G_0S^'/_!YIO_R17Y]?\.=? M^"7'_1BG[.?_ (0&G_XT?\.=?^"7'_1BG[.?_A :?_C0!^@O_"8>%/\ H9_# MG_@\TW_Y(H_X3#PI_P!#/X<_\'FF_P#R17Y]?\.=?^"7'_1BG[.?_A :?_C1 M_P .=?\ @EO_ -&*_LY\\C_B@-/_ ,: /L+Q5\?/A?X,\7?"[P5KGBK2X];^ M,'B?7O"7@R.TO;&[M9M6\-^ _%7Q'U3^T[N.[":9:IX;\':R\%S,I26_6UL> M)+N(UZ'_ ,)AX4_Z&?PY_P"#S3?_ )(K\]V_X(X_\$LG:)Y/V#_V;9)('9[> M23X=:5)+;2/&T;R6TCAI+>22&22*1X61Y(9)(G+1NRE__#G7_@EQ_P!&*?LY M_P#A :?_ (T ?H+_ ,)AX4_Z&?PY_P"#S3?_ )(H_P"$P\*?]#/X<_\ !YIO M_P D5^?7_#G7_@EQ_P!&*?LY_P#A :?_ (T?\.=?^"7'_1BG[.?_ (0&G_XT M ?H+_P )AX4_Z&?PY_X/--_^2*/^$P\*?]#/X<_\'FF__)%?GU_PYU_X):;_ /)%?GU_PYU_X):;_\D5^?7_#G7_@EQ_T8 MI^SG_P"$!I_^-'_#G7_@EQ_T8I^SG_X0&G_XT ?H+_PF'A3_ *&?PY_X/--_ M^2*/^$P\*?\ 0S^'/_!YIO\ \D5^?7_#G7_@EQ_T8I^SG_X0&G_XT?\ #G7_ M ()%/^AG\.?^#S3?\ Y(H_X3#PI_T,_AS_ M ,'FF_\ R17Y]?\ #G7_ ()%/^AG\.?\ @\TW_P"2*/\ A,/"G_0S^'/_ >:;_\ M)%?GU_PYU_X)"]<6ZL(U\RVMELYY"!=QBO1?^$P\*?]#/X<_P#!YIO_ ,D5^>__ M YQ_P""60E,_P#PP?\ LVBX>)8&N!\.M*%R\"2/,ENUP )FMTE>29("YB26 M2654#R.S.'_!';_@EN>!^PK^SD3[> =._P : /T&_P"$P\*?]#/X<_\ !YIO M_P D4?\ "8>%/^AG\.?^#S3?_DBOSZ_X:;_\D4?\)AX4_P"AG\.? M^#S3?_DBOSZ_X:;_\ )%'_ F'A3_H9_#G_@\TW_Y(K\^O^'.O_!+C_HQ3]G/_ ,(#3_\ M&C_ASK_P2X_Z,4_9S_\ " T__&@#]!?^$P\*?]#/X<_\'FF__)%'_"8>%/\ MH9_#G_@\TW_Y(K\^O^'.O_!+C_HQ3]G/_P (#3_\:/\ ASK_ ,$N/^C%/V<_ M_" T_P#QH _07_A,/"G_ $,_AS_P>:;_ /)%'_"8>%/^AG\.?^#S3?\ Y(K\ M^O\ ASK_ ,$N/^C%/V<__" T_P#QH_X:;_P#)%'_"8>%/^AG\.?\ @\TW_P"2*_/K_ASK_P $ MN/\ HQ3]G/\ \(#3_P#&C_ASK_P2X_Z,4_9S_P#" T__ !H _07_ (3#PI_T M,_AS_P 'FF__ "11_P )?X4_Z&?PY_X/--_^2*_/K_ASK_P2X_Z,4_9S_P#" M T__ !H_X*_B%X,:34;ZPTZY&M_#'X@>)_AIXI06\EX[/:)XG\):NFG7:$QW^GK:ZA# MF*Y05Z#_ ,)AX4_Z&?PY_P"#S3?_ )(K\]H_^".'_!+*%-D'[!W[-D$>Z23R M[?X=:5!'YDKM+-+LB")YDTKO--)C?-*[RRL\CLQD_P"'.O\ P2X_Z,4_9S_\ M(#3_ /&@#]!?^$P\*?\ 0S^'/_!YIO\ \D4?\)AX4_Z&?PY_X/--_P#DBOSZ M_P"'.O\ P2W/3]A7]G,_]R!I_P#C1_PYU_X)%/^AG\.?\ @\TW_P"2*/\ A,/"G_0S^'/_ >:;_\ )%?GU_PYU_X) M%/^AG M\.?^#S3?_DBC_A,/"G_0S^'/_!YIO_R17Y]?\.=?^"7'_1BG[.?_ (0&G_XT M?\.=?^"7'_1BG[.?_A :?_C0!^@O_"8>%/\ H9_#G_@\TW_Y(KS+XU^*_#,W MP;^+4,'B/P_-/-\,O'L4,,>LZ>\DLLGA75ECBC1)R[O(Y5%5 68G"@G KY'_ M .'.O_!+C_HQ3]G/_P (#3_\:5?^".__ 2Y4AE_85_9T!'0CP!IX(]P'[*'3="\->&/#NGV^E:%H6CZ?;*D%CIFD MZ;:VUC8VD*+%;VT,<2*%4"OXT_\ @\$_YQX?]W:_^^RT ?T_?\$UO^4<_P"P M'_V93^RO_P"J+\"5]K5\4_\ !-;_ )1S_L!_]F4_LK_^J+\"5]K4 %%%% !1 M110 4444 %%%% !1110 4444 %>$?M!C]H.?X?RZ?^S&WPPM?BAJ_B7PQI"^ M(?BTNNWOA#P1X5O=4MX_&/C5_#/AV6RU'QOKOA[0?MEUX;\%G6_#-CKVN-80 MZEXDTFP2XF/N]?(_[:OPL_:+^,GP,U3X=?LR_%'PS\'_ !OXC\1>'8/$OB_Q M GB>WNIOAK'?K-XZ\,^%O$'A&:/7O!7BKQ9I,;>']/\ '.FQ7>H^%K:^O-3T MB"/6(K"[M0#\[O!W[=/[3/BKQKJ_[*.F>*O@EXF^,NO\*;GQTTNI?%'X911W/PB\4>&=&^(UUX2M/' M2]N=9MIK74?#\&W\3_\ @H)^U'X._82_:/\ BO\ #[X&>#_BY^T?^S+\0?V@ MO@W\1-2;7K+P/\#=%U+X!6%_JVH_&7Q#I^J:_>^-U\-^(/"XT/5]-^&GA?\ MX2+Q#/XIU8>&7US3M%1_%<'I>D?L5?'31_AG\ 8/!NE_LJ_!;XD_L?\ Q(G\ M5?L\^&?AM8_$_5/@WJOA#Q+X)UOP%\1/"OQ,?7A8^-GUGQ;I/BC6]2E\9V$V MLZQ)XGALO$6MC7+^[U,S^A0_L,^)3^Q%^U#^SI>_$#0KCXO?M:6_[0/B[XC_ M ! BT/48O!.G?%?]H*VU!=3E\/\ AY]0EUI? _@^*XTK0-#M+O5)-9U#1]#A MO;V>WOKV6" J_MR_M9_M ?L\_!OX3>//@Q\&-*\=KXO\9_!"P^)OQ)\6Z]I M6C> ?A3X*^(/Q1^&O@77+F'PO#K$?C3QIXYUF'QO-:^"?#>D6]OH=G-'OV9H/@1H_BC2O#NKPZ]\!M7/B'4M M.O+_ $UHOA#\5?AY\0M3@%C:W-O="36K+P5=:;8N9]MI=7]O<7 FBADC?ZXH M **** "BBB@ HHHH **** "BBB@ HHHH **** "ODK]I?_AJ>:]\)V_P \?? M GX-> [#2O''BCXT?&3XR^'M8\?7?AFRT#1H)/">C>&_A_9>)_A]HLNFZG?2 MZCJOC3QKXC\?:9!X6\/Z T&GZ3J=WJYN]*^M:_.+]O7]F7]H[]IN_P#A1X8^ M'OBCX-7?[/VA7FN:Y\;O@7\66^(^D:3\<]:A.F/\/]'\6>(?AU,;^_\ AGX; MO(=0UGQ)\.+VT?1/'^I?V-:^*3?:!IUSH^H 'R!\'?V^OVK_ -JGP!X%D^%% MI\&OA=\0-!_9%U;]K+XCWWB7P?XL\<^#_BH'^)_Q*^&OPO\ #/P[T^X\6>"O M$7@CX<_&6P^%6O\ Q'M_'NM+XCUS0O"WB'PA;:7X>UQGOKT^T>,O^"@/QCU7 M3/\ @G!XZ^$'P(TX?!O]LGQA^S[_ ,+3^*_C3Q7H\]CX#TOXU^'=3U2W^&O@ M/PMI.JQ^*/$OQ'BO[4+JWB;5+'2_!7AO1;.>>(>(M8U.'3].ZSQ]^RA^U5K? MB2P^+GP\\9_L\_#GXM^/OV<+K]ECXV:2GA[Q[K7PST7P18^*=?U[P#XY^#UK M%O#5H()[W2H-(@-WZUXM_8MMG^#O[$WP5 M^'OBB#1O#'['GQ:_9W\9V=SXAL[C4=0\3^$?@/X;U#PVNCB2RGMEM=?UVWN; M:X;4IA-9QSI-?$'QJ^.OA7XEZ_H'A/7_$&F_$B'Q#I=CX<^*^G7FN>(/&.C^ - M.^'GB7PO8>!O &HWOB;Q9#]OO;W1/UQ4;0!DG'+OBK*(?$&NPS:?X1CGTKPA8/IMU^KH&!@=!0 M%%% ! M1110 4444 %%%% !1110 4444 %%%% $4FWHQQG .1E2N>0>GT)!R,CKG%?D MM^U=^T#^VM^S9XG'Q9O]9_9N/P=U;]I/X)? OX0?LV0>&_&?B#XT_';PS\2] M=\.>%-?U_3OB3!XBTNR\.?%>PN]Z%^MC+N^O3/I]/QP<="5&:_*2;]EG]LEOVS?%/[3/B#6_V6OBYHUEKR:' M^S]9_$-?B]I^L_LX_!S4+/2K/Q=H_@'PQI"ZEX);XI^-9+6_U#Q9\5)UB\0Z MU:RZ=X/BN=*\(V,FG70!R7A/]M_XYW_B+X5_'+5I/AO=?LO?'+]L[Q=^QEX2 M^'&G>&M2B^)'A?\ LOQEX[^&'A'XQ7_Q+?Q;ZKI-Q'?^O?"G]J?]ICX@?M9?M9_ [Q)\!/#OPZ\,?"?X M%_#SXA_L^:+XE\._BKJ7B;QA\9_"$OB#XA:OX5F\2^'/AMX3\2ZI\.] M&B\*:)9Q^)?$FFZ#=7'B;Q"T.IWH\*Z9R/A#_@G_ /$G1/''@/P+JWQ'\#7? M[)7P=_:G\5_MA_#;P[8:#X@@^,MU\0?$6M>+?&>C_#WQ7K$^HR>$1X"\'_$/ MX@^*?%=IK6F69U[6[:P\,^'[G3]-B@U#4KGZ?O?VB_$:+PH M/BG^S#\.O@1X;DTK0K74/$_@;Q5X%\6_%_Q+'X_B.N+?>&]9CB/Q)TR33=&U M+29[9KS0IUU%;FRO/(4 ^>_V4/VE?CMXJ_:>^*/[,OQA\6_"#XJ:YX!^#/A# MXG?$'Q'\'_"NM^"-(^"7Q2\2>([O1]2_9ZNO^$A\3>)+GXG6UII\#:]HWQ!L M(O#VHPV-HT7B[PUHMUX@T&"3]/4^XOT]<_CGUK\_O@Y^S1\>KKX]^"OVB_VH MO'?PM\2_$+X2?!GQE\#/!%Q\'O#WB#P[:^-=&\?Z]X%\0>+/'/Q*BUV9OLVM M7M[\/=(ET?P1X>\[PIX:NM4UV\L[RZDGM$M?T"48 &<]>3SU.>O?_/ Z4 +1 M110 4444 %%%% !1110 4444 %%%% !1110!5NC(J%HD6214=HXVD\I99%5B MD32[7"+(X52[(_E_?"L1BOQ0\<_MH?M>?LE_$?P);_M4:E^SS\1+3XC_ ._ M:L^.WC'X(_ [P_XKTKQ?^SUX6_9Y\"ZS\1]#UP_$G7_$FH6OQ&\!:Y':Z+\* M-<\6^)? WPT\SXE^(=*E\+6M]9&[TJW_ &LU".\DL[O^SC:KJ0M+@:#_AS\._ M ]IK,.G^%OAYH%[%X>T>&VGUMH]3\4:CJ>JWP!Z)\%/VH?VD-&^)_@?X<_'R MU\$_%#5OCM^R9XF_:S^%VD?!CPHW@;6/#>L>#=1\$V_BSX *WC3XA:KI/C>4 M67Q+\)#P9\0]3U/P.FJ7UCKS>(M*T6R-G+#T/[*G[:_CKQA\ ?VG?C?^U]X0 M\)? FZ^ '[0?Q?\ A]K/@KPKK3>,W\*^$O UIX5N_"_AS4/$5M(]IXY^)-^/ M$5KI.H'PK:6NF:UXOO8M \*65TGV&ZU#:_9I_9.^-O@[XL>!_BY^T;\1?AWX MUUWX(?L^7'[,GP=MOAEH'B70K/4?"&J:UX0U?Q5\2_B!'XFU34FC^(/BY/A[ MX*LIM"T!Y/#N@1V&JR66H7_]L+'87-"_8"\(:YX2^._@CXS:]K7B30OBE^VC MXD_:\\*3?#GQ?\0/A1X@\'ZO._A2]\%6DOB7P7XET77+K5O"VL>&_P"U&E@O MXM(N[O[!.VGF6RC90 _X)L_M0?&?]K#X*_$/XA?'KX>:'\)?'OAW]H[XW?#* M+X;Z-)<7-QX/\,>!O$D5GX8T/Q1J,UY>0ZKXWL-(NK>'QE?Z>++3'U];V"PT M^UM[=0WZ%5\)_L,?L9R?L<>'OCEH4_Q&\8_$1OBW^T9\4_C18WGB[QU\0O'% MUHNA^.-7^WZ-HUS>>/\ Q'X@N[CQ+;VS./%GB2WDAG\6:D5U+4_M%R!(/NM1 MM &P[#B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** /#OVA&^ M/[?#JZL_V98_AG'\6M6UGP[HVFZW\77UN;P3X-\/ZEK-I!XN\:W.@^'/L^K> M,M5\->'OMVHZ#X+BUCP[;>)-:AL+"_\ $>BV#W5XOY3>%OVZOVE]8\>^+/V4 M+3Q1\$?&/QAB_;+M/V6O!?[47AWP)K]K\++K1K#X#ZI^T)\4-1U+X43>/+Q] M1^*OP>TO1[SX;^(/"V@_$>3PTWBW4M'N]4U329K36="A_1[]L[X:_M%?%WX$ M:]\/?V8?BEX;^#GQ%\2:OX=L]3\;^(8?$*SP?#]=4BF\=:+X8UKPM*FM^$/% MOB70DN-!T7QK80WM[X3>_FUO3+4ZM:V,\/R-H_[$WQQTKX4_ W2/">E?LL?! M;X@?LC_%:S^(?[.V@_#2W^*>L?"K5M)U7PAXG\#_ !&\.?%>Y\2_9?&][JOC MC0O&?B"XO?&UI);GQ3?R^%K76['17/BRTZ+]I[]L?XL>$_B5^S?\ M#CP)XU/PSL?'_P"SIXJ^//Q4\>Z7^R/\8/VJGTX6>H?#K1_"UE%X:^&.KZ9# MX$\-2R:UXWU;Q'XL\5:E<6.GVVCZ/9;X/M379]FTO]B3Q6G[&O[5_P "M:\? M>'[KXR?MA1_M#>+OB/XYL=&U6#P%HGQ/^/WAVXT"5/#/A^?4IM=_X0?P1IT6 M@Z%I,5YJ?]MZKI^AG4KR2UU#4IK>#T;QU\+OVL]%A^'EC\"OBA\*6\,Z=\*- M+^%OCOP%\6/"^K3>'HM3T^*V@7XK>"]:\*0KXKE\2+8+=://X-\0ZF?">H6* MZ?=++IFIP75U>@'U)X UBW\0^!O!^O6GBG1/'-MK7AC0=5A\;>&H(;7P]XPC MO]+M;I/$^AVUMJ&K6]MI&NK*-3TZV@U74XK:TN8H4U"\5!<2=?7B_P"SG\$O M#_[-OP(^$?P$\*ZCJ&K^'_A'X!\-> ],U?5E@34M6A\/Z;!9/JM[%:I':6]S MJ,\".Q[=>.>F#U)I](PW?@"+37_'G MPH^*'[-/P(^!/PL^#'C?XE^/?B;\:SXVT%S=Z3X/N-!TCQ7X!T_ MP1\-K?1+*\U3Q5\0%U_Q-XDDO;ZPTO0O"!:TFN;OX>;_ (*'?M1_$GX6_$7X MY_#_ ,(_#WX7:9^RM^R+\!OVG/CW\'OB!X:U_P 0^*OB%XH^+/PRO_C1XG^% M7ASQ-'XC\,3_ OL_"7P]T:5="\1:QX5\0ZUJOB77;#^V- TRPL+A+OZ>_;/ M_98_:=_:$^,WPJUWPOKWP \8?LZ?#72(O$$O[.OQL'Q,L/#GBWXXV/B*/5/# MGQ&\>2^ Q"-.L[,>$?AUXFL)?#5IXHDE\7ZE;ZGJ>GZ$-,Y;XQ_L M/?M%?$S5OC5]T^*2X\1?#[Q-K'A)=/\>VD*:;=6.B>)5NKF1+O1Y #M_&?[8/QGC_: MU_8H^%/@[X-6&G?LW_M(V_BF\\3?&[QAXBTB?6M:UT/POH^L+=WVO:?\Y_"G_@HC\0_C9\< MO!][X$\_L[S?#CQS\*OBQH%MJ&E?#_P 2^.?!-_K7A?\ M:UAM;KX1:E^T'JFL^$$\4Z+^S-+/&NKSZ!?65S>W_B+0?$/P$\*?^%K>)/C?I?PNO;]I6\'?\(-I?Q)\4WUW_P ) M3$#XLO?#5G9^'7M8))+C5B ?JG" %('W0?E^G?C^'YLC:22,'_=VO_OL MM?VJ5_%7_P '@G_./#_N[7_WV6@#^G[_ ()K?\HY_P!@/_LRG]E?_P!47X$K M[6KXI_X)K?\ *.?]@/\ [,I_97_]47X$K[6H **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%&<$[?]J[X[_!CP9\$?$'P9\+>"_"'PBTC]GQ=*-OXP^#/ MA?X@:_J>LWWQ1^!7Q/\ $6HZO=Z]KMXB.FM6NGVNG16EK;Z>CI+-+ZQ_PR;\ M6/\ I(5^VE_X+_V,O_H/JQ_V;O\ D\#_ (*,?]E(_9S_ /68?AY7W=0!\4_\ M,F_%C_I(5^VE_P""_P#8R_\ H/J/^&3OBQ_TD*_;2_\ !?\ L9?_ $'M?:U8 MVO:C=:5HVLZGI^E7.N7^FZ5?WUCHMG)##=ZO>VEI-<6VDVDMR5@CNM2F1+2W MDF(A2256E8(#0KO1:.Z2OMK;_,%KIW/C_P#X91^*W/\ QL+_ &TN "?^)=^Q MGG!X!Q_PQ[DY[8Z]J0?LI?%4CA%? UU M_P %$?\ @HLL]PEO_P $RO' MDN)?($P\?23>3YI\D2M;^$VA:<0X\UX6:'S M.8V,9X^=/BG_ ,%$_P#@I2OQ2^#*6W[+/B?X5+-JNJ+8_"F;PEXKUD_&RY2T M9M3TBXO[[1[?4ECTS2B\]M%HD N--NM^LSS7:V\=M!]/A>$G* M?O9KEWV8\VT<3*2T3WCINVDFUW0P%:;5G3L]?XL.R?\ -V?;;7O;]AQ^R?\ M%<]/^"A7[:1_[A_[&7_T'M(?V4/BN./^'A7[:9^FG?L9MWQV_8]/?_/!KX!' M_!1/_@HZ 2O_ 3,\:;SCACM=7M[B"32M2AU)+53.J7,9\_%Y%F&!H/$8CZG.$9*-L/F&!Q$VVU M%6IT,15GK??EMU=EJ93PM6$7*3A:.]JD&_N3;_#?0^_3^RA\5@"3_P %"OVT ML#J?[._8S('XC]CVD/[*7Q5'/_#PS]M'CK_Q+_V,OK_T9[Z<_3FO%?VUOVG] M;_9M^,$/B/2_ OA+Q>O@G]A7]LGX\QG5+?4;;Q//JOPCUCX+OIGARR\0VMU) M!H_@W67\127'C20Z-J5]%::;8ZA9RV_V![>\^;/$/[9?[5WPI\2_%'X3?$;X MU? 3QAXK/PM_9&\6_!_Q/\*/@'XQ\5^--6\=?M(>,_B_H^I?#BP^#6F?%2Z@ M\1:[J&G_ ZM8OA3?ZUXW\'>%&TV6_\ &?Q%\0Z3HEG]1W'4=Q1_PRC\5O^DA?[:1 MXS@:=^QF3@].!^QZ3D\X'4X;^ZV/R\^"_P"W)^W5\??%-C\$=%\2_"+X5^-_ M"FJ?MR:1\0/'7C7X,6?B37Y+S]F#Q/\ ZR\%V!^&W@3X_>(_ VA>(+M/B?J M_A[XBZ?I/Q6\565KV-_%+O#FI?#/P[X M(;P'J8TGQLEKXMU:Y\6^(]#TB6ULSIC3:D@/US_X9/\ BN>G_!0K]M,_33OV M,_4C_HSWKD$8I/\ AE#XK@X/_!0K]M/M_P P[]C/N<#)_P"&/<#)'&<5\>?\ M%$=!OO&G@_\ X)U>#K?X::?\<(?%7[0/AZVU+X3>+?B%=_#?P[X^BMOV&OV+?B+I/CC6); M6>X^&-AXJU[XE^(]-_X2F+P;:)H_A+P[>"SUE[F]\0B^N)P#];#^RC\55QG_ M (*%_MI#)Q_R#_V,NO Q_P F>^I /H>*/^&4?BKD#_AX9^VCST_XE_[&7/0\ M'_ACW!&"""."#D<5^?>M_MX_M*>)?V=_@M=^$?$GA>P_: UJQ_:CU#QQI7@+ MX 2?%!O$_A_]ESXH:O\ ";7?B:+'QY\\7:G\0?B_-J MR:OKND>#/ 5IX@NS>W5OY'I/_!1_]M3XA? 7XP_M'^"]1^ 7AG2OA?\ !?\ M85\2^'OA[K/P[\2^(+?Q7\0OVMO!7PVU+Q+<:]XSLOB'9SZ-X.\'ZSXQDN_# MEGH6EZGJ&H:=,;*_U$_8+>[O@#]8/^&4?BKG'_#PS]M'.,_\@_\ 8RZ9QG_D MSWIGC/K2+^RG\5&Z?\%#/VTC@@'_ (EW[&?!/0'_ (P]ZGH/4Y'4&OST^)W[ M7'[;_P "KO\ ; U7Q;\4OV?/&'A']B/X@?LSOK-S_P *4\0>#M2^,/@G]H*/ MP-=>*-%UFY3XK:]8_"V[^'6G>)+R;P_XKTB'QB/$;OG7- T^*R O>8\&_P#! M33]H#P]XR^(VJ^-+*Q^*?PMO?V%_VC/VSOA#<#X*M\ F\46'P7U#P;=>'/\ MA7UKJGQF^(/Q9\2_"CQCI?C&2RL_&/Q3^$_PCUG4[?2;+Q1X=TW6-.UB>SL@ M#]-!^RC\5CT_X*%_MHGC/_(/_8R]O^K/>HR 1U!.#S1_PRA\5O\ I(7^VC[C M^S_V,LCZC_ACW(QWSC'?%?"WQ5_:L_;9^$.D_L[_ U3Q5\*/CE\6?VKO%D% M[X2\2_!7X3>'8M6^&/A"Q^"VK_%;7-&7XZ M_>_%+PC-J'A./Q#KC^'M;U7P\MC=>Q_"3]KW]HO4/&'[//@7XV^"O!/PY\0^ M,_V*/V=_B'\-/!WA3Q-8ZEX(^(OCOP=X:TCQ-H7B MN\\1>+O Z>*O%=[X-U6Z_P"$:O/$8DT&>?4 #Z&_X90^*V"?^'A?[:6!DG&G M_L9'IUZ?L>]1CD=<\=2*:/V4OBJ20/\ @H7^VE\N W_$N_8S&-W3.?V/>,]? MIR>*_%7X&?MB?M)^+-5O/CC\5?%W@SXK^'_B7\9/^"74^C_"J3X?ZK:Z#\,6 M^-'P5M_'7B>_^%%W'\1-1GM-8:]EN7T6YN+6XM+C7+O^V;JWO_,-H/T \"?M M9?'V+]D35OVM?BG\:?V=])T;XL_!+P)\6_A3X2T+X2_$+Q%XD^#>L?$CQ%;: M+I'A?5?#WA+QGKGBSX]P65QXJ\(^$K*#1-"\$:SKGQ.2YT:;^S=-U.-], /J ML?LH_%8C(_X*%?MID<'/]G?L9XP>G_-GE'_#*/Q6_P"DA?[:7&<_\2[]C/C' M7_FSWMW].E?E#\*/VK/V@_B]^U]\#?AG\;/[0T;Q3\!?VK/%VAPKJOACP[\' M]9UW0?'G_!/CX@?%#3-&^*G@'X>?&3X\>$],N=%UJY:ZMS+XVDO(-*ETS4=7 M\-:%K-IY4OVG^Q]^TW^T;XP^.=G\+_VF]7TSP=XN\:_#SQ'\0M ^$=]\!-0\ M,:5<67ARX\%RZEKGP!_:5\%?%?XL?"/X^?#OP^/'FF:/K,VKS^"?B48)_#?B MBX\#Z#::S>Z=9@'T9_PRC\5LX_X>%_MI9YX.G?L9CH"?^C/>N 3].:3_ (92 M^*O_ $D+_;2'4O['O8=?3OS7Y@_L^?&K]J5O#/P%^!WP2^(_@' MP6/'\7_!3WXK^+/'_P 4_ GB+XP:]8W7P2_; ET;PAH6@:0OC[P=$^EWL'C* M^TW4X[_5"VFZ9!8C1Q ]E!:2_0'PN_;)_:2_:3U#X&VO@3Q/\"_@8)OV+?@% M^V%\6KKXC^%M;\8Z#XVN/BQXOUSPYX@\"^%;M/&WA"?P/X3\-6G@O7;JX\97 M$WB?5++5/%OA&SO-,6&TNQJ0!]??\,H_%; /_#PO]M+G./\ B7?L9]N M]?0=^V:/^&4OBK_TD,_;1Y&1_P 2_P#8RP1@$D'_ (8]Q@ C)[9&>HKY ^$G M[;WQ[\6?$+X&^*]>UCX2:E\*/VIO'W[7?PV\'_"SPYX>OX/'/P7O/V8;#XC7 M>F>(M<\*+R+XARZ^/A;?P?$#1V\)>#X/"6J>+]$L]*OK^&Q\W5?$?AG^U MC_P4 ^)=C^QAILGQS_9-\ ^(_P!K/]ESXQ_M1ZM?:W\$O$=QIG@>W^'&C?!^ M\T+P#X6L9?C/87/BBTN[GQOJ^K>._$NJ7-G=:+H"7,VDV+R:3'/=@'Z6_P## M*/Q5X_XV%_MI<],:?^QD?4_]&>]>#Q[$=:/^&4?BJ.D\2:/_P (%8:"GQ"MU^$EO_PA_BX^/M2\ M/7\&L7>G1:@HT[I],_:]_:WUCX3:5XRF^)7P_M_'?QR_:6^-7P:^!7PF^%W[ M,>N_$WXA/H'P)^(_QC\/ZC_9MMK'QJ\$^#=6\0:UX3\#Z-KOCKQ9\2?&/PT^ M''PZTW2]=FAU'5-5U;1-+H ^]?\ AE#XK'./^"A?[:/!VG_B7_L9<$&?C#XV_9:^+GA3P'IFMKJVF M_$;QAI7A*_UBSM["Z:XTK4?B)I7@N%O%EIHVO^(M,\0#4K7V+PU^V]^WS8:1 MX&\,_$'P1X5\*7O[17C?]FSP;\*?COXW\)?";0O#W@34_CAJOB.T\200_"/X M8_M3?&;7/B1X:LM)T&QN_A%XPU[Q+\-K+QQXBUN7PMJD,-WIB-J !^CY_90^ M*P*@_P#!0O\ ;1RQPO\ Q+_V,N>O3_C#WN 2/4 D=*=_PR;\6/\ I(5^VE_X M+_V,O_H/J\<_X)B2^/6\)_M>V?Q,\<:-\0_%^B?\% /VE="U/Q1X:^WP>';X M:5<>$;.TBTK0]1UOQ%+X0-K BQ:QX-M=8OK'PQXD&M:1:7$T%N)I?TYH ^*? M^&3OBQG'_#PK]M+/7_D'_L9?_0>T?\,G?%C_ *2%?MI=V6CVLD,-UJUW:6LT]MI=M+<,L$5SJ,\ M:6EM),1"DLJM(P0&@<4Y-)6NVDKM)7;MN]%\SY!_X92^*N#_ ,;"_P!M/@9. M-._8S)QG&<#]CWD?2C_AE'XK9Q_P\*_;3['/]F_L9XY..O\ PQYC/X^E?GS= M_P#!1;_@HPEU#=" M7RT19"#7Y@?M3_MD?\%$_%7Q9OM7N-,_:,_9E:7P[H4"_"SP6_Q$M]&T]889 ME.O(#HMJGVK7&82W!.['E1CS,XS\SC>*SA;]Y*+:3_I$7]E+XJLQ5?^"A7[:9(X/_$N_8SP#C.,_P## M'O7UQT[TO_#*/Q6R!_P\+_;2RQP!_9W[&?/&?^C/>@'4G@>M?F#\.O\ @H9_ MP4@TWP'X+T]?^"?7CSQZ++PIX>M/^$YU.W^(W]I^,S;Z1:0GQ3J1C\,2H;[Q M!L_M2YP[XENGYK=_:8_:!_:&_:'_ .";'[9UM\=OV>OB!^RYJEAHG@7P_I.K M6&M^)O#6J:UI/BGXA>%-.U6X\+ZK-;Z#XHT?5M)M9&634[$I"LE[;?9;L3PW M"IZ6%S;#8RI2HTJ>+52K!5'[7!XBC""LF[U*E-4VTW;E4KO=7V?R'$7A[G_# M6&Q>-Q]7(JF%P=3V,9SGCK2G]D_P"*XSG_ (*%?MI\ M?]0[]C,]?3'['O/X9Q7YQ:=^TQJ/P>_;%T?2?VA_&&HR^(/V,?V!?VP-8^+U MW/=SZ=9?$3P+X6^('[-FM_#+XU6ND27TUMJU]XZ\&^;I5UJ(MQ)9_$:W\9>' M[!((I8[63Q/_ ()Z?&+QOX,\9?'7X??&/X@?'7X7ZW^UM^R;KG[9^J?$7X[? M"[XN?"S1/A%^T-I4FLZ;^T)8?#-OC-X?\-:3K7ACX:>"/&?P;\1VT?A!IO#: M6O@[5]9F%LEW+<7'J?UIM^OYGP[^;6C4G&45)-*5X\R5UKNKJ]U>Z9^Q7_#) M_P 5^,_\%"OVTAGIG3OV,\G@G '_ Q[G. >.M'_ R?\6#_ ,Y"?VT_QT[] MC,?S_8]'/MUK\<-$\&3_ +,/AW3]-\:_#RQ\!^-OC-^RO^U1X>\$?M'_ ++7 M[1_B#X@?!_\ :WU7P[\!==^)FG>/_C=X%\F.>E?C7^PU^U#X MTG_;#T[XV:O!\>[G3?\ @I/X<^/>H:%X>^)OPL^,?@'X0:!XE^$NJW_C/]C7 M0_AUXT\?^'M%^'6OW'Q _9CLO$SZG/X!U2ZEUS4;6QN[@7/V=;M]J['[.UG_ M ,$Z=&_;@\;?&&?1_P!O/7/A-XN^+6D_&Z;Q_KEA\6+C]J'P+9S:UXB_9_T7 M1$U5+.YT'P_XP*? ZX_9^M]#:QG\'>=X<;PW)=R7%Z #]>1^RC\56QC_ (*% M_MHG)P/^)?\ L9 M?,/$#65UX7XGU3XF:SXS\'^,%\2?% M+X1?L^Z)X=^'/Q*\8V?B;P/\,KG5] TW2_B7\;H? ,VB2^#_ /A9&@VE[I>C MO\1&\)W-Q;FZUT ^S_\ AE'XJ\?\;"_VT>H?"_QC#X4_9\O-:^(/PB\&^))%UBX^)MM M??$R/Q'HGQ+N=2T6SU6'PC+I?B[3],T5+G5M)OI;B( _8L?LH_%4]/\ @H9^ MVB>G_,/_ &,N_0_\F>]#V/3\Q2_\,H?%;)'_ \+_;1R.O\ Q+_V,N.O4_\ M#'N,\'C.>.E?(.C?M=_M*^*+CPG^SI;>+OA%X=^-.K_ME?&G]E2\_:+O? 6H MW_@#5](^#'PENOC6_B?PI\'F\<6BS>//$6EI#\.]5\*3_$=]*\.^)M*\6ZO; MW&JII]OHJ^.ZO^WY^UWK/PC^''QEMK#0/!7PP\/>$OB)+\;?BU\.?@=??M,^ M'+'QG\+OC)\4_A9JOBOQC\-/#GQ9\*_&CX?_ U_1_A8OCC3/'/P\\'?&.^ MLK77/%%IJ4]C8> FUC5P#](/^&4/BMDC_AX5^VGQUSIW[&8QUYY_8]Z<'GIW MSBC_ (90^*W0?\%"_P!M$D G L/V,2<#&3@?L?<]17XZ^$?VS_C?;:?\#?VH M/#_B+P@?AAX7_9<_X*M?&WQ)\ /A/X/UJU^'?QBUCX!_&_1K#PSKNFZ]KWC& MYU?2;SQ%IE_9:H/$>J:%J=YH4-]XJN181)XPFM-&^W_V7?VQ?VGTM=?\0?M6 M?"/QWJ/@#5_AW\-OB)X$\8?##X.^'O$/C&;7/'5[J%KJ/A70O@Q^S?\ &_\ M:K^(7C#X96UC;Z=KWAOXTZOIGA+3[V.XU'1M7TV.^LH9YP#ZL'[)_P 5R 1_ MP4*_;3P0"#_9W[&?0C(_YL]IO_#*/Q5_Z2&?MHCV.G_L9 \''0_L>YZ@CW/' M6OB?XJ_LD_LN>-?^"CG[,E[J/P4T*XL_BU\ OVI?BOXUL=9M/%6D3>)?&NE> M+OV=;GPYXE\5^&;J^L%A\4:$GB/78[>/5],MK_2)-:UFS>""X=XH[GP^_;(_ M:*\<>+?A/J4GBCX26?P\_:I\=_MC?!3X<> O#GA#4;SX@?L_:W^S5HOQ3_X1 MWQOK_B2Z\8?9OB;/=W7PJNY?'WA.?PYX&M?#6H^*_#^G:=J]S'9O<:F ?99_ M92^*H)!_X*%_MI KU!T[]C/C@M_T9[Z GZ<]Q2G]E'XK 9/_ 4+_;2 QNR= M/_8R^[@G/_)GO3 )/ICFOQBA_;I_:W^"W[!OP"\2>'OB_;?%OXK^#/V$X?VK M?BQ+?_L^1^++W5- NK3Q'?>'=?\ C/\ $7QK^T#\+/ 7P\\(ZG/X3U+PLNK: M+XI\<_&#QUKBZ]XBT;X;&ST*2QNOU*_X)R>,=2\<:7^V/XJU&YU$_P!K_MD^ M-M8L;&^U&[U.+0;+6?@Y\$]:71=-:]D#6NEV-QJ-R(+2**SMDFDFE2%6FDD8 M ]5_X9/^*_'_ !L)_;3YYYT[]C,=L\Y_8]X_''IUIH_91^*I.!_P4+_;1)! MXT_]C+N,CG_ACW'(Y'MS7\]?[.WA;4])\'?\$ZM4N?V;_"O[/OB/XW?'CP_' MI/\ P4,_X7WK'B;6]7USP_XUUOQ+=_#WQCX0MM"TS4(O&7[2?AG1_$'PV\)^ M'O%6M:MX+O+J\O=.U74CK47AS2M6^G_'G[=?[?GQ>^#?[27Q'\$^"K_X7?"' M5?"?[;O@3PYXJ&@_"+3-0^!MW\!M"^*^E^&?'FA^+S^TW)\4OB/\1I]:^%]P MGBOP"/@5X'O_ 0?$UQXCTZ>>P^'SR>) #]=A^RA\5CR/^"A?[:73/\ R#_V M,LX],KLS7=]/K]S!X9@LM4MG&H'RY)-5E8QM2\+_M4_MW_ !!O/@6= M(^)/P \,6W[3/[7W[3G[/F@VMQ\%/$>M3?"SX?\ [/C_ +1_V3Q%?MI?\ @O\ V,O_ *#VOA@_M??M MI^-/V?\ X,>+_!^CZ?=:W_PEG[17A#X\>//@W\$K3XX>+K.[^!/QKO?@SH/B MWPG^S)JOQL\!>-;_ ,!>+X;+4/%OC*?P%KGQ0\8^#=7M=(\)Z1X7UR+Q#%JM MI^JG[.7Q,@^,OP'^$GQ6M?%/A7QQ!\0/ ?AWQ5'XO\#Z-XF\.>$O$:ZOI\5T M=7T'P[XT2/Q=X?L+PN98]"\2HFN:.Q?3M347=M+0!XE_PR;\6/\ I(5^VE_X M+_V,O_H/J/\ ADWXL?\ 20K]M+_P7_L9?_0?5]K44 ?%!_9/^*XZ_P#!0K]M M+GI_Q+OV,OR_Y,]Z^@ZGL*7_ (9.^+'_ $D*_;2_\%_[&0_]\]KW+XX^._&_ MP\\%RZ_\/OAWJ/Q-\1?;K.SA\/:=*\;Q6]P9?/U&X2".:[FM[?8D;):P2S*\ MR/MV*QKXLE_:W_:KM()IKK]DC5X+>VCFEN+F;_A*4@@A@1I99I)7T01101HK M.\TKQHJ!W)XVGY+.^-,FX?Q?U+,%F2J_5WB74PV58_%T%"_P>UH49P=1J_NJ M7EHT8U,13I-1DY7TTC3G+?;X8M?C?R/7O^&4?BM_TD+_ &TO_!=^QG_]![_^ MOG'0TO\ PRA\5@,_\/"_VTL9Q_R#_P!C+Z_]&>U\7^#/^"@WQGUOQMK-KI/@ M#2/&=UXHFT\>&O VGZC?FYT1]-L6COX=+>VL7N]6;4J1E#'4*B_=NW\.K:]TMU3:UNFM M;I;H]9_X90^*V ?^'A?[:6#T/]G_ +&6.N/^C/?_ -?X&C_AE#XK\#_AX5^V MGD]!_9W[&>?R_P"&/<_X5^>GQ:\>?&2P_P""@_@K]HG2-/\ '?AR[^$G[ 7A MSQM\6/@%'JNJZG8^*/A?X@_:*\7Z/\3X$\(V]]:Z9??$'PKI&F:7X[\%ZH]D MNL>9X;E\,B::WUFZL9OCC5OBM;?&[]A?]DW]E[1O'_QHUC2/VGOC-^VU\4/' MWCOX"^%?BQ\9OB?IW[/GPI_:&^-]YX3U_3;/X/Z7XG\>:7H7B#XL>(/@QX=T M_7UAM]*LM+AU#2UNEM[?[(?TNA6AB*%'$4N9TJ].-6+G3G1DE.,91C.E54:L M)6E=J45;6+2:L=2=TGW2?WG[HC]E'XK$X'_!0O\ ;2)ZX_L[]C//_K'O8\'T M/!P>*=_PR?\ %?./^'A7[:>?^P=^QG_]![_GGT./S0C\6^,?V\_V7?\ @G_X MFN/^%5>//BG;Z;\0(/C7^Q5^T%XX\8_!<_'CQY\'UT[X5_&:YBCTW3[[7=.\ M??!OQ=IVK^*-(\.^-O OB#1=+'BZVU+Q!I&C:A;:1K5AQOP[\$?!SX_?%S]C MGX ^./AQ\0)?!GPJ^)O_ 4&^'WCSX%? O\5="^'GC;P-H/PFUC2O!W@W MQOH-QIUKXX^%?@G3_$]C!\*;C7DN]9\+:+J3>&-1@TG5M*N-,L-1GZP']E#X MK@A3_P %"OVT\GIC3OV,R/Q(_8](!/8'K@XZ&C_AE#XK9Q_P\*_;2S@'']G? ML9YP<\X_X8]SU!'L>#S7Y!?&GXBVGPT\"_M'_L/?"?7/B;J/PG^(O[;7P]_9 MO^'-K\-+#XD?&/XB_#CX6:E\+_"?QG_;5\'?##0/ ]CXA^(+^'?A3X8LO$V@ M65AH4>HI\/M5\?VNC)/I%O9VEMI^Q\(?CGK'Q5_9O_8O_9P^*WBSXE^$/A]X M;_;(^('[%/[4GB/QM#XP^%/C[Q7X=^%7@3X@Z[^SEX)^(Q\3P:%\0O"EI^TA MI%I\&+/Q*-830=:\8-KMYX8GNPOBAX;T _67_AE#XK=_^"A7[:0R"0#IW[&8 M) ZX!_8]SQD?F/44?\,G_%<]/^"A7[:?&?\ F&_L9]N./^,/.?;&<]J^9/@6 M/@K\&?V^[?\ 9_\ V4-=M5^&_B;X"_%;Q/\ 'WX+^%/$6HZ]X*^#GQ-^%?Q' M\ >#O!GBUO#]]?ZBGPS\7_$"W\3>-/#&NZ5 -)3QQ;^!]*UP:;>RZ%=ZK)^9 M_P"U3X.\;S^+?^"H_P %_MI >IT[]C(>W?]CT=^/KQ7P!X9_:V^.'CKXS_ !4^!?P4UGX%_!/5KKXH M_M,?$"'XG>.O 6M^(&\4^%?@O\-/V:]0L-%U;P4WCCPQ'=^//$UY\7DU3QWX MQBUG38?#7@SPPEM8^$I[TR7MO\P>%/\ @H3^U;N^-'Q]T2^;Q:_[0MS_ ,$R M? WP>^"K>%-)U;2/@-XA_:J^&B:IKGB'PS>^+/BG\/\ 0_&]BE\-5?0-$U_Q M#\,K#Q[XEU;PK_:7B/21*UM. ?L]_P ,H?%;_I(7^VEG&$M.\%^*_$'A#XMZ[XGT6V\&? M$)?AOJTWQ&5/@[HILM1EU#2FM+3QS?R>)VN;3Q"\]MH\@)_P";/>P(SZ=.M*/V4/BL2 /^"A?[:66Z?\2_]C+D M?^(>_7'K@XZ''Q)XD_;,_:N\.?$OXC>-IM8^$-]\#OAU_P %$/"W[&%O\*+/ MX=Z^WCSQ5X.\8^%OA]<_\)G'?$GC>9].TJT\%7VCZWI>FQ6 M]VUE>7AFA^3?VA?VR/VA?B#^RS;OXZ\9?#36/#W[6G[+^G_M/^ (/@UIVO>& M/$GP!M_!?[1G[.6D/X UKQ?%XKU>;Q]IFJ:/\6(-!U+QD=.\#W,/B_PMKFEI MHCV&K-!I0!^QO_#*'Q6//_#PO]M'@9_Y!_[&70_]V>_YZ4A_91^*PSG_ (*% M_MI<=?\ B7?L9_\ T'O^>E?(GC7]M_X\>'?BGXF\#_P!N;0OV M%[_X%:=X9U.]^+>NW6K>$](UFX^*5C\0AXF@B@\3C4M?LM4TOX81^ Y["[\! M6$VIR^)VO;U+BS\,TG]N;]NFXT#X:>/=.\2?LS>.K'XW_L3?$3]N7PU\,?#_ M ()\2P^*_!>D?#OQU\#;_5OA1!JT/CV]?QG9/\*?'_B[1M)\?W&B:!>ZK\4- M+M8#X>MK"-]-< _2W_AE+XJYV_\ #PO]M,GVT[]C,C\Q^QZ1Z#ZD#J:?_P , MG_%?./\ AX5^VEGCC^S_ -C(=03W_8]] ?RJ3]F+]H'4?VF_AI\6/C/I5QH5 MU\&]9\:^,M%_9\U?1;:=;CQ/\.O!NCVOAW4?&.I:D;ZYCOI-;^(-EXQ@TW[+ M;645MI6EV>PW&_A#X\^&6A>'_@I_P $E/"_ M[9.O:K\3/ ?B7XG^+OB%XST37/B!I[> KO5%^('A<:1X8\3:)X),6I>)R-7\ M1Z3J)@N[2VU2.:XMX@#]=3^RC\5@"?\ AX5^VF<9Z:;^QH2<=< ?L>_/_#'N..^>F#GY9>/OVE/C M[^TSKG[/WQ/C\I?!C]M;]N/X\>. M=7\3>'_AWH/@7X$^+/B'^TU\(],\3^-- ^#]EX6^"$_P_;U[=13E_9/^*[ ,O_ 4*_;2( M(R#_ &?^QER#T/\ R9[7E7_!-[]K7XC_ +:'PX\;_%GQU;^#_"EOI/B/1_ 6 MG?#31M+UNS\2Z'JF@>&=,N_$?C_7M2U^ZAN[KPE\8[O5HO'7P6MHM"LX&^$= M[X2UV;5M8OO$%[;:7^E,?W%/))Y.X8.23G(R<'.>.W3M0!\6?\,F_%C_ *2% M?MI?^"_]C+_Z#ZO,M7\+_&/X"_M#_LAZ1-^UM\?OC%X3^-/Q4^(_P\\;>"_B MUH_[.KZ'-I.B?LV?&OXIZ3J&EWOPQ^ ?PQ\3Z;K5AXK^'N@2)<+X@FL;C3VU M"QN]/G%TDL/Z1U\3_M,?\G(?\$Z/^SDOBW_ZQ+^U)0!]J1J5'/!.,@$D< #C M/KC/&!WQDFI*** "BBB@ HHHH **** "BBB@ HHHH *_BK_X/!/^<>'_ '=K M_P"^RU_:I7\5?_!X)_SCP_[NU_\ ?9: /Z?O^":W_*.?]@/_ +,I_97_ /5% M^!*^UJ_CP_8\_P"#GG]@CX(?LD?LL_!?Q7\)?VO]0\4_"#]G'X(?"_Q+?>'? M /P8NO#U]K_P^^&?AGPGK-WH5SJ7Q]TG4;G1[K4=)N9M,N+_ $O3+V:R>WDN MK"RG:2VC^C?^(LW_ ()T?]$7_;6_\-S\"_\ Z(^@#^H*BOY??^(LW_@G1_T1 M?]M;_P -S\"__HCZ/^(LW_@G1_T1?]M;_P -S\"__HCZ /Z@J*_E]_XBS?\ M@G1_T1?]M;_PW/P+_P#HCZ/^(LW_ ()T?]$7_;6_\-S\"_\ Z(^@#^H*BOY? M?^(LW_@G1_T1?]M;_P -S\"__HCZ/^(LW_@G1_T1?]M;_P -S\"__HCZ /Z@ MJ*_E]_XBS?\ @G1_T1?]M;_PW/P+_P#HCZ/^(LW_ ()T?]$7_;6_\-S\"_\ MZ(^@#^H*BOY??^(LW_@G1_T1?]M;_P -S\"__HCZ/^(LW_@G1_T1?]M;_P - MS\"__HCZ /Z@J*_E]_XBS?\ @G1_T1?]M;_PW/P+_P#HCZ/^(LW_ ()T?]$7 M_;6_\-S\"_\ Z(^@#^H*BOY??^(LW_@G1_T1?]M;_P -S\"__HCZ/^(LW_@G M1_T1?]M;_P -S\"__HCZ /Z@J*_E]_XBS?\ @G1_T1?]M;_PW/P+_P#HCZ/^ M(LW_ ()T?]$7_;6_\-S\"_\ Z(^@#^H*BOY??^(LW_@G1_T1?]M;_P -S\"_ M_HCZ/^(LW_@G1_T1?]M;_P -S\"__HCZ /U,^$?QC^$?PW_;,_X*%:;\0OBI M\-O >IZAX_\ V<[VUTWQGXZ\+>%M0NK$?LR_#^'[;:6.N:K87=Q9F>.2W2[C MA-N\\4\*R-);S(OUY_PU1^S#_P!'&_ ?_P ._P##S_YHZ_FD\6_\'+/_ 1[ M\?ZL=?\ '?[&O[0?C773;PVAUKQ=^SQ^R]XDU8VEN"+>U.I:S\>+V\-O "1# M"9O+C!(15R:YC_B(C_X(D?\ 1@_Q<_\ $6?V2?\ Y]M ']07_#5'[,/_ $<; M\!__ \'P\_^:.FG]J?]F$]?VC?@1US_ ,E@^'GM_P!3%ST'!R/7-?R__P#$ M1'_P1(_Z,'^+G_B+/[)/_P ^VC_B(C_X(D?]&#_%S_Q%G]DG_P"?;0!_3_\ M\-2_LPG/_&1WP)Y_ZK!\/,],=?\ A(LU _[3?[*\LL$\O[0WP"EFM7>2UFD^ M+?PYDEMGDB:"5[>1O$!>%I8':"4QE3)"S1/E&93_ ##_ /$1'_P1(_Z,'^+G M_B+/[)/_ ,^VC_B(C_X(D?\ 1@_Q<_\ $6?V2?\ Y]M"=M5H[6NNW;T\@6FU MU]_]?UYG]0 _:F_9A Q_PT=\"".^?B_\.^?_ "X<<]\8KS/XM?$']@SX\>"[ M_P"'7QE^*'[,7Q*\"ZE>Z5J5YX5\6_$WX:ZKH\NI:'?P:IHVH"VF\0_N[[2M M2M;>_P!/O(V2XL[N&.>WDCD4$?SE_P#$1'_P1(_Z,'^+G_B+/[)/_P ^VC_B M(C_X(D?]&#_%S_Q%G]DG_P"?;2LK6MI_7W@?NWHOAW_@G#X#\+:MH/P=^)/[ M+7PBUJY\)^/?"?AWQEX:\>'O M#E_JF@ZSI^H:!KDVAZ?#J^FW=O&8S\K?L\?LE_\ !.;X5Z/\6=.^*_QL_8Q^ M,8^+UA\,-$U[0=%TSX)_"7X<66C_ >O/$&L^![BP\#:1X\\42Q^,++Q'XL\ M0ZU<>+!XB5[&)?$LT MK//KESH6FW>IR7-S;)*.6\>>!O\ @E!\4-!\!^%_B';_ +$?C'PW\,/"ESX$ M\ :#KWB7X07^D>%O!%Y;VEK<^#=,T^76#:IX5DAL++_BGI8I=)66TMKA+1;B M".5?PE_XB(_^")'_ $8/\7/_ !%G]DG_ .?;1_Q$1_\ !$C_ *,'^+G_ (BS M^R3_ //MH _I.U;XQ_L3Z]<>"KO6_C#^S5JUU\.-637O -QJ'Q.^&EU/X/UJ M/1KWP]'JGAZ677V?2[]-"U+4-)6ZM6CF^P7ES;;_ "YG#6-;^-W[&'B37?!_ MB?Q!\9_V;M9\1_#[4M3UCP/KFI?%#X:7>I^$]5UK1+[PWJVH:!>2Z^TVF7>H M^']2U#1KR>U:.2?3;RYM)"T,TBM_-3_Q$1_\$2/^C!_BY_XBS^R3_P#/MH_X MB(_^")'_ $8/\7/_ !%G]DG_ .?;0!^\OC#PK_P2O^(&D>$- \:3_L8>(]$\ M!:WXH\1>#M*U/QA\*)K'P_JWCC6Y/$OC6?3X!KBHD'C#7YI-8\4Z?()-.\0: M@[7.K6EW();+P%INO^%+#Q?\([70-7 MT_X6Q:;!\-[&_P!+AUA+2XM/ T&CZ5!X6MWB,6BP:=916*0QVT*I_/Q_Q$1_ M\$2/^C!_BY_XBS^R3_\ /MH_XB(_^")'_1@_Q<_\19_9)_\ GVT ?T5:_P", MO^"?GBM?B%'XF\??LH>((OBS<>%+KXG1:QX]^%.H0^/KGP*M@G@R;Q;%=:U) M'KDGAB/2M-CT4WZS?8([&U2':L,87SGX9>%/^"5OP9\07GBSX52?L6^ _$U] MIVNZ+K[F;\&_^(B/_@B1_P!&#_%S_P 19_9)_P#GVT?\1$?_ 1(_P"C!_BY_P"( ML_LD_P#S[: /W+M/AG_P23L/ 'B+X6V5C^Q':?#_ ,5^(]*\7>(/#-OXJ^$T M-CJ'B7052/0-9,B:XMY;7F@0H;70GL[FW71K.6YL],2UM;JYAEZ+Q1X?_P"" M6_C3P-\.OAGXIN_V,=:\ ?".*-)U']C33-?\(:1\ M.M!\+ZGI_B_X2V<^@Z1\(KB2Z^%MCI:P:U'#:0_#R:60^#C'$'\/1NT&F/;P M$QUFV/A+_@E7IEG\5M/L#^Q3:V'QQ@FM/BU9Q>*?A%]F\=V4^I76M26.MPMK M+1O8?VW>7.MQV-LMO:PZU*=6AA34%6Y7\'/^(B/_ ((D?]&#_%S_ ,19_9)_ M^?;1_P 1$?\ P1(_Z,'^+G_B+/[)/_S[: /WN^'N@?\ !+CX47>F:C\-[W]C M/P;J>CZH^N:?JFA^,/A-:ZI#K)/V1OAOXD\6HT6O:QX4\?\ MPQTR\N[9[V;46L8&B\0%--TUKZ=[HZ9I:66GF58";8BVMQ%_/_\ \1$?_!$C M_HP?XN?^(L_LD_\ S[:/^(B/_@B1_P!&#_%S_P 19_9)_P#GVT ?T4:!XO\ M^"?/A:\T?4/#?CS]D_0[WP_IWQ!TC0[K3/'WPKLY]*TSXK^([?Q?\2[&PDAU MQ6MK;QUXIM+;Q!XIBC*KK.K01WM[YLZAZXCQ)HG_ 2Z\86'PMTGQ1>_L8Z[ MI7P2M;'3_A/IFH^+?A)<:=X$TO3)=/GL-'T&Q;6?LMOHEI/I6F7$.BR12Z6M MSI]G_\ !-WPK\2O%WQC\-^*?V1="^*7CVRN]/\ &'CK M2_'7PJL_$.O6FH1V<6J17E[#KBL#K":?8?VU+ L,VLM9VKZI)=M!&5\"^)WP M3_X)F?%OQ[\"M=\9_$G]E+5_AI^S[\*O'WPL\#?!*^\6_".Z\!6.G^-=3^'= M];ZEID)\11OH;^&K+X?IHEKI^GQ+8ZCI&N:A8ZBKVJK"_P"-W_$1'_P1(_Z, M'^+G_B+/[)/_ ,^VC_B(D_X(D=/^&"/BYC(/_)K7[)/49 /_ "6WJ,G'ID^I MH _H+\07/_!-GQ7\0? _Q6\1>)?V0=8^(OPUL[#3_ 7B^]\;?">75_"MCI/V M@Z+:Z3-_;8CA@T%KJYD\/1M%(N@RSRRZ/]BD=F.9XRT__@F/\0O NE_#/QGK M?['_ (@\ Z'XLUKQWHGA6]\=?"T:7HWC/Q)J&M:KXB\4:3'!K\,NG:WKVH>( M]?NM9U"SEAGU.36=3^VM,M]W3^)+.UA2RUB2 M7S+ZWF=(V7DM"^'?_!)GPQX(\=?#;0+;]B;2_ GQ,;36\=^%[;Q7\)?[*\2+ MHEP+S0(;R&36W>*U\.7JB]\-VEG);6OAV]S>:+#8W),I_"[_ (B(_P#@B1_T M8/\ %S_Q%G]DG_Y]M'_$1'_P1(_Z,'^+G_B+/[)/_P ^V@#^C#X2>._V!?@+ MX7E\$_!;XD?LM?"_PC<:UJ/B2Y\.^"OB+\,-!TJ[\1:QY/\ ;&OWEK9:]&MW MK6KO;PS:IJ=SYM[J-PGVF\FFN&:5O4O^&J/V8?\ HXWX#_\ AW_AY_\ -'7\ MOO\ Q$1_\$2/^C!_BY_XBS^R3_\ /MH_XB(_^")'_1@_Q<_\19_9)_\ GVT M?U _\-4?LPYS_P -&_ ?IC_DK_P\_P#FBIK?M2_LP-U_:-^!'MCXP?#SCC'_ M $,6/0\Y&0..*_F _P"(B/\ X(D?]&#_ !<_\19_9)_^?;1_Q$1_\$2/^C!_ MBY_XBS^R3_\ /MH _I__ .&I?V82,']H[X$Y[D?&'X> ]/;Q%T[X.?RXI%_: MD_9@0;5_:.^!"CL!\7_AV /H!XA _P ^M?S _P#$1'_P1(_Z,'^+G_B+/[)/ M_P ^VC_B(C_X(D?]&#_%S_Q%G]DG_P"?;0M%RK:][:[JVOX!_7_!MW\]S^G\ M?M2_LP#(_P"&CO@2023S\8/AX>N3U/B(GC/!))]\5R7C?XT_L6_$KPOJ_@CQ M_P#&;]FWQEX/U];5-;\,^(_BA\-=5T35$LKVUU*T2]T^Z\0/;SK;:A96=]"' M0[+JVAF'SHI'\UO_ !$1_P#!$C_HP?XN?^(L_LD__/MH_P"(B/\ X(D?]&#_ M !<_\19_9)_^?;1UO97VO;7I_D'W[WZ^A_0OX_UG_@G/\5=>O/%'Q)\6_LA^ M.?$FH^!9/AAJ&N^)_&GPDU?5[[X;R^*]'\=/X#O-0NM8>ZN?"3>,O#^B>)VT M">2333K6F6M^;?[0A<]AXE^+/[#WC+Q%X,\6^*_BS^S)XB\3_#J;Q!/X$UW6 M/B3\,+_4_"4GBS0Y?#7B@:%=W&NO+I\?B#0)I=(UB&$K#?V#?9[F.1%0+_-Q M_P 1$?\ P1(_Z,'^+G_B+/[)/_S[:/\ B(C_ .")'_1@_P 7/_$6?V2?_GVT M;)+HM@^_YMNWDNR\C]W/ '@K_@E/\++[Q9J7P[?]C#PA>>.-"UOPOXG?1?&7 MPKMH]2\,^)/._P"$@\.);?V^UMIV@ZTL\D>IZ/I<-EIUY!Y<$]L\,,,:9OP^ M^&?_ 26^%4'B.U^'L/[%_A>W\6^#]4^'WB""P\;_#%XK_P-KEB^F:UX1"7? MB.Y%GX>U?39#I^IZ38BUL[^R6.UNH98(8HT_#7_B(C_X(D?]&#_%S_Q%G]DG M_P"?;1_Q$1_\$2/^C!_BY_XBS^R3_P#/MH _HZU;XD?L'Z]I/P^T'6?B;^RW MJ.B_";7?#'B?X8Z5=?$3X6R6'@#Q#X+L9=,\):QX1MO[<$6@W_AS3IY[#2+C M3U@>RLIYK6(K!(\9^)+:&6"V\61W-OXBMWM?&-K'-)]E\7VGD>);9V\Z#58Y55Q^*7_$1 M'_P1(_Z,'^+G_B+/[)/_ ,^VC_B(C_X(D?\ 1@_Q<_\ $6?V2?\ Y]M '](' MBSXI?L.>/_A[>_"KQ]\7OV;O'?P]U/1K30=4\+^,_BK\.O$^G:IIM@D"6:ZD M-9\1WDU]=VSVUO=0:G,M<\(KXU^%K6.J>+M-6"/3?%%Y,)- T.#6(=.VO"=(TVZMH?M-E;21?C3_ ,1$?_!$ MC_HP?XN?^(L_LD__ #[:/^(B/_@B1_T8/\7/_$6?V2?_ )]M '[]7UK_ ,$S M-5^$%C\ -1U[]D"Z^#.D7D%_I7PZ?QW\+1XQ\.?# MN"X\9?"F&#PKXL[BUCG@T.[6YTM)7N7%INO+LS_ M (.?\1$?_!$C_HP?XN?^(L_LD_\ S[:/^(B/_@B1_P!&#_%S_P 19_9)_P#G MVT ?T%K<_P#!-F.7P!-#XE_9 MW^%6O^-_%'PW^R^-OA/:IX)UWXE37UQ\0; M_P .Q6VMQ1Z^AF8(53X,W'_ 3;_9W/B%O@9XK_ M &2?A4_BN6W?Q#+X+\??"[1YM4CLC,;"QFG@U[SH]*TXW%P=-T>W>'2M.-Q. M;&SMS-(6_GU_XB(_^")'_1@_Q<_\19_9)_\ GVT?\1$?_!$C_HP?XN?^(L_L MD_\ S[: /Z5KWXW?L8:CXOT#X@:A\9_V;KSQSX6T;7_#OASQ;<_%#X:2^(-$ MT'Q5>)='TS4VU\W5GIVNW/A[0I]5M()$AO9=(T]YU=K6$KYYX;U3_@G) MX.^*WB?XY^%?%_[)/A_XO^-(+BV\4_$32?'OPLLO$^M1WHL1J+W6H0:ZC+<: ML=,TY]9NK=8;G6'L;5]3ENVA0C^>S_B(C_X(D?\ 1@_Q<_\ $6?V2?\ Y]M' M_$1'_P $2/\ HP?XN?\ B+/[)/\ \^V@#]N-3^#/_!'S6K+0=,UCP_\ L+:I MI?AFW\3V6AZ5?^(OA#=:78Z=XRU6ZUWQ+I(TV;6GL9]%U36KZ]U:31;J"?2H M-1N[J\M+.WGGE=OH_P #_%G]A_X9V.L:9\/?BW^S-X,L/$&M/XDURT\.?$SX M9Z7#J_B"32]+T236M12UU]/MFIR:/HFCZ;)>7'F3/9:996[.8[=%'\W'_$1' M_P $2/\ HP?XN?\ B+/[)/\ \^VC_B(C_P"")'_1@_Q<_P#$6?V2?_GVT ?T M-ZKK_P#P3KUSX4V7P,UCQE^R1J?P=TV72+C3/AK>>.OA3/X.TVYT#78/%&AW M6G:(^MFSL;O1_$EK;Z[I=W:QQ7-AJT,=]:RQ7"*XYE-*_P""7\?Q,\7?&1=1 M_8T/Q0\>Z=K>D^,?&LGB_P"$LNM>(++Q-I<&A^)EU"676GB>X\2Z+;QZ3XBO MDACO]J7-U;SSI)^!7_ !$1_P#!$C_HP?XN?^(L_LD__/MH_P"(B/\ MX(D?]&#_ !<_\19_9)_^?;0!^X]U\+O^"1]\?!1OK#]B2^7X=>'M&\)^"8[W MQ7\)[N'P]X:\.:K+KGAO1;."XUV2%['PWK,\VJ>'(KI+C^P+Z1KG2#9R$,/9 MM,\;?\$_]%_X1 Z1\0?V4]-/@#Q9XM\=^"#9?$#X66Y\)^-/'O\ PD/_ FO MBG0#'KB_V7KOBK_A+?$W]O:E:^7?QOX8_X):?$CPQH MG@SQO?\ ['7B#PQX;U[Q5XG\/Z1<^.OAA!!HVO>.=5OM=\::CILMEXAMKFTE M\6:WJ5[K'B..&=(-9U2?^T-0BN+N.*9/H?1/VC?V2?#6CZ7X>\._'C]G?0]! MT2PM=*T;1M)^*?PTT_2]*TRQA2VLM/T^QM-?BMK.SM+>..&WMX(TBBB1410H M K^9'_B(C_X(D?\ 1@_Q<_\ $6?V2?\ Y]M'_$1'_P $2/\ HP?XN?\ B+/[ M)/\ \^V@#^H+_AJC]F'_ *.-^ __ (=_X>?_ #1T?\-4?LP_]'&_ ?\ \._\ M//\ YHZ_E]_XB(_^")'_ $8/\7/_ !%G]DG_ .?;1_Q$1_\ !$C_ *,'^+G_ M (BS^R3_ //MH _J /[4W[,!()_:-^!&0"/^2P?#SH>HQ_PD7?\ H*B?]J#] MER1'CD_:*^ LD67QH_9HL[N!B\%U:_$;X507$+D;2\4T6LI)$VTE M?_-%C@\]/3.:_F _XB(_^")'_ M $8/\7/_ !%G]DG_ .?;1_Q$1_\ !$C_ *,'^+G_ (BS^R3_ //MJ*=&E17+ M1I4Z,;\W+2A&FK]VH**;#OIOOIZ?Y+[C^E/_ (75^Q;_ ,)O-\2O^%S?LVGX M@7'A.+P)/XQ/Q/\ AF?$,W@N'5KC7H?"TFIG7_M+Z%'K5WYT7PI?>!='E\%^,_A)X>;2?!>I^ M,=6^(6H^%=,&F:Q;K8:!?>.==UCQ9=Z5:"*SN->U&YU*2)KE]X_GG_XB(_\ M@B1_T8/\7/\ Q%G]DG_Y]M'_ !$1_P#!$C_HP?XN?^(L_LD__/MK3_A@/WQ\ M9Z-_P2^^(?A_6O"OC34_V.?$/A_Q%\1=6^+NL:=?>-OA6$N_BCK\,=OKWQ 6 M>#78;NV\6ZY;Q);:SK=I<07VJVYD@OY;B*:99,'Q1\/_ /@E#XT\%> ?AUXG M?]C75O!7PLDUB?X=Z!+XZ^&4-KX.N/$4<$7B&YT.:T\1P7EI=:^MK;_VW="Y M:XU9X(Y-0DN)$#5^%G_$1'_P1(_Z,'^+G_B+/[)/_P ^VC_B(C_X(D?]&#_% MS_Q%G]DG_P"?;0!_0UX+US_@G3\.G\ 2^!?&'[)'A6;X6:3XHT/X=7&B^.OA M3977@W3/'#Z7)XT@T&YCUL7%E+XMDT72I/$MXDGVW7)+&"34KBY=2QL:OXG_ M .">6OQ?%2#7/&W[)6KP?'!M(D^,$.I>.?A1>0_$J?0-(M-!T*[\8Q3ZT\>M MWVC:/86&GZ7?7BR7EA;V-D+6:)K2W:/^=W_B(C_X(D?]&#_%S_Q%G]DG_P"? M;1_Q$1_\$2/^C!_BY_XBS^R3_P#/MH _-+FS\6)_PF%MI_P#9]D=% M'B5=4DT(P?\ $FDL!-<"6[XD\"?\$I/&'Q0O/C3XIE_8VU[XIZEK6C^(]4\: M:GX[^&=SJVKZ]X?@L;;1=6UC?XC^R:O?Z;;Z;IT%K<:E;73QPV-I%DI;Q*OX M4?\ $1'_ ,$2/^C!_BY_XBS^R3_\^VC_ (B(_P#@B1_T8/\ %S_Q%G]DG_Y] MM '[\>/M/_X)B_%+2-4T'XAZQ^QWXOTC6_'U[\4]7LM:\:_"JY34?B+J>CVG MA[5?&-V_]N)++KNK:#866BZM>-)NU/2K:'3[X7%H@BJSXHB_X)F^-;WQ9J/B MS6_V.M?N_'7P\T?X3>,)-1\8_"69/$?PV\.7ZZIX:\':I!_;*V]SHOAG44CO M/#<#1;] N(HI=(DLWC0C^?[_ (B(_P#@B1_T8/\ %S_Q%G]DG_Y]M'_$1'_P M1(_Z,'^+G_B+/[)/_P ^V@#][CH7_!+P_!X? ZE^QS_ ,*:76?^$C'P^_X3 M?X6C0AXE^WC4_P#A)MHU_P"U_P#"2F] F;Q#]J_MEO\ 5->F']W6U82?\$U- M*\+^(/!&F:]^QUIW@_Q9I/@C0O$_ABR\8?".UT/7]'^&R01^ -.U?3(=82UO MK7P>MM!_8$=Q&_\ 9S1*\!5\L?Y]_P#B(C_X(D?]&#_%S_Q%G]DG_P"?;1_Q M$1_\$2/^C!_BY_XBS^R3_P#/MH _HMF\;_\ !/\ G:]:;X@_LIR-J/Q1TOXV MWY?X@?"PF\^+^B#2AH_Q*N#_ &YF7QII@T/1Q9>('SJ-N--L_+G'D1X\]TSP M[_P2UT9_B5)I=W^QC9GXPW5I>_$](O%WPE\KQK/8^(#XLM1K4#:TT,MO%XH) M\1BRACALGUS&JR6[WP$X_!3_ (B(_P#@B1_T8/\ %S_Q%G]DG_Y]M'_$1'_P M1(_Z,'^+G_B+/[)/_P ^V@#^@^_U'_@G/J/Q=C^/\WC3]DS_ (7C;Z;_ &99 M?%3_ (3WX4OXQM(UL+G3+>YAU.769@=1M=.O+C3[;4Y8)K^'3II-/2?["[6S M?!GPA_9J_9G^#WCWXE_&+P[^W9^R=!\9O%'PX\<_#/P7X_\ #W@3]G?P9#H5 MG\2/%^D>+O&?BWXC>%_#?C^TT7XI>-M7O/#>@1.]BOP[\$V\]KJ=_;>!HY]9 MNE7\X_\ B(C_ .")'_1@_P 7/_$6?V2?_GVTG_$1%_P1'_Z,'^+?7/\ R:S^ MR3U]?^2V]>!SUXH _HG^"7CW]B;X _!OX>? KX>_'?X":;X ^&?@[2O!'A[3 M6^+WPX);2=,LUMFEO!'X@CBDO-1E,]]J$B1HL]W=3R8^XTFT\;_">"PF^#"2ZI,OPOEM8]:$+^!Q+K>KR#P\ MRG3@^I7K"'-Q)G^>G_B(D_X(D?\ 1A'Q<]/^36OV2>GI_P EM]Z/^(B/_@B1 M_P!&#_%S_P 19_9)_P#GVT ?O+=^%?\ @E??_$GP_P#&&\F_8MN/BAX4E\*7 M/AOQS)XK^$9\0Z)?>!+9+'P7JNG7HUD&WUOPMIT46EZ%KBK_ &QIVDQII=O> MI8*+>F:OX1_X)5Z]XV\=_$?6I/V+=4\<_$W1==\/>/\ Q+>^+?A-/J/BO2?% M.FV^C>*+?5F?6S%-+XFT>UATKQ%>K$E]KFF^;8ZI$_$FN^,/"_Q6_9A\/>*?$^A^%O#7B+7M&^(_P +].U+6] \$6]W9^#](U.X MM==C:\LO#-G?WEEHD,X<:;9SO:VOEP!8U[P?M3_LP@ #]HWX$<<<_&#X>D_B M3XCR:_E^_P"(B/\ X(D?]&#_ !<_\19_9)_^?;1_Q$1_\$2/^C!_BY_XBS^R M3_\ /MH _J"_X:H_9A_Z.-^ _P#X=_X>?_-'7RM\9_C1\'?B)^T]_P $\=)^ M'WQ9^&7CK5[3]HCXN7UQI'@[Q]X3\3ZM#9+^Q3^U#%)?2:9H>K7]\EC%++%% M->&W^S0S3V\,LJ27,"R?A-_Q$1_\$2/^C!_BY_XBS^R3_P#/MKI?"?\ P/ >LQ>(O W[&7[0/@SQ!!#/;P:[X3_9V_9=\.ZS#;W49ANH(M3T?X[V=[ M'#14E?R^_\19G M_!.<=/@M^VL/^Z<_ OM_W<=1_P 19O\ P3H_Z(O^VM_X;GX%_P#T1] ']05% M?R^_\19O_!.C_HB_[:W_ (;GX%__ $1]'_$6;_P3H_Z(O^VM_P"&Y^!?_P!$ M?0!_4%17\OO_ !%F_P#!.C_HB_[:W_AN?@7_ /1'T?\ $6;_ ,$Z/^B+_MK? M^&Y^!?\ ]$?0!_4%17\OO_$6;_P3H_Z(O^VM_P"&Y^!?_P!$?1_Q%F_\$Z/^ MB+_MK?\ AN?@7_\ 1'T ?U!45_+[_P 19O\ P3H_Z(O^VM_X;GX%_P#T1]'_ M !%F_P#!.C_HB_[:W_AN?@7_ /1'T ?U!45_+[_Q%F_\$Z/^B+_MK?\ AN?@ M7_\ 1'T?\19O_!.C_HB_[:W_ (;GX%__ $1] ']05?Q5_P#!X)_SCP_[NU_] M]EK[2_XBS?\ @G1_T1?]M;_PW/P+_P#HCZ_G+_X. ?\ @L7^S+_P4@7]DEO@ M=X&^.WA4?!P_'K_A)_\ A:WACX?Z&;[_ (6%_P *8_L7^P?^$0^)WCG[5]E_ 8X0;5O[4_M#^R_)^T:=]D^V^=<_9 #__9 end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.6.0.2
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2016
Feb. 09, 2017
Jun. 30, 2016
Document and Entity Information [Abstract]      
Entity Registrant Name LIGAND PHARMACEUTICALS INC    
Entity Central Index Key 0000886163    
Document Type 10-K    
Document Period End Date Dec. 31, 2016    
Amendment Flag false    
Document Fiscal Year Focus 2016    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Common Stock, Shares Outstanding   20,919,894  
Entity Public Float     $ 2.3
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 18,752 $ 97,428
Short-term investments 122,296 102,791
Accounts receivable, net 14,700 6,170
Note receivable from Viking 3,207 4,782
Inventory 1,923 1,633
Other current assets 2,175 1,908
Total current assets 163,053 214,712
Deferred income taxes 123,891 189,083
Investment in Viking 8,345 29,728
Intangible assets, net 204,705 48,347
Goodwill 72,207 12,238
Commercial license rights 25,821 8,554
Property and equipment, net 1,819 372
Other assets 1,744 27
Total assets 601,585 503,061
Current liabilities:    
Accounts payable 2,734 4,083
Accrued liabilities 6,397 5,405
Current contingent liabilities 5,088 10,414
Current lease exit obligations   934
2019 convertible senior notes, net 212,910 201,985
Total current liabilities 227,129 222,821
Long-term contingent liabilities 2,916 3,033
Other long-term liabilities 687 297
Total liabilities 230,732 226,151
Commitments and contingencies
Equity component of currently redeemable convertible notes (Note 5) 29,563 39,628
Stockholders’ equity:    
Common stock, $0.001 par value; 33,333,333 shares authorized; 20,909,301 and 19,949,012 shares issued and outstanding at December 31, 2016 and 2015, respectively 21 20
Additional paid-in capital 769,653 661,850
Accumulated other comprehensive income 2,743 4,903
Accumulated deficit (431,127) (429,491)
Total stockholders’ equity 341,290 237,282
Total liabilities and stockholders’ equity $ 601,585 $ 503,061
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Common stock, par value (in USD per share) $ 0.001 $ 0.001
Common stock, shares authorized (shares) 33,333,333 33,333,333
Common stock, shares issued (shares) 20,909,301 19,949,012
Common stock, shares outstanding (shares) 20,909,301 19,949,012
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenues:      
Royalties $ 59,423 $ 38,194 $ 29,994
Material sales 22,502 27,662 28,488
License fees, milestones and other revenues 27,048 6,058 6,056
Total revenues 108,973 71,914 64,538
Operating costs and expenses:      
Cost of sales [1] 5,571 5,807 9,136
Amortization of intangibles 10,643 2,375 2,375
Research and development 21,221 11,005 9,747
General and administrative 26,621 24,378 22,570
Lease exit and termination costs 1,032 1,020 1,084
Total operating costs and expenses 65,088 44,585 44,912
Income from operations 43,885 27,329 19,626
Other (expense) income:      
Interest expense, net (12,178) (11,802) (4,860)
Increase in contingent liabilities (3,334) (5,013) (5,135)
Gain on deconsolidation of Viking 0 28,190 0
Loss from Viking (23,132) (5,143) 0
Other income, net 2,719 1,768 1,671
Total other income (expense), net (35,925) 8,000 (8,324)
Income before income tax benefit (expense) 7,960 35,329 11,302
Income tax benefit (expense) (10,327) 192,115 (410)
Income (loss) from operations (2,367) 227,444 10,892
Discontinued operations:      
Gain on sale of Oncology Product Line before income taxes 1,139 0 0
Income tax expense on discontinued operations (408) 0 0
Income from discontinued operations 731 0 0
Net (loss) income including noncontrolling interests: (1,636) 227,444 10,892
Less: Net loss attributable to noncontrolling interests 0 (2,380) (1,132)
Net (loss) income $ (1,636) $ 229,824 $ 12,024
Basic per share amounts(1):      
Income (loss) from continuing operations (in usd per share) [2] $ (0.11) $ 11.61 $ 0.59
Income from discontinued operations (in usd per share) [2] 0.04 0.00 0.00
Net income (in usd per share) [2] $ (0.08) $ 11.61 $ 0.59
Weighted average shares outstanding (shares): 20,831 19,790 20,419
Diluted per share amounts(1):      
Income (loss) from continuing operations (in usd per share) [2] $ (0.11) $ 10.83 $ 0.56
Income from discontinued operations (in usd per share) [2] 0.04 0.00 0.00
Net (loss) income (in usd per share) [2] $ (0.08) $ 10.83 $ 0.56
Weighted average number of common shares-diluted (shares) 20,831 21,228 21,433
[1] Excludes amortization of intangibles
[2] The sum of net income per share amounts may not equal the total due to rounding
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Statement of Comprehensive Income [Abstract]      
Net (loss) income $ (1,636) $ 229,824 $ 12,024
Unrealized net gain on available-for-sale securities, net of tax 93 1,933 3,872
Less:Reclassification of net realized gains included in net income, net of tax (2,253) (1,965) (1,833)
Comprehensive (loss) income $ (3,796) $ 229,792 $ 14,063
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Noncontrolling interest
Balance at beginning of period at Dec. 31, 2013 $ 49,613 $ 21 $ 718,017 $ 2,914 $ (671,339)  
Balance at beginning of period (in shares) at Dec. 31, 2013   20,468,521        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Consolidation of Viking (778)         $ (778)
Issuance of common stock under employee stock compensation plans, net 4,561   4,561      
Issuance of common stock under employee stock compensation plans (in shares)   360,054        
Shares issued in OMT acquisition 0          
Stock-based compensation 11,270   11,270      
Repurchase of common stock $ (67,955) $ (1) (67,954)      
Repurchase of common stock (in shares) (1,253,425) (1,253,425)        
Sale of warrants $ 11,638   11,638      
Purchase of convertible bond hedge (48,143)   (48,143)      
Equity component of convertible debt issuance, net of issuance costs 51,271   51,271      
Other comprehensive income 2,039     2,039    
Net income 12,024       12,024  
Net loss in noncontrolling interests (1,132)         (1,132)
Balance at end of period at Dec. 31, 2014 24,408 $ 20 680,660 4,953 (659,315) (1,910)
Balance at end of period (in shares) at Dec. 31, 2014   19,575,150        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under employee stock compensation plans, net 8,849   8,849      
Issuance of common stock under employee stock compensation plans (in shares)   379,982        
Shares issued in OMT acquisition 0          
Stock-based compensation 12,458   12,458      
Repurchase of common stock $ (489)   (489)      
Repurchase of common stock (in shares) (6,120) (6,120)        
Equity component of convertible debt issuance, net of issuance costs $ (39,628)   (39,628)      
Other comprehensive income (50)     (50)    
Net income 229,824       229,824  
Net loss in noncontrolling interests (2,380)         (2,380)
Deconsolidation of Viking 4,290         $ 4,290
Balance at end of period at Dec. 31, 2015 237,282 $ 20 661,850 4,903 (429,491)  
Balance at end of period (in shares) at Dec. 31, 2015   19,949,012        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under employee stock compensation plans, net 5,416   5,416      
Issuance of common stock under employee stock compensation plans (in shares)   210,626        
Shares issued in OMT acquisition 77,331 $ 1 77,330      
Shares issued in OMT acquisition (shares)   790,163        
Stock-based compensation 18,893   18,893      
Repurchase of common stock $ (3,901)   (3,901)      
Repurchase of common stock (in shares) (40,500) (40,500)        
Equity component of convertible debt issuance, net of issuance costs $ 10,065   10,065      
Other comprehensive income (2,160)     (2,160)    
Net income (1,636)       (1,636)  
Net loss in noncontrolling interests 0          
Balance at end of period at Dec. 31, 2016 $ 341,290 $ 21 $ 769,653 $ 2,743 $ (431,127)  
Balance at end of period (in shares) at Dec. 31, 2016   20,909,301        
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities      
Net (loss) income $ (1,636) $ 227,444 $ 10,892
Less: gain from discontinued operations 731 0 0
Income (loss) from continuing operations (2,367) 227,444 10,892
Adjustments to reconcile net income to net cash used in operating activities:      
Change in estimated fair value of contingent liabilities 3,334 5,013 5,135
Realized gain on sale of short-term investment (2,352) (2,603) (1,538)
Gain on disposal of assets 183 0 0
Depreciation and amortization 11,290 2,627 2,657
Gain on deconsolidation of Viking 0 (28,190) 0
Loss on equity investment in Viking 23,132 5,143 0
Change in fair value of the convertible debt receivable from Viking and warrants (462) 765 0
Amortization of Premium (discount) on investments, net 348 0 0
Amortization of debt discount and issuance fees 10,925 10,274 3,694
Non-cash milestone revenue 0 0 (1,211)
Stock-based compensation 18,893 12,458 11,270
Deferred income taxes 10,697 (192,132) 410
Other 0 107 206
Changes in operating assets and liabilities, net of acquisition:      
Accounts receivable, net (8,525) 6,489 (10,412)
Inventory (244) (401) 4,369
Restricted cash 0 1,261 0
Other current assets 558 51 (426)
Other long term assets (32) (325) (1,439)
Accounts payable and accrued liabilities (2,369) (4,027) (3,121)
Deferred revenue (8) (2,227) 80
Net cash provided by operating activities of continuing operations 63,001 41,727 20,566
Net cash used in operating activities of discontinued operations 0 0 0
Net cash provided by operating activities 63,001 41,727 20,566
Investing activities      
Purchase of commercial license rights (17,695) (4,030) (1,000)
Reduction of cash due to deconsolidation of Viking 0 (247) 0
Purchase of commercial license rights (92,502) 0 0
Payments to CVR holders and other contingency payments (8,777) (6,740) (3,493)
Purchases of property and equipment (1,850) (93) (6)
Purchases of short-term investments (164,438) (166,025) 0
Proceeds from sale of short-term investments 24,596 16,039 2,342
Proceeds from maturity of short-term investments 118,874 57,234 0
Proceeds received from repayment of Viking note receivable 300 0 0
Other, net 0 0 130
Net cash used in investing activities (143,192) (112,862) (2,027)
Financing activities      
Repayment of debt 0 0 (9,366)
Gross proceeds from issuance of 2019 Convertible Senior Notes 0 0 245,000
Payment of debt issuance costs 0 0 (5,711)
Proceeds from issuance of warrants 0 0 11,638
Purchase of convertible bond hedge 0 0 (48,143)
Net proceeds from stock option exercises and ESPP 6,415 8,849 4,561
Taxes paid related to net share settlement of equity awards (999) 0 0
Share repurchases (3,901) (489) (67,954)
Net cash provided by financing activities 1,515 8,360 130,025
Net (decrease) increase in cash and cash equivalents (78,676) (62,775) 148,564
Cash and cash equivalents at beginning of year 97,428 160,203 11,639
Cash and cash equivalents at end of year 18,752 97,428 160,203
Supplemental disclosure of cash flow information      
Interest paid 1,838 1,822 494
Taxes paid 38 28 18
Supplemental schedule of non-cash investing and financing activities      
Stock issued for acquisition, net of issuance cost (77,331) 0 0
Stock and warrant received for repayment of Viking notes receivable 1,200 0 0
Accrued inventory purchases 646 1,333 3,246
Unrealized gain on AFS investments (1,109) 3,005 3,872
Viking Therapeutics, Inc.      
Investing activities      
Purchase of Viking common stock and warrant (700) (9,000) 0
Purchase of Common Stock [Member]      
Investing activities      
Purchase of Viking common stock and warrant $ (1,000) $ 0 $ 0
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
Basis of Presentation and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies

Business

Ligand is a biopharmaceutical company with a business model based on developing or acquiring assets which generate royalty, milestone or other passive revenue for the Company and using a lean corporate cost structure. We operate in one business segment: development and licensing of biopharmaceutical assets.

Principles of Consolidation

The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Basis of Presentation
 
The Company’s accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of the Company and its wholly-owned subsidiaires. All intercompany transactions and balances have been eliminated in consolidation.

Upon the occurrence of certain circumstances, holders of the 2019 Convertible Senior Notes may redeem all or a portion of their notes, which may require the use of a substantial amount of cash. At December 31, 2016, we had a working capital deficit of $64.1 million, which includes the 2019 Convertible Senior notes that are currently redeemable as of December 31, 2016 but excludes another $29.6 million that is classified as mezzanine equity.  As noted in Note 6, the debt may change from current to non-current period over period, primarily as a result of changes in the Company’s stock price. Management believes that it is remote that holders of the notes would choose to convert their notes early because the fair value of the security that a noteholder can currently realize in an active market is greater than the conversion value the noteholder would realize upon early conversion. In the unlikely event that all the debt was converted, we have 3 business days following a 50 trading day observation period from the convert date to pay the principal in cash. We have positive operating income and positive cash flow from operations for the three years ended December 31, 2016 and, accordingly, while there can be no assurance, we believe we have the ability to raise additional capital through our active S-3, by liquidating assets, or via alternative financing arrangements such as convertible or high yield debt.

Reclassifications

Certain reclassifications have been made to the previously issued statement of operations for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity and operating cash flows as previously reported.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates

Recent Accounting Pronouncements
 
 In May 2014, the FASB issued new guidance related to revenue recognition, Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASC 606”), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. ASC 606 defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The new guidance becomes effective in calendar year 2018 and early adoption in calendar year 2017 is permitted. Two methods of adoption are permitted: (a) full retrospective adoption, meaning the standard is applied to all periods presented; or (b) modified retrospective adoption, meaning the cumulative effect of applying the new guidance is recognized at the date of initial application as an adjustment to the opening retained earnings balance.

We are undertaking a substantial effort to be ready for adoption of ASC 606. Some of our contracts have distinct terms which will need to be evaluated separately.  We have started our preliminary assessment of these contracts and although we have not completed our assessment and are in the process of reviewing our contracts, we anticipate this standard will have a material impact on our consolidated financial statements by accelerating the timing of revenue recognition for revenues related to royalties, and potentially certain contingent milestone based payments. We intend to adopt ASC 606 starting as of January 1, 2018 using the modified retrospective method. 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements -Going Concern (Subtopic 205-40). This accounting standard requires management to perform interim and annual assessments of the entity's ability to continue its business operations within one year of the date of issuance of its financial statements. The Company must then provide certain disclosure if there is substantial doubt about its ability to continue as a going concern. As of December 31, 2016, the Company has adopted this standard with no impact to the financial statements.

In March 2016, the FASB issued ASU 2016-09 amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. The guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. In addition, the guidance provides for an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur. The updated guidance is effective in fiscal year 2018 and early adoption in fiscal year 2017 is permitted. We are currently evaluating the adoption timing as well as the impact of the new guidance on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments which requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The new standard will be effective for us in fiscal year 2020 and early adoption in fiscal 2019 is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.

In August 2016 the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. The guidance addresses the classification of cash flows related to (1) debt prepayment or extinguishment costs, (2) settlement of zero-coupon debt instruments or other debt instruments with coupon rates that are insignificant in relation to the effective interest rate of the borrowing, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance, including bank-owned life insurance, (6) distributions received from equity method investees and (7) beneficial interests in securitization transactions. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The new guidance will be effective for fiscal year 2018 and early adoption is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. We expect contingent consideration payment presentation will change to conform to the standard.

We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.

Concentrations of Business Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and investments. The Company invests its excess cash principally in United States government debt securities, investment grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.
A relatively small number of partners accounts for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
 
December 31,
 
2016
 
2015
 
2014
Partner A
41
%
 
27
%
 
37
%
Partner B
14
%
 
23
%
 
31
%
Partner C
—

 
18
%
 
10
%


The Company obtains Captisol from a single supplier, Hovione. If this supplier were not able to supply the requested amounts of Captisol, the Company would be unable to continue to derive revenues from the sale of Captisol until it obtained an alternative source, which could take a considerable length of time.

Cash Equivalents & Short Term Investments

Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt securities that have effective maturities greater than three months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss). The Company determines the cost of investments based on the specific identification method.
Accounts Receivable

Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company considers receivables past due based on the contractual payment terms which range from 30 to 90 days. The Company reserves specific receivables if collectibility is no longer reasonably assured. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.
Inventory
Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. The Company analyzes its inventory levels periodically and writes down inventory to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. There were no write downs related to obsolete inventory recorded for the years ended December 31, 2016 and 2015.
Property and Equipment
Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.
Goodwill and Intangible Assets

Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The change in the carrying value of goodwill during the year ended December 31, 2016, was due to the acquisition of OMT. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2016 by assessing qualitative factors, noting no impairment.

Intangible assets related to acquired IPR&D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered to be indefinite-lived, they are not amortized but are tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company performed its annual assessment for IPR&D impairment in 2016, noting no impairment.

Commercial license rights

Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015 and Cormatrix in May 2016. Individual commercial license rights acquired are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made. As of December 31, 2016, management does not believe there have been any events or circumstances indicating that the carrying amount of its commercial license rights may not be recoverable.

Royalty income earned from Cormatrix were $1.5 million for the year ended December 31, 2016. Accounts receivable due from Cormatrix were $0.2 million at December 31, 2016.

Relationships between the CorMatrix Parties
    
As previously disclosed in Ligand’s filings, Jason Aryeh is a director of both Ligand and CorMatrix. Mr. Aryeh beneficially owns equity of CorMatrix representing less than 1% of CorMatrix’s outstanding equity. Mr. Aryeh recused himself from all of the board’s consideration of the purchase agreement between the Company and CorMatrix, including any financial analysis, the terms of the purchase agreement and the vote to approve the Purchase Agreement and the related transactions.
Contingent Liabilities

In connection with the Company’s acquisition of CyDex in January 2011, the Company recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. See footnote 7, Other Balance Sheet Details. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the Company’s acquisition of Metabasis in January 2010, the Company issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement.

Any change in fair value is recorded in the Company's consolidated statement of operations.
Revenue Recognition

We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been provided, title has transferred or access has been given, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured.

Royalties on sales of products commercialized by the Company’s partners are recognized in the quarter reported by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between 30 and 60 days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received.
Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a 20% restocking fee. To date, product returns have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period.

The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price.
Many of the Company's revenue arrangements for Captisol involve a license agreement and the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company, and in a hypothetical stand-alone transaction, the customer would be able to procure inventory from another manufacturer in the absence of contractual provisions for exclusive supply by the Company.
Other nonrefundable, up-front license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. Management evaluates the determination of gross versus net reporting based on each individual agreement.
Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company’s performance obligations under the arrangement.

Preclinical Study and Clinical Trial Accruals

Substantial portions of the Company’s preclinical studies and all of the Company’s clinical trials have been performed by third-party laboratories, CROs.  The Company accounts for a significant portion of its clinical study costs according to the terms of its contracts with CROs. The terms of its CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. The Company's objective is to reflect the appropriate preclinical and clinical trial expenses in its financial statements in the same period as the services occur. As part of the process of preparing its financial statements, the Company relies on cost information provided by its CROs. The Company is also required to estimate certain of its expenses resulting from its obligations under its CRO contracts. Accordingly, the Company's preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates. No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.

Research and Development Expenses

Research and development expense consists of labor, material, equipment, and allocated facilities costs of the Company’s scientific staff who are working pursuant to the Company’s collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for the Company’s research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided

Stock-Based Compensation

The Company incurs share-based compensation expense related to restricted stock, its ESPP, and stock options

Restricted stock units (RSU) and performance stock units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Company’s common stock on the date of grant. The Company recognizes share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration estimated forfeitures. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.

The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The Company looks to historical volatility of the Company's stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that the Company has never declared or paid regular cash dividends on its common stock and does not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards

The Company grants options and restricted stock awards to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and restricted stock awards granted to certain non-employee directors vest in equal monthly installments over one year from the date of grant. Options granted to employees vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. Restricted stock awards granted to employees vest over three years. All option awards generally expire ten years from the date of grant.

Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.
 
Income Taxes

The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when the Company believes it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise the Company considers all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.

The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.

Discontinued Operations

In 2006, we entered into a purchase agreement with Eisai pursuant to which Eisai agreed to acquire our Oncology product line which included four marketed oncology drugs: ONTAK, Targretin capsules, Targretin gel and Panretin gel. Certain liabilities were recorded associated with the disposal of the product line. During the year ended December 31, 2016 we recognized a $1.1 million gain due to subsequent changes in certain estimates and liabilities previously recorded. We recorded a provision for income taxes related to the gain of $0.4 million.
Income Per Share
    
Basic income (loss) per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period

Potentially dilutive common shares consist of shares issuable under 2019 convertible senior notes, stock options and restricted stock. 2019 convertible senior notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options; the average amount of unrecognized compensation expense for restricted stock; and estimated tax benefits that will be recorded in additional paid-in capital when expenses related to equity awards become deductible. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded

The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Weighted average shares outstanding:
20,831

 
19,790

 
20,419

Dilutive potential common shares:
 
 
 
 
 
   Restricted stock
—

 
56

 
36

   Stock options
—

 
882

 
978

   2019 Convertible Senior Notes
—

 
499

 
—

Shares used to compute diluted income per share
20,831

 
21,228

 
21,433

Potentially dilutive shares excluded from calculation due to anti-dilutive effect
3,544

 
3,333

 
5,104



Comprehensive Income (Loss)

Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities less reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.6.0.2
Investment in Viking
 12 Months Ended
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Investment in Viking
Investment in Viking

In 2014, the Company entered into a MLA with Viking to license the rights to five of the Company's programs to Viking. Under the terms of the MLA, no consideration was exchanged upon execution, but rather Viking agreed to issue shares of Viking common stock with an aggregate value of approximately $29.2 million upon consummation of Viking's IPO. As part of this transaction, the Company also extended a $2.5 million convertible loan to Viking under a LSA. As a result of these transactions, the Company determined it held a variable interest in Viking. The Company considered certain criteria in the accounting guidance for VIEs, and determined that Viking was a VIE and Ligand was the primary beneficiary of Viking. As a result, the Company consolidated Viking on its financial statements from May 2014 through May 2015, the effective date of Viking's IPO. The Company recorded 100% of the losses incurred as net loss attributable to noncontrolling interest because it was the primary beneficiary with no equity interest in the VIE.

In May 2015, Viking completed the Viking IPO and issued the Company approximately 3.7 million shares of Viking common stock with an aggregate value of $29.2 million based on the IPO price of $8.00 per share. In connection with the Viking IPO, the Company purchased 1.1 million shares of Viking common stock for an aggregate price of $9.0 million at the initial public offering price. Upon completion of Viking’s IPO, the Company determined that Viking was no longer a VIE and the Company did not have any other element of control that would require consolidation of Viking. In May 2015, the Company deconsolidated Viking and began to account for its equity investment in Viking under the equity method and records its proportional share of Viking gains and losses in Loss from Viking Therapeutics in the Company's consolidated statement of operations. Viking is considered a related party as the Company maintains a seat on Viking's board of directors.

In January 2016, the Company entered into an amendment to the LSA with Viking to extend the maturity of the convertible loan to May 2017, reduce the interest rate from 5.0% to 2.5%, and extend the lock up period by one year such that the Company may not sell, transfer, or dispose of any Viking securities prior to January 23, 2017. Additionally, upon the consummation of a subsequent capital financing transaction, Viking will be required to repay $1.5 million of the Viking Note obligation to the Company, with at least $0.3 million to be paid in cash and the remaining amount to be paid in the form and at the price of the Viking equity securities sold in the financing transaction. Upon maturity or further payments, the Company may elect to receive equity of Viking common stock or cash equal to 200% of the principal amount plus accrued and unpaid interest. The Company has opted to account for the Viking convertible note receivable at fair value.

In April 2016, Viking closed its underwritten public offering of 7.5 million shares of common stock and warrants to purchase up to 7.5 million shares of its common stock at a price of $1.25 per share of its common stock and related warrants. The warrant has an exercise price of $1.50 per share, immediately exercisable and will expire on April 13, 2021. As part of this public offering, the Company purchased 560,000 shares of common stock and warrants to purchase 560,000 shares of Viking's common stock for a total purchase price of $0.7 million. The purchased shares of common stock and warrants are subject to the same terms as the shares issued in this offering. In addition, on April 13, 2016, pursuant to the terms of the amendment to the LSA that was entered in January 2016 between Ligand and Viking, Viking repaid $0.3 million of the convertible notes in cash, and issued the Company 960,000 shares of its common stock and warrants to purchase 960,000 shares of its common stock as repayment of $1.2 million of the convertible notes. The shares received as part of the repayment, like all Viking securities held by the Company, are subject to a lock-up period that ends on January 23, 2017 in accordance with the amended LSA. A gain of $0.3 million representing the fair market value of the warrants is included within other income for the year ended December 31, 2016. As of December 31, 2016, the aggregate fair value of the note receivable was 3.2 million .
 
The Company's ownership in Viking decreased to 32.7% after the public offering and the repayment of the convertible notes and further decreased to 30.3% as of December 31, 2016. Accordingly, the book value of the Company's equity method investment in Viking decreased by $10.7 million. The resulting net loss was recognized in Loss from Viking in the Company's consolidated statement of operations for the year ended December 31, 2016.

The Company reviews its investment in Viking on a regular basis and assesses whether events, changes in circumstances or the passage of time, in management's judgment, indicate that a loss in the market value of the investment may be other than temporary. This might include, but would not necessarily be limited to, the period of time during which the carrying value of our investment is significantly above the observed market value, a deterioration in Viking's financial condition, or an adverse event relating to its lead clinical programs.

Based on the sustained low Viking common stock unit price during the year ended December 31, 2016, the Company determined that an other than temporary decrease in the value of its investment in Viking had occurred. The Company wrote down the value of its investment in Viking to its estimated fair value which resulted in impairment charges of $7.4 million for the year ended December 31, 2016.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combinations
 12 Months Ended
Dec. 31, 2016
Business Combinations [Abstract]  
Business Combinations
Business Combinations

On January 8, 2016, the Company acquired substantially all of the assets and liabilities of OMT. OMT is a biotechnology company engaged in the genetic engineering of animals for the generation of human therapeutic antibodies through its OmniAb® technology, which currently offers three transgenic animal platforms for license, including OmniRat®, OmniMouse® and OmniFlic®. The transaction, which was accounted for as a business combination, initially added 16 partnerships to the Company's portfolio and provides the Company with opportunities for further licensing and collaborations in the area. The aggregate acquisition consideration was $173.4 million, consisting of (in thousands, except per share amounts):

Cash consideration
$
96,006

Total share consideration:
 
  Actual number of shares issued
790

  Multiplied by: Ligand closing share price on January 8, 2016
98

Total share consideration
$
77,373

Total consideration
$
173,379


The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):

     Cash and cash equivalents
$
3,504

     Accounts receivable
5

     Income tax receivable
136

     Prepaid expenses and other current assets
1

     Deferred tax liabilities, net
(55,708
)
     Intangible asset with finite life - core technology
167,000

     Liabilities assumed
(1,528
)
     Goodwill
59,969

Total consideration
$
173,379



The fair value of the core technology, or OMT's OmniAb technology, was based on the discounted cash flow method that estimated the present value of a hypothetical royalty stream derived from the licensing of the OmniAb technology. These projected cash flows were discounted to present value using a discount rate of 15.5%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 20 years.

The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed was $60.0 million and was recorded as goodwill, which is not deductible for tax purposes and is primarily attributable to OMT’s potential revenue growth from combining the OMT and Ligand businesses and workforce, as well as the benefits of access to different markets and customers.

The following table presents supplemental pro forma information for the three and twelve months ended December 31, 2016 and December 31, 2015, as if the acquisition of OMT had occurred on January 1, 2015 (in thousands except for income per share):

 
Three months ended
Twelve months ended
December 31,
December 31,
2016
 
2015
2016
 
2015
Revenue
$
38,185

 
$
24,571

$
111,449

 
$
80,365

Net (loss) income
$
(3,126
)
 
5,888

$
632

 
$
222,788

 
 
 
 
 
 
 
Basic (loss) income per share:
$
(0.15
)
 
$
0.30

$
0.03

 
$
11.26

Diluted (loss) income per share:
$
(0.15
)
 
$
0.27

$
0.03

 
$
10.50



The unaudited pro forma consolidated results include pro forma adjustments that assume the acquisition occurred on January 1, 2015. The primary adjustments include: (i) the $0.3 million and $0.9 million for the three and twelve months ended December 31, 2015, respectively, for share based compensation expenses related to the stock awards issued to the retained OMT employees after the acquisition, (ii) additional intangible amortization expense of  $2.1 million and $6.3 million was included in the three and twelve months ended December 31, 2015, respectively and (iii) a platform license fee of $3.0 million paid by OMT during the twelve months ended December 31, 2015. The license agreement was terminated upon acquisition by Ligand. The adjustments also include $2.5 million license revenue recognized by OMT from January 1, 2016 to the acquisition date. The unaudited pro forma consolidated results are not necessarily indicative of what our consolidated results of operations actually would have been had we completed the acquisition on January 1, 2015. In addition, the unaudited pro forma consolidated results do not purport to project the future results of operations of the combined company nor do they reflect the expected realization of any cost savings associated with the acquisition.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurement
 12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurement
Fair Value Measurement

The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The Company establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:
Level 1 - Observable inputs such as quoted prices in active markets
Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly
Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions
The following table provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2016 and 2015 (in thousands):

Fair Value Measurements at Reporting Date Using
December 31, 2016
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Short-term investments (1)
$
122,296

 
$
3,054

 
$
119,242

 
$
—

Note receivable Viking (2)
3,207

 
—

 
—

 
3,207

Investment in warrants (3)
684

 
684

 
—

 
—

     Total assets
$
126,187

 
$
3,054

 
$
119,242

 
$
3,207

Liabilities:
 
 
 
 
 
 
 
Current contingent liabilities - CyDex (4a)
$
101

 
$
—

 
$
—

 
$
101

Long-term contingent liabilities - Metabasis (5)
1,413

 
—

 
1,413

 
—

Long-term contingent liabilities - CyDex (4)
1,503

 
—

 
—

 
1,503

Liability for amounts owed to former licensees (6)
371

 
371

 
—

 
—

     Total liabilities
$
3,388

 
$
371

 
$
1,413

 
$
1,604


Fair Value Measurements at Reporting Date Using
December 31, 2015
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents (7)
$
3,015

 
$
—

 
$
3,015

 
$
—

Short-term investments (1)
92,775

 
6,786

 
85,989

 
—

Note receivable Viking (2)
4,782

 
—

 
—

 
4,782

     Total assets
$
100,572

 
$
6,786

 
$
89,004

 
$
4,782

Liabilities:
 
 
 
 
 
 
 
Current contingent liabilities - CyDex(4)
$
7,812

 
$
—

 
$
—

 
$
7,812

Current contingent liabilities-Metabasis (5)
2,602

 
—

 
2,602

 
—

Long-term contingent liabilities - Metabasis (5)
1,355

 
—

 
1,355

 
—

Long-term contingent liabilities - CyDex (4)
1,678

 
—

 
—

 
1,678

Liability for amounts owed to former licensees (6)
794

 
794

 
—

 
—

     Total liabilities
$
14,241

 
$
794


$
3,957


$
9,490


    

(1) Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.

(2) The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 75% at December 31, 2016 and 65% at December 31, 2015. Changes in these assumptions may materially affect the fair value estimate. For the year ended December 31, 2016 and December 31, 2015, the Company reported a decrease in the fair value of the Viking convertible notes of $0.2 million and$0.8 million respectively in "Other, net" of the consolidated statement of operations.

(3) Investment in warrants, which the Company received as a result of Viking’s partial repayment of the Viking note receivable and the Company’s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities.

(4) The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.

(4a) The fair value of the liabilities for short-term CyDex contingent liabilities at December 31, 2016 disclosed herein represents the fair value of the estimated contingent considerations owed to former license holder only, which is determined based on the methodology described in (4) above. The contingent considerations owed to the Cydex CVR holders at December 31, 2016 is determined based on actual amount owed at December 31, 2016 as the Cydex CVR agreement ended at December 31, 2016.

(5) The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR.

(6) The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.

(7) Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.












The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:

 
 
December 31,
 
 
2016
 
2015
Range of annual revenue subject to revenue sharing (1)
 
N/A
 
$22.5 million
Revenue volatility
 
25%
 
25%
Average of probability of commercialization
 
12.5%
 
73%
Sales beta
 
N/A
 
0.40
Credit rating
 
BB
 
BB
Equity risk premium
 
6%
 
6%
Market price of risk
 
3.2%
 
N/A

(1)
For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual $5.0 million amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017.


A reconciliation of the level 3 financial instruments as of December 31, 2016 is as follows (in thousands):

Assets:
 
Fair value of level 3 financial instruments as of December 31, 2015
$
4,782

Viking note receivable fair market value adjustment

(215
)
Cash payment received as partial repayment of note receivable

(300
)
Fair market value of stock received as partial repayment of note receivable

(1,060
)
Fair value of level 3 financial instrument assets as of December 31, 2016
$
3,207

 
 
Liabilities
 
Fair value of level 3 financial instruments as of December 31, 2015
$
9,490

Payments to CVR holders and other contingency payments
(6,158
)
Fair value adjustments to contingent liabilities
3,259

Other (1)
(4,987
)
Fair value of level 3 financial instruments as of December 31, 2016
$
1,604


(1)
Balance represents Cydex CVR obligation, which was determined based on actual amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016.

Other Fair Value Measurements-2019 Convertible Senior Notes

In August 2014, the Company issued the 2019 Convertible Senior Notes. The Company uses a quoted market rate in an inactive market, which is classified as a Level 2 input, to estimate the current fair value of its 2019 Convertible Senior Notes. The estimated fair value of the 2019 Senior Convertible Notes was $331.7 million as of December 31, 2016. The carrying value of the notes does not reflect the market rate. See Note 7 Financing Arrangements for additional information.

Viking

The Company records its investment in Viking under the equity method of accounting. The investment is subsequently adjusted for the Company’s share of Viking's operating results, and if applicable, cash contributions and distributions. See Note 2 Investment in Viking for additional information. The market value of the Company's investment in Viking was $7.5 million as of December 31, 2016.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
Lease Obligations
 12 Months Ended
Dec. 31, 2016
Leases [Abstract]  
Lease Obligations
Lease Obligations
The Company leases office facilities in California and Kansas. These leases expire between 2017 and 2023. Total rent expense, net under all office leases for 2016, 2015 and 2014 was $0.3 million, $0.4 million and $0.7 million, respectively. The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of December 31, 2016 (in thousands):

Operating lease obligations:
 
Lease
Termination
Date
 
Less than 1
year
 
1-2 years
 
3-4 years
 
Thereafter
 
Total
Corporate headquarters-San Diego, CA
 
April 2023
 
$
128

 
$
267

 
$
283

 
$
197

 
$
875

Office and research facility-La Jolla, CA
 
June 2019
 
718

 
1,111

 
—

 
—

 
1,829

Bioscience and Technology Business Center-Lawrence, KS
 
December 2017
 
54

 
—

 
—

 
—

 
54

Total operating lease obligations
 
 
 
$
900

 
$
1,378

 
$
283

 
$
197

 
$
2,758

 
 
 
 
 
 
 
 
 
 
 
 
 
Sublease payments expected to be received:
 
 
 
 
 
 
 
 
 
 
 
 
Office and research facility-La Jolla, CA
 
June 2019
 
656

 
1,002

 
—

 
—

 
1,658

Net operating lease obligations
 
 
 
$
244

 
$
376

 
$
283

 
$
197

 
$
1,100



Lease termination

In November 2015, the Company entered into a lease termination agreement with its current lessor for the corporate headquarters facility located in La Jolla, California. The termination agreement accelerated the expiration date of the lease to April 2016, through which date, the Company is obligated to pay all base rent, operating expenses and other obligations due under the current lease.

In conjunction with the execution of the termination agreement, the Company entered into a new lease agreement with a different lessor for its corporate headquarters located in San Diego, California. The new lease has an initial term of approximately 7 years and commenced in May 2016. The base rent under the new facility lease agreement is approximately $0.1 million per year for the first year, escalating 3.0% annually thereafter over the initial term. The Company has an option to extend the term of the lease for an additional five years. The lease is subject to additional charges for property management, common area maintenance and other costs.

Lease exit obligations

As of December 31, 2016 and 2015, the Company had lease exit obligations of $0 million and $0.9 million, respectively. The Company no longer records a lease obligation with respect to its vacated space expiring in June 2019 as the sublease proceeds offset the estimated lease exit obligations. For the years ended December 31, 2016 and 2015, the Company made cash payments, net of sublease payments received of $1.7 million and $3.3 million, respectively. The Company recognized adjustments for accretion and changes in leasing assumptions of $0.7 million, $0.9 million and $1.1 million for the years ended December 31, 2016, 2015 and 2014, respectively.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.6.0.2
Financing Arrangements
 12 Months Ended
Dec. 31, 2016
Debt Disclosure [Abstract]  
Financing Arrangements
Financing Arrangements

2019 Convertible Senior Notes

In August 2014, the Company issued $245.0 million aggregate principal amount of its 2019 Convertible Senior Notes, resulting in net proceeds of $239.3 million. The 2019 Convertible Senior Notes are convertible into common stock at an initial conversion rate of 13.3251 shares per $1,000 principal amount of convertible notes, subject to adjustment upon certain events, which is equivalent to an initial conversion price of approximately $75.05 per share of common stock. The notes bear cash interest at a rate of 0.75% per year, payable semi-annually.

Holders of the 2019 Convertible Senior Notes may convert the notes at any time prior to the close of business on the business day immediately preceding May 15, 2019, under any of the following circumstances:

(1) during any fiscal quarter (and only during such fiscal quarter) commencing after December 31, 2014, if,
for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Company's common stock on such trading day is greater than 130% of the conversion price on such trading day;

(2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of the Company's common stock on such trading day and the conversion rate on each such trading day; or

(3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.
    
As of December 31 2016, the Company's last reported sale price exceeded the 130% threshold described above and accordingly the Convertible Notes have been classified as a current liability as of December 31, 2016. As a result, the related unamortized discount of $29.6 million was classified as temporary equity component of currently redeemable convertible notes on our consolidated balance sheet. The determination of whether or not the Convertible Notes are convertible as described above is made each quarter until maturity, conversion or repurchase. It is possible that the Convertible Notes may not be convertible in future periods, in which case the Convertible Notes would be classified as long-term debt, and the unamortized discount would be classified as permanent equity unless one of the other conversion events described above were to occur.

On or after May 15, 2019 until the close of business on the second scheduled trading day immediately preceding August 15, 2019, holders of the notes may convert all or a portion of their notes at any time. Upon conversion, Ligand must deliver cash to settle the principal and may deliver cash or shares of common stock, at the option of the Company, to settle any premium due upon conversion.
    
The Company accounted for the debt and equity components of the 2019 Convertible Senior Notes by allocating the $245.0 million total proceeds between the debt component and the embedded conversion option, or equity component, due to Ligand's ability to settle the 2019 Convertible Senior Notes in cash for the principal portion and to settle any premium in cash or common stock, at the Company's election. The debt allocation was performed in a manner that reflected the Company's non-convertible borrowing rate for similar debt of 5.83% derived from independent valuation analysis. The initial debt value of $192.5 million accretes at 5.83% to reach $245.0 million at the maturity date. The equity component of the 2019 Convertible Senior Notes was recognized as a debt discount and represents the difference between the $245.0 million proceeds at issuance of the 2019 Convertible Senior Notes and the fair value of the debt allocation on their respective issuance dates. The debt discount is amortized to interest expense using the effective interest method over the expected life of a similar liability without an equity component. As of December 31, 2016, the “if-converted value” exceeded the principal amount of the 2019 Convertible Senior Notes by $86.7 million.    

In connection with the issuance of the 2019 Convertible Senior Notes, the Company incurred $5.7 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees. The portions of these costs allocated to the equity components totaling $1.2 million were recorded as a reduction to additional paid-in capital. The portions of these costs allocated to the liability components totaling $4.5 million were recorded as assets on the balance sheet at the time the debt was issued.  Beginning in 2016, the unamortized issuance costs allocated to the liability components are recorded as part of debt discount on the consolidated balance sheet upon the Company's respective adoption of ASU 2015-03, Interest-Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs. Issuance cost included in the unamortized debt discount was $2.5 million and $3.4 million as of December 31, 2016 and 2015, respectively.
 
The Company determined the expected life of the debt discount for the 2019 Convertible Senior Notes to be equal to the original five-year term of the notes. The carrying value of the equity component related to the 2019 Convertible Senior Notes as of December 31, 2016, net of issuance costs, was $51.3 million.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Convertible Bond Hedge and Warrant Transactions

In August 2014, to minimize the impact of potential dilution to the Company's common stock upon conversion of the 2019 Convertible Senior Notes, in August 2014, the Company entered into convertible bond hedges and sold warrants covering 3,264,643 shares of its common stock. The convertible bond hedges have an exercise price of $75.05 per share and are exercisable when and if the 2019 Convertible Senior Notes are converted. If upon conversion of the 2019 Convertible Senior Notes, the price of the Company's common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by the Company and are not part of the terms of the 2019 Convertible Senior Notes. Holders of the 2019 Convertible Senior Notes and warrants will not have any rights with respect to the convertible bond hedges. The Company paid $48.1 million for these convertible bond hedges and recorded the amount as a reduction to additional paid-in capital.

Concurrently with the convertible bond hedge transactions, the Company entered into warrant transactions whereby it sold warrants to acquire approximately 3,264,643 shares of common stock with an exercise price of approximately $125.08 per share, subject to certain adjustments. None of the warrants have been exercised as of December 31, 2016. The warrants have various expiration dates ranging from November 13, 2019 to April 22, 2020. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The Company received $11.6 million for these warrants and recorded this amount to additional paid-in capital. The common stock issuable upon exercise of the warrants will be in unregistered shares, and the Company does not have the obligation and does not intend to file any registration statement with the Securities and Exchange Commission registering the issuance of the shares under the warrants.

The following table summarizes information about the liability components the Company's financing arrangement (dollars in thousands):
 
December 31, 2016
 
December 31, 2015

2019 Convertible Senior Notes
 
 
 
     Principal amount outstanding
$
245,000

 
$
245,000

     Unamortized discount
(32,090
)
 
(43,015
)
Total current portion of notes payable
$
212,910

 
$
201,985


As of December 31, 2016, there were no events of default or violation of any covenants under the Company's financing obligations.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details
 12 Months Ended
Dec. 31, 2016
Other Balance Sheet Details [Abstract]  
Other Balance Sheet Details
Balance Sheet Account Details

Short-term Investments
The following table summarizes the various investment categories at December 31, 2016 and 2015 (in thousands):
 
Cost
 
Gross unrealized
gains
 
Gross unrealized
losses
 
Estimated
fair value
December 31, 2016
 
 
 
 
 
 
 
Short-term investments
 
 
 
 
 
 
 
     Bank deposits
$
40,715

 
$
19

 
$
—

 
$
40,734

     Corporate bonds
11,031

 
—

 
(5
)
 
11,026

     Corporate equity securities
1,512

 
1,542

 
—

 
3,054

     Commercial paper
33,074

 
2

 
(9
)
 
33,067

     Agency bonds
7,294

 
1

 
—

 
7,295

     U.S. Government bonds
7,508

 
—

 
(1
)
 
7,507

     Municipal bonds
19,624

 
—

 
(11
)
 
19,613

 
$
120,758

 
$
1,564

 
$
(26
)
 
$
122,296

December 31, 2015
 
 
 
 
 
 
 
Short-term investments
 
 
 
 
 
 
 
     Bank deposits
$
43,043

 
$
—

 
$
(4
)
 
$
43,039

     Corporate bonds
41,238

 
—

 
(35
)
 
41,203

     Commercial paper
1,747

 
—

 
—

 
1,747

     Asset backed securities
10,020

 
—

 
(5
)
 
10,015

     Corporate equity securities
1,843

 
4,944

 
—

 
6,787

 
$
97,891

 
$
4,944

 
$
(44
)
 
$
102,791



Other current assets consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Prepaid expenses
$
1,864

 
$
1,177

Other receivables
311

 
731

 
$
2,175

 
$
1,908



Property and equipment is stated at cost and consists of the following (in thousands):
 
December 31,
 
2016
 
2015
Lab and office equipment
$
1,067

 
$
2,248

Leasehold improvements
1,754

 
273

Computer equipment and software
569

 
632

 
3,390

 
3,153

Less accumulated depreciation and amortization
(1,571
)
 
(2,781
)
 
$
1,819

 
$
372


Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $0.2 million, $0.2 million, and $0.3 million was recognized for the years ended December 31, 2016, 2015, and 2014, respectively and is included in operating expenses.

Goodwill and identifiable intangible assets consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Indefinite lived intangible assets
 
 
 
     IPR&D
$
12,246

 
$
12,556

     Goodwill
72,207

 
12,238

Definite lived intangible assets
 
 
 
     Complete technology
182,577

 
15,267

          Less: Accumulated amortization
(12,792
)
 
(3,762
)
     Trade name
2,642

 
2,642

          Less: Accumulated amortization
(784
)
 
(652
)
     Customer relationships
29,600

 
29,600

          Less: Accumulated amortization
(8,784
)
 
(7,304
)
Total goodwill and other identifiable intangible assets, net
$
276,912

 
$
60,585



Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $10.6 million, $2.4 million, and $2.4 million was recognized for the years ended December 31, 2016 and 2015, and 2014. Estimated amortization expense for the years ending December 31, 2017 through 2021 is $10.6 million per year. For each of the years ended December 31, 2016, 2015, and 2014, there was no impairment of intangible assets with finite lives.

Commercial license rights consist of the following (in thousands):
 
December 31,
 
December 31,
 
2016
 
2015
CorMatrix
$
17,696

 
$
—

Selexis
8,602

 
8,602

 
26,298

 
8,602

Less: accumulated amortization
(477
)
 
(48
)
     Total commercial rights, net
$
25,821

 
$
8,554



Accrued liabilities consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Compensation
$
2,603

 
$
1,711

Legal
829

 
726

Amounts owed to former licensees
899

 
915

Royalties owed to third parties
942

 
823

Other
1,124

 
1,230

 
$
6,397

 
$
5,405



In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. We pay CyDex shareholders, through 2016, 20% of all CyDex-related revenue, but only to the extent that, and beginning only when, CyDex-related revenue for the year exceeds $15.0 million; plus an additional 10% of all CyDex-related revenue recognized during such year, but only to the extent, and beginning only when aggregate CyDex-related revenue for such year exceeds $35.0 million.

In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones.
  
Contingent liabilities consist of the following (in millions):
 
December 31, 2014
Payments
Fair Value Adjustment
December 31, 2015
Payments
Fair Value Adjustment
December 31, 2016
Cydex
$
11.5

$
(5.8
)
$
3.8

$
9.5

(6.2
)
$
3.3

$
6.6

Metabasis
3.7

(0.9
)
1.2

4.0

(2.6
)
0.1

1.5

Total
15.2

(6.7
)
5.0

13.5

(8.8
)
3.4

8.1


Other long-term liabilities consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Deferred rent
$
357

 
$
—

Deposits
43

 
268

Other
287

 
29

 
$
687

 
$
297
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity
 12 Months Ended
Dec. 31, 2016
Equity [Abstract]  
Stockholders' Equity
Stockholders’ Equity

Share-based Compensation Expense

The following table summarizes stock-based compensation expense (in thousands):
 
December 31,
 
2016
 
2015
 
2014
Stock-based compensation expense as a component of:
 
 
 
 
 
Research and development expenses
$
8,836

 
$
4,080

 
$
3,595

General and administrative expenses
10,057

 
8,378

 
7,675

 
$
18,893

 
$
12,458

 
$
11,270



Stock Plans

In May 2009, the Company’s stockholders approved the amendment and restatement of the Company’s 2002 Stock Incentive Plan (the “Amended 2002 Plan”). The Company’s 2002 Stock Incentive Plan was amended to (i) increase the number of shares available for issuance under the Amended 2002 Plan by 1.3 million shares, (ii) revise the list of performance criteria that may be used by the compensation committee for purposes of granting awards under the Amended 2002 Plan that are intended to qualify as performance-based compensation under Section 162(m) of the Internal Revenue Code, as amended, and (iii) eliminate the automatic option grant program for non-employee directors, the director fee stock issuance program and the director fee option grant program, which programs have been superseded by the Company’s amended and restated Director Compensation Policy. Additionally, in May 2012 and May 2016, the Company’s stockholders approved an amendment and restatement of the Company’s 2002 Stock Incentive Plan to increase the number of shares available for issuance by 1.8 million and 0.9 million shares, respectively. As of December 31, 2016, there were 1.0 million shares available for future option grants or direct issuance under the Amended 2002 Plan.
Following is a summary of the Company’s stock option plan activity and related information:
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term in
Years
 
Aggregate
Intrinsic
Value
(In  thousands)
Balance at December 31, 2015
1,683,341

 
$
34.19

 
6.48
 
$
124,800

Granted
263,489

 
92.09

 
 
 
 
Exercised
(164,440
)
 
38.08

 
 
 
 
Forfeited
(28,115
)
 
60.17

 
 
 
 
Balance at December 31, 2016
1,754,275

 
42.12

 
6.19
 
104,247

Exercisable at December 31, 2016
1,298,561

 
30.21

 
5.44
 
92,723

Options vested and expected to vest as of December 31, 2016
1,752,275

 
$
42.12

 
6.19
 
$
104,247



The weighted-average grant-date fair value of all stock options granted during 2016, 2015 and 2014 was $46.53, $35.39 and $46.20 per share, respectively. The total intrinsic value of all options exercised during 2016, 2015 and 2014 was approximately $12.0 million, $20.7 million and $15.3 million, respectively.
Cash received from options exercised, net of fees paid, in 2016, 2015 and 2014 was $6.2 million, $8.7 million and $4.4 million, respectively.
Following is a further breakdown of the options outstanding as of December 31, 2016:
 
Range of exercise prices
Options
outstanding
 
Weighted
average
remaining  life
in years
 
Weighted average
exercise price
 
Options
exercisable
 
Weighted average
exercise price
$8.58 - $12.53
247,574

 
3.94
 
$
9.98

 
247,574

 
$
9.98

$10.12 - $12.81
76,100

 
4.92
 
11.38

 
76,100

 
11.38

$14.47 - $14.47
288,887

 
5.11
 
14.47

 
274,887

 
14.47

$16.14 - $21.00
106,242

 
1.85
 
17.76

 
106,242

 
17.76

$21.92 - $21.92
225,105

 
6.13
 
21.92

 
213,199

 
21.92

$32.00 - $53.34
72,330

 
6.02
 
36.18

 
62,747

 
34.73

$56.26 - $59.26
183,595

 
8.11
 
56.26

 
70,877

 
56.26

$63.58 - $68.62
26,382

 
7.50
 
67.20

 
21,976

 
67.50

$74.42 - $74.42
227,856

 
7.12
 
74.42

 
162,233

 
74.42

$85.79 - $138.53
298,204

 
9.03
 
93.19

 
62,726

 
89.71

$8.58 – $138.53
1,752,275

 
6.19
 
$
42.12

 
1,298,561

 
$
30.21



The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:

 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Risk-free interest rate
1.3%-1.9%
 
1.7%-2.0%
 
1.9%
 
Expected volatility
48%-50%
 
50%-58%
 
62%-69%
 
Expected term
6.6 to 6.7 years
 
6.5 years
 
6.0 years
 
Forfeiture rate
5.00%
 
8.52%
 
8.6%-9.7%
 

As of December 31, 2016, there was $17.5 million of total unrecognized compensation cost related to non-vested stock options. That cost is expected to be recognized over a weighted average period of 2.22 years.
Restricted Stock Activity
The following is a summary of the Company’s restricted stock activity and related information:
 
 
Shares
 
Weighted-Average
Grant Date Fair
Value
Outstanding at December 31, 2015
130,749

 
$
60.36

Granted
234,855

 
95.31

Vested
(54,421
)
 
66.79

Forfeited
(2,483
)
 
67.95

Outstanding at December 31, 2016
308,700

 
$
86.61


As of December 31, 2016, unrecognized compensation cost related to non-vested stock awards amounted to $13.8 million. That cost is expected to be recognized over a weighted average period of 1.14 years.

Employee Stock Purchase Plan

As of December 31, 2016, 70,406 shares of the Company's common stock are available for future issuance under it's Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a six month offering period or purchase date, whichever is lower. There were 1,961, 3,374 and 3,774 shares issued under the ESPP in 2016, 2015 and 2014, respectively.

Share Repurchases
    
During the years ended December 31, 2016, 2015 and 2014 the Company repurchased 40,500 shares for $3.9 million, 6,120 shares for $0.5 million, and 1,253,425 shares for $68.0 million, respectively.
    
In September 2015, the Company's Board of Directors authorized the Company to repurchase up to $200.0 million of its own stock in privately negotiated and open market transactions for a period of up to three years, subject to the Company's evaluation of market conditions. Authorization to repurchase up to an additional $195.6 million of its common stock remained as of December 31, 2016.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.6.0.2
Litigation
 12 Months Ended
Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]  
Litigation
Litigation

The Company records an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, The Company records the minimum estimated liability related to the claim in accordance with FASB ASC Topic 450 Contingencies. As additional information becomes available, the Company assesses the potential liability related to its pending litigation and revises its estimates. Revisions in the Company's estimates of potential liability could materially impact its results of operations.

Securities Litigation

In 2012, a federal securities class action and shareholder derivative lawsuit was filed in Pennsylvania alleging that the Company and its chief executive officer assisted various breaches of fiduciary duties based on the Company’s purchase of a licensing interest in a development-stage pharmaceutical program from the Genaera Liquidating Trust in 2010 and the Company’s subsequent sale of half of its interest in the transaction to Biotechnology Value Fund, Inc.  Plaintiff filed a second amended complaint in February 2015, which the Company moved to dismiss in March 2015.  The district court granted the motion to dismiss on November 11, 2015.  The plaintiff has appealed that ruling to the U.S. Third Circuit Court of Appeals.  The Company intends to continue to vigorously defend against the claims against the Company and its chief executive officer.  The outcome of the matter is not presently determinable.

Paragraph IV Certification by Par Pharmaceuticals

On January 7, 2016, the Company received a paragraph IV certification from Par Sterile Products, LLC, a subsidiary of Par Pharmaceuticals, Inc., or Par, advising us that it had filed an ANDA with the FDA seeking approval to market a generic version of Merck’s NOXAFIL-IV product. On February 19, 2016, Merck filed an action against Par in the United States District Court for the District of New Jersey, asserting that Par's manufacture, use or sale of the product for which the ANDA was submitted would infringe Merck's U.S. Patent No. 9,023,790. On October 31, 2016, the parties entered into a consent judgment dismissing all claims, counterclaims, affirmative defenses and demands. The parties have reported to the court that they entered into a confidential settlement agreement, and that they submitted the agreement to the Federal Trade Commission and the United States Department of Justice pursuant to Section 112(a) of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.

Class Action Lawsuit

In November 2016, a putative shareholder class action lawsuit was filed in the United States District Court for the Southern District of California against the Company, its chief executive officer and chief financial officer. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder, and seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company’s securities between November 9, 2015 and November 14, 2016, inclusive. The complaint’s allegations relate generally to the Company’s November 2016 restatement of certain prior period financial statements.  In January 2017, a purported Company shareholder filed a motion for appointment of lead counsel and lead plaintiff. The motion is scheduled to be heard by the Court in March 2017. No trial date has been set. The Company believes that the lawsuit is without merit and intends to vigorously defend against the lawsuit.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes
 12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Current expense (benefit):
 
 
 
 
 
 
Federal
$
21

 
$
11

 
$
15

 
State
12

 
7

 
19

 
 
33

 
18

 
34

 
Deferred expense (benefit):
 
 
 
 
 
 
Federal
10,534

 
(167,413
)
 
406

 
State
(240
)
 
(24,720
)
 
(30
)
 
 
$
10,327

 
$
(192,115
)
 
$
410

 


A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows:
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Amounts computed at statutory federal rate
$
2,786

 
$
13,198

 
$
3,843

State taxes net of federal benefit
175

 
386

 
697

Meals & entertainment
16

 
16

 
9

Imputed interest
(1
)
 
(161
)
 
53

Section 162(m) limitation
94

 
197

 
490

Contingent liabilities
1,225

 
1,684

 
1,748

Stock-based compensation
263

 
140

 
89

Expired NOLs
—

 
232

 
88

Research and development credits
(1,525
)
 
304

 
(113
)
Change in uncertain tax positions
1,423

 
27,188

 
7

Rate change for changes in state law
25

 
(5,756
)
 
119

APIC Excess Tax Benefit True Up

(622
)
 
—

 
—

Increase in deferred tax assets from completion of 382 analysis
(120
)
 
3,329

 
43

Avinza true up
—


(2,107
)

—

Change in valuation allowance
6,283

 
(231,370
)
 
(7,243
)
Other
305

 
605

 
580

 
$
10,327

 
$
(192,115
)
 
$
410

 
    
Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2016 and 2015 are shown below. The Company assesses the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company's evaluation of evidence resulted in management concluding that the majority of the Company's deferred tax assets will be realized. However, the Company maintains a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December 31, 2016, 2015 and 2014. The valuation allowance increased $6.3 million in 2016, decreased $231.7 million in 2015 and decreased $7.2 million in 2014.
 
December 31,
 
2016
 
2015
 
(in thousands)
Deferred assets:
 
 
 
Net operating loss carryforwards
$
150,226

 
$
160,595

Research credit carryforwards
26,878

 
25,613

Fixed assets and intangibles
4,385

 
8,839

Accrued expenses
943

 
1,523

Contingent liabilities
578

 
707

Deferred revenue
—

 
3

Present value of royalties
591

 
3,007

Deferred rent
45

 
68

Capital Loss Carryforward
4,432

 
—

Viking Equity Method Investment
5,692

 
1,840

Other
19,312

 
15,441

 
213,082

 
217,636

Valuation allowance for deferred tax assets
(15,349
)
 
(9,066
)
Net deferred tax assets
$
197,733

 
$
208,570

Deferred tax liabilities:
 
 
 
Retrophin fair value adjustment
$
(52
)
 
$
(1,256
)
Convertible debt
(1,196
)
 
(1,844
)
Identified intangibles
(68,631
)
 
(12,770
)
Identified indefinite lived intangibles
(3,963
)
 
(3,617
)
Total
$
123,891

 
$
189,083



    
Sections 382 and 383 of the U.S. tax code impose limitations (“382 and 383 limitations”) on the annual utilization of operating loss and credit carryforwards whenever a greater than fifty percent change in the ownership of a company occurs within a three year period. In addition to the annual limitations on operating loss and credit carryforwards, Section 382 can also restrict the utilization of certain post change losses if the tax basis in assets exceeds the fair value of assets (“net unrealized built in loss”) at the date of an ownership change. Companies with operating loss and credit carryforwards are required to test the cumulative three year change whenever there is an equity transaction that impacts the ownership of holders of more than five percent of the Company’s stock. During 2016, the Company completed a rollforward analysis through December 31, 2016. As a result of the rollforward analysis, it was determined that no additional ownership changes occurred at the Company within the meaning of section 382 since June 20, 2007. Future changes in the ownership of the Company could place additional restrictions on the Company’s ability to utilize operating loss and credit carryforwards arising through December 31, 2016.

As of December 31, 2016, the Company had federal and state net operating loss carryforwards set to expire through 2036 of $446.3 million and $140.5 million of state net operating loss carryforwards. The Company also has $21.9 million of federal research and development credit carryforwards, which expire through 2036. The Company has $19.4 million of California research and development credit carryforwards that have no expiration date.  
The Company accounts for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company’s remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.
A reconciliation of the amount of unrecognized tax benefits at December 31, 2016, 2015 and 2014 is as follows (in thousands):
 
December 31,
 
2016
 
2015
 
2014
Balance at beginning of year
$
36,452

 
$
8,524

 
$
8,504

     Additions based on tax positions related to the current year
70

 
154

 
40

     Additions for tax positions of prior years
2,408

 
28,224

 
—

     Reductions for tax positions of prior years
(160
)
 
(450
)
 
(20
)
Balance at end of year
$
38,770

 
$
36,452

 
$
8,524



Included in the balance of unrecognized tax benefits at December 31, 2016 is $35.5 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.
The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2016 and December 31, 2015, the Company recognized an immaterial amount of interest and penalties. The Company files income tax returns in the United States and in various state jurisdictions with varying statutes of limitations. The federal statute of limitation remains open for the 2013 tax year to present.  The state income tax returns generally remain open for the 2012 tax years through present.  Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized.

In March 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting (''ASU 2016-09''). ASU 2016-09 simplifies how several aspects of share-based payments are accounted for and presented in the financial statements.  ASU 2016-09 is effective for public companies for annual reporting periods beginning after December 15, 2016. The Company will adopt this ASU in the first quarter of 2017. The Company has excess tax federal and state benefits for which a benefit could not be previously recognized of approximately $13.7 million and $11.5 million, respectively. Upon adoption the balance of the unrecognized excess tax benefits will be reversed with the impact recorded to retained earnings including any change to the valuation allowance as a result of the adoption.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Unaudited Quarterly Financial Information
 12 Months Ended
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]  
Summary of Unaudited Quarterly Financial Information
Summary of Unaudited Quarterly Financial Information

The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for fiscal years 2016 and 2015 are as follows (in thousands, except per share amounts):
 
First Quarter
 
Second Quarter
 
 Third Quarter
 
Fourth Quarter
2016
 
 
 
 
 
 
 
Total revenues
$
29,648

 
$
19,521

 
$
21,619

 
$
38,185

Total operating costs and expenses
14,552

 
15,552

 
16,153

 
18,831

Income tax (expense) benefit
(3,694
)
 
3,881

 
(160
)
 
(10,354
)
Income (loss) from continuing operations
5,877

 
(6,170
)
 
1,051

 
(3,125
)
Income from discontinued operations
731

 
—

 
—

 
—

Net income (loss)
6,608

 
(6,170
)
 
1,051

 
(3,125
)
Basic per share amounts:
 
 
 
 
 
 
 
     Net income (loss)
$
0.32

 
$
(0.30
)
 
$
0.05

 
$
0.15

Diluted per share amounts:
 
 
 
 
 
 
 
     Net income (loss)
0.30

 
(0.30
)
 
0.05

 
0.15

 
 
 
 
 
 
 
 
Weighted average shares—basic
20,708

 
20,832

 
20,887

 
20,898

Weighted average shares—diluted
22,284

 
20,832

 
22,997

 
20,898

 
 
 
 
 
 
 
 
2015
 
 
 
 
 
 
 
Total revenues
$
14,602

 
$
18,418

 
$
17,701

 
$
21,193

Total operating costs and expenses
11,253

 
14,053

 
9,104

 
10,175

Income tax (expense) benefit
(15
)
 
(265
)
 
191,881

 
514

(Loss) income from continuing operations
(89
)
 
22,027

 
199,165

 
6,341

Net loss attributable to noncontrolling interests
(843
)
 
(1,537
)
 
—

 
—

Net income
754

 
23,564

 
199,165

 
6,341

Basic per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.19

 
$
10.01

 
$
0.32

Diluted per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.11

 
$
9.28

 
$
0.29

 
 
 
 
 
 
 
 
Weighted average shares—basic
19,612

 
19,725

 
19,887

 
19,933

Weighted average shares—diluted
20,631

 
21,276

 
21,460

 
21,542
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Reclassifications
Reclassifications

Certain reclassifications have been made to the previously issued statement of operations for comparability purposes. These reclassifications had no effect on the reported net income, stockholders' equity and operating cash flows as previously reported.
Principles of Consolidation
Principles of Consolidation

The accompanying consolidated financial statements include Ligand and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates
Recent Accounting Pronouncements
Recent Accounting Pronouncements
 
 In May 2014, the FASB issued new guidance related to revenue recognition, Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASC 606”), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition guidance. The new guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. ASC 606 defines a five-step approach for recognizing revenue, which may require a company to use more judgment and make more estimates than under the current guidance. The new guidance becomes effective in calendar year 2018 and early adoption in calendar year 2017 is permitted. Two methods of adoption are permitted: (a) full retrospective adoption, meaning the standard is applied to all periods presented; or (b) modified retrospective adoption, meaning the cumulative effect of applying the new guidance is recognized at the date of initial application as an adjustment to the opening retained earnings balance.

We are undertaking a substantial effort to be ready for adoption of ASC 606. Some of our contracts have distinct terms which will need to be evaluated separately.  We have started our preliminary assessment of these contracts and although we have not completed our assessment and are in the process of reviewing our contracts, we anticipate this standard will have a material impact on our consolidated financial statements by accelerating the timing of revenue recognition for revenues related to royalties, and potentially certain contingent milestone based payments. We intend to adopt ASC 606 starting as of January 1, 2018 using the modified retrospective method. 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements -Going Concern (Subtopic 205-40). This accounting standard requires management to perform interim and annual assessments of the entity's ability to continue its business operations within one year of the date of issuance of its financial statements. The Company must then provide certain disclosure if there is substantial doubt about its ability to continue as a going concern. As of December 31, 2016, the Company has adopted this standard with no impact to the financial statements.

In March 2016, the FASB issued ASU 2016-09 amending several aspects of share-based payment accounting. This guidance requires all excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled, with prospective application required. The guidance also changes the classification of such tax benefits or tax deficiencies on the statement of cash flows from a financing activity to an operating activity, with retrospective or prospective application allowed. The guidance requires the classification of employee taxes paid when an employer withholds shares for tax-withholding purposes as a financing activity on the statement of cash flows, with retrospective application required. In addition, the guidance provides for an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur. The updated guidance is effective in fiscal year 2018 and early adoption in fiscal year 2017 is permitted. We are currently evaluating the adoption timing as well as the impact of the new guidance on our consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments which requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. The new standard will be effective for us in fiscal year 2020 and early adoption in fiscal 2019 is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements.

In August 2016 the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. The guidance addresses the classification of cash flows related to (1) debt prepayment or extinguishment costs, (2) settlement of zero-coupon debt instruments or other debt instruments with coupon rates that are insignificant in relation to the effective interest rate of the borrowing, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance, including bank-owned life insurance, (6) distributions received from equity method investees and (7) beneficial interests in securitization transactions. The guidance also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. The new guidance will be effective for fiscal year 2018 and early adoption is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements. We expect contingent consideration payment presentation will change to conform to the standard.

We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.
Concentrations of Credit Risk
Concentrations of Business Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and investments. The Company invests its excess cash principally in United States government debt securities, investment grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.
Cash Equivalents and Short-term Investments
Cash Equivalents & Short Term Investments

Cash equivalents consist of all investments with maturities of three months or less from the date of acquisition. Short-term investments primarily consist of investments in debt securities that have effective maturities greater than three months and less than twelve months from the date of acquisition. The Company classifies its short-term investments as "available-for-sale". Such investments are carried at fair value, with unrealized gains and losses included in the statement of comprehensive income (loss). The Company determines the cost of investments based on the specific identification method.
Accounts Receivable
Accounts Receivable

Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company considers receivables past due based on the contractual payment terms which range from 30 to 90 days. The Company reserves specific receivables if collectibility is no longer reasonably assured. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve.
Inventory
Inventory
Inventory, which consists of finished goods, is stated at the lower of cost or market value. The Company determines cost using the first-in, first-out method. The Company analyzes its inventory levels periodically and writes down inventory to its net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.
Property and Equipment, net
Property and Equipment
Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from three to ten years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense.
Goodwill
Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. The change in the carrying value of goodwill during the year ended December 31, 2016, was due to the acquisition of OMT. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment in the fourth quarter of 2016 by assessing qualitative factors, noting no impairment.
Acquired in-process research and development

Intangible assets related to acquired IPR&D are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered to be indefinite-lived, they are not amortized but are tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company performed its annual assessment for IPR&D impairment in 2016, noting no impairment.
Commercial license rights
Commercial license rights

Commercial license rights represent a portfolio of future milestone and royalty payment rights acquired from Selexis in April 2013 and April 2015 and Cormatrix in May 2016. Individual commercial license rights acquired are carried at allocated cost and approximate fair value. The carrying value of the license rights will be reduced on a pro-rata basis as revenue is realized over the term of the agreement. Declines in the fair value of license rights below their carrying value that are deemed to be other than temporary are reflected in earnings in the period such determination is made.
Contingent Liabilities
Contingent Liabilities

In connection with the Company’s acquisition of CyDex in January 2011, the Company recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. See footnote 7, Other Balance Sheet Details. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. In connection with the Company’s acquisition of Metabasis in January 2010, the Company issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement.

Any change in fair value is recorded in the Company's consolidated statement of operations.
Revenue Recognition
Revenue Recognition

We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been provided, title has transferred or access has been given, the price is fixed or determinable, there are no remaining customer acceptance requirements, and collectability of the resulting receivable is reasonably assured.

Royalties on sales of products commercialized by the Company’s partners are recognized in the quarter reported by the respective partner. Generally, the Company receives royalty reports from its licensees approximately one quarter in arrears due to the fact that its agreements require partners to report product sales between 30 and 60 days after the end of the quarter. The Company recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. Under this accounting policy, the royalty revenues reported are not based upon estimates and such royalty revenues are typically reported to the Company by its partners in the same period in which payment is received.
Revenue from material sales of Captisol is recognized upon transfer of title, which normally passes upon shipment to the customer, provided all other revenue recognition criteria have been met. All product returns are subject to the Company's credit and exchange policy, approval by the Company and a 20% restocking fee. To date, product returns have not been material to net material sales in any related period. The Company records revenue net of product returns, if any, and sales tax collected and remitted to government authorities during the period.

The Company analyzes its revenue arrangements and other agreements to determine whether there are multiple elements that should be separated and accounted for individually or as a single unit of accounting. For multiple element contracts, arrangement consideration is allocated at the inception of the arrangement to all deliverables on the basis of relative selling price, using a hierarchy to determine selling price. Management first considers VSOE, then TPE and if neither VSOE nor TPE exist, the Company uses its best estimate of selling price.
Many of the Company's revenue arrangements for Captisol involve a license agreement and the supply of manufactured Captisol product. Licenses may be granted to pharmaceutical companies for the use of Captisol product in the development of pharmaceutical compounds. The supply of the Captisol product may be for all phases of clinical trials and through commercial availability of the host drug or may be limited to certain phases of the clinical trial process. Management believes that the Company's licenses have stand-alone value at the outset of an arrangement because the customer obtains the right to use Captisol in its formulations without any additional input by the Company, and in a hypothetical stand-alone transaction, the customer would be able to procure inventory from another manufacturer in the absence of contractual provisions for exclusive supply by the Company.
Other nonrefundable, up-front license fees are recognized as revenue upon delivery of the license, if the license is determined to have standalone value that is not dependent on any future performance by the Company under the applicable collaboration agreement. Nonrefundable contingent event-based payments are recognized as revenue when the contingent event is met, which is usually the earlier of when payments are received or collections are assured, provided that it does not require future performance by the Company. The Company occasionally has sub-license obligations related to arrangements for which it receives license fees, milestones and royalties. Management evaluates the determination of gross versus net reporting based on each individual agreement.
Sales-based contingent payments from partners are accounted for similarly to royalties, with revenue recognized upon achievement of the sales targets assuming all other revenue recognition criteria for milestones are met. Revenue from development and regulatory milestones is recognized when earned, as evidenced by written acknowledgement from the collaborator, provided that (1) the milestone event is substantive, its achievability was not reasonably assured at the inception of the agreement, and the Company has no further performance obligations relating to that event, and (2) collectability is reasonably assured. If these criteria are not met, the milestone payment is recognized over the remaining period of the Company’s performance obligations under the arrangement.
Preclinical Study and Clinical Trial Accruals
Preclinical Study and Clinical Trial Accruals

Substantial portions of the Company’s preclinical studies and all of the Company’s clinical trials have been performed by third-party laboratories, CROs.  The Company accounts for a significant portion of its clinical study costs according to the terms of its contracts with CROs. The terms of its CRO contracts may result in payment flows that do not match the periods over which services are provided to us under such contracts. The Company's objective is to reflect the appropriate preclinical and clinical trial expenses in its financial statements in the same period as the services occur. As part of the process of preparing its financial statements, the Company relies on cost information provided by its CROs. The Company is also required to estimate certain of its expenses resulting from its obligations under its CRO contracts. Accordingly, the Company's preclinical study and clinical trial accrual is dependent upon the timely and accurate reporting of CROs and other third-party vendors. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate as more information becomes available concerning changing circumstances, and conditions or events that may affect such estimates. No material adjustments to preclinical study and clinical trial accrued expenses have been recognized to date.
Research and Development Expenses
Research and Development Expenses

Research and development expense consists of labor, material, equipment, and allocated facilities costs of the Company’s scientific staff who are working pursuant to the Company’s collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for the Company’s research programs including in-licensing costs, CRO costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided
Share-Based Compensation
Stock-Based Compensation

The Company incurs share-based compensation expense related to restricted stock, its ESPP, and stock options

Restricted stock units (RSU) and performance stock units (PSU) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of the Company’s common stock on the date of grant. The Company recognizes share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration estimated forfeitures. PSU represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, the Company reassesses the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment.

The Company uses the Black-Scholes-Merton option-pricing model to estimate the fair value of stock purchases under ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. The Company looks to historical volatility of the Company's stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that the Company has never declared or paid regular cash dividends on its common stock and does not anticipate paying such cash dividends. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards

The Company grants options and restricted stock awards to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and restricted stock awards granted to certain non-employee directors vest in equal monthly installments over one year from the date of grant. Options granted to employees vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. Restricted stock awards granted to employees vest over three years. All option awards generally expire ten years from the date of grant.

Stock-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.
Income Taxes
Income Taxes

The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date.

Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when the Company believes it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise the Company considers all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.

The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense.
Income Per Share
Income Per Share
    
Basic income (loss) per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period

Potentially dilutive common shares consist of shares issuable under 2019 convertible senior notes, stock options and restricted stock. 2019 convertible senior notes have a dilutive impact when the average market price of the Company’s common stock exceeds the applicable conversion price of the respective notes. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options; the average amount of unrecognized compensation expense for restricted stock; and estimated tax benefits that will be recorded in additional paid-in capital when expenses related to equity awards become deductible. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded
Comprehensive Income (Loss)
Comprehensive Income (Loss)

Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented in unrealized gains and losses on available-for-sale securities less reclassification adjustments for realized gains or losses included in net income (loss). The unrealized gains or losses are reported on the Consolidated Statements of Comprehensive Income (Loss).
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of major customers
A relatively small number of partners accounts for a significant percentage of our revenue. Revenue from significant partners, which is defined as 10% or more of our total revenue, was as follows:
 
December 31,
 
2016
 
2015
 
2014
Partner A
41
%
 
27
%
 
37
%
Partner B
14
%
 
23
%
 
31
%
Partner C
—

 
18
%
 
10
%
Summary of computation of basic and diluted net income (loss) per share
The following table presents the calculation of weighted average shares used to calculate basic and diluted earnings per share (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
Weighted average shares outstanding:
20,831

 
19,790

 
20,419

Dilutive potential common shares:
 
 
 
 
 
   Restricted stock
—

 
56

 
36

   Stock options
—

 
882

 
978

   2019 Convertible Senior Notes
—

 
499

 
—

Shares used to compute diluted income per share
20,831

 
21,228

 
21,433

Potentially dilutive shares excluded from calculation due to anti-dilutive effect
3,544

 
3,333

 
5,104
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combinations (Tables)
 12 Months Ended
Dec. 31, 2016
Business Combinations [Abstract]  
Schedule of Business Acquisitions by Acquisition, Consideration Transferred
The aggregate acquisition consideration was $173.4 million, consisting of (in thousands, except per share amounts):

Cash consideration
$
96,006

Total share consideration:
 
  Actual number of shares issued
790

  Multiplied by: Ligand closing share price on January 8, 2016
98

Total share consideration
$
77,373

Total consideration
$
173,379
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The acquisition consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):

     Cash and cash equivalents
$
3,504

     Accounts receivable
5

     Income tax receivable
136

     Prepaid expenses and other current assets
1

     Deferred tax liabilities, net
(55,708
)
     Intangible asset with finite life - core technology
167,000

     Liabilities assumed
(1,528
)
     Goodwill
59,969

Total consideration
$
173,379
Schedule of Pro Forma Information
The following table presents supplemental pro forma information for the three and twelve months ended December 31, 2016 and December 31, 2015, as if the acquisition of OMT had occurred on January 1, 2015 (in thousands except for income per share):

 
Three months ended
Twelve months ended
December 31,
December 31,
2016
 
2015
2016
 
2015
Revenue
$
38,185

 
$
24,571

$
111,449

 
$
80,365

Net (loss) income
$
(3,126
)
 
5,888

$
632

 
$
222,788

 
 
 
 
 
 
 
Basic (loss) income per share:
$
(0.15
)
 
$
0.30

$
0.03

 
$
11.26

Diluted (loss) income per share:
$
(0.15
)
 
$
0.27

$
0.03

 
$
10.50
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurement (Tables)
 12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Schedule of assets and liabilities measured on recurring basis
The following table provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2016 and 2015 (in thousands):

Fair Value Measurements at Reporting Date Using
December 31, 2016
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Short-term investments (1)
$
122,296

 
$
3,054

 
$
119,242

 
$
—

Note receivable Viking (2)
3,207

 
—

 
—

 
3,207

Investment in warrants (3)
684

 
684

 
—

 
—

     Total assets
$
126,187

 
$
3,054

 
$
119,242

 
$
3,207

Liabilities:
 
 
 
 
 
 
 
Current contingent liabilities - CyDex (4a)
$
101

 
$
—

 
$
—

 
$
101

Long-term contingent liabilities - Metabasis (5)
1,413

 
—

 
1,413

 
—

Long-term contingent liabilities - CyDex (4)
1,503

 
—

 
—

 
1,503

Liability for amounts owed to former licensees (6)
371

 
371

 
—

 
—

     Total liabilities
$
3,388

 
$
371

 
$
1,413

 
$
1,604


Fair Value Measurements at Reporting Date Using
December 31, 2015
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents (7)
$
3,015

 
$
—

 
$
3,015

 
$
—

Short-term investments (1)
92,775

 
6,786

 
85,989

 
—

Note receivable Viking (2)
4,782

 
—

 
—

 
4,782

     Total assets
$
100,572

 
$
6,786

 
$
89,004

 
$
4,782

Liabilities:
 
 
 
 
 
 
 
Current contingent liabilities - CyDex(4)
$
7,812

 
$
—

 
$
—

 
$
7,812

Current contingent liabilities-Metabasis (5)
2,602

 
—

 
2,602

 
—

Long-term contingent liabilities - Metabasis (5)
1,355

 
—

 
1,355

 
—

Long-term contingent liabilities - CyDex (4)
1,678

 
—

 
—

 
1,678

Liability for amounts owed to former licensees (6)
794

 
794

 
—

 
—

     Total liabilities
$
14,241

 
$
794


$
3,957


$
9,490


    

(1) Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.

(2) The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 75% at December 31, 2016 and 65% at December 31, 2015. Changes in these assumptions may materially affect the fair value estimate. For the year ended December 31, 2016 and December 31, 2015, the Company reported a decrease in the fair value of the Viking convertible notes of $0.2 million and$0.8 million respectively in "Other, net" of the consolidated statement of operations.

(3) Investment in warrants, which the Company received as a result of Viking’s partial repayment of the Viking note receivable and the Company’s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities.

(4) The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.

(4a) The fair value of the liabilities for short-term CyDex contingent liabilities at December 31, 2016 disclosed herein represents the fair value of the estimated contingent considerations owed to former license holder only, which is determined based on the methodology described in (4) above. The contingent considerations owed to the Cydex CVR holders at December 31, 2016 is determined based on actual amount owed at December 31, 2016 as the Cydex CVR agreement ended at December 31, 2016.

(5) The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR.

(6) The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.

(7) Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.
Significant unobservable inputs used in determining the fair value of contingent liabilities
The following table represents significant unobservable inputs used in determining the fair value of contingent liabilities assumed in the acquisition of CyDex:

 
 
December 31,
 
 
2016
 
2015
Range of annual revenue subject to revenue sharing (1)
 
N/A
 
$22.5 million
Revenue volatility
 
25%
 
25%
Average of probability of commercialization
 
12.5%
 
73%
Sales beta
 
N/A
 
0.40
Credit rating
 
BB
 
BB
Equity risk premium
 
6%
 
6%
Market price of risk
 
3.2%
 
N/A

(1)
For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual $5.0 million amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017.
Reconciliation of the level 3 financial instruments
A reconciliation of the level 3 financial instruments as of December 31, 2016 is as follows (in thousands):

Assets:
 
Fair value of level 3 financial instruments as of December 31, 2015
$
4,782

Viking note receivable fair market value adjustment

(215
)
Cash payment received as partial repayment of note receivable

(300
)
Fair market value of stock received as partial repayment of note receivable

(1,060
)
Fair value of level 3 financial instrument assets as of December 31, 2016
$
3,207

 
 
Liabilities
 
Fair value of level 3 financial instruments as of December 31, 2015
$
9,490

Payments to CVR holders and other contingency payments
(6,158
)
Fair value adjustments to contingent liabilities
3,259

Other (1)
(4,987
)
Fair value of level 3 financial instruments as of December 31, 2016
$
1,604
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2
Lease Obligations (Tables)
 12 Months Ended
Dec. 31, 2016
Leases [Abstract]  
Payments expected to received from sublease agreements
The following table provides a summary of operating lease obligations and payments expected to be received from sublease agreements as of December 31, 2016 (in thousands):

Operating lease obligations:
 
Lease
Termination
Date
 
Less than 1
year
 
1-2 years
 
3-4 years
 
Thereafter
 
Total
Corporate headquarters-San Diego, CA
 
April 2023
 
$
128

 
$
267

 
$
283

 
$
197

 
$
875

Office and research facility-La Jolla, CA
 
June 2019
 
718

 
1,111

 
—

 
—

 
1,829

Bioscience and Technology Business Center-Lawrence, KS
 
December 2017
 
54

 
—

 
—

 
—

 
54

Total operating lease obligations
 
 
 
$
900

 
$
1,378

 
$
283

 
$
197

 
$
2,758

 
 
 
 
 
 
 
 
 
 
 
 
 
Sublease payments expected to be received:
 
 
 
 
 
 
 
 
 
 
 
 
Office and research facility-La Jolla, CA
 
June 2019
 
656

 
1,002

 
—

 
—

 
1,658

Net operating lease obligations
 
 
 
$
244

 
$
376

 
$
283

 
$
197

 
$
1,100
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.6.0.2
Financing Arrangements (Tables)
 12 Months Ended
Dec. 31, 2016
Debt Disclosure [Abstract]  
Summary of carrying values and coupon rates on financing arrangements
The following table summarizes information about the liability components the Company's financing arrangement (dollars in thousands):
 
December 31, 2016
 
December 31, 2015

2019 Convertible Senior Notes
 
 
 
     Principal amount outstanding
$
245,000

 
$
245,000

     Unamortized discount
(32,090
)
 
(43,015
)
Total current portion of notes payable
$
212,910

 
$
201,985
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details (Tables)
 12 Months Ended
Dec. 31, 2016
Other Balance Sheet Details [Abstract]  
Schedule of investment categories
The following table summarizes the various investment categories at December 31, 2016 and 2015 (in thousands):
 
Cost
 
Gross unrealized
gains
 
Gross unrealized
losses
 
Estimated
fair value
December 31, 2016
 
 
 
 
 
 
 
Short-term investments
 
 
 
 
 
 
 
     Bank deposits
$
40,715

 
$
19

 
$
—

 
$
40,734

     Corporate bonds
11,031

 
—

 
(5
)
 
11,026

     Corporate equity securities
1,512

 
1,542

 
—

 
3,054

     Commercial paper
33,074

 
2

 
(9
)
 
33,067

     Agency bonds
7,294

 
1

 
—

 
7,295

     U.S. Government bonds
7,508

 
—

 
(1
)
 
7,507

     Municipal bonds
19,624

 
—

 
(11
)
 
19,613

 
$
120,758

 
$
1,564

 
$
(26
)
 
$
122,296

December 31, 2015
 
 
 
 
 
 
 
Short-term investments
 
 
 
 
 
 
 
     Bank deposits
$
43,043

 
$
—

 
$
(4
)
 
$
43,039

     Corporate bonds
41,238

 
—

 
(35
)
 
41,203

     Commercial paper
1,747

 
—

 
—

 
1,747

     Asset backed securities
10,020

 
—

 
(5
)
 
10,015

     Corporate equity securities
1,843

 
4,944

 
—

 
6,787

 
$
97,891

 
$
4,944

 
$
(44
)
 
$
102,791
Schedule of other current assets
Other current assets consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Prepaid expenses
$
1,864

 
$
1,177

Other receivables
311

 
731

 
$
2,175

 
$
1,908
Schedule of property and equipment
Property and equipment is stated at cost and consists of the following (in thousands):
 
December 31,
 
2016
 
2015
Lab and office equipment
$
1,067

 
$
2,248

Leasehold improvements
1,754

 
273

Computer equipment and software
569

 
632

 
3,390

 
3,153

Less accumulated depreciation and amortization
(1,571
)
 
(2,781
)
 
$
1,819

 
$
372
Summary of goodwill and other identifiable intangible assets
Goodwill and identifiable intangible assets consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Indefinite lived intangible assets
 
 
 
     IPR&D
$
12,246

 
$
12,556

     Goodwill
72,207

 
12,238

Definite lived intangible assets
 
 
 
     Complete technology
182,577

 
15,267

          Less: Accumulated amortization
(12,792
)
 
(3,762
)
     Trade name
2,642

 
2,642

          Less: Accumulated amortization
(784
)
 
(652
)
     Customer relationships
29,600

 
29,600

          Less: Accumulated amortization
(8,784
)
 
(7,304
)
Total goodwill and other identifiable intangible assets, net
$
276,912

 
$
60,585
Schedule of commercial license rights
Commercial license rights consist of the following (in thousands):
 
December 31,
 
December 31,
 
2016
 
2015
CorMatrix
$
17,696

 
$
—

Selexis
8,602

 
8,602

 
26,298

 
8,602

Less: accumulated amortization
(477
)
 
(48
)
     Total commercial rights, net
$
25,821

 
$
8,554
Schedule of accrued liabilities
Accrued liabilities consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Compensation
$
2,603

 
$
1,711

Legal
829

 
726

Amounts owed to former licensees
899

 
915

Royalties owed to third parties
942

 
823

Other
1,124

 
1,230

 
$
6,397

 
$
5,405
Schedule of contingent liabilities
Contingent liabilities consist of the following (in millions):
 
December 31, 2014
Payments
Fair Value Adjustment
December 31, 2015
Payments
Fair Value Adjustment
December 31, 2016
Cydex
$
11.5

$
(5.8
)
$
3.8

$
9.5

(6.2
)
$
3.3

$
6.6

Metabasis
3.7

(0.9
)
1.2

4.0

(2.6
)
0.1

1.5

Total
15.2

(6.7
)
5.0

13.5

(8.8
)
3.4

8.1
Schedule of other long-term liabilities
Other long-term liabilities consist of the following (in thousands):
 
December 31,
 
2016
 
2015
Deferred rent
$
357

 
$
—

Deposits
43

 
268

Other
287

 
29

 
$
687

 
$
297
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2016
Equity [Abstract]  
Schedule for accounting for share-based compensation
The following table summarizes stock-based compensation expense (in thousands):
 
December 31,
 
2016
 
2015
 
2014
Stock-based compensation expense as a component of:
 
 
 
 
 
Research and development expenses
$
8,836

 
$
4,080

 
$
3,595

General and administrative expenses
10,057

 
8,378

 
7,675

 
$
18,893

 
$
12,458

 
$
11,270
Stock option plan activity
Following is a summary of the Company’s stock option plan activity and related information:
 
 
Shares
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term in
Years
 
Aggregate
Intrinsic
Value
(In  thousands)
Balance at December 31, 2015
1,683,341

 
$
34.19

 
6.48
 
$
124,800

Granted
263,489

 
92.09

 
 
 
 
Exercised
(164,440
)
 
38.08

 
 
 
 
Forfeited
(28,115
)
 
60.17

 
 
 
 
Balance at December 31, 2016
1,754,275

 
42.12

 
6.19
 
104,247

Exercisable at December 31, 2016
1,298,561

 
30.21

 
5.44
 
92,723

Options vested and expected to vest as of December 31, 2016
1,752,275

 
$
42.12

 
6.19
 
$
104,247
Stock option plan activity, by exercise price range
Following is a further breakdown of the options outstanding as of December 31, 2016:
 
Range of exercise prices
Options
outstanding
 
Weighted
average
remaining  life
in years
 
Weighted average
exercise price
 
Options
exercisable
 
Weighted average
exercise price
$8.58 - $12.53
247,574

 
3.94
 
$
9.98

 
247,574

 
$
9.98

$10.12 - $12.81
76,100

 
4.92
 
11.38

 
76,100

 
11.38

$14.47 - $14.47
288,887

 
5.11
 
14.47

 
274,887

 
14.47

$16.14 - $21.00
106,242

 
1.85
 
17.76

 
106,242

 
17.76

$21.92 - $21.92
225,105

 
6.13
 
21.92

 
213,199

 
21.92

$32.00 - $53.34
72,330

 
6.02
 
36.18

 
62,747

 
34.73

$56.26 - $59.26
183,595

 
8.11
 
56.26

 
70,877

 
56.26

$63.58 - $68.62
26,382

 
7.50
 
67.20

 
21,976

 
67.50

$74.42 - $74.42
227,856

 
7.12
 
74.42

 
162,233

 
74.42

$85.79 - $138.53
298,204

 
9.03
 
93.19

 
62,726

 
89.71

$8.58 – $138.53
1,752,275

 
6.19
 
$
42.12

 
1,298,561

 
$
30.21
Stock option weighted average assumptions
The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:

 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Risk-free interest rate
1.3%-1.9%
 
1.7%-2.0%
 
1.9%
 
Expected volatility
48%-50%
 
50%-58%
 
62%-69%
 
Expected term
6.6 to 6.7 years
 
6.5 years
 
6.0 years
 
Forfeiture rate
5.00%
 
8.52%
 
8.6%-9.7%
 
Restricted stock activity
The following is a summary of the Company’s restricted stock activity and related information:
 
 
Shares
 
Weighted-Average
Grant Date Fair
Value
Outstanding at December 31, 2015
130,749

 
$
60.36

Granted
234,855

 
95.31

Vested
(54,421
)
 
66.79

Forfeited
(2,483
)
 
67.95

Outstanding at December 31, 2016
308,700

 
$
86.61
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Schedule of the components of income tax benefit
The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):
 
Year Ended December 31,
 
2016
 
2015
 
2014
 
Current expense (benefit):
 
 
 
 
 
 
Federal
$
21

 
$
11

 
$
15

 
State
12

 
7

 
19

 
 
33

 
18

 
34

 
Deferred expense (benefit):
 
 
 
 
 
 
Federal
10,534

 
(167,413
)
 
406

 
State
(240
)
 
(24,720
)
 
(30
)
 
 
$
10,327

 
$
(192,115
)
 
$
410

 
Schedule of deferred tax assets and liabilities
Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2016 and 2015 are shown below. The Company assesses the positive and negative evidence to determine if sufficient future taxable income will be generated to use the existing deferred tax assets. The Company's evaluation of evidence resulted in management concluding that the majority of the Company's deferred tax assets will be realized. However, the Company maintains a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December 31, 2016, 2015 and 2014. The valuation allowance increased $6.3 million in 2016, decreased $231.7 million in 2015 and decreased $7.2 million in 2014.
 
December 31,
 
2016
 
2015
 
(in thousands)
Deferred assets:
 
 
 
Net operating loss carryforwards
$
150,226

 
$
160,595

Research credit carryforwards
26,878

 
25,613

Fixed assets and intangibles
4,385

 
8,839

Accrued expenses
943

 
1,523

Contingent liabilities
578

 
707

Deferred revenue
—

 
3

Present value of royalties
591

 
3,007

Deferred rent
45

 
68

Capital Loss Carryforward
4,432

 
—

Viking Equity Method Investment
5,692

 
1,840

Other
19,312

 
15,441

 
213,082

 
217,636

Valuation allowance for deferred tax assets
(15,349
)
 
(9,066
)
Net deferred tax assets
$
197,733

 
$
208,570

Deferred tax liabilities:
 
 
 
Retrophin fair value adjustment
$
(52
)
 
$
(1,256
)
Convertible debt
(1,196
)
 
(1,844
)
Identified intangibles
(68,631
)
 
(12,770
)
Identified indefinite lived intangibles
(3,963
)
 
(3,617
)
Total
$
123,891

 
$
189,083
Schedule of effective income tax rate reconciliation
A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows:
 
 
Year Ended December 31,
 
2016
 
2015
 
2014
Amounts computed at statutory federal rate
$
2,786

 
$
13,198

 
$
3,843

State taxes net of federal benefit
175

 
386

 
697

Meals & entertainment
16

 
16

 
9

Imputed interest
(1
)
 
(161
)
 
53

Section 162(m) limitation
94

 
197

 
490

Contingent liabilities
1,225

 
1,684

 
1,748

Stock-based compensation
263

 
140

 
89

Expired NOLs
—

 
232

 
88

Research and development credits
(1,525
)
 
304

 
(113
)
Change in uncertain tax positions
1,423

 
27,188

 
7

Rate change for changes in state law
25

 
(5,756
)
 
119

APIC Excess Tax Benefit True Up

(622
)
 
—

 
—

Increase in deferred tax assets from completion of 382 analysis
(120
)
 
3,329

 
43

Avinza true up
—


(2,107
)

—

Change in valuation allowance
6,283

 
(231,370
)
 
(7,243
)
Other
305

 
605

 
580

 
$
10,327

 
$
(192,115
)
 
$
410
Schedule of unrecognized tax benefits
A reconciliation of the amount of unrecognized tax benefits at December 31, 2016, 2015 and 2014 is as follows (in thousands):
 
December 31,
 
2016
 
2015
 
2014
Balance at beginning of year
$
36,452

 
$
8,524

 
$
8,504

     Additions based on tax positions related to the current year
70

 
154

 
40

     Additions for tax positions of prior years
2,408

 
28,224

 
—

     Reductions for tax positions of prior years
(160
)
 
(450
)
 
(20
)
Balance at end of year
$
38,770

 
$
36,452

 
$
8,524
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Unaudited Quarterly Financial Information (Tables)
 12 Months Ended
Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results and cash flows of interim periods. Summarized quarterly data for fiscal years 2016 and 2015 are as follows (in thousands, except per share amounts):
 
First Quarter
 
Second Quarter
 
 Third Quarter
 
Fourth Quarter
2016
 
 
 
 
 
 
 
Total revenues
$
29,648

 
$
19,521

 
$
21,619

 
$
38,185

Total operating costs and expenses
14,552

 
15,552

 
16,153

 
18,831

Income tax (expense) benefit
(3,694
)
 
3,881

 
(160
)
 
(10,354
)
Income (loss) from continuing operations
5,877

 
(6,170
)
 
1,051

 
(3,125
)
Income from discontinued operations
731

 
—

 
—

 
—

Net income (loss)
6,608

 
(6,170
)
 
1,051

 
(3,125
)
Basic per share amounts:
 
 
 
 
 
 
 
     Net income (loss)
$
0.32

 
$
(0.30
)
 
$
0.05

 
$
0.15

Diluted per share amounts:
 
 
 
 
 
 
 
     Net income (loss)
0.30

 
(0.30
)
 
0.05

 
0.15

 
 
 
 
 
 
 
 
Weighted average shares—basic
20,708

 
20,832

 
20,887

 
20,898

Weighted average shares—diluted
22,284

 
20,832

 
22,997

 
20,898

 
 
 
 
 
 
 
 
2015
 
 
 
 
 
 
 
Total revenues
$
14,602

 
$
18,418

 
$
17,701

 
$
21,193

Total operating costs and expenses
11,253

 
14,053

 
9,104

 
10,175

Income tax (expense) benefit
(15
)
 
(265
)
 
191,881

 
514

(Loss) income from continuing operations
(89
)
 
22,027

 
199,165

 
6,341

Net loss attributable to noncontrolling interests
(843
)
 
(1,537
)
 
—

 
—

Net income
754

 
23,564

 
199,165

 
6,341

Basic per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.19

 
$
10.01

 
$
0.32

Diluted per share amounts:
 
 
 
 
 
 
 
Net income
$
0.04

 
$
1.11

 
$
9.28

 
$
0.29

 
 
 
 
 
 
 
 
Weighted average shares—basic
19,612

 
19,725

 
19,887

 
19,933

Weighted average shares—diluted
20,631

 
21,276

 
21,460

 
21,542
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Details 6) - Customer Concentration Risk - Revenue
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Partner A      
Revenue, Major Customer      
Total revenues 41.00% 27.00% 37.00%
Partner B      
Revenue, Major Customer      
Total revenues 14.00% 23.00% 31.00%
Partner C      
Revenue, Major Customer      
Total revenues 0.00% 18.00% 10.00%
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Details Textual)
 12 Months Ended
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Jan. 31, 2010
right
Basis of Presentation [Line Items]        
Working capital deficit $ 64,100,000      
Mezzanine equity excluded from working capital deficit $ 30,000,000      
Days after threshold consecutive trading days to complete payment of principal 3 days      
Number of consecutive trading days 50 days      
Maturity period of cash and cash equivalents, maximum 3 months      
Write-downs related to obsolete inventory $ 0 $ 0    
Goodwill impairment 0      
Royalty revenue 59,423,000 38,194,000 $ 29,994,000  
Accounts receivable, net $ 14,700,000 6,170,000    
Restocking fee (percent) 20.00%      
Share-based Compensation [Abstract]        
Expected dividend rate (percent) 0.00%      
Gain on disposition of product line $ 1,100,000      
Provision for taxes on gain $ 408,000 $ 0 $ 0  
Stock Options | 2002 Stock Incentive Plan        
Share-based Compensation [Abstract]        
Award expiration period 10 years      
Stock Options | Vest 1/8 on the six month anniversary of the date of grant | 2002 Stock Incentive Plan        
Share-based Compensation [Abstract]        
Award vesting period 6 months      
Award vesting right percentage 12.50%      
Stock Options | Vest 1/48 each month for forty-two months | 2002 Stock Incentive Plan        
Share-based Compensation [Abstract]        
Award vesting period 42 months      
Award vesting right percentage 2.08%      
Director        
Basis of Presentation [Line Items]        
Mr. Aryeh's ownership percentage in CorMatrix (percent, less than) 1.00%      
Director | 2002 Stock Incentive Plan        
Share-based Compensation [Abstract]        
Award vesting period 1 year      
Minimum        
Basis of Presentation [Line Items]        
Property and equipment, useful life 3 years      
Sales/revenues from partners reporting period 30 days      
Maximum        
Basis of Presentation [Line Items]        
Property and equipment, useful life 10 years      
Sales/revenues from partners reporting period 60 days      
Metabasis Therapeutics        
Basis of Presentation [Line Items]        
Number of contingent value rights | right       4
IPR&D        
Basis of Presentation [Line Items]        
Impairment charge $ 0      
CorMatrix        
Basis of Presentation [Line Items]        
Royalty revenue 1,500,000      
Accounts receivable, net $ 200,000      
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Significant Accounting Policies (Details) - shares
shares in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]                      
Weighted average shares outstanding (shares): 20,898 20,887 20,832 20,708 19,933 19,887 19,725 19,612 20,831 19,790 20,419
Dilutive potential common shares:                      
Restricted stock (shares)                 0 56 36
Stock options (shares)                 0 882 978
2019 Convertible Senior Notes (shares)                 0 499 0
Shares used to compute diluted income per share (shares) 20,898 22,997 20,832 22,284 21,542 21,460 21,276 20,631 20,831 21,228 21,433
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)                 3,544 3,333 5,104
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.6.0.2
Investment in Viking (Details Textual)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended 13 Months Ended
Apr. 13, 2016
USD ($)
shares
Apr. 30, 2016
USD ($)
$ / shares
shares
Jan. 31, 2016
USD ($)
May 31, 2015
USD ($)
$ / shares
shares
Apr. 30, 2015
May 31, 2014
USD ($)
program
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
May 31, 2015
$ / shares
Aug. 31, 2014
$ / shares
shares
Variable Interest Entity [Line Items]                      
Warrants to purchase number of shares (shares) | shares                     3,264,643
Exercise price per share of warrants (in USD per share) | $ / shares                     $ 125.08
Proceeds received from repayment of Viking note receivable             $ 300 $ 0 $ 0    
Note receivable from Viking             $ 3,207 $ 4,782      
Viking                      
Variable Interest Entity [Line Items]                      
Number of programs licensed | program           5          
Loss recorded (percent)                   100.00%  
Debt | Viking                      
Variable Interest Entity [Line Items]                      
Convertible loan facility extended           $ 2,500          
Repayment in equity (percent)         200.00%            
Common Stock                      
Variable Interest Entity [Line Items]                      
Aggregate value of shares received in Viking IPO       $ 29,200              
Shares of Viking stock purchased (shares) | shares       1,100,000              
Purchase of Viking common stock       $ 9,000              
Equity Method Investee                      
Variable Interest Entity [Line Items]                      
Shares sold in Viking IPO (shares) | shares   7,500,000                  
Initial offering price per share (in usd per share) | $ / shares   $ 1.25                  
Shares of Viking stock purchased (shares) | shares   560,000                  
Purchase of Viking common stock   $ 700                  
Interest rate on note due from Viking (percent)     2.50%         5.00%      
Extension of lock-up period     1 year                
Amount of loan to be repaid upon consummation of first capital financing transaction     $ 1,500                
Amount of loan to be repaid in cash upon consummation of first capital financing transaction     $ 300                
Warrants to purchase number of shares (shares) | shares   7,500,000                  
Exercise price per share of warrants (in USD per share) | $ / shares   $ 1.50                  
Warrants purchased (shares) | shares   560,000                  
Proceeds received from repayment of Viking note receivable $ 300                    
Shares received pursuant to MLA amendment (shares) | shares 960,000                    
Warrants received, licensing agreement (shares) | shares 960,000                    
Value of consideration received for repayment of convertible notes $ 1,200                    
Aggregate ownership, percent   32.70%         30.30%        
Decrease in equity method investment   $ (10,700)                  
Other than temporary impairment of investment in Viking             $ 7,400        
Equity Method Investee | IPO | Common Stock                      
Variable Interest Entity [Line Items]                      
Shares sold in Viking IPO (shares) | shares       3,700,000              
Aggregate offering price       $ 29,200              
Initial offering price per share (in usd per share) | $ / shares       $ 8.00           $ 8.00  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combinations (Details)
$ in Thousands
 12 Months Ended
Jan. 08, 2016
USD ($)
program
platform
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Business Acquisition [Line Items]      
Finite-lived intangible asset, useful life   20 years  
Goodwill   $ 72,207 $ 12,238
OMT, Inc.      
Business Acquisition [Line Items]      
Number of transgenic animal platforms | platform 3    
Number of partnered programs added | program 16    
Consideration transferred $ 173,400    
Goodwill $ 59,969    
Core Technology | OMT, Inc.      
Business Acquisition [Line Items]      
Projected cash flow discount rate (percent) 15.50%    
Finite-lived intangible asset, useful life 20 years    
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combinations - Consideration Transferred (Details) - OMT, Inc.
$ / shares in Units, shares in Thousands, $ in Thousands
Jan. 08, 2016
USD ($)
$ / shares
shares
Business Acquisition [Line Items]  
Cash consideration $ 96,006
Actual number of shares issued (shares) | shares 790
Multiplied by: Ligand closing share price on January 8, 2016 (in USD per share) | $ / shares $ 98
Total share consideration $ 77,373
Total consideration $ 173,379
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combinations - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Jan. 08, 2016
Dec. 31, 2015
Business Acquisition [Line Items]      
Goodwill $ 72,207   $ 12,238
OMT, Inc.      
Business Acquisition [Line Items]      
Cash and cash equivalents   $ 3,504  
Accounts receivable   5  
Income tax receivable   136  
Prepaid expenses and other current assets   1  
Deferred tax liabilities, net   (55,708)  
Intangible asset with finite life - core technology   167,000  
Liabilities assumed   (1,528)  
Goodwill   59,969  
Total consideration   $ 173,379  
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.6.0.2
Business Combinations - Pro Forma Information (Details) - OMT, Inc. - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Jan. 07, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Business Acquisition [Line Items]          
Revenue   $ 38,185 $ 24,571 $ 111,449 $ 80,365
Net (loss) income   $ (3,126) $ 5,888 $ 632 $ 222,788
Basic (loss) income per share (in USD per share):   $ (0.15) $ 0.30 $ 0.03 $ 11.26
Diluted (loss) income per share (in USD per share):   $ (0.15) $ 0.27 $ 0.03 $ 10.50
Pro forma adjustment for share-based compensation expense     $ 300   $ 900
Pro forma adjustment for additional amortization of intangible assets     $ 2,100   6,300
Pro forma adjustment for platform license fee paid         $ 3,000
Pro forma adjustment for revenue of OMT, Inc. prior to acquisition date $ 2,500        
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurement (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Convertible Notes Receivable, Fair Value, Period Increase (Decrease) $ (200) $ (800)
Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 126,187 100,572
Liabilities, fair value 3,388 14,241
Recurring | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 101 7,812
Recurring | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2]   2,602
Recurring | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 1,413 1,355
Recurring | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 1,503 1,678
Recurring | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3] 371 794
Recurring | Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [4]   3,015
Recurring | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 122,296 92,775
Recurring | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] $ 3,207 $ 4,782
Revenue volatility (percent) 75.00% 65.00%
Recurring | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] $ 684  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 3,054 $ 6,786
Liabilities, fair value 371 794
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2]   0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3] 371 794
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [4]   0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 3,054 6,786
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] 0 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] 684  
Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 119,242 89,004
Liabilities, fair value 1,413 3,957
Recurring | Significant Other Observable Inputs (Level 2) | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2]   2,602
Recurring | Significant Other Observable Inputs (Level 2) | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 1,413 1,355
Recurring | Significant Other Observable Inputs (Level 2) | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3] 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [4]   3,015
Recurring | Significant Other Observable Inputs (Level 2) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 119,242 85,989
Recurring | Significant Other Observable Inputs (Level 2) | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [6] 0 0
Recurring | Significant Other Observable Inputs (Level 2) | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] 0  
Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 3,207 4,782
Liabilities, fair value 1,604 9,490
Recurring | Significant Unobservable Inputs (Level 3) | Current portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 101 7,812
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities-Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2]   0
Recurring | Significant Unobservable Inputs (Level 3) | Long-term portion of contingent liabilities - Metabasis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [2] 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Long-term portion of contingent liabilities - CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [1] 1,503 1,678
Recurring | Significant Unobservable Inputs (Level 3) | Liability for restricted investments owed to former licensees    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Liabilities, fair value [3] 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Short-term investments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [5] 0 0
Recurring | Significant Unobservable Inputs (Level 3) | Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value 3,207 [6] $ 4,782
Recurring | Significant Unobservable Inputs (Level 3) | Investment in warrants    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Assets, fair value [7] $ 0  
[1] The fair value of the liabilities for CyDex contingent liabilities were determined based on the income approach using a Monte Carlo analysis. The fair value is subjective and is affected by changes in inputs to the valuation model including management’s assumptions regarding revenue volatility, probability of commercialization of products, estimates of timing and probability of achievement of certain revenue thresholds and developmental and regulatory milestones which may be achieved and affect amounts owed to former license holders and CVR holders. Changes in these assumptions can materially affect the fair value estimate.
[2] The liability for CVRs for Metabasis are determined using quoted market prices in a market that is not active for the underlying CVR.
[3] The liability for amounts owed to former licensees are determined using quoted market prices in active markets for the underlying investment received from a partner, a portion of which is owed to former licensees.
[4] Highly liquid investments with maturities less than 90 days from the purchase date are recorded as cash equivalents that are classified as Level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.
[5] Investments in equity securities, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities. Short-term investments in marketable securities with maturities greater than 90 days are classified as level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market.
[6] The fair value of the convertible note receivable from Viking at December 31, 2015 was determined using a probability weighted option pricing model. The fair value is subjective and is affected by certain significant input to the valuation model such as the estimated volatility of the common stock, which was estimated to be 75% at December 31, 2016 and 65% at December 31, 2015. Changes in these assumptions may materially affect the fair value estimate. For the year ended December 31, 2016 and December 31, 2015, the Company reported a decrease in the fair value of the Viking convertible notes of $0.2 million and$0.8 million respectively in "Other, net" of the consolidated statement of operations.
[7] Investment in warrants, which the Company received as a result of Viking’s partial repayment of the Viking note receivable and the Company’s purchase of Viking common stock and warrants in April 2016, are classified as level 1 as the fair value is determined using quoted market prices in active markets for the same securities.
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurement (Details 1) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Fair Value Disclosures [Abstract]    
Change in fair value of Viking convertible notes $ 0.2 $ 0.8
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurement (Details 2) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Assets:      
Fair value of level 3 financial instruments as of December 31, 2015 $ 4,782    
Fair market value of stock received as partial repayment of note receivable (215)    
Cash payment received as partial repayment of note receivable (300)    
Viking note receivable fair market value adjustment (1,060)    
Fair value of level 3 financial instrument assets as of December 31, 2016 3,207 $ 4,782  
Liabilities      
Fair value of level 3 financial instruments as of December 31, 2015 9,490    
Other [1] 4,987    
Fair value of level 3 financial instruments as of December 31, 2016 1,604 9,490  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Payments to CVR holders and other contingency payments (8,777) (6,740) $ (3,493)
Fair value adjustments to contingent liabilities 3,400 5,000  
Viking Therapeutics, Inc.      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity Method Investment, Quoted Market Value 7,500    
2019 Convertible Senior Notes | Senior Notes      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Fair value of convertible debt 331,700    
CyDex      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Payments to CVR holders and other contingency payments (6,158) (5,848)  
Fair value adjustments to contingent liabilities $ 3,259 $ 3,800  
[1] Balance represents Cydex CVR obligation, which was determined based on actual amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016.
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.6.0.2
Fair Value Measurements - Unobservable Inputs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amount owed to Cydex CVR holders $ 2,916 $ 3,033
CyDex    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Revenue Threshold for Revenue Sharing   15,000
Range of annual revenue subject to revenue sharing [1]   $ 22,500
Revenue volatility (percent) 25.00% 25.00%
Average of probability of commercialization (percent) 12.50% 73.00%
Sales beta (decimal)   0.40
Credit rating (non-numeric) BB BB
Equity risk premiun (percent) 6.00% 6.00%
Market price of risk (percent) 3.20%  
Amount owed to Cydex CVR holders $ 5,000  
[1] For the December 31, 2015 valuation date, revenue subject to revenue sharing represent management’s estimate of the range of total annual revenue subject to revenue sharing (i.e. annual revenues in excess of $15 million) through December 31, 2016, which is the term of the CVR agreement. For the December 31, 2016 valuation date, the Cydex CVR was determined based on the actual $5.0 million amount owed to Cydex CVR holders as the Cydex CVR agreement ended at December 31, 2016. This amount was subsequently paid in February 2017.
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2
Lease Obligations (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
USD ($)
Payments expected to received from sublease agreements  
Operating lease obligation, Less than 1 year $ 900
Operating lease obligation, 1-2 years 1,378
Operating leases obligation, 3-4 years 283
Operating lease obligation, Thereafter 197
Operating lease obligation, Total 2,758
Operating lease obligation, Less than 1 year, net 244
Operating lease obligation, 1-2 years, net 376
Operating lease obligation, 3-4 years, net 283
Operating lease obligation, Thereafter, net 197
Operating lease obligation, net, Total $ 1,100
Corporate Headquarters - San Diego, CA | CALIFORNIA  
Payments expected to received from sublease agreements  
Lease Termination Date Apr. 30, 2023
Operating lease obligation, Less than 1 year $ 128
Operating lease obligation, 1-2 years 267
Operating leases obligation, 3-4 years 283
Operating lease obligation, Thereafter 197
Operating lease obligation, Total $ 875
Office and Research Facility - La Jolla, CA | CALIFORNIA  
Payments expected to received from sublease agreements  
Lease Termination Date Jun. 30, 2019
Operating lease obligation, Less than 1 year $ 718
Operating lease obligation, 1-2 years 1,111
Operating leases obligation, 3-4 years 0
Operating lease obligation, Thereafter 0
Operating lease obligation, Total 1,829
Sublease payments expected to be received, Less than 1 year 656
Sublease payments expected to be received, 1-2 years 1,002
Sublease payments expected to be received, 3-4 years 0
Sublease payments expected to be received, Thereafter 0
Sublease payments expected to be received, Total $ 1,658
Bioscience and Technology Business Center - Lawrence, KS | KANSAS  
Payments expected to received from sublease agreements  
Lease Termination Date Dec. 01, 2017
Operating lease obligation, Less than 1 year $ 54
Operating lease obligation, Total $ 54
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2
Lease Obligations (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
May 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating Leased Assets [Line Items]        
Lease expiration year, Maximum   2023    
Rent expense   $ 300 $ 400 $ 700
Lease exit and termination costs   1,032 1,020 1,084
Rent expense, net of sublease income   1,700 3,300  
Adjustment for accretion and changes in lease assumptions   700 900 $ 1,100
Corporate Headquarters - San Diego, CA | CALIFORNIA        
Operating Leased Assets [Line Items]        
Rent expense $ 100      
Initial term of lease 7 years      
Annual escalation of operating lease (percent) 3.00%      
Renewal term of lease 5 years      
Contract Termination        
Operating Leased Assets [Line Items]        
Lease exit and termination costs   $ 0 $ 900  
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.6.0.2
Financing Arrangements (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Notes Payable, Current and Noncurrent [Abstract]    
Total current portion of notes payable $ 212,910 $ 201,985
2019 Convertible Senior Notes    
Notes Payable, Current and Noncurrent [Abstract]    
Principal amount outstanding 245,000 245,000
Unamortized discount $ (32,090) $ (43,015)
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.6.0.2
Financing Arrangements (Details Textual)
 1 Months Ended 12 Months Ended
Aug. 31, 2014
USD ($)
d
$ / shares
shares
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Debt Instrument [Line Items]        
Number of consecutive trading days   50 days    
Carrying value of equity component   $ 29,563,000 $ 39,628,000  
Equity component of convertible debt issuance, net of issuance costs   10,065,000 (39,628,000) $ 51,271,000
Warrants to purchase number of shares (shares) | shares 3,264,643      
Exercise price per share of convertible bond hedges | $ / shares $ 75.05      
Payments for convertible bond hedges   0 0 48,143,000
Exercise price per share of warrants (in USD per share) | $ / shares $ 125.08      
Sale of warrants $ 11,600,000     $ 11,638,000
2019 Convertible Senior Notes        
Debt Instrument [Line Items]        
Principal amount outstanding   245,000,000 245,000,000  
Senior Notes        
Debt Instrument [Line Items]        
Payments for convertible bond hedges 48,100,000      
Senior Notes | 2019 Convertible Senior Notes        
Debt Instrument [Line Items]        
Principal amount outstanding 245,000,000.0      
Net proceeds from debt issuance $ 239,300,000      
Convertible debt conversion ratio 0.0133251      
Debt conversion price per share | $ / shares $ 75.05      
Interest on debt instrument (percent) 0.75%      
Carrying value of equity component   51,300,000    
Proceeds from issuance of debt $ 245,000,000      
Discount rate (percent) 5.83%      
Convertible debt, noncurrent $ 192,500,000      
If-converted value of debt in excess of principal   86,700,000    
Debt issuance cost 5,700,000      
Equity component of convertible debt issuance, net of issuance costs 1,200,000      
Unamortized debt issuance costs $ 4,500,000      
Debt issuance costs, net   $ 2,500,000 $ 3,400,000  
Term of debt (duration) 5 years      
Senior Notes | 2019 Convertible Senior Notes | Debt Instrument, Redemption, Period One        
Debt Instrument [Line Items]        
Number of trading days | d 20      
Number of consecutive trading days 30 days      
Stock price trigger threshold (percent) 130.00%      
Senior Notes | 2019 Convertible Senior Notes | Debt Instrument, Redemption, Period Two        
Debt Instrument [Line Items]        
Number of trading days | d 5      
Number of consecutive trading days 10 days      
Debt threshold trigger price (percent) 98.00%      
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details - Investment categories (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Short-term investments    
Schedule of Available-for-sale Securities [Line Items]    
Cost $ 120,758 $ 97,891
Gross unrealized gains 1,564 4,944
Gross unrealized losses (26) (44)
Estimated fair value 122,296 102,791
Bank Deposits    
Schedule of Available-for-sale Securities [Line Items]    
Cost 40,715 43,043
Gross unrealized gains 19 0
Gross unrealized losses 0 (4)
Estimated fair value 40,734 43,039
Corporate Bonds    
Schedule of Available-for-sale Securities [Line Items]    
Cost 11,031 41,238
Gross unrealized gains 0 0
Gross unrealized losses (5) (35)
Estimated fair value 11,026 41,203
Corporate Equity Securities    
Schedule of Available-for-sale Securities [Line Items]    
Cost 1,512 1,843
Gross unrealized gains 1,542 4,944
Gross unrealized losses 0 0
Estimated fair value 3,054 6,787
Commercial Paper    
Schedule of Available-for-sale Securities [Line Items]    
Cost 33,074 1,747
Gross unrealized gains 2 0
Gross unrealized losses (9) 0
Estimated fair value 33,067 1,747
Agency bonds    
Schedule of Available-for-sale Securities [Line Items]    
Cost 7,294  
Gross unrealized gains 1  
Gross unrealized losses 0  
Estimated fair value 7,295  
U.S. Government bonds    
Schedule of Available-for-sale Securities [Line Items]    
Cost 7,508  
Gross unrealized gains 0  
Gross unrealized losses (1)  
Estimated fair value 7,507  
Asset-backed Securities    
Schedule of Available-for-sale Securities [Line Items]    
Cost   10,020
Gross unrealized gains   0
Gross unrealized losses   (5)
Estimated fair value   $ 10,015
Municipal bonds    
Schedule of Available-for-sale Securities [Line Items]    
Cost 19,624  
Gross unrealized gains 0  
Gross unrealized losses (11)  
Estimated fair value $ 19,613  
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details (Details) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Other Balance Sheet Details [Abstract]    
Prepaid expenses $ 1,864 $ 1,177
Other receivables 311 731
Other current assets $ 2,175 $ 1,908
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details - Property and Equipment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Property, Plant and Equipment [Line Items]      
Property and equipment , gross $ 3,390 $ 3,153  
Less accumulated depreciation and amortization (1,571) (2,781)  
Property and equipment, net 1,819 372  
Depreciation 200 200 $ 300
Lab and office equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment , gross 1,067 2,248  
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment , gross 1,754 273  
Computer equipment and software      
Property, Plant and Equipment [Line Items]      
Property and equipment , gross $ 569 $ 632  
Minimum      
Property, Plant and Equipment [Line Items]      
Property and equipment, useful life 3 years    
Maximum      
Property, Plant and Equipment [Line Items]      
Property and equipment, useful life 10 years    
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details - Goodwill and Other Intangible Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]      
Goodwill $ 72,207,000 $ 12,238,000  
Total goodwill and other identifiable intangible assets, net $ 276,912,000 60,585,000  
Finite-lived intangible asset, useful life 20 years    
Amortization expense $ 10,600,000 2,400,000 $ 2,400,000
Amortization expense, 2017 10,600,000    
Amortization expense, 2018 10,600,000    
Amortization expense, 2019 10,600,000    
Amortization expense, 2020 10,600,000    
Amortization expense, 2021 10,600,000    
Impairment of intangible assets with finite lives 0    
Customer relationships      
Finite-Lived Intangible Assets [Line Items]      
Definite lived intangible assets 29,600,000 29,600,000  
Less: Accumulated amortization (8,784,000) (7,304,000)  
Trade name      
Finite-Lived Intangible Assets [Line Items]      
Definite lived intangible assets 2,642,000 2,642,000  
Less: Accumulated amortization (784,000) (652,000)  
Complete technology      
Finite-Lived Intangible Assets [Line Items]      
Definite lived intangible assets 182,577,000 15,267,000  
Less: Accumulated amortization (12,792,000) (3,762,000)  
Licensing agreements      
Finite-Lived Intangible Assets [Line Items]      
Definite lived intangible assets 26,298,000 8,602,000  
Less: Accumulated amortization (477,000) (48,000)  
Total goodwill and other identifiable intangible assets, net 25,821,000 8,554,000  
Acquired in-process research and development      
Finite-Lived Intangible Assets [Line Items]      
IPR&D 12,246,000 12,556,000  
CorMatrix | Licensing agreements      
Finite-Lived Intangible Assets [Line Items]      
Definite lived intangible assets 17,696,000 0  
Selexis | Licensing agreements      
Finite-Lived Intangible Assets [Line Items]      
Definite lived intangible assets $ 8,602,000 $ 8,602,000  
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details (Details 1) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Other Balance Sheet Details [Abstract]    
Compensation $ 2,603 $ 1,711
Legal 829 726
Amounts owed to former licensees 899 915
Royalties owed to third parties 942 823
Other 1,124 1,230
Accrued liabilities $ 6,397 $ 5,405
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details - Contingent Liabilities (Details) - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Business Acquisition [Line Items]      
Revenue royalty payable on all Cydex-related revenue (percent) 20.00%    
Cydex-related revenue amount that triggers royalty payments $ 15,000,000.0    
Additional revenue royalty payable when higher threshold of Cydex-related revenue met (percent) 10.00%    
Cydex-related revenue amount that triggers additional royalty payments $ 35,000,000.0    
Contingent Liability [Roll Forward]      
Commercial rights, beginning 13,500,000 $ 15,200,000  
Payments (8,777,000) (6,740,000) $ (3,493,000)
Fair Value Adjustment 3,400,000 5,000,000  
Commercial rights, ending 8,100,000 13,500,000 15,200,000
CyDex      
Contingent Liability [Roll Forward]      
Commercial rights, beginning 9,500,000 11,497,000  
Payments (6,158,000) (5,848,000)  
Fair Value Adjustment 3,259,000 3,800,000  
Commercial rights, ending 6,600,000 9,500,000 11,497,000
Metabasis      
Contingent Liability [Roll Forward]      
Commercial rights, beginning 4,000,000 3,652,000  
Payments (2,618,000) (865,000)  
Fair Value Adjustment 74,000 1,172,000  
Commercial rights, ending $ 1,500,000 $ 4,000,000 $ 3,652,000
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.6.0.2
Other Balance Sheet Details (Details 2) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Other Balance Sheet Details [Abstract]    
Deferred rent $ 357 $ 0
Deposits 43 268
Other 287 29
Other long-term liabilities $ 687 $ 297
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Shares [Rollforward]    
Balance at Beginning of Period (shares) 1,683,341  
Granted (shares) 263,489  
Exercised (shares) (164,440)  
Forfeited (shares) (28,115)  
Balance at End of Period (shares) 1,754,275 1,683,341
Exercisable at December 31, 2016 (shares) 1,298,561  
Options vested and expected to vest as of December 31, 2016 (shares) 1,752,275  
Weighted Average Exercise Price [Roll Forward]    
Balance at Beginning of Period (in usd per share) $ 34.19  
Granted (in usd per share) 92.09  
Exercised (in usd per share) 38.08  
Forfeited (in usd per share) 60.17  
Balance at End of Period (in usd per share) 42.12 $ 34.19
Exercisable at December 31, 2016 (in usd per share) 30.21  
Options vested and expected to vest as of December 31, 2016 (in usd per share) $ 42.12  
Weighted Average Remaining Contractual Term in Years 6 years 2 months 9 days 6 years 5 months 23 days
Exercisable, Weighted Average Remaining Contractual Term in Years 5 years 5 months 9 days  
Options vested and expected to vest, Weighted Average Remaining Contractual Term in Years 6 years 2 months 9 days  
Aggregate Intrinsic Value $ 104,247 $ 124,800
Exercisable, Aggregate Intrinsic Value 92,723  
Options vested and expected to vest, Aggregate Intrinsic Value $ 104,247  
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity (Details 1)
 12 Months Ended
Dec. 31, 2016
$ / shares
shares
$8.58 – $138.53  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower $ 8.58
Range of exercise prices (per share), upper $ 138.53
Options outstanding (shares) | shares 1,752,275
Weighted average remaining life in years 6 years 2 months 9 days
Weighted average exercise price (per share) $ 42.12
Options exercisable (shares) | shares 1,298,561
Weighted average exercise price (per share) $ 30.21
$8.58 - $12.53  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 8.58
Range of exercise prices (per share), upper $ 12.53
Options outstanding (shares) | shares 247,574
Weighted average remaining life in years 3 years 11 months 9 days
Weighted average exercise price (per share) $ 9.98
Options exercisable (shares) | shares 247,574
Weighted average exercise price (per share) $ 9.98
$10.12 - $12.81  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 10.12
Range of exercise prices (per share), upper $ 12.81
Options outstanding (shares) | shares 76,100
Weighted average remaining life in years 4 years 11 months 1 day
Weighted average exercise price (per share) $ 11.38
Options exercisable (shares) | shares 76,100
Weighted average exercise price (per share) $ 11.38
$14.47 - $14.47  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 14.47
Range of exercise prices (per share), upper $ 14.47
Options outstanding (shares) | shares 288,887
Weighted average remaining life in years 5 years 1 month 10 days
Weighted average exercise price (per share) $ 14.47
Options exercisable (shares) | shares 274,887
Weighted average exercise price (per share) $ 14.47
$16.14 - $21.00  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 16.14
Range of exercise prices (per share), upper $ 21
Options outstanding (shares) | shares 106,242
Weighted average remaining life in years 1 year 10 months 6 days
Weighted average exercise price (per share) $ 17.76
Options exercisable (shares) | shares 106,242
Weighted average exercise price (per share) $ 17.76
$21.92 - $21.92  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 21.92
Range of exercise prices (per share), upper $ 21.92
Options outstanding (shares) | shares 225,105
Weighted average remaining life in years 6 years 1 month 17 days
Weighted average exercise price (per share) $ 21.92
Options exercisable (shares) | shares 213,199
Weighted average exercise price (per share) $ 21.92
$32.00 - $53.34  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 32.00
Range of exercise prices (per share), upper $ 53.34
Options outstanding (shares) | shares 72,330
Weighted average remaining life in years 6 years 7 days
Weighted average exercise price (per share) $ 36.18
Options exercisable (shares) | shares 62,747
Weighted average exercise price (per share) $ 34.73
$56.26 - $59.26  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 56.26
Range of exercise prices (per share), upper $ 59.26
Options outstanding (shares) | shares 183,595
Weighted average remaining life in years 8 years 1 month 10 days
Weighted average exercise price (per share) $ 56.26
Options exercisable (shares) | shares 70,877
Weighted average exercise price (per share) $ 56.26
$63.58 - $68.62  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 63.58
Range of exercise prices (per share), upper $ 68.62
Options outstanding (shares) | shares 26,382
Weighted average remaining life in years 7 years 6 months
Weighted average exercise price (per share) $ 67.20
Options exercisable (shares) | shares 21,976
Weighted average exercise price (per share) $ 67.50
$74.42 - $74.42  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 74.42
Range of exercise prices (per share), upper $ 74.42
Options outstanding (shares) | shares 227,856
Weighted average remaining life in years 7 years 1 month 13 days
Weighted average exercise price (per share) $ 74.42
Options exercisable (shares) | shares 162,233
Weighted average exercise price (per share) $ 74.42
$85.79 - $138.53  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Range of exercise prices (per share), lower 85.79
Range of exercise prices (per share), upper $ 138.59
Options outstanding (shares) | shares 298,204
Weighted average remaining life in years 9 years 11 days
Weighted average exercise price (per share) $ 93.19
Options exercisable (shares) | shares 62,726
Weighted average exercise price (per share) $ 89.71
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity (Details 2) - Restricted Stock
 12 Months Ended
Dec. 31, 2016
$ / shares
shares
Shares [Rollforward]  
Nonvested at Beginning of Period (shares) | shares 130,749
Granted (shares) | shares 234,855
Vested (shares) | shares (54,421)
Forfeited (shares) | shares (2,483)
Nonvested at End of Period (shares) | shares 308,700
Weighted-Average Grant Date Fair Value [Roll Forward]  
Nonvested at Beginning of Period (in usd per share) | $ / shares $ 60.36
Granted (in usd per share) | $ / shares 95.31
Vested (in usd per share) | $ / shares 66.79
Forfeited (in usd per share) | $ / shares 67.95
Nonvested at End of Period (in usd per share) | $ / shares $ 86.61
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
May 31, 2012
May 29, 2009
May 31, 2016
Sep. 30, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Corporate Share Repurchase [Abstract]              
Shares repurchased in period (shares)         40,500 6,120 1,253,425
Shares repurchased in period, value         $ 3,901,000 $ 489,000 $ 67,955,000
Stock repurchase program, authorized amount       $ 200,000,000.0      
Stock repurchase program, period in force       3 years      
Stock repurchase program, remaining authorized repurchase amount         $ 195,600,000    
Stock Options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average grant date fair value per share of stock options (in USD per share)         $ 46.53 $ 35.39 $ 46.20
Intrinsic value of options exercised         $ 12,000,000 $ 20,700,000 $ 15,300,000
Unrecognized compensation cost         $ 17,500,000    
Weighted-average period in which cost is expected to be recognized         2 years 2 months 20 days    
Cash received from options exercised         $ 6,200,000 $ 8,700,000 $ 4,400,000
Restricted Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted-average period in which cost is expected to be recognized         1 year 1 month 20 days    
Unrecognized compensation cost, restricted stock         $ 13,800,000    
2002 Stock Incentive Plan | Stock Options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Increase the number of shares under the 2002 Stock Incentive Plan (shares) 1,800,000 1,300,000 900,000        
Shares available for future option grants (shares)         1,000,000    
Amended ESPP              
Employee Stock Purchase Plan [Abstract]              
Shares allowed to purchase in employee stock purchase plan (shares)         1,250    
Percentage lesser of fair market value taken as purchase price of share         85.00%    
Common stock issued under amended ESSP (shares)         1,961 3,374 3,774
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity - Share-base Compensation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense $ 18,893 $ 12,458 $ 11,270
Research and development expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense 8,836 4,080 3,595
General and administrative expenses      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based compensation expense $ 10,057 $ 8,378 $ 7,675
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.6.0.2
Stockholders' Equity - Assumptions (Details)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate (percent)     1.90%
Expected term   6 years 6 months 6 years
Forfeiture rate (percent) 5.00% 8.52%  
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate (percent) 1.30% 1.70%  
Expected volatility (percent) 48.00% 50.00% 62.00%
Expected term 6 years 7 months 6 days    
Forfeiture rate (percent)     8.60%
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Risk-free interest rate (percent) 1.90% 2.00%  
Expected volatility (percent) 50.00% 58.00% 69.00%
Expected term 6 years 8 months 12 days    
Forfeiture rate (percent)     9.70%
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Current expense (benefit):                      
Federal                 $ 21 $ 11 $ 15
State                 12 7 19
Total Current Income Tax Benefit                 33 18 34
Deferred expense (benefit):                      
Federal                 10,534 (167,413) 406
State                 (240) (24,720) (30)
Income tax expense from continuing operations $ 10,354 $ 160 $ (3,881) $ 3,694 $ (514) $ (191,881) $ 265 $ 15 $ 10,327 $ (192,115) $ 410
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Details 2) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]                      
Amounts computed at statutory federal rate                 $ 2,786 $ 13,198 $ 3,843
State taxes net of federal benefit                 175 386 697
Meals & entertainment                 16 16 9
Imputed interest                 (1) (161) 53
Section 162(m) limitation                 94 197 490
Contingent liabilities                 1,225 1,684 1,748
Stock-based compensation                 263 140 89
Expired NOLs                 0 232 88
Research and development credits                 (1,525) 304 (113)
Change in uncertain tax positions                 1,423 27,188 7
Rate change for changes in state law                 25 (5,756) 119
APIC Excess Tax Benefit True Up                 (622) 0 0
Increase in deferred tax assets from completion of 382 analysis                 (120) 3,329 43
Avinza true up                 0 (2,107) 0
Change in valuation allowance                 6,283 (231,370) (7,243)
Other                 305 605 580
Income tax expense from continuing operations $ 10,354 $ 160 $ (3,881) $ 3,694 $ (514) $ (191,881) $ 265 $ 15 $ 10,327 $ (192,115) $ 410
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Details 1) - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Deferred assets:    
Net operating loss carryforwards $ 150,226 $ 160,595
Research credit carryforwards 26,878 25,613
Fixed assets and intangibles 4,385 8,839
Accrued expenses 943 1,523
Contingent liabilities 578 707
Deferred revenue 0 3
Present value of royalties 591 3,007
Deferred rent 45 68
Capital Loss Carryforward 4,432 0
Viking Equity Method Investment 5,692 1,840
Other 19,312 15,441
Deferred tax assets 213,082 217,636
Valuation allowance for deferred tax assets (15,349) (9,066)
Net deferred tax assets 197,733 208,570
Deferred tax liabilities:    
Retrophin fair value adjustment (52) (1,256)
Convertible debt (1,196) (1,844)
Identified intangibles (68,631) (12,770)
Identified indefinite lived intangibles (3,963) (3,617)
Total $ 123,891 $ 189,083
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Details 3) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of period $ 36,452 $ 8,524 $ 8,504
Additions based on tax positions related to the current year 70 154 40
Additions for tax positions of prior years 2,408 28,224 0
Reductions for tax positions of prior years (160) (450) (20)
Balance at end of period $ 38,770 $ 36,452 $ 8,524
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.6.0.2
Income Taxes (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating Loss Carryforwards [Line Items]      
Valuation allowance, change in amount $ 6.3 $ (231.7) $ (7.2)
Unrecognized tax benefits that would impact effective tax rate 35.5    
Realization Of Excess Tax Benefits From Share Based Compensation      
Operating Loss Carryforwards [Line Items]      
Deferred tax assets not recognized related to share-based compensation 13.7 $ 11.5  
Research Tax Credit Carryforward      
Operating Loss Carryforwards [Line Items]      
Tax credit carryforward 21.9    
California and New Jersey Research Tax Credit Carryforward      
Operating Loss Carryforwards [Line Items]      
Tax credit carryforward 19.4    
Internal Revenue Service (IRS)      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforward 446.3    
State and Local Jurisdiction      
Operating Loss Carryforwards [Line Items]      
Operating loss carryforward $ 140.5    
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.6.0.2
Summary of Unaudited Quarterly Financial Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 38,185 $ 21,619 $ 19,521 $ 29,648 $ 21,193 $ 17,701 $ 18,418 $ 14,602 $ 108,973 $ 71,914 $ 64,538
Total operating costs and expenses 18,831 16,153 15,552 14,552 10,175 9,104 14,053 11,253 65,088 44,585 44,912
Income tax (expense) benefit (10,354) (160) 3,881 (3,694) 514 191,881 (265) (15) (10,327) 192,115 (410)
(Loss) income from continuing operations (3,125) 1,051 (6,170) 5,877 6,341 199,165 22,027 (89)      
Income from discontinued operations       731         731 0 0
Less: Net loss attributable to noncontrolling interests         0 0 (1,537) (843) 0 (2,380) (1,132)
Net income $ (3,125) $ 1,051 $ (6,170) $ 6,608 $ 6,341 $ 199,165 $ 23,564 $ 754 $ (1,636) $ 229,824 $ 12,024
Basic per share amounts(1):                      
Net income (loss) (in usd per share) $ 0.15 $ 0.05 $ (0.30) $ 0.32 $ 0.32 $ 10.01 $ 1.19 $ 0.04 $ (0.08) [1] $ 11.61 [1] $ 0.59 [1]
Diluted per share amounts(1):                      
Net income (loss) (in usd per share) $ 0.15 $ 0.05 $ (0.30) $ 0.30 $ 0.29 $ 9.28 $ 1.11 $ 0.04 $ (0.08) [1] $ 10.83 [1] $ 0.56 [1]
Weighted average shares—basic (shares) 20,898 20,887 20,832 20,708 19,933 19,887 19,725 19,612 20,831 19,790 20,419
Weighted average shares—diluted (shares) 20,898 22,997 20,832 22,284 21,542 21,460 21,276 20,631 20,831 21,228 21,433
[1] The sum of net income per share amounts may not equal the total due to rounding
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 78 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 287 477 1 true 90 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.ligand.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.ligand.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.ligand.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.ligand.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.ligand.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 1005000 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.ligand.com/role/ConsolidatedStatementOfStockholdersEquity CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1006000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.ligand.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.ligand.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - Investment in Viking Sheet http://www.ligand.com/role/InvestmentInViking Investment in Viking Notes 9 false false R10.htm 2104100 - Disclosure - Business Combinations Sheet http://www.ligand.com/role/BusinessCombinations Business Combinations Notes 10 false false R11.htm 2106100 - Disclosure - Fair Value Measurement Sheet http://www.ligand.com/role/FairValueMeasurement Fair Value Measurement Notes 11 false false R12.htm 2108100 - Disclosure - Lease Obligations Sheet http://www.ligand.com/role/LeaseObligations Lease Obligations Notes 12 false false R13.htm 2109100 - Disclosure - Financing Arrangements Sheet http://www.ligand.com/role/FinancingArrangements Financing Arrangements Notes 13 false false R14.htm 2111100 - Disclosure - Other Balance Sheet Details Sheet http://www.ligand.com/role/OtherBalanceSheetDetails Other Balance Sheet Details Notes 14 false false R15.htm 2112100 - Disclosure - Stockholders' Equity Sheet http://www.ligand.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2117100 - Disclosure - Litigation Sheet http://www.ligand.com/role/Litigation Litigation Notes 16 false false R17.htm 2118100 - Disclosure - Income Taxes Sheet http://www.ligand.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 2119100 - Disclosure - Summary of Unaudited Quarterly Financial Information Sheet http://www.ligand.com/role/SummaryOfUnauditedQuarterlyFinancialInformation Summary of Unaudited Quarterly Financial Information Notes 18 false false R19.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.ligand.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 2301302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables 20 false false R21.htm 2304301 - Disclosure - Business Combinations (Tables) Sheet http://www.ligand.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.ligand.com/role/BusinessCombinations 21 false false R22.htm 2306301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.ligand.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.ligand.com/role/FairValueMeasurement 22 false false R23.htm 2308301 - Disclosure - Lease Obligations (Tables) Sheet http://www.ligand.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.ligand.com/role/LeaseObligations 23 false false R24.htm 2309301 - Disclosure - Financing Arrangements (Tables) Sheet http://www.ligand.com/role/FinancingArrangementsTables Financing Arrangements (Tables) Tables http://www.ligand.com/role/FinancingArrangements 24 false false R25.htm 2311301 - Disclosure - Other Balance Sheet Details (Tables) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsTables Other Balance Sheet Details (Tables) Tables http://www.ligand.com/role/OtherBalanceSheetDetails 25 false false R26.htm 2312301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.ligand.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.ligand.com/role/StockholdersEquity 26 false false R27.htm 2318301 - Disclosure - Income Taxes (Tables) Sheet http://www.ligand.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.ligand.com/role/IncomeTaxes 27 false false R28.htm 2319301 - Disclosure - Summary of Unaudited Quarterly Financial Information (Tables) Sheet http://www.ligand.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTables Summary of Unaudited Quarterly Financial Information (Tables) Tables http://www.ligand.com/role/SummaryOfUnauditedQuarterlyFinancialInformation 28 false false R29.htm 2401403 - Disclosure - Summary of Significant Accounting Policies (Details 6) Sheet http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesDetails6 Summary of Significant Accounting Policies (Details 6) Details http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 2401404 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 2401405 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.ligand.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 2402401 - Disclosure - Investment in Viking (Details Textual) Sheet http://www.ligand.com/role/InvestmentInVikingDetailsTextual Investment in Viking (Details Textual) Details http://www.ligand.com/role/InvestmentInViking 32 false false R33.htm 2404402 - Disclosure - Business Combinations (Details) Sheet http://www.ligand.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://www.ligand.com/role/BusinessCombinationsTables 33 false false R34.htm 2404403 - Disclosure - Business Combinations - Consideration Transferred (Details) Sheet http://www.ligand.com/role/BusinessCombinationsConsiderationTransferredDetails Business Combinations - Consideration Transferred (Details) Details 34 false false R35.htm 2404404 - Disclosure - Business Combinations - Assets Acquired and Liabilities Assumed (Details) Sheet http://www.ligand.com/role/BusinessCombinationsAssetsAcquiredAndLiabilitiesAssumedDetails Business Combinations - Assets Acquired and Liabilities Assumed (Details) Details 35 false false R36.htm 2404405 - Disclosure - Business Combinations - Pro Forma Information (Details) Sheet http://www.ligand.com/role/BusinessCombinationsProFormaInformationDetails Business Combinations - Pro Forma Information (Details) Details 36 false false R37.htm 2406402 - Disclosure - Fair Value Measurement (Details) Sheet http://www.ligand.com/role/FairValueMeasurementDetails Fair Value Measurement (Details) Details http://www.ligand.com/role/FairValueMeasurementTables 37 false false R38.htm 2406403 - Disclosure - Fair Value Measurement (Details 1) Sheet http://www.ligand.com/role/FairValueMeasurementDetails1 Fair Value Measurement (Details 1) Details http://www.ligand.com/role/FairValueMeasurementTables 38 false false R39.htm 2406404 - Disclosure - Fair Value Measurement (Details 2) Sheet http://www.ligand.com/role/FairValueMeasurementDetails2 Fair Value Measurement (Details 2) Details http://www.ligand.com/role/FairValueMeasurementTables 39 false false R40.htm 2406405 - Disclosure - Fair Value Measurements - Unobservable Inputs (Details) Sheet http://www.ligand.com/role/FairValueMeasurementsUnobservableInputsDetails Fair Value Measurements - Unobservable Inputs (Details) Details 40 false false R41.htm 2408402 - Disclosure - Lease Obligations (Details) Sheet http://www.ligand.com/role/LeaseObligationsDetails Lease Obligations (Details) Details http://www.ligand.com/role/LeaseObligationsTables 41 false false R42.htm 2408403 - Disclosure - Lease Obligations (Details Textual) Sheet http://www.ligand.com/role/LeaseObligationsDetailsTextual Lease Obligations (Details Textual) Details http://www.ligand.com/role/LeaseObligationsTables 42 false false R43.htm 2409402 - Disclosure - Financing Arrangements (Details) Sheet http://www.ligand.com/role/FinancingArrangementsDetails Financing Arrangements (Details) Details http://www.ligand.com/role/FinancingArrangementsTables 43 false false R44.htm 2409403 - Disclosure - Financing Arrangements (Details Textual) Sheet http://www.ligand.com/role/FinancingArrangementsDetailsTextual Financing Arrangements (Details Textual) Details http://www.ligand.com/role/FinancingArrangementsTables 44 false false R45.htm 2411402 - Disclosure - Other Balance Sheet Details - Investment categories (Details) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsInvestmentCategoriesDetails Other Balance Sheet Details - Investment categories (Details) Details 45 false false R46.htm 2411403 - Disclosure - Other Balance Sheet Details (Details) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsDetails Other Balance Sheet Details (Details) Details http://www.ligand.com/role/OtherBalanceSheetDetailsTables 46 false false R47.htm 2411404 - Disclosure - Other Balance Sheet Details - Property and Equipment (Details) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsPropertyAndEquipmentDetails Other Balance Sheet Details - Property and Equipment (Details) Details 47 false false R48.htm 2411405 - Disclosure - Other Balance Sheet Details - Goodwill and Other Intangible Assets (Details) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsGoodwillAndOtherIntangibleAssetsDetails Other Balance Sheet Details - Goodwill and Other Intangible Assets (Details) Details 48 false false R49.htm 2411406 - Disclosure - Other Balance Sheet Details (Details 1) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsDetails1 Other Balance Sheet Details (Details 1) Details http://www.ligand.com/role/OtherBalanceSheetDetailsTables 49 false false R50.htm 2411407 - Disclosure - Other Balance Sheet Details - Contingent Liabilities (Details) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsContingentLiabilitiesDetails Other Balance Sheet Details - Contingent Liabilities (Details) Details 50 false false R51.htm 2411408 - Disclosure - Other Balance Sheet Details (Details 2) Sheet http://www.ligand.com/role/OtherBalanceSheetDetailsDetails2 Other Balance Sheet Details (Details 2) Details http://www.ligand.com/role/OtherBalanceSheetDetailsTables 51 false false R52.htm 2412402 - Disclosure - Stockholders' Equity (Details) Sheet http://www.ligand.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.ligand.com/role/StockholdersEquityTables 52 false false R53.htm 2412403 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.ligand.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://www.ligand.com/role/StockholdersEquityTables 53 false false R54.htm 2412404 - Disclosure - Stockholders' Equity (Details 2) Sheet http://www.ligand.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://www.ligand.com/role/StockholdersEquityTables 54 false false R55.htm 2412405 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.ligand.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.ligand.com/role/StockholdersEquityTables 55 false false R56.htm 2412406 - Disclosure - Stockholders' Equity - Share-base Compensation (Details) Sheet http://www.ligand.com/role/StockholdersEquityShareBaseCompensationDetails Stockholders' Equity - Share-base Compensation (Details) Details 56 false false R57.htm 2412407 - Disclosure - Stockholders' Equity - Assumptions (Details) Sheet http://www.ligand.com/role/StockholdersEquityAssumptionsDetails Stockholders' Equity - Assumptions (Details) Details 57 false false R58.htm 2418402 - Disclosure - Income Taxes (Details) Sheet http://www.ligand.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.ligand.com/role/IncomeTaxesTables 58 false false R59.htm 2418403 - Disclosure - Income Taxes (Details 2) Sheet http://www.ligand.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) Details http://www.ligand.com/role/IncomeTaxesTables 59 false false R60.htm 2418404 - Disclosure - Income Taxes (Details 1) Sheet http://www.ligand.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://www.ligand.com/role/IncomeTaxesTables 60 false false R61.htm 2418405 - Disclosure - Income Taxes (Details 3) Sheet http://www.ligand.com/role/IncomeTaxesDetails3 Income Taxes (Details 3) Details http://www.ligand.com/role/IncomeTaxesTables 61 false false R62.htm 2418406 - Disclosure - Income Taxes (Details Textual) Sheet http://www.ligand.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.ligand.com/role/IncomeTaxesTables 62 false false R63.htm 2419402 - Disclosure - Summary of Unaudited Quarterly Financial Information (Details) Sheet http://www.ligand.com/role/SummaryOfUnauditedQuarterlyFinancialInformationDetails Summary of Unaudited Quarterly Financial Information (Details) Details http://www.ligand.com/role/SummaryOfUnauditedQuarterlyFinancialInformationTables 63 false false All Reports Book All Reports lgnd-20151231.xml lgnd-20151231.xsd lgnd-20151231_cal.xml lgnd-20151231_def.xml lgnd-20151231_lab.xml lgnd-20151231_pre.xml true true ZIP 83 0000886163-17-000021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000886163-17-000021-xbrl.zip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ʁ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end